US20100204199A1 - Cyclic 11-beta hydroxysteroid dehydrogenase type i inhibitors - Google Patents
Cyclic 11-beta hydroxysteroid dehydrogenase type i inhibitors Download PDFInfo
- Publication number
- US20100204199A1 US20100204199A1 US12/759,867 US75986710A US2010204199A1 US 20100204199 A1 US20100204199 A1 US 20100204199A1 US 75986710 A US75986710 A US 75986710A US 2010204199 A1 US2010204199 A1 US 2010204199A1
- Authority
- US
- United States
- Prior art keywords
- alkyl
- aryl
- heterocyclyl
- cycloalkyl
- occurrence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000004122 cyclic group Chemical group 0.000 title claims description 53
- 108090000874 11-beta-hydroxysteroid dehydrogenases Proteins 0.000 title abstract description 19
- 102000004277 11-beta-hydroxysteroid dehydrogenases Human genes 0.000 title abstract description 19
- 239000003112 inhibitor Substances 0.000 title abstract description 9
- 150000001875 compounds Chemical class 0.000 claims abstract description 471
- 150000003839 salts Chemical class 0.000 claims abstract description 16
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims abstract description 4
- 239000012453 solvate Substances 0.000 claims abstract description 3
- 125000000217 alkyl group Chemical group 0.000 claims description 499
- 125000003118 aryl group Chemical group 0.000 claims description 487
- 125000000623 heterocyclic group Chemical group 0.000 claims description 387
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 346
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 220
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims description 211
- 239000001257 hydrogen Substances 0.000 claims description 186
- 229910052739 hydrogen Inorganic materials 0.000 claims description 186
- 125000005843 halogen group Chemical group 0.000 claims description 161
- 238000000034 method Methods 0.000 claims description 150
- 150000002431 hydrogen Chemical class 0.000 claims description 149
- 125000005842 heteroatom Chemical group 0.000 claims description 138
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 136
- 229910052717 sulfur Inorganic materials 0.000 claims description 136
- 229910052760 oxygen Inorganic materials 0.000 claims description 135
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 133
- -1 —OH Chemical group 0.000 claims description 124
- 125000003342 alkenyl group Chemical group 0.000 claims description 119
- 125000001188 haloalkyl group Chemical group 0.000 claims description 111
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 93
- 125000000304 alkynyl group Chemical group 0.000 claims description 78
- 229910020008 S(O) Inorganic materials 0.000 claims description 54
- 229910052799 carbon Inorganic materials 0.000 claims description 44
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 41
- 229920006395 saturated elastomer Polymers 0.000 claims description 37
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 35
- 125000003545 alkoxy group Chemical group 0.000 claims description 35
- 125000004432 carbon atom Chemical group C* 0.000 claims description 35
- 229910052757 nitrogen Inorganic materials 0.000 claims description 35
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 33
- 101001110310 Lentilactobacillus kefiri NADP-dependent (R)-specific alcohol dehydrogenase Proteins 0.000 claims description 31
- 229910004749 OS(O)2 Inorganic materials 0.000 claims description 26
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 26
- 239000003814 drug Substances 0.000 claims description 21
- 230000008569 process Effects 0.000 claims description 20
- 125000003831 tetrazolyl group Chemical group 0.000 claims description 18
- 229940124597 therapeutic agent Drugs 0.000 claims description 18
- 206010012601 diabetes mellitus Diseases 0.000 claims description 14
- 241000235648 Pichia Species 0.000 claims description 13
- 208000001145 Metabolic Syndrome Diseases 0.000 claims description 12
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 12
- 244000005700 microbiome Species 0.000 claims description 12
- 208000008589 Obesity Diseases 0.000 claims description 11
- 235000020824 obesity Nutrition 0.000 claims description 11
- 238000002360 preparation method Methods 0.000 claims description 10
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 9
- 208000010067 Pituitary ACTH Hypersecretion Diseases 0.000 claims description 7
- 208000020627 Pituitary-dependent Cushing syndrome Diseases 0.000 claims description 7
- 201000001421 hyperglycemia Diseases 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 208000028698 Cognitive impairment Diseases 0.000 claims description 6
- 208000010412 Glaucoma Diseases 0.000 claims description 6
- 206010020772 Hypertension Diseases 0.000 claims description 6
- 208000010877 cognitive disease Diseases 0.000 claims description 6
- 201000008482 osteoarthritis Diseases 0.000 claims description 6
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 6
- 230000002255 enzymatic effect Effects 0.000 claims description 5
- 241000222120 Candida <Saccharomycetales> Species 0.000 claims description 4
- 241000223252 Rhodotorula Species 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 4
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 2
- 125000004365 octenyl group Chemical group C(=CCCCCCC)* 0.000 claims description 2
- 125000003107 substituted aryl group Chemical group 0.000 claims description 2
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 25
- 201000010099 disease Diseases 0.000 abstract description 15
- 238000002560 therapeutic procedure Methods 0.000 abstract description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 146
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 90
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 90
- 125000004093 cyano group Chemical group *C#N 0.000 description 86
- 238000005160 1H NMR spectroscopy Methods 0.000 description 84
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 82
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 75
- 239000000203 mixture Substances 0.000 description 71
- 238000004128 high performance liquid chromatography Methods 0.000 description 64
- 239000000243 solution Substances 0.000 description 64
- 239000007787 solid Substances 0.000 description 62
- 239000002904 solvent Substances 0.000 description 54
- 239000011541 reaction mixture Substances 0.000 description 53
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 51
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 50
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 42
- 235000019439 ethyl acetate Nutrition 0.000 description 42
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 40
- 238000002953 preparative HPLC Methods 0.000 description 39
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 36
- 229910001868 water Inorganic materials 0.000 description 32
- 102000004190 Enzymes Human genes 0.000 description 31
- 108090000790 Enzymes Proteins 0.000 description 31
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 31
- 239000012044 organic layer Substances 0.000 description 30
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 24
- 239000003921 oil Substances 0.000 description 24
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 23
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 22
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 21
- 229910052786 argon Inorganic materials 0.000 description 21
- 238000006243 chemical reaction Methods 0.000 description 21
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 20
- 238000004440 column chromatography Methods 0.000 description 20
- 230000005764 inhibitory process Effects 0.000 description 20
- 125000001424 substituent group Chemical group 0.000 description 20
- 241000282414 Homo sapiens Species 0.000 description 19
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 19
- 239000003795 chemical substances by application Substances 0.000 description 19
- 229910052681 coesite Inorganic materials 0.000 description 19
- 229910052906 cristobalite Inorganic materials 0.000 description 19
- 239000012043 crude product Substances 0.000 description 19
- 239000000377 silicon dioxide Substances 0.000 description 19
- 229910052682 stishovite Inorganic materials 0.000 description 19
- 229910052905 tridymite Inorganic materials 0.000 description 19
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 18
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 18
- 230000002401 inhibitory effect Effects 0.000 description 18
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 17
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 17
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 16
- 239000003153 chemical reaction reagent Substances 0.000 description 16
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 15
- 230000000694 effects Effects 0.000 description 15
- 239000000725 suspension Substances 0.000 description 15
- 230000009467 reduction Effects 0.000 description 14
- 241000699670 Mus sp. Species 0.000 description 13
- ORILYTVJVMAKLC-UHFFFAOYSA-N adamantane Chemical compound C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 13
- 238000005897 peptide coupling reaction Methods 0.000 description 13
- 230000002265 prevention Effects 0.000 description 13
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 12
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 12
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 12
- 238000004293 19F NMR spectroscopy Methods 0.000 description 11
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 11
- 239000007832 Na2SO4 Substances 0.000 description 11
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 11
- 125000001072 heteroaryl group Chemical group 0.000 description 11
- 229960000890 hydrocortisone Drugs 0.000 description 11
- 229910052938 sodium sulfate Inorganic materials 0.000 description 11
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 11
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 10
- 244000286779 Hansenula anomala Species 0.000 description 10
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 10
- 239000002253 acid Substances 0.000 description 10
- 208000035475 disorder Diseases 0.000 description 10
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 10
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 9
- 241001452677 Ogataea methanolica Species 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 125000004414 alkyl thio group Chemical group 0.000 description 9
- UQUPQEUNHVVNKW-UHFFFAOYSA-N azetidin-1-ium-3-ol;chloride Chemical compound Cl.OC1CNC1 UQUPQEUNHVVNKW-UHFFFAOYSA-N 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 150000002576 ketones Chemical class 0.000 description 9
- 238000010992 reflux Methods 0.000 description 9
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 8
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 8
- 229910004373 HOAc Inorganic materials 0.000 description 8
- 125000004429 atom Chemical group 0.000 description 8
- 239000002585 base Substances 0.000 description 8
- 239000012230 colorless oil Substances 0.000 description 8
- 239000007858 starting material Substances 0.000 description 8
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 8
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 239000012267 brine Substances 0.000 description 7
- 235000005911 diet Nutrition 0.000 description 7
- 230000037213 diet Effects 0.000 description 7
- 150000002148 esters Chemical class 0.000 description 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 7
- 125000001041 indolyl group Chemical group 0.000 description 7
- 230000014759 maintenance of location Effects 0.000 description 7
- GXHFUVWIGNLZSC-UHFFFAOYSA-N meldrum's acid Chemical compound CC1(C)OC(=O)CC(=O)O1 GXHFUVWIGNLZSC-UHFFFAOYSA-N 0.000 description 7
- 125000004076 pyridyl group Chemical group 0.000 description 7
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 6
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 6
- 235000014683 Hansenula anomala Nutrition 0.000 description 6
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical class [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 6
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 6
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 6
- 239000003054 catalyst Substances 0.000 description 6
- 229960004544 cortisone Drugs 0.000 description 6
- 229940093499 ethyl acetate Drugs 0.000 description 6
- 239000000706 filtrate Substances 0.000 description 6
- 239000008103 glucose Substances 0.000 description 6
- 208000031225 myocardial ischemia Diseases 0.000 description 6
- 239000012071 phase Substances 0.000 description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 125000001544 thienyl group Chemical group 0.000 description 6
- FUFLCEKSBBHCMO-KJQYFISQSA-N 11-dehydrocorticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 FUFLCEKSBBHCMO-KJQYFISQSA-N 0.000 description 5
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 5
- 206010022489 Insulin Resistance Diseases 0.000 description 5
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 5
- 150000001412 amines Chemical class 0.000 description 5
- 125000004658 aryl carbonyl amino group Chemical group 0.000 description 5
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 5
- OBZHEBDUNPOCJG-SZTGPWMUSA-N carbenoxolone Chemical compound C([C@H]1C2=CC(=O)[C@@H]34)[C@](C)(C(O)=O)CC[C@@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@H]1[C@@]3(C)CC[C@@H](OC(=O)CCC(O)=O)C1(C)C OBZHEBDUNPOCJG-SZTGPWMUSA-N 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 229910052736 halogen Inorganic materials 0.000 description 5
- 150000002367 halogens Chemical class 0.000 description 5
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 5
- 208000027866 inflammatory disease Diseases 0.000 description 5
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 5
- BRKADVNLTRCLOW-UHFFFAOYSA-M magnesium;fluorobenzene;bromide Chemical compound [Mg+2].[Br-].FC1=CC=[C-]C=C1 BRKADVNLTRCLOW-UHFFFAOYSA-M 0.000 description 5
- WHQSYGRFZMUQGQ-UHFFFAOYSA-N n,n-dimethylformamide;hydrate Chemical compound O.CN(C)C=O WHQSYGRFZMUQGQ-UHFFFAOYSA-N 0.000 description 5
- 239000000651 prodrug Substances 0.000 description 5
- 229940002612 prodrug Drugs 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 5
- 238000011084 recovery Methods 0.000 description 5
- 238000012216 screening Methods 0.000 description 5
- 150000003573 thiols Chemical class 0.000 description 5
- 238000000825 ultraviolet detection Methods 0.000 description 5
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 4
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 4
- 125000005986 4-piperidonyl group Chemical group 0.000 description 4
- 125000002471 4H-quinolizinyl group Chemical group C=1(C=CCN2C=CC=CC12)* 0.000 description 4
- 201000001320 Atherosclerosis Diseases 0.000 description 4
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 4
- 101000928753 Homo sapiens 11-beta-hydroxysteroid dehydrogenase 1 Proteins 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 150000001299 aldehydes Chemical class 0.000 description 4
- 125000005236 alkanoylamino group Chemical group 0.000 description 4
- 239000003472 antidiabetic agent Substances 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 125000004104 aryloxy group Chemical group 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- OSJRGDBEYARHLX-UHFFFAOYSA-N azido(trimethyl)stannane Chemical compound [N-]=[N+]=[N-].C[Sn+](C)C OSJRGDBEYARHLX-UHFFFAOYSA-N 0.000 description 4
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 4
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 description 4
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 4
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 4
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 4
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 4
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 4
- 229960000530 carbenoxolone Drugs 0.000 description 4
- FZFAMSAMCHXGEF-UHFFFAOYSA-N chloro formate Chemical compound ClOC=O FZFAMSAMCHXGEF-UHFFFAOYSA-N 0.000 description 4
- 238000006114 decarboxylation reaction Methods 0.000 description 4
- 238000010511 deprotection reaction Methods 0.000 description 4
- GUVUOGQBMYCBQP-UHFFFAOYSA-N dmpu Chemical compound CN1CCCN(C)C1=O GUVUOGQBMYCBQP-UHFFFAOYSA-N 0.000 description 4
- 125000002541 furyl group Chemical group 0.000 description 4
- 125000004446 heteroarylalkyl group Chemical group 0.000 description 4
- 230000007062 hydrolysis Effects 0.000 description 4
- 238000006460 hydrolysis reaction Methods 0.000 description 4
- 125000002883 imidazolyl group Chemical group 0.000 description 4
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 4
- 239000010410 layer Substances 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 4
- 239000012038 nucleophile Substances 0.000 description 4
- 125000002971 oxazolyl group Chemical group 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 239000012286 potassium permanganate Substances 0.000 description 4
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 4
- 125000003373 pyrazinyl group Chemical group 0.000 description 4
- 125000003226 pyrazolyl group Chemical group 0.000 description 4
- 125000000714 pyrimidinyl group Chemical group 0.000 description 4
- 238000010791 quenching Methods 0.000 description 4
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 4
- 238000002821 scintillation proximity assay Methods 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 4
- 125000000335 thiazolyl group Chemical group 0.000 description 4
- CFOAUYCPAUGDFF-UHFFFAOYSA-N tosmic Chemical compound CC1=CC=C(S(=O)(=O)C[N+]#[C-])C=C1 CFOAUYCPAUGDFF-UHFFFAOYSA-N 0.000 description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 description 3
- 125000001376 1,2,4-triazolyl group Chemical group N1N=C(N=C1)* 0.000 description 3
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 208000004476 Acute Coronary Syndrome Diseases 0.000 description 3
- 208000024827 Alzheimer disease Diseases 0.000 description 3
- 206010002383 Angina Pectoris Diseases 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 208000020084 Bone disease Diseases 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- 229910021589 Copper(I) bromide Inorganic materials 0.000 description 3
- OMFXVFTZEKFJBZ-UHFFFAOYSA-N Corticosterone Natural products O=C1CCC2(C)C3C(O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 OMFXVFTZEKFJBZ-UHFFFAOYSA-N 0.000 description 3
- VMQMZMRVKUZKQL-UHFFFAOYSA-N Cu+ Chemical class [Cu+] VMQMZMRVKUZKQL-UHFFFAOYSA-N 0.000 description 3
- 206010012289 Dementia Diseases 0.000 description 3
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 3
- QMMFVYPAHWMCMS-UHFFFAOYSA-N Dimethyl sulfide Chemical compound CSC QMMFVYPAHWMCMS-UHFFFAOYSA-N 0.000 description 3
- 208000002705 Glucose Intolerance Diseases 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 108010010369 HIV Protease Proteins 0.000 description 3
- 208000035150 Hypercholesterolemia Diseases 0.000 description 3
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 3
- 208000031226 Hyperlipidaemia Diseases 0.000 description 3
- 206010022562 Intermittent claudication Diseases 0.000 description 3
- 102000007330 LDL Lipoproteins Human genes 0.000 description 3
- 206010049287 Lipodystrophy acquired Diseases 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 3
- 206010033645 Pancreatitis Diseases 0.000 description 3
- 208000018262 Peripheral vascular disease Diseases 0.000 description 3
- 208000017442 Retinal disease Diseases 0.000 description 3
- 206010038923 Retinopathy Diseases 0.000 description 3
- 241000223253 Rhodotorula glutinis Species 0.000 description 3
- 229910006124 SOCl2 Inorganic materials 0.000 description 3
- 208000006011 Stroke Diseases 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- OJFKUJDRGJSAQB-UHFFFAOYSA-N TAK-632 Chemical compound C1=C(NC(=O)CC=2C=C(C=CC=2)C(F)(F)F)C(F)=CC=C1OC(C(=C1S2)C#N)=CC=C1N=C2NC(=O)C1CC1 OJFKUJDRGJSAQB-UHFFFAOYSA-N 0.000 description 3
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 150000001266 acyl halides Chemical class 0.000 description 3
- IYKFYARMMIESOX-UHFFFAOYSA-N adamantanone Chemical compound C1C(C2)CC3CC1C(=O)C2C3 IYKFYARMMIESOX-UHFFFAOYSA-N 0.000 description 3
- 210000000577 adipose tissue Anatomy 0.000 description 3
- 229940125708 antidiabetic agent Drugs 0.000 description 3
- 125000005110 aryl thio group Chemical group 0.000 description 3
- 125000004604 benzisothiazolyl group Chemical group S1N=C(C2=C1C=CC=C2)* 0.000 description 3
- 125000005512 benztetrazolyl group Chemical group 0.000 description 3
- 125000002619 bicyclic group Chemical group 0.000 description 3
- 230000002210 biocatalytic effect Effects 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 150000001721 carbon Chemical group 0.000 description 3
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 208000024980 claudication Diseases 0.000 description 3
- OMFXVFTZEKFJBZ-HJTSIMOOSA-N corticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OMFXVFTZEKFJBZ-HJTSIMOOSA-N 0.000 description 3
- 230000003111 delayed effect Effects 0.000 description 3
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 239000003862 glucocorticoid Substances 0.000 description 3
- 230000004217 heart function Effects 0.000 description 3
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 3
- 201000008980 hyperinsulinism Diseases 0.000 description 3
- 208000006575 hypertriglyceridemia Diseases 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 3
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 3
- 125000000842 isoxazolyl group Chemical group 0.000 description 3
- 208000017169 kidney disease Diseases 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 208000006132 lipodystrophy Diseases 0.000 description 3
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 3
- 238000004949 mass spectrometry Methods 0.000 description 3
- 238000001819 mass spectrum Methods 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- 125000002950 monocyclic group Chemical group 0.000 description 3
- 208000010125 myocardial infarction Diseases 0.000 description 3
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-Butyllithium Substances [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 3
- 230000004770 neurodegeneration Effects 0.000 description 3
- 208000015122 neurodegenerative disease Diseases 0.000 description 3
- 201000001119 neuropathy Diseases 0.000 description 3
- 230000007823 neuropathy Effects 0.000 description 3
- 150000002825 nitriles Chemical class 0.000 description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 125000001979 organolithium group Chemical group 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 208000033808 peripheral neuropathy Diseases 0.000 description 3
- 125000003386 piperidinyl group Chemical group 0.000 description 3
- 125000004928 piperidonyl group Chemical group 0.000 description 3
- 239000008057 potassium phosphate buffer Substances 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 201000009104 prediabetes syndrome Diseases 0.000 description 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 125000002098 pyridazinyl group Chemical group 0.000 description 3
- 125000000168 pyrrolyl group Chemical group 0.000 description 3
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 3
- 208000037803 restenosis Diseases 0.000 description 3
- 239000012279 sodium borohydride Substances 0.000 description 3
- 229910000033 sodium borohydride Inorganic materials 0.000 description 3
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- XRRXRQJQQKMFBC-UHFFFAOYSA-N tert-butyl 3-hydroxyazetidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CC(O)C1 XRRXRQJQQKMFBC-UHFFFAOYSA-N 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- 230000029663 wound healing Effects 0.000 description 3
- LQUPKVMEAATBSL-UHFFFAOYSA-L zinc;2,3,4-trichlorophenolate Chemical compound [Zn+2].[O-]C1=CC=C(Cl)C(Cl)=C1Cl.[O-]C1=CC=C(Cl)C(Cl)=C1Cl LQUPKVMEAATBSL-UHFFFAOYSA-L 0.000 description 3
- 125000004502 1,2,3-oxadiazolyl group Chemical group 0.000 description 2
- 125000004511 1,2,3-thiadiazolyl group Chemical group 0.000 description 2
- 125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 description 2
- 125000004514 1,2,4-thiadiazolyl group Chemical group 0.000 description 2
- 125000004506 1,2,5-oxadiazolyl group Chemical group 0.000 description 2
- 125000004517 1,2,5-thiadiazolyl group Chemical group 0.000 description 2
- 125000001781 1,3,4-oxadiazolyl group Chemical group 0.000 description 2
- 125000004520 1,3,4-thiadiazolyl group Chemical group 0.000 description 2
- FPIRBHDGWMWJEP-UHFFFAOYSA-N 1-hydroxy-7-azabenzotriazole Chemical compound C1=CN=C2N(O)N=NC2=C1 FPIRBHDGWMWJEP-UHFFFAOYSA-N 0.000 description 2
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 2
- APISVOVOJVZIBA-UHFFFAOYSA-N 2-(triphenyl-$l^{5}-phosphanylidene)acetonitrile Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)(=CC#N)C1=CC=CC=C1 APISVOVOJVZIBA-UHFFFAOYSA-N 0.000 description 2
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 2
- YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 2
- BKOOMYPCSUNDGP-UHFFFAOYSA-N 2-methylbut-2-ene Chemical compound CC=C(C)C BKOOMYPCSUNDGP-UHFFFAOYSA-N 0.000 description 2
- GAMYYCRTACQSBR-UHFFFAOYSA-N 4-azabenzimidazole Chemical compound C1=CC=C2NC=NC2=N1 GAMYYCRTACQSBR-UHFFFAOYSA-N 0.000 description 2
- CYBHWCLUGRHMCK-UHFFFAOYSA-N 4aH-carbazole Chemical compound C1=CC=C2C3C=CC=CC3=NC2=C1 CYBHWCLUGRHMCK-UHFFFAOYSA-N 0.000 description 2
- BGVLOJBYTSTMBP-UHFFFAOYSA-N 6-chloro-3-methoxy-1,2-benzoxazole Chemical compound ClC1=CC=C2C(OC)=NOC2=C1 BGVLOJBYTSTMBP-UHFFFAOYSA-N 0.000 description 2
- 208000004611 Abdominal Obesity Diseases 0.000 description 2
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- 241000937413 Axia Species 0.000 description 2
- 229910015845 BBr3 Inorganic materials 0.000 description 2
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 2
- 241000235646 Cyberlindnera jadinii Species 0.000 description 2
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 108010050375 Glucose 1-Dehydrogenase Proteins 0.000 description 2
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 238000006000 Knoevenagel condensation reaction Methods 0.000 description 2
- 229920003091 Methocel™ Polymers 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- VZUNGTLZRAYYDE-UHFFFAOYSA-N N-methyl-N'-nitro-N-nitrosoguanidine Chemical compound O=NN(C)C(=N)N[N+]([O-])=O VZUNGTLZRAYYDE-UHFFFAOYSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 241000320412 Ogataea angusta Species 0.000 description 2
- BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 description 2
- 102000004316 Oxidoreductases Human genes 0.000 description 2
- 108090000854 Oxidoreductases Proteins 0.000 description 2
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000012317 TBTU Substances 0.000 description 2
- 241001276012 Wickerhamomyces ciferrii Species 0.000 description 2
- 241001489164 Wickerhamomyces silvicola Species 0.000 description 2
- BBAWTPDTGRXPDG-UHFFFAOYSA-N [1,3]thiazolo[4,5-b]pyridine Chemical compound C1=CC=C2SC=NC2=N1 BBAWTPDTGRXPDG-UHFFFAOYSA-N 0.000 description 2
- 241000222124 [Candida] boidinii Species 0.000 description 2
- CLZISMQKJZCZDN-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium Chemical compound C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 CLZISMQKJZCZDN-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- UNGMXQVELCJRIH-UHFFFAOYSA-N adamantane-2-carboxylic acid Chemical compound C1C(C2)CC3CC1C(C(=O)O)C2C3 UNGMXQVELCJRIH-UHFFFAOYSA-N 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 150000001336 alkenes Chemical class 0.000 description 2
- 125000004450 alkenylene group Chemical group 0.000 description 2
- 125000003282 alkyl amino group Chemical group 0.000 description 2
- 150000001350 alkyl halides Chemical class 0.000 description 2
- 230000029936 alkylation Effects 0.000 description 2
- 238000005804 alkylation reaction Methods 0.000 description 2
- 125000002947 alkylene group Chemical group 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- 239000003524 antilipemic agent Substances 0.000 description 2
- 125000004659 aryl alkyl thio group Chemical group 0.000 description 2
- 125000002102 aryl alkyloxo group Chemical group 0.000 description 2
- 125000005160 aryl oxy alkyl group Chemical group 0.000 description 2
- 239000012131 assay buffer Substances 0.000 description 2
- 125000004931 azocinyl group Chemical group N1=C(C=CC=CC=C1)* 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 2
- 125000004623 carbolinyl group Chemical group 0.000 description 2
- 150000001735 carboxylic acids Chemical class 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 description 2
- 125000004230 chromenyl group Chemical group O1C(C=CC2=CC=CC=C12)* 0.000 description 2
- NKNDPYCGAZPOFS-UHFFFAOYSA-M copper(i) bromide Chemical compound Br[Cu] NKNDPYCGAZPOFS-UHFFFAOYSA-M 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 125000004856 decahydroquinolinyl group Chemical group N1(CCCC2CCCCC12)* 0.000 description 2
- FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Substances CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000012065 filter cake Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000003818 flash chromatography Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 125000003838 furazanyl group Chemical group 0.000 description 2
- 229960004580 glibenclamide Drugs 0.000 description 2
- 230000004110 gluconeogenesis Effects 0.000 description 2
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 2
- 150000004795 grignard reagents Chemical class 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 125000004447 heteroarylalkenyl group Chemical group 0.000 description 2
- 125000005553 heteroaryloxy group Chemical group 0.000 description 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 125000002632 imidazolidinyl group Chemical group 0.000 description 2
- 125000002636 imidazolinyl group Chemical group 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 125000004926 indolenyl group Chemical group 0.000 description 2
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 2
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- 125000001977 isobenzofuranyl group Chemical group C=1(OC=C2C=CC=CC12)* 0.000 description 2
- 125000003384 isochromanyl group Chemical group C1(OCCC2=CC=CC=C12)* 0.000 description 2
- 125000005438 isoindazolyl group Chemical group 0.000 description 2
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 2
- 125000001786 isothiazolyl group Chemical group 0.000 description 2
- NXPHGHWWQRMDIA-UHFFFAOYSA-M magnesium;carbanide;bromide Chemical compound [CH3-].[Mg+2].[Br-] NXPHGHWWQRMDIA-UHFFFAOYSA-M 0.000 description 2
- CUONGYYJJVDODC-UHFFFAOYSA-N malononitrile Chemical compound N#CCC#N CUONGYYJJVDODC-UHFFFAOYSA-N 0.000 description 2
- NUJOXMJBOLGQSY-UHFFFAOYSA-N manganese dioxide Chemical compound O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 210000001589 microsome Anatomy 0.000 description 2
- 125000002757 morpholinyl group Chemical group 0.000 description 2
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 2
- 229910052759 nickel Inorganic materials 0.000 description 2
- 125000004930 octahydroisoquinolinyl group Chemical group C1(NCCC2CCCC=C12)* 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 125000001715 oxadiazolyl group Chemical group 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 125000000160 oxazolidinyl group Chemical group 0.000 description 2
- QNNHQVPFZIFNFK-UHFFFAOYSA-N oxazolo[4,5-b]pyridine Chemical compound C1=CC=C2OC=NC2=N1 QNNHQVPFZIFNFK-UHFFFAOYSA-N 0.000 description 2
- 238000007248 oxidative elimination reaction Methods 0.000 description 2
- 125000004430 oxygen atom Chemical group O* 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- RGSFGYAAUTVSQA-UHFFFAOYSA-N pentamethylene Natural products C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- 125000004934 phenanthridinyl group Chemical group C1(=CC=CC2=NC=C3C=CC=CC3=C12)* 0.000 description 2
- 125000004625 phenanthrolinyl group Chemical group N1=C(C=CC2=CC=C3C=CC=NC3=C12)* 0.000 description 2
- 125000004624 phenarsazinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3[As]=C12)* 0.000 description 2
- 125000001791 phenazinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3N=C12)* 0.000 description 2
- 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 2
- 125000005954 phenoxathiinyl group Chemical group 0.000 description 2
- 125000001644 phenoxazinyl group Chemical group C1(=CC=CC=2OC3=CC=CC=C3NC12)* 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 2
- 125000004193 piperazinyl group Chemical group 0.000 description 2
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 2
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 2
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 2
- 125000002755 pyrazolinyl group Chemical group 0.000 description 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 2
- 125000001422 pyrrolinyl group Chemical group 0.000 description 2
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 2
- 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 238000003259 recombinant expression Methods 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 229940124530 sulfonamide Drugs 0.000 description 2
- 125000004434 sulfur atom Chemical group 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 150000003509 tertiary alcohols Chemical class 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 2
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 2
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 2
- MJMNMZORBRTNGP-NFOLICFBSA-J tetrasodium;[(2r,3r,4r,5r)-2-(6-aminopurin-9-yl)-5-[[[[(2r,3s,4r,5r)-5-(3-carbamoyl-4h-pyridin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-oxidophosphoryl]oxy-oxidophosphoryl]oxymethyl]-4-hydroxyoxolan-3-yl] phosphate;tetrahydrate Chemical compound O.O.O.O.[Na+].[Na+].[Na+].[Na+].C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP([O-])(=O)OP([O-])(=O)OC[C@@H]2[C@H]([C@@H](OP([O-])([O-])=O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 MJMNMZORBRTNGP-NFOLICFBSA-J 0.000 description 2
- 150000003536 tetrazoles Chemical class 0.000 description 2
- 125000004627 thianthrenyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3SC12)* 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 229910052723 transition metal Inorganic materials 0.000 description 2
- 150000003624 transition metals Chemical class 0.000 description 2
- 125000004306 triazinyl group Chemical group 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- 125000001834 xanthenyl group Chemical group C1=CC=CC=2OC3=CC=CC=C3C(C12)* 0.000 description 2
- 229910052727 yttrium Inorganic materials 0.000 description 2
- 238000011911 α-alkylation Methods 0.000 description 2
- 125000004933 β-carbolinyl group Chemical group C1(=NC=CC=2C3=CC=CC=C3NC12)* 0.000 description 2
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 1
- DDYAPMZTJAYBOF-ZMYDTDHYSA-N (3S)-4-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S,3R)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-4-amino-1-[[(2S,3S)-1-[[(1S)-1-carboxyethyl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-amino-3-(1H-imidazol-4-yl)propanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxypropanoyl]amino]hexanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]amino]-5-oxopentanoyl]amino]-4-oxobutanoic acid Chemical class [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O DDYAPMZTJAYBOF-ZMYDTDHYSA-N 0.000 description 1
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
- BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- NCADHSLPNSTDMJ-UHFFFAOYSA-N 1-[(2-methylpropan-2-yl)oxycarbonyl]azetidine-3-carboxylic acid Chemical compound CC(C)(C)OC(=O)N1CC(C(O)=O)C1 NCADHSLPNSTDMJ-UHFFFAOYSA-N 0.000 description 1
- BRSCYENHLCPOAU-UHFFFAOYSA-N 1-benzhydrylazetidin-1-ium-3-carboxylate Chemical compound C1C(C(=O)O)CN1C(C=1C=CC=CC=1)C1=CC=CC=C1 BRSCYENHLCPOAU-UHFFFAOYSA-N 0.000 description 1
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
- 102000006739 11-beta-Hydroxysteroid Dehydrogenase Type 2 Human genes 0.000 description 1
- 108010086356 11-beta-Hydroxysteroid Dehydrogenase Type 2 Proteins 0.000 description 1
- NVJDJNFWMHOWDB-UHFFFAOYSA-N 2,2-dimethyl-5-(3-methylidene-9-bicyclo[3.3.1]nonanylidene)-1,3-dioxane-4,6-dione Chemical compound O=C1OC(C)(C)OC(=O)C1=C1C2CCCC1CC(=C)C2 NVJDJNFWMHOWDB-UHFFFAOYSA-N 0.000 description 1
- VEJDERDUSQOCKA-UHFFFAOYSA-N 2-(4-fluorophenyl)adamantan-2-ol Chemical compound C1C2CC(C3)CC1CC3C2(O)C1=CC=C(F)C=C1 VEJDERDUSQOCKA-UHFFFAOYSA-N 0.000 description 1
- WGAAVKZZRSJUGC-UHFFFAOYSA-N 2-(4-fluorophenyl)adamantane-2-carbonitrile Chemical compound C1=CC(F)=CC=C1C1(C#N)C(C2)CC3CC2CC1C3 WGAAVKZZRSJUGC-UHFFFAOYSA-N 0.000 description 1
- TZIKHLIKPKWUEX-UHFFFAOYSA-N 2-(4-fluorophenyl)adamantane-2-carboxylic acid Chemical compound C1C2CC(C3)CC1CC3C2(C(=O)O)C1=CC=C(F)C=C1 TZIKHLIKPKWUEX-UHFFFAOYSA-N 0.000 description 1
- YMUCPDIEOYFNBF-UHFFFAOYSA-N 2-(azetidin-3-yloxymethyl)-5-methyl-1,3,4-oxadiazole;hydrochloride Chemical compound Cl.O1C(C)=NN=C1COC1CNC1 YMUCPDIEOYFNBF-UHFFFAOYSA-N 0.000 description 1
- KJLQSWULHSLSOM-UHFFFAOYSA-N 2-(chloromethyl)-5-methyl-1,3,4-oxadiazole Chemical compound CC1=NN=C(CCl)O1 KJLQSWULHSLSOM-UHFFFAOYSA-N 0.000 description 1
- DFDMKJOFONGPBX-UHFFFAOYSA-N 2-[2-(3-cyanophenyl)-2-adamantyl]acetic acid Chemical compound C1C2CC(C3)CC1CC3C2(CC(=O)O)C1=CC=CC(C#N)=C1 DFDMKJOFONGPBX-UHFFFAOYSA-N 0.000 description 1
- FDSKWNBTSSYTDR-UHFFFAOYSA-N 2-[2-(3-hydroxyphenyl)-2-adamantyl]acetic acid Chemical compound C1C2CC(C3)CC1CC3C2(CC(=O)O)C1=CC=CC(O)=C1 FDSKWNBTSSYTDR-UHFFFAOYSA-N 0.000 description 1
- FWMIGZNHURKJGV-UHFFFAOYSA-N 2-[2-(3-methoxyphenyl)-2-adamantyl]acetic acid Chemical compound COC1=CC=CC(C2(CC(O)=O)C3CC4CC(C3)CC2C4)=C1 FWMIGZNHURKJGV-UHFFFAOYSA-N 0.000 description 1
- JISSSAVHYKGFHT-UHFFFAOYSA-N 2-[2-(4-fluorophenyl)-2-adamantyl]acetamide Chemical compound C1C2CC(C3)CC1CC3C2(CC(=O)N)C1=CC=C(F)C=C1 JISSSAVHYKGFHT-UHFFFAOYSA-N 0.000 description 1
- XXKCDMKSNNHWFU-UHFFFAOYSA-N 2-[2-(4-fluorophenyl)-2-adamantyl]acetic acid Chemical compound C1C2CC(C3)CC1CC3C2(CC(=O)O)C1=CC=C(F)C=C1 XXKCDMKSNNHWFU-UHFFFAOYSA-N 0.000 description 1
- CERMIVBDHDLVNB-UHFFFAOYSA-N 2-[2-(4-fluorophenyl)-2-adamantyl]propanedioic acid Chemical compound C1C2CC(C3)CC1CC3C2(C(C(O)=O)C(=O)O)C1=CC=C(F)C=C1 CERMIVBDHDLVNB-UHFFFAOYSA-N 0.000 description 1
- MORDUGLIIWRBQG-UHFFFAOYSA-N 2-[9-(4-fluorophenyl)-3-hydroxy-9-bicyclo[3.3.1]nonanyl]-1-(3-hydroxyazetidin-1-yl)ethanone Chemical compound C1C(O)CN1C(=O)CC1(C=2C=CC(F)=CC=2)C2CCCC1CC(O)C2 MORDUGLIIWRBQG-UHFFFAOYSA-N 0.000 description 1
- HDNXHWJGTNBEIL-UHFFFAOYSA-N 2-[9-(4-fluorophenyl)-3-methylidene-9-bicyclo[3.3.1]nonanyl]acetic acid Chemical compound C1C(=C)CC2CCCC1C2(CC(=O)O)C1=CC=C(F)C=C1 HDNXHWJGTNBEIL-UHFFFAOYSA-N 0.000 description 1
- YZQNCQTYHVLWDX-UHFFFAOYSA-N 2-[9-(4-fluorophenyl)-3-oxo-9-bicyclo[3.3.1]nonanyl]acetic acid Chemical compound C1C(=O)CC2CCCC1C2(CC(=O)O)C1=CC=C(F)C=C1 YZQNCQTYHVLWDX-UHFFFAOYSA-N 0.000 description 1
- 125000005273 2-acetoxybenzoic acid group Chemical group 0.000 description 1
- RAFLFXSCOGLFIE-UHFFFAOYSA-N 2-benzyladamantane-2-carboxylic acid Chemical compound C1C2CC(C3)CC1CC3C2(C(=O)O)CC1=CC=CC=C1 RAFLFXSCOGLFIE-UHFFFAOYSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
- 125000006040 2-hexenyl group Chemical group 0.000 description 1
- ZQXSFZAMFNRZOQ-UHFFFAOYSA-N 2-methylpropan-2-ol;hydrate Chemical compound O.CC(C)(C)O ZQXSFZAMFNRZOQ-UHFFFAOYSA-N 0.000 description 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- ZNGINKJHQQQORD-UHFFFAOYSA-N 2-trimethylsilylethanol Chemical compound C[Si](C)(C)CCO ZNGINKJHQQQORD-UHFFFAOYSA-N 0.000 description 1
- 238000005084 2D-nuclear magnetic resonance Methods 0.000 description 1
- 125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 1
- 125000000474 3-butynyl group Chemical group [H]C#CC([H])([H])C([H])([H])* 0.000 description 1
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
- 125000006041 3-hexenyl group Chemical group 0.000 description 1
- OHCHDDUKNOFKRB-UHFFFAOYSA-N 3-methylidenebicyclo[3.3.1]nonan-9-one Chemical compound C1CCC2CC(=C)CC1C2=O OHCHDDUKNOFKRB-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- VFNJWHFPIRNNRQ-UHFFFAOYSA-N 4-oxoadamantane-1-carboxylic acid Chemical compound C1C(C2)CC3CC1(C(=O)O)CC2C3=O VFNJWHFPIRNNRQ-UHFFFAOYSA-N 0.000 description 1
- SIYYOHROEIZBBC-UHFFFAOYSA-N 5-(2-adamantylidene)-2,2-dimethyl-1,3-dioxane-4,6-dione Chemical compound O=C1OC(C)(C)OC(=O)C1=C1C(C2)CC3CC2CC1C3 SIYYOHROEIZBBC-UHFFFAOYSA-N 0.000 description 1
- MUMIKKGLAOYYPB-UHFFFAOYSA-N 5-[2-(4-fluorophenyl)-2-adamantyl]-2h-tetrazole Chemical compound C1=CC(F)=CC=C1C1(C=2NN=NN=2)C(C2)CC3CC2CC1C3 MUMIKKGLAOYYPB-UHFFFAOYSA-N 0.000 description 1
- RKLHLNZENIGXKL-UHFFFAOYSA-N 5-[9-(4-fluorophenyl)-3-methylidene-9-bicyclo[3.3.1]nonanyl]-2,2-dimethyl-1,3-dioxane-4,6-dione Chemical compound O=C1OC(C)(C)OC(=O)C1C1(C=2C=CC(F)=CC=2)C2CCCC1CC(=C)C2 RKLHLNZENIGXKL-UHFFFAOYSA-N 0.000 description 1
- XVMSFILGAMDHEY-UHFFFAOYSA-N 6-(4-aminophenyl)sulfonylpyridin-3-amine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=N1 XVMSFILGAMDHEY-UHFFFAOYSA-N 0.000 description 1
- ORIQLMBUPMABDV-UHFFFAOYSA-N 6-chloropyridine-3-carbonitrile Chemical compound ClC1=CC=C(C#N)C=N1 ORIQLMBUPMABDV-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 108700012434 CCL3 Proteins 0.000 description 1
- 101100451537 Caenorhabditis elegans hsd-1 gene Proteins 0.000 description 1
- 206010065941 Central obesity Diseases 0.000 description 1
- 102000000013 Chemokine CCL3 Human genes 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- RKWGIWYCVPQPMF-UHFFFAOYSA-N Chloropropamide Chemical compound CCCNC(=O)NS(=O)(=O)C1=CC=C(Cl)C=C1 RKWGIWYCVPQPMF-UHFFFAOYSA-N 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 241001489166 Cyberlindnera fabianii Species 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 1
- 108010088406 Glucagon-Like Peptides Proteins 0.000 description 1
- 240000004670 Glycyrrhiza echinata Species 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- 239000007818 Grignard reagent Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000845090 Homo sapiens 11-beta-hydroxysteroid dehydrogenase type 2 Proteins 0.000 description 1
- GRRNUXAQVGOGFE-UHFFFAOYSA-N Hygromycin-B Natural products OC1C(NC)CC(N)C(O)C1OC1C2OC3(C(C(O)C(O)C(C(N)CO)O3)O)OC2C(O)C(CO)O1 GRRNUXAQVGOGFE-UHFFFAOYSA-N 0.000 description 1
- RAXXELZNTBOGNW-UHFFFAOYSA-O Imidazolium Chemical compound C1=C[NH+]=CN1 RAXXELZNTBOGNW-UHFFFAOYSA-O 0.000 description 1
- 108010065920 Insulin Lispro Proteins 0.000 description 1
- 229930194542 Keto Natural products 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 239000012448 Lithium borohydride Substances 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 229910003844 NSO2 Inorganic materials 0.000 description 1
- 229910021585 Nickel(II) bromide Inorganic materials 0.000 description 1
- 238000010934 O-alkylation reaction Methods 0.000 description 1
- GWJNIIDJQHWKQB-UHFFFAOYSA-N O=[PH2]C#N Chemical class O=[PH2]C#N GWJNIIDJQHWKQB-UHFFFAOYSA-N 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- 229910019213 POCl3 Inorganic materials 0.000 description 1
- NFHFRUOZVGFOOS-UHFFFAOYSA-N Pd(PPh3)4 Substances [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 229910019020 PtO2 Inorganic materials 0.000 description 1
- 108091007187 Reductases Proteins 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- 102000009105 Short Chain Dehydrogenase-Reductases Human genes 0.000 description 1
- 108010048287 Short Chain Dehydrogenase-Reductases Proteins 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229940100389 Sulfonylurea Drugs 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 229910003074 TiCl4 Inorganic materials 0.000 description 1
- JLRGJRBPOGGCBT-UHFFFAOYSA-N Tolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 description 1
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 1
- GLYOPNLBKCBTMI-UHFFFAOYSA-N [2-chloro-2-(1-chloro-2-phenylethoxy)ethyl]benzene Chemical compound C=1C=CC=CC=1CC(Cl)OC(Cl)CC1=CC=CC=C1 GLYOPNLBKCBTMI-UHFFFAOYSA-N 0.000 description 1
- FEXQMRQHXTYLDS-UHFFFAOYSA-M [Br-].FC1=CC=C(C[Mg+])C=C1 Chemical compound [Br-].FC1=CC=C(C[Mg+])C=C1 FEXQMRQHXTYLDS-UHFFFAOYSA-M 0.000 description 1
- FPKOJRUTXSGNSO-UHFFFAOYSA-N [PH3]=CC#N Chemical compound [PH3]=CC#N FPKOJRUTXSGNSO-UHFFFAOYSA-N 0.000 description 1
- ZBIKORITPGTTGI-UHFFFAOYSA-N [acetyloxy(phenyl)-$l^{3}-iodanyl] acetate Chemical compound CC(=O)OI(OC(C)=O)C1=CC=CC=C1 ZBIKORITPGTTGI-UHFFFAOYSA-N 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 229960001466 acetohexamide Drugs 0.000 description 1
- VGZSUPCWNCWDAN-UHFFFAOYSA-N acetohexamide Chemical compound C1=CC(C(=O)C)=CC=C1S(=O)(=O)NC(=O)NC1CCCCC1 VGZSUPCWNCWDAN-UHFFFAOYSA-N 0.000 description 1
- OFLXLNCGODUUOT-UHFFFAOYSA-N acetohydrazide Chemical compound C\C(O)=N\N OFLXLNCGODUUOT-UHFFFAOYSA-N 0.000 description 1
- WEVYAHXRMPXWCK-FIBGUPNXSA-N acetonitrile-d3 Chemical compound [2H]C([2H])([2H])C#N WEVYAHXRMPXWCK-FIBGUPNXSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 150000001263 acyl chlorides Chemical class 0.000 description 1
- UBIAKEDDKXHXTB-UHFFFAOYSA-N adamantane-2,6-dione Chemical compound C1C(C2=O)CC3C(=O)C1CC2C3 UBIAKEDDKXHXTB-UHFFFAOYSA-N 0.000 description 1
- 229910001573 adamantine Inorganic materials 0.000 description 1
- YKIOKAURTKXMSB-UHFFFAOYSA-N adams's catalyst Chemical compound O=[Pt]=O YKIOKAURTKXMSB-UHFFFAOYSA-N 0.000 description 1
- 238000007259 addition reaction Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 description 1
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 description 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 1
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 description 1
- 125000001118 alkylidene group Chemical group 0.000 description 1
- 125000004419 alkynylene group Chemical group 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- BHELZAPQIKSEDF-UHFFFAOYSA-N allyl bromide Chemical compound BrCC=C BHELZAPQIKSEDF-UHFFFAOYSA-N 0.000 description 1
- 238000005937 allylation reaction Methods 0.000 description 1
- 150000004716 alpha keto acids Chemical class 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 230000000879 anti-atherosclerotic effect Effects 0.000 description 1
- 230000001837 anti-cortisol effect Effects 0.000 description 1
- 230000001708 anti-dyslipidemic effect Effects 0.000 description 1
- 230000001346 anti-hypertriglyceridemic effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000002253 anti-ischaemic effect Effects 0.000 description 1
- 230000003063 anti-neuropathic effect Effects 0.000 description 1
- 239000000883 anti-obesity agent Substances 0.000 description 1
- 230000002946 anti-pancreatic effect Effects 0.000 description 1
- 230000002769 anti-restenotic effect Effects 0.000 description 1
- 239000003529 anticholesteremic agent Substances 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 229940125710 antiobesity agent Drugs 0.000 description 1
- 239000002830 appetite depressant Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000012300 argon atmosphere Substances 0.000 description 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 1
- 125000001691 aryl alkyl amino group Chemical group 0.000 description 1
- 125000005100 aryl amino carbonyl group Chemical group 0.000 description 1
- 125000001769 aryl amino group Chemical group 0.000 description 1
- 125000005129 aryl carbonyl group Chemical group 0.000 description 1
- 125000005199 aryl carbonyloxy group Chemical group 0.000 description 1
- 150000001502 aryl halides Chemical class 0.000 description 1
- 125000005135 aryl sulfinyl group Chemical group 0.000 description 1
- 125000004657 aryl sulfonyl amino group Chemical group 0.000 description 1
- 125000005164 aryl thioalkyl group Chemical group 0.000 description 1
- 125000005325 aryloxy aryl group Chemical group 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- GMWFCJXSQQHBPI-UHFFFAOYSA-N azetidin-3-ol Chemical compound OC1CNC1 GMWFCJXSQQHBPI-UHFFFAOYSA-N 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- IAWYWVVBKGWUEP-UHFFFAOYSA-N benzyl phenylmethoxycarbonyloxy carbonate Chemical compound C=1C=CC=CC=1COC(=O)OOC(=O)OCC1=CC=CC=C1 IAWYWVVBKGWUEP-UHFFFAOYSA-N 0.000 description 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 description 1
- 150000001602 bicycloalkyls Chemical group 0.000 description 1
- 239000012867 bioactive agent Substances 0.000 description 1
- BWBZTXSPTHTBBM-UHFFFAOYSA-L bis(3-methylimidazol-3-ium-1-yl)methanone;trifluoromethanesulfonate Chemical compound [O-]S(=O)(=O)C(F)(F)F.[O-]S(=O)(=O)C(F)(F)F.CN1C=C[N+](C(=O)[N+]2=CN(C)C=C2)=C1 BWBZTXSPTHTBBM-UHFFFAOYSA-L 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- KXZJHVJKXJLBKO-UHFFFAOYSA-N chembl1408157 Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=CC=1C1=CC=C(O)C=C1 KXZJHVJKXJLBKO-UHFFFAOYSA-N 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- LADPCMZCENPFGV-UHFFFAOYSA-N chloromethoxymethylbenzene Chemical compound ClCOCC1=CC=CC=C1 LADPCMZCENPFGV-UHFFFAOYSA-N 0.000 description 1
- 229960001761 chlorpropamide Drugs 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- DOBRDRYODQBAMW-UHFFFAOYSA-N copper(i) cyanide Chemical compound [Cu+].N#[C-] DOBRDRYODQBAMW-UHFFFAOYSA-N 0.000 description 1
- 125000005112 cycloalkylalkoxy group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 238000013481 data capture Methods 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000017858 demethylation Effects 0.000 description 1
- 238000010520 demethylation reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- FFHWGQQFANVOHV-UHFFFAOYSA-N dimethyldioxirane Chemical compound CC1(C)OO1 FFHWGQQFANVOHV-UHFFFAOYSA-N 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 229910001882 dioxygen Inorganic materials 0.000 description 1
- QLBHNVFOQLIYTH-UHFFFAOYSA-L dipotassium;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [K+].[K+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O QLBHNVFOQLIYTH-UHFFFAOYSA-L 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 238000010931 ester hydrolysis Methods 0.000 description 1
- UREBWPXBXRYXRJ-UHFFFAOYSA-N ethyl acetate;methanol Chemical compound OC.CCOC(C)=O UREBWPXBXRYXRJ-UHFFFAOYSA-N 0.000 description 1
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 1
- MFFXVVHUKRKXCI-UHFFFAOYSA-N ethyl iodoacetate Chemical compound CCOC(=O)CI MFFXVVHUKRKXCI-UHFFFAOYSA-N 0.000 description 1
- FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- WIGIZIANZCJQQY-RUCARUNLSA-N glimepiride Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)N[C@@H]2CC[C@@H](C)CC2)C=C1 WIGIZIANZCJQQY-RUCARUNLSA-N 0.000 description 1
- 230000009229 glucose formation Effects 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 125000004438 haloalkoxy group Chemical group 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000005114 heteroarylalkoxy group Chemical group 0.000 description 1
- 125000005368 heteroarylthio group Chemical group 0.000 description 1
- VHHHONWQHHHLTI-UHFFFAOYSA-N hexachloroethane Chemical compound ClC(Cl)(Cl)C(Cl)(Cl)Cl VHHHONWQHHHLTI-UHFFFAOYSA-N 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 239000011539 homogenization buffer Substances 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 102000056091 human HSD11B2 Human genes 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 230000000640 hydroxylating effect Effects 0.000 description 1
- UWYVPFMHMJIBHE-OWOJBTEDSA-N hydroxymaleic acid group Chemical group O/C(/C(=O)O)=C/C(=O)O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
- GRRNUXAQVGOGFE-NZSRVPFOSA-N hygromycin B Chemical compound O[C@@H]1[C@@H](NC)C[C@@H](N)[C@H](O)[C@H]1O[C@H]1[C@H]2O[C@@]3([C@@H]([C@@H](O)[C@@H](O)[C@@H](C(N)CO)O3)O)O[C@H]2[C@@H](O)[C@@H](CO)O1 GRRNUXAQVGOGFE-NZSRVPFOSA-N 0.000 description 1
- 229940097277 hygromycin b Drugs 0.000 description 1
- 230000003345 hyperglycaemic effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- BQNQIHYLDYHYQP-UHFFFAOYSA-M magnesium;1-chloro-3-methanidylbenzene;chloride Chemical compound [Mg+2].[Cl-].[CH2-]C1=CC=CC(Cl)=C1 BQNQIHYLDYHYQP-UHFFFAOYSA-M 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000006883 memory enhancing effect Effects 0.000 description 1
- 230000006371 metabolic abnormality Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 235000020938 metabolic status Nutrition 0.000 description 1
- HNQIVZYLYMDVSB-UHFFFAOYSA-N methanesulfonimidic acid Chemical compound CS(N)(=O)=O HNQIVZYLYMDVSB-UHFFFAOYSA-N 0.000 description 1
- HMDSVNJTEVZVSC-UHFFFAOYSA-N methyl 2-[9-(4-fluorophenyl)-3-hydroxy-9-bicyclo[3.3.1]nonanyl]acetate Chemical compound C1C(O)CC2CCCC1C2(CC(=O)OC)C1=CC=C(F)C=C1 HMDSVNJTEVZVSC-UHFFFAOYSA-N 0.000 description 1
- 125000005911 methyl carbonate group Chemical class 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 230000003228 microsomal effect Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 229910052750 molybdenum Inorganic materials 0.000 description 1
- 239000011733 molybdenum Substances 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- MKKQZYCNTBOGTL-UHFFFAOYSA-N n'-acetyl-1-benzhydrylazetidine-3-carbohydrazide Chemical compound C1C(C(=O)NNC(=O)C)CN1C(C=1C=CC=CC=1)C1=CC=CC=C1 MKKQZYCNTBOGTL-UHFFFAOYSA-N 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- IPLJNQFXJUCRNH-UHFFFAOYSA-L nickel(2+);dibromide Chemical compound [Ni+2].[Br-].[Br-] IPLJNQFXJUCRNH-UHFFFAOYSA-L 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- YCWSUKQGVSGXJO-NTUHNPAUSA-N nifuroxazide Chemical group C1=CC(O)=CC=C1C(=O)N\N=C\C1=CC=C([N+]([O-])=O)O1 YCWSUKQGVSGXJO-NTUHNPAUSA-N 0.000 description 1
- 238000010641 nitrile hydrolysis reaction Methods 0.000 description 1
- 150000002826 nitrites Chemical class 0.000 description 1
- 235000020925 non fasting Nutrition 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 125000002524 organometallic group Chemical group 0.000 description 1
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 125000004043 oxo group Chemical group O=* 0.000 description 1
- MUMZUERVLWJKNR-UHFFFAOYSA-N oxoplatinum Chemical compound [Pt]=O MUMZUERVLWJKNR-UHFFFAOYSA-N 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 238000005949 ozonolysis reaction Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- LUYQYZLEHLTPBH-UHFFFAOYSA-N perfluorobutanesulfonyl fluoride Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)S(F)(=O)=O LUYQYZLEHLTPBH-UHFFFAOYSA-N 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- XYFCBTPGUUZFHI-UHFFFAOYSA-O phosphonium Chemical compound [PH4+] XYFCBTPGUUZFHI-UHFFFAOYSA-O 0.000 description 1
- FAIAAWCVCHQXDN-UHFFFAOYSA-N phosphorus trichloride Chemical compound ClP(Cl)Cl FAIAAWCVCHQXDN-UHFFFAOYSA-N 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229960005235 piperonyl butoxide Drugs 0.000 description 1
- 125000004591 piperonyl group Chemical group C(C1=CC=2OCOC2C=C1)* 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 125000005547 pivalate group Chemical group 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229910003446 platinum oxide Inorganic materials 0.000 description 1
- 238000013105 post hoc analysis Methods 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- OVARTBFNCCXQKS-UHFFFAOYSA-N propan-2-one;hydrate Chemical compound O.CC(C)=O OVARTBFNCCXQKS-UHFFFAOYSA-N 0.000 description 1
- VVWRJUBEIPHGQF-MDZDMXLPSA-N propan-2-yl (ne)-n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)\N=N\C(=O)OC(C)C VVWRJUBEIPHGQF-MDZDMXLPSA-N 0.000 description 1
- VVWRJUBEIPHGQF-UHFFFAOYSA-N propan-2-yl n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)N=NC(=O)OC(C)C VVWRJUBEIPHGQF-UHFFFAOYSA-N 0.000 description 1
- NWELCUKYUCBVKK-UHFFFAOYSA-N pyridin-2-ylhydrazine Chemical compound NNC1=CC=CC=N1 NWELCUKYUCBVKK-UHFFFAOYSA-N 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 125000006413 ring segment Chemical group 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- UKLNMMHNWFDKNT-UHFFFAOYSA-M sodium chlorite Chemical compound [Na+].[O-]Cl=O UKLNMMHNWFDKNT-UHFFFAOYSA-M 0.000 description 1
- 229960002218 sodium chlorite Drugs 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 150000003413 spiro compounds Chemical class 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 150000003461 sulfonyl halides Chemical class 0.000 description 1
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- YNNZWLQTTLFNGO-UHFFFAOYSA-N tert-butyl 3-(2h-tetrazol-5-yl)azetidine-1-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CC1C1=NNN=N1 YNNZWLQTTLFNGO-UHFFFAOYSA-N 0.000 description 1
- ISVRTCNCGHGOIB-UHFFFAOYSA-N tert-butyl 3-[(5-methyl-1,3,4-oxadiazol-2-yl)methoxy]azetidine-1-carboxylate Chemical compound O1C(C)=NN=C1COC1CN(C(=O)OC(C)(C)C)C1 ISVRTCNCGHGOIB-UHFFFAOYSA-N 0.000 description 1
- WEFREESWPHICPL-UHFFFAOYSA-N tert-butyl 3-cyanoazetidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CC(C#N)C1 WEFREESWPHICPL-UHFFFAOYSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000004001 thioalkyl group Chemical group 0.000 description 1
- XJDNKRIXUMDJCW-UHFFFAOYSA-J titanium tetrachloride Chemical compound Cl[Ti](Cl)(Cl)Cl XJDNKRIXUMDJCW-UHFFFAOYSA-J 0.000 description 1
- 229960002277 tolazamide Drugs 0.000 description 1
- OUDSBRTVNLOZBN-UHFFFAOYSA-N tolazamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1CCCCCC1 OUDSBRTVNLOZBN-UHFFFAOYSA-N 0.000 description 1
- 229960005371 tolbutamide Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- DBGVGMSCBYYSLD-UHFFFAOYSA-N tributylstannane Chemical compound CCCC[SnH](CCCC)CCCC DBGVGMSCBYYSLD-UHFFFAOYSA-N 0.000 description 1
- GGUBFICZYGKNTD-UHFFFAOYSA-N triethyl phosphonoacetate Chemical compound CCOC(=O)CP(=O)(OCC)OCC GGUBFICZYGKNTD-UHFFFAOYSA-N 0.000 description 1
- RXJKFRMDXUJTEX-UHFFFAOYSA-N triethylphosphine Chemical compound CCP(CC)CC RXJKFRMDXUJTEX-UHFFFAOYSA-N 0.000 description 1
- YOIAWAIKYVEKMF-UHFFFAOYSA-N trifluoromethanesulfonic acid Chemical compound OS(=O)(=O)C(F)(F)F.OS(=O)(=O)C(F)(F)F YOIAWAIKYVEKMF-UHFFFAOYSA-N 0.000 description 1
- 125000001889 triflyl group Chemical group FC(F)(F)S(*)(=O)=O 0.000 description 1
- 125000004385 trihaloalkyl group Chemical group 0.000 description 1
- XPEMYYBBHOILIJ-UHFFFAOYSA-N trimethyl(trimethylsilylperoxy)silane Chemical compound C[Si](C)(C)OO[Si](C)(C)C XPEMYYBBHOILIJ-UHFFFAOYSA-N 0.000 description 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 125000002948 undecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000005500 uronium group Chemical group 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
- VWQVUPCCIRVNHF-UHFFFAOYSA-N yttrium atom Chemical compound [Y] VWQVUPCCIRVNHF-UHFFFAOYSA-N 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- GTLDTDOJJJZVBW-UHFFFAOYSA-N zinc cyanide Chemical compound [Zn+2].N#[C-].N#[C-] GTLDTDOJJJZVBW-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/52—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen
- C07C57/62—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen containing six-membered aromatic rings and other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C61/00—Compounds having carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C61/16—Unsaturated compounds
- C07C61/28—Unsaturated compounds polycyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C255/57—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and carboxyl groups, other than cyano groups, bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
- C07C311/51—Y being a hydrogen or a carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/46—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings and other rings, e.g. cyclohexylphenylacetic acid
- C07C57/50—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings and other rings, e.g. cyclohexylphenylacetic acid containing condensed ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
- C07C59/54—Unsaturated compounds containing hydroxy or O-metal groups containing six-membered aromatic rings and other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
- C07C59/56—Unsaturated compounds containing hydroxy or O-metal groups containing halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
- C07C59/72—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings and other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/76—Unsaturated compounds containing keto groups
- C07C59/88—Unsaturated compounds containing keto groups containing halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C61/00—Compounds having carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C61/16—Unsaturated compounds
- C07C61/39—Unsaturated compounds containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C61/00—Compounds having carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C61/16—Unsaturated compounds
- C07C61/40—Unsaturated compounds containing halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C62/00—Compounds having carboxyl groups bound to carbon atoms of rings other than six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C62/08—Saturated compounds containing ether groups, groups, groups, or groups
- C07C62/12—Saturated compounds containing ether groups, groups, groups, or groups polycyclic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C62/00—Compounds having carboxyl groups bound to carbon atoms of rings other than six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C62/30—Unsaturated compounds
- C07C62/38—Unsaturated compounds containing keto groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D203/00—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom
- C07D203/04—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D203/06—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D203/16—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with acylated ring nitrogen atoms
- C07D203/18—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with acylated ring nitrogen atoms by carboxylic acids, or by sulfur or nitrogen analogues thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/12—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/14—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/42—Oxygen atoms attached in position 3 or 5
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/40—Acylated substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
- C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/04—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/04—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/44—Acylated amino or imino radicals
- C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D277/82—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
- C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
- C07D285/135—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
- C07D295/205—Radicals derived from carbonic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/36—Systems containing two condensed rings the rings having more than two atoms in common
- C07C2602/46—Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing nine carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/56—Ring systems containing bridged rings
- C07C2603/58—Ring systems containing bridged rings containing three rings
- C07C2603/60—Ring systems containing bridged rings containing three rings containing at least one ring with less than six members
- C07C2603/66—Ring systems containing bridged rings containing three rings containing at least one ring with less than six members containing five-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/56—Ring systems containing bridged rings
- C07C2603/58—Ring systems containing bridged rings containing three rings
- C07C2603/70—Ring systems containing bridged rings containing three rings containing only six-membered rings
- C07C2603/74—Adamantanes
Definitions
- the steroid hormone cortisol is a key regulator of many physiological processes.
- an excess of cortisol as occurs in Cushing's Disease, provokes severe metabolic abnormalities including: type 2 diabetes, cardiovascular disease, obesity, and osteoporosis.
- Many patients with these diseases do not show significant increases in plasma cortisol levels.
- individual tissues can regulate their glucocorticoid tone via the in situ conversion of inactive cortisone to the active hormone cortisol.
- the normally high plasma concentration of cortisone provides a ready supply of precursor for conversion to cortisol via the intracellular enzyme 11-beta-hydroxysteroid dehydrogenase type I (11beta-HSD1).
- 11beta-HSD1 is a member of the short chain dehydrogenase superfamily of enzymes. By catalyzing the conversion of cortisone to cortisol, 11beta-HSD1 controls the intracellular glucocorticoid tone according to its expression and activity levels. In this manner, 11beta-HSD1 can determine the overall metabolic status of the organ. 11beta-HSD1 is expressed at high levels in the liver and at lower levels in many metabolically active tissues including the adipose, the CNS, the pancreas, and the pituitary. Taking the example of the liver, it is predicted that high levels of 11beta-HSD1 activity will stimulate gluconeogenesis and overall glucose output. Conversely, reduction of 11beta-HSD1 activity will downregulate gluconeogenesis resulting in lower plasma glucose levels.
- mice expressing 2 ⁇ the normal level of 11beta-HSD1 in only the adipose tissue show abdominal obesity, hyperglycemia, and insulin resistance.
- 11beta-HSD1 gene is ablated by homologous recombination, the resulting mice are resistant to diet induced obesity and the accompanying dysregulation of glucose metabolism (N. M.
- 11beta-HSD1 has been shown to be effective in treating metabolic syndrome and atherosclerosis in high fat fed mice (Hermanowski-Vosatka et al., J. Exp. Med., 202(4):517-527 (2002)). Based in part on these studies, it is believed that local control of cortisol levels is important in metabolic diseases in these model systems. In addition, the results of these studies also suggest that inhibition of 11beta-HSD1 will be a viable strategy for treating metabolic diseases such as type 2 diabetes, obesity, and the metabolic syndrome.
- the compounds of the present invention inhibit the activity of the enzyme 11-beta-hydroxysteroid dehydrogenase type I. Consequently, the compounds of the present invention may be used in the treatment of multiple diseases or disorders associated with 11-beta-hydroxysteroid dehydrogenase type I, such as diabetes and related conditions, microvascular complications associated with diabetes, the macrovascular complications associated with diabetes, cardiovascular diseases, Metabolic Syndrome and its component conditions, inflammatory diseases and other maladies.
- diseases or disorders associated with 11-beta-hydroxysteroid dehydrogenase type I such as diabetes and related conditions, microvascular complications associated with diabetes, the macrovascular complications associated with diabetes, cardiovascular diseases, Metabolic Syndrome and its component conditions, inflammatory diseases and other maladies.
- diseases or disorders associated with the activity of the enzyme 11-beta-hydroxysteroid dehydrogenase type I that can be prevented, inhibited, or treated according to the present invention include, but are not limited to, diabetes, hyperglycemia, impaired glucose tolerance, insulin resistance, hyperinsulinemia, retinopathy, neuropathy, nephropathy, delayed wound healing, atherosclerosis and its sequelae (acute coronary syndrome, myocardial infarction, angina pectoris, peripheral vascular disease, intermitant claudication), abnormal heart function, myocardial ischemia, stroke, Metabolic Syndrome, hypertension, obesity, dislipidemia, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, low HDL, high LDL, non-cardiac ischemia, infection, cancer, vascular restenosis, pancreatitis, neurodegenerative disease, lipid disorders, cognitive impairment and dementia, bone disease, HIV protease associated lipodystrophy, glaucoma and inflammatory diseases, such as,
- the present invention provides for compounds of formula I, pharmaceutical compositions employing such compounds, and for methods of using such compounds.
- the present invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of formula I, alone or in combination with a pharmaceutically acceptable carrier.
- a method for preventing, inhibiting, or treating the progression or onset of diseases or disorders associated with the activity of the enzyme 11-beta-hydroxysteroid dehydrogenase type I, such as defined above and hereinafter, wherein a therapeutically effective amount of a compound of formula I is administered to a mammalian, i.e., human, patient in need of treatment.
- the compounds of the invention can be used alone, in combination with other compounds of the present invention, or in combination with one or more other agent(s).
- the present invention provides a method for preventing, inhibiting, or treating the diseases as defined above and hereinafter, wherein a therapeutically effective amount of a combination of a compound of formula I and another compound of formula I and/or at least one other type of therapeutic agent, is administered to a mammalian, i.e., human, patient in need of treatment.
- A is a 5- to 20-membered non-aromatic bi-, tri- or polycyclic ring system optionally containing 1-3 heteroatoms selected from N, O, S, S(O) and S(O) 2 , which may be optionally substituted with one or more R 4 's;
- X is —C( ⁇ O)OH, —C( ⁇ O)C( ⁇ O)OH, —C( ⁇ O)NR 9 R 9 , tetrazolyl, or —C( ⁇ O)NHS(O) 2 R 9 ;
- W is absent, (—CR 8a R 8b —) m , (—CR 8a R 8b —) m —O—, (—CR 8a R 8b —) m —N(R 14 )—, C 3-6 cycloalkyl, alkenyl or alkynyl, wherein the cycloalkyl or alkenyl may be optionally substituted with one or more R 8a 's;
- n 1-3;
- Z is —CN, C 3-10 alkyl, cycloalkyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl, all of which may be optionally substituted with one or more R 4 's, and the heterocyclyl and heterocyclylalkyl contain 1-4 heteroatoms selected from N, O, and S;
- R 4 is independently selected from hydrogen, alkyl, aryl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, halo, ⁇ O, —NH 2 , —CN, —NO 2 , —C( ⁇ O)OH, —C( ⁇ O)OR 10 , —OR 10 , —OH, —OCF 3 , —SH, —SR 10 , —C( ⁇ O)NR 9 R 9 , —NR 9 R 9 , —S(O) 2 NR 9 R 9 , —NR 9 S(O) 2 CF 3 , —C( ⁇ O)NR 9 S(O) 2 R 9 , —S(O) 2 NR 9 C( ⁇ O)OR 9 , —S(O) 2 NR 9 C( ⁇ O)NR 9 R 9 , —C( ⁇ O)NR 9 S(O) 2 CF 3 , —C( ⁇ O)R 10 , —S(O) 2
- R 5 is independently selected from hydrogen, alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, halo, —NH 2 , —CN, —NO 2 , —C( ⁇ O)OH, —C( ⁇ O)OR 10 , —OCF 3 , —OR 10 , —OH, —SH, —SR 10 , —C( ⁇ O)NR 9 R 9 , —NR 9 R 9 , —S(O) 2 NR 9 R 9 , —NR 9 S(O) 2 CF 3 , —C( ⁇ O)NR 9 S(O) 2 R 9 , —S(O) 2 NR 9 C( ⁇ O)OR 9 , —S(O) 2 NR 9 C( ⁇ O)OR 9 , —S(O) 2 NR 9 C( ⁇ O)NR 9 R
- R 8 at each occurrence, is independently alkyl, aryl or heterocyclyl
- R 8a at each occurrence, is independently hydrogen, alkyl or aryl
- R 8b at each occurrence, is independently hydrogen, —C( ⁇ O)OH, alkyl, —OH, halo, —CN, —OR 10 , —C( ⁇ O)R 10 or —C( ⁇ O)NR 9 R 9 , wherein the alkyl may be optionally substituted with one or more R 9a 's; or
- R 8a and R 8b are taken together with the carbon to which both are attached to form a 3- to 7-membered ring, which may optionally contain 1-4 heteroatoms selected from N, O, and S and be optionally substituted with 0-3 R 9a ;
- R 9 is independently hydrogen, alkyl, alkoxy, cycloalkyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl, wherein the alkyl, cycloalkyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl may be optionally substituted with 0-5 R 9a , and the heterocyclyl or heterocyclylalkyl contain 1-4 heteroatoms selected from N, O, and S; or
- R 9 's together with the nitrogen to which they are attached form a unsaturated, saturated or partially saturated cyclic ring system containing from 2-10 carbon atoms and from 0-4 additional heteroatoms selected from N, O, S, S(O) and S(O) 2 , wherein said ring system may be optionally substituted or fused with one or more R 9a 's;
- R 9a is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, halo, ⁇ O, —NH 2 , —CN, —NO 2 , —C( ⁇ O)OH, —C( ⁇ O)OR 14 , —OCF 3 , —OR 10 , —OH, —OCF 3 , —SH, —SR 14 ,
- R 10 is independently selected from alkyl, cycloalkyl, alkenyl, alkynyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl, wherein the alkyl, cycloalkyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl may be optionally substituted with 0-3 R 10a , and the heterocyclyl and heterocyclylalkyl contain 1-4 heteroatoms selected from N, O, and S;
- R 10a is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, halo, —NH 2 , —CN, —NO 2 , —C( ⁇ O)OH, —C( ⁇ O)OR 14 , —OCF 3 , —OR 14 , —OH, —SH, —SR 14 , —C( ⁇ O)NR 14 R 14 , —NR 14 R 14 , —S(O) 2 NR 14 R 14 , —NR 14 S(O) 2 CF 3 , —C( ⁇ O)NR 14 S(O) 2 R 14 , —S(O) 2 NR 14 C( ⁇ O)OR 14 , —S(O) 2 NR 14 C( ⁇ O)NR 14 R 14 , —C( ⁇ O)NR 14 S(S(O) 2 R
- R 14 is independently selected from hydrogen, alkyl, cycloalkyl, aryl or arylalkyl, wherein the alkyl, cycloalkyl, aryl or arylalkyl may be optionally substituted with 0-3 R 14a ;
- R 14a is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, halo, —NH 2 , —CN, —NO 2 , —C( ⁇ O)OH, —C( ⁇ O)OR 15 , —OCF 3 , —OR 15 , —OH, —SH, —SR 15 , —C( ⁇ O)NR 15 R 15 , —NR 15 R 15 , —S(O) 2 NR 15 R 15 , —NR 15 S(O) 2 CF 3 , —C( ⁇ O)NR 15 S(O) 2 R 15 , —S(O) 2 NR 15 C( ⁇ O)OR 15 , —S(O) 2 NR 15 C( ⁇ O)NR 15 R 15 , —C( ⁇ O)NR 15 S(S(O) 2 R
- R 15 is independently selected from hydrogen, alkyl, cycloalkyl, aryl or arylalkyl;
- the compound is not a compound of the following structure:
- R is optionally substituted phenyl
- the compound is not a compound of the following structure:
- the compound is not a compound of the following structure:
- compounds of formula I are those in which A is a 5- to 20-membered non-aromatic bi-, tri- or polycyclic ring system optionally containing 1-3 heteroatoms selected from N, O, S, S(O) and S(O) 2 , which is substituted with at least one R 4 .
- compounds of formula I are those in which:
- A is a 6- to 15-membered non-aromatic bi-, tri- or polycyclic ring system optionally containing 1-3 heteroatoms selected from N, O, S, S(O) and S(O) 2 , which may be optionally substituted with one or more R 4 's;
- X is —C( ⁇ O)OH, —C( ⁇ O)C( ⁇ O)OH, —C( ⁇ O)NR 9 R 9 , or tetrazolyl;
- W is absent, (—CR 8a R 8b —) m , (—CR 8a R 8b —) m —O—, (—CR 8a R 8b —) m —N(R 14 )—, or alkenyl, wherein the alkenyl may be optionally substituted with one or more R 8a 's;
- n 1-3;
- Z is CN, C 3-10 alkyl, cycloalkyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl, all of which may be optionally substituted with one or more R 4 's, and the heterocyclyl and heterocyclylalkyl contain 1-4 heteroatoms selected from N, O, and S;
- R 4 is independently selected from hydrogen, alkyl, aryl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, halo, ⁇ O, —NH 2 , —CN, —NO 2 , —C( ⁇ O)OH, —C( ⁇ O)OR 10 , —OR 10 , —OH, —OCF 3 , —SH, —SR 10 , —C( ⁇ O)NR 9 R 9 , —NR 9 R 9 , —S(O) 2 NR 9 R 9 , —NR 9 S(O) 2 CF 3 , —C( ⁇ O)NR 9 S(O) 2 R 9 , —S(O) 2 NR 9 C( ⁇ O)OR 9 , —S(O) 2 NR 9 C( ⁇ O)NR 9 R 9 , —C( ⁇ O)NR 9 S(O) 2 CF 3 , —C( ⁇ O)R 10 , —S(O) 2
- R 5 is independently selected from hydrogen, alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, halo, —NH 2 , —CN, —NO 2 , —C( ⁇ O)OH, —C( ⁇ O)OR 10 , —OCF 3 , —OR 10 , —OH, —SH, —SR 10 , —C( ⁇ O)NR 9 R 9 , —NR 9 R 9 , —S(O) 2 NR 9 R 9 , —NR 9 S(O) 2 CF 3 , —C( ⁇ O)NR 9 S(O) 2 R 9 , —S(O) 2 NR 9 C( ⁇ O)OR 9 , —S(O) 2 NR 9 C( ⁇ O)OR 9 , —S(O) 2 NR 9 C( ⁇ O)NR 9 R
- R 8 at each occurrence, is independently alkyl, aryl or heterocyclyl
- R 8a at each occurrence, is independently hydrogen, alkyl or aryl
- R 8b at each occurrence, is independently hydrogen, —C( ⁇ O)OH, alkyl, —OH, halo, —CN, —OR 10 , —C( ⁇ O)R 10 or —C( ⁇ O)NR 9 R 9 , wherein the alkyl may be optionally substituted with one or more R 9a 's; or
- R 8a and R 8b are taken together with the carbon to which both are attached to form a 3- to 7-membered ring, which may optionally contain 1-4 heteroatoms selected from N, O, and S and be optionally substituted with 0-3 R 9a ;
- R 9 is independently hydrogen, alkyl, alkoxy, cycloalkyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl, wherein the alkyl, cycloalkyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl may be optionally substituted with 0-5 R 9a , and the heterocyclyl or heterocyclylalkyl contain 1-4 heteroatoms selected from N, O, and S; or
- R 9 's together with the nitrogen to which they are attached form a unsaturated, saturated or partially saturated cyclic ring system containing from 2-10 carbon atoms and from 0-4 additional heteroatoms selected from N, O, S, S(O) and S(O) 2 , wherein said ring system may be optionally substituted or fused with one or more R 9a 's;
- R 9a is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, halo, ⁇ O, —NH 2 , —CN, —NO 2 , —C( ⁇ O)OH, —C( ⁇ O)OR 14 , —OCF 3 , —OR 10 , —OH, —SH, —SR 14 , —C( ⁇ O)NR 14 R 14 , —NR 14 R 14 , —S(O) 2 NR 14 R 14 , —NR 14 S(O) 2 CF 3 , —C( ⁇ O)NR 14 S(O) 2 R 10 , —S(O) 2 NR 14 C( ⁇ O)OR 10 , —S(O) 2 NR 14 C( ⁇ O)NR 14 R 14 , —C( ⁇ O)
- R 10 is independently selected from alkyl, cycloalkyl, alkenyl, alkynyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl, wherein the alkyl, cycloalkyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl may be optionally substituted with 0-3 R 10a , and the heterocyclyl and heterocyclylalkyl contain 1-4 heteroatoms selected from N, O, and S;
- R 10a is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, halo, —NH 2 , —CN, —NO 2 , —C( ⁇ O)OH, —C( ⁇ O)OR 14 , —OCF 3 , —OR 14 , —OH, —SH, —SR 14 , —C( ⁇ O)NR 14 R 14 , —NR 14 R 14 , —S(O) 2 NR 14 R 14 , —NR 14 S(O) 2 CF 3 , —C( ⁇ O)NR 14 S(O) 2 R 14 , —S(O) 2 NR 14 C( ⁇ O)OR 14 , —S(O) 2 NR 14 C( ⁇ O)NR 14 R 14 , —C( ⁇ O)NR 14 S(S(O) 2 R
- R 14 is independently selected from hydrogen, alkyl, cycloalkyl, aryl or arylalkyl, wherein the alkyl, cycloalkyl, aryl or arylalkyl may be optionally substituted with 0-3 R 14a ;
- R 14a is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, halo, —NH 2 , —CN, —NO 2 , —C( ⁇ O)OH, —C( ⁇ O)OR 15 , —OCF 3 , —OR 15 , —OH, —SH, —SR 15 , —C( ⁇ O)NR 15 R 15 , —NR 15 R 15 , —S(O) 2 NR 15 R 15 , —NR 15 S(O) 2 CF 3 , —C( ⁇ O)NR 15 S(O) 2 R 15 , —S(O) 2 NR 15 C( ⁇ O)OR 15 , —S(O) 2 NR 15 C( ⁇ O)NR 15 R 15 , —C( ⁇ O)NR 15 S(S(O) 2 R
- R 15 is independently selected from hydrogen, alkyl, cycloalkyl, aryl or arylalkyl.
- compounds of formula I are those in which:
- A is a 7- to 14-membered non-aromatic bi-, tri- or polycyclic ring system optionally containing 1-3 heteroatoms selected from N, O, S, S(O) and S(O) 2 , which may be optionally substituted with one or more R 4 's;
- X is —C( ⁇ O)OH, —C( ⁇ O)NR 9 R 9 , or tetrazolyl
- W is absent, (—CR 8a R 8b —) m , (—CR 8a R 8b —) m —O— or alkenyl, wherein the alkenyl may be optionally substituted with one or more R 8a 's;
- n 1-2;
- Z is CN, C 3-10 alkyl, cycloalkyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl, all of which may be optionally substituted with one or more R 4 's, and the heterocyclyl and heterocyclylalkyl contain 1-4 heteroatoms selected from N, O, and S;
- R 4 is independently selected from hydrogen, alkyl, aryl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, halo, ⁇ O, —NH 2 , —CN, —NO 2 , —C( ⁇ O)OH, —C( ⁇ O)OR 10 , —OR 10 , —OH, —OCF 3 , —SH, —SR 10 , —C( ⁇ O)NR 9 R 9 , —NR 9 R 9 , —S(O) 2 NR 9 R 9 , —NR 9 S(O) 2 CF 3 , —C( ⁇ O)NR 9 S(O) 2 R 9 , —S(O) 2 NR 9 C( ⁇ O)OR 9 , —S(O) 2 NR 9 C( ⁇ O)NR 9 R 9 , —C( ⁇ O)NR 9 S(O) 2 CF 3 , —C( ⁇ O)R 10 , —S(O) 2
- R 5 is independently selected from hydrogen, alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, halo, —NH 2 , —CN, —NO 2 , —C( ⁇ O)OH, —C( ⁇ O)OR 10 , —OCF 3 , —OR 10 , —OH, —SH, —SR 10 , —C( ⁇ O)NR 9 R 9 , —NR 9 R 9 , —S(O) 2 NR 9 R 9 , —NR 9 S(O) 2 CF 3 , —C( ⁇ O)NR 9 S(O) 2 R 9 , —S(O) 2 NR 9 C( ⁇ O)OR 9 , —S(O) 2 NR 9 C( ⁇ O)OR 9 , —S(O) 2 NR 9 C( ⁇ O)NR 9 R
- R 8 at each occurrence, is independently alkyl, aryl or heterocyclyl
- R 8a at each occurrence, is independently hydrogen, alkyl or aryl
- R 8b at each occurrence, is independently hydrogen, —C( ⁇ O)OH, alkyl, —OH, halo, —CN, —OR 10 , —C( ⁇ O)R 10 or —C( ⁇ O)NR 9 R 9 , wherein the alkyl may be optionally substituted with one or more R 9a 's; or
- R 8a and R 8b are taken together with the carbon to which both are attached to form a 3- to 7-membered ring, which may optionally contain 1-4 heteroatoms selected from N, O, and S and be optionally substituted with 0-3 R 9a ;
- R 9 is independently hydrogen, alkyl, alkoxy, cycloalkyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl, wherein the alkyl, cycloalkyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl may be optionally substituted with 0-5 R 9a , and the heterocyclyl or heterocyclylalkyl contain 1-4 heteroatoms selected from N, O, and S; or
- R 9 's together with the nitrogen to which they are attached form a unsaturated, saturated or partially saturated cyclic ring system containing from 2-10 carbon atoms and from 0-4 additional heteroatoms selected from N, O, S, S(O) and S(O) 2 , wherein said ring system may be optionally substituted or fused with one or more R 9a 's;
- R 9a is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, halo, ⁇ O, —NH 2 , —CN, —NO 2 , —C( ⁇ O)OH, —C( ⁇ O)OR 14 , —OCF 3 , —OR 10 , —OH, —SH, —SR 14 , —C( ⁇ O)NR 14 R 14 , —NR 14 R 14 , —S(O) 2 NR 14 R 14 , —NR 14 S(O) 2 CF 3 , —C( ⁇ O)NR 14 S(O) 2 R 10 , —S(O) 2 NR 14 C( ⁇ O)OR 10 , —S(O) 2 NR 14 C( ⁇ O)NR 14 R 14 , —C( ⁇ O)
- R 10 is independently selected from alkyl, cycloalkyl, alkenyl, alkynyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl, wherein the alkyl, cycloalkyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl may be optionally substituted with 0-3 R 10a , and the heterocyclyl and heterocyclylalkyl contain 1-4 heteroatoms selected from N, O, and S;
- R 10a is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, halo, —NH 2 , —CN, —NO 2 , —C( ⁇ O)OH, —C( ⁇ O)OR 14 , —OCF 3 , —OR 14 , —OH, —SH, —SR 14 , —C( ⁇ O)NR 14 R 14 , —NR 14 R 14 , —S(O) 2 NR 14 R 14 , —NR 14 S(O) 2 CF 3 , —C( ⁇ O)NR 14 S(O) 2 R 14 , —S(O) 2 NR 14 C( ⁇ O)OR 14 , —S(O) 2 NR 14 C( ⁇ O)NR 14 R 14 , —C( ⁇ O)NR 14 S(S(O) 2 R
- R 14 is independently selected from hydrogen, alkyl, cycloalkyl, aryl or arylalkyl, wherein the alkyl, cycloalkyl, aryl or arylalkyl may be optionally substituted with 0-3 R 14a ;
- R 14a is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, halo, —NH 2 , —CN, —NO 2 , —C( ⁇ O)OH, —C( ⁇ O)OR 15 , —OCF 3 , —OR 15 , —OH, —SH, —SR 15 , —C( ⁇ O)NR 15 R 15 , —NR 15 R 15 , —S(O) 2 NR 15 R 15 , —NR 15 S(O) 2 CF 3 , —C( ⁇ O)NR 15 S(O) 2 R 15 , —S(O) 2 NR 15 C( ⁇ O)OR 15 , —S(O) 2 NR 15 C( ⁇ O)NR 15 R 15 , —C( ⁇ O)NR 15 S(S(O) 2 R
- R 15 is independently selected from hydrogen, alkyl, cycloalkyl, aryl or arylalkyl.
- compounds of formula I are those in which:
- A is a 7- to 14-membered non-aromatic bi-, tri- or polycyclic ring system optionally containing 1-3 heteroatoms selected from N, O, S, S(O) and S(O) 2 , which may be optionally substituted with one or more R 4 's;
- X is —C( ⁇ O)OH, —C( ⁇ O)NR 9 R 9 , or tetrazolyl
- W is absent, (—CR 8a R 8b —) m , (—CR 8a R 8b ) m —O— or alkenyl, wherein the alkenyl may be optionally substituted with one or more R 8a 's;
- n 1-2;
- Z is cycloalkyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl, all of which may be optionally substituted with one or more R 4 's, and the heterocyclyl and heterocyclylalkyl contain 1-4 heteroatoms selected from N, O, and S;
- R 4 is independently selected from hydrogen, alkyl, aryl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, halo, ⁇ O, —NH 2 , —CN, —NO 2 , —C( ⁇ O)OH, —C( ⁇ O)OR 10 , —OR 10 , —OH, —OCF 3 , —SH, —SR 10 , —C( ⁇ O)NR 9 R 9 , —NR 9 R 9 , —S(O) 2 NR 9 R 9 , —NR 9 S(O) 2 CF 3 , —C( ⁇ O)NR 9 S(O) 2 R 9 , —S(O) 2 NR 9 C( ⁇ O)OR 9 , —S(O) 2 NR 9 C( ⁇ O)NR 9 R 9 , —C( ⁇ O)NR 9 S(O) 2 CF 3 , —C( ⁇ O)R 10 , —S(O) 2
- R 5 is independently selected from hydrogen, alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, halo, —NH 2 , —CN, —NO 2 , —C( ⁇ O)OH, —C( ⁇ O)OR 10 , —OCF 3 , —OR 10 , —OH, —SH, —SR 10 , —C( ⁇ O)NR 9 R 9 , —NR 9 R 9 , —S(O) 2 NR 9 R 9 , —NR 9 S(O) 2 CF 3 , —C( ⁇ O)NR 9 S(O) 2 R 9 , —S(O) 2 NR 9 C( ⁇ O)OR 9 , —S(O) 2 NR 9 C( ⁇ O)OR 9 , —S(O) 2 NR 9 C( ⁇ O)NR 9 R
- R 8 at each occurrence, is independently alkyl, aryl or heterocyclyl
- R 8a at each occurrence, is independently hydrogen, alkyl or aryl
- R 8b at each occurrence, is independently hydrogen, —C( ⁇ O)OH, alkyl, —OH, halo, —CN, —OR 10 , —C( ⁇ O)R 10 or —C( ⁇ O)NR 9 R 9 , wherein the alkyl may be optionally substituted with one or more R 9a 's; or
- R 8a and R 8b are taken together with the carbon to which both are attached to form a 3- to 7-membered ring, which may optionally contain 1-4 heteroatoms selected from N, O, and S and be optionally substituted with 0-3 R 9a ;
- R 9 is independently hydrogen, alkyl, alkoxy, cycloalkyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl, wherein the alkyl, cycloalkyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl may be optionally substituted with 0-5 R 9a , and the heterocyclyl or heterocyclylalkyl contain 1-4 heteroatoms selected from N, O, and S; or
- R 9 's together with the nitrogen to which they are attached form a unsaturated, saturated or partially saturated cyclic ring system containing from 2-10 carbon atoms and from 0-4 additional heteroatoms selected from N, O, S, S(O) and S(O) 2 , wherein said ring system may be optionally substituted or fused with one or more R 9a 's;
- R 9a is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, halo, ⁇ O, —NH 2 , —CN, —NO 2 , —C( ⁇ O)OH, —C( ⁇ O)OR 14 , —OCF 3 , —OR 10 , —OH, —SH, —SR 14 , —C( ⁇ O)NR 14 R 14 , —NR 14 R 14 , —S(O) 2 NR 14 R 14 , —NR 14 S(O) 2 CF 3 , —C( ⁇ O)NR 14 S(O) 2 R 10 , —S(O) 2 NR 14 C( ⁇ O)OR 10 , —S(O) 2 NR 14 C( ⁇ O)NR 14 R 14 , —C( ⁇ O)
- R 10 is independently selected from alkyl, cycloalkyl, alkenyl, alkynyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl, wherein the alkyl, cycloalkyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl may be optionally substituted with 0-3 R 10a , and the heterocyclyl and heterocyclylalkyl contain 1-4 heteroatoms selected from N, O, and S;
- R 10a is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, halo, —NH 2 , —CN, —NO 2 , —C( ⁇ O)OH, —C( ⁇ O)OR 14 , —OCF 3 , —OR 14 , —OH, —SH, —SR 14 , —C( ⁇ O)NR 14 R 14 , —NR 14 R 14 , —S(O) 2 NR 14 R 14 , —NR 14 S(O) 2 CF 3 , —C( ⁇ O)NR 14 S(O) 2 R 14 , —S(O) 2 NR 14 C( ⁇ O)OR 14 , —S(O) 2 NR 14 C( ⁇ O)NR 14 R 14 , —C( ⁇ O)NR 14 S(S(O) 2 R
- R 14 is independently selected from hydrogen, alkyl, cycloalkyl, aryl or arylalkyl, wherein the alkyl, cycloalkyl, aryl or arylalkyl may be optionally substituted with 0-3 R 14a ;
- R 14a is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, halo, —NH 2 , —CN, —NO 2 , —C( ⁇ O)OH, —C( ⁇ O)OR 15 , —OCF 3 , —OR 15 , —OH, —SH, —SR 15 , —C( ⁇ O)NR 15 R 15 , —NR 15 R 15 , —S(O) 2 NR 15 R 15 , —NR 15 S(O) 2 CF 3 , —C( ⁇ O)NR 15 S(O) 2 R 15 , —S(O) 2 NR 15 C( ⁇ O)OR 15 , —S(O) 2 NR 15 C( ⁇ O)NR 15 R 15 , —C( ⁇ O)NR 15 S(S(O) 2 R
- R 15 is independently selected from hydrogen, alkyl, cycloalkyl, aryl or arylalkyl.
- compounds of formula I are those in which:
- A is a 7- to 14-membered non-aromatic bi-, tri- or polycyclic ring system optionally containing 1-3 heteroatoms selected from N, O, S, S(O) and S(O) 2 , which may be optionally substituted with one or more R 4 's;
- X is —C( ⁇ O)OH, —C( ⁇ O)NR 9 R 9 , or tetrazolyl
- W is absent, (—CR 8a R 8b —) m , (—CR 8a R 8b ) m —O— or alkenyl, wherein the alkenyl may be optionally substituted with one or more R 8a 's;
- n 1-2;
- Z is aryl, arylalkyl, heterocyclyl or heterocyclylalkyl, all of which may be optionally substituted with one or more R 4 's, and the heterocyclyl and heterocyclylalkyl contain 1-4 heteroatoms selected from N, O, and S;
- R 4 is independently selected from hydrogen, alkyl, aryl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, halo, ⁇ O, —NH 2 , —CN, —NO 2 , —C( ⁇ O)OH, —C( ⁇ O)OR 10 , —OR 10 , —OH, —OCF 3 , —SH, —SR 10 , —C( ⁇ O)NR 9 R 9 , —NR 9 R 9 , —S(O) 2 NR 9 R 9 , —NR 9 S(O) 2 CF 3 , —C( ⁇ O)NR 9 S(O) 2 R 9 , —S(O) 2 NR 9 C( ⁇ O)OR 9 , —S(O) 2 NR 9 C( ⁇ O)NR 9 R 9 , —C( ⁇ O)NR 9 S(O) 2 CF 3 , —C( ⁇ O)R 10 , —S(O) 2
- R 5 is independently selected from hydrogen, alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, halo, —NH 2 , —CN, —NO 2 , —C( ⁇ O)OH, —C( ⁇ O)OR 10 , —OCF 3 , —OR 10 , —OH, —SH, —SR 10 , —C( ⁇ O)NR 9 R 9 , —NR 9 R 9 , —S(O) 2 NR 9 R 9 , —NR 9 S(O) 2 CF 3 , —C( ⁇ O)NR 9 S(O) 2 R 9 , —S(O) 2 NR 9 C( ⁇ O)OR 9 , —S(O) 2 NR 9 C( ⁇ O)OR 9 , —S(O) 2 NR 9 C( ⁇ O)NR 9 R
- R 8 at each occurrence, is independently alkyl, aryl or heterocyclyl
- R 8a at each occurrence, is independently hydrogen, alkyl or aryl
- R 8b at each occurrence, is independently hydrogen, —C( ⁇ O)OH, alkyl, —OH, halo, —CN, —OR 10 , —C( ⁇ O)R 10 or —C( ⁇ O)NR 9 R 9 , wherein the alkyl may be optionally substituted with one or more R 9a 's; or
- R 8a and R 8b are taken together with the carbon to which both are attached to form a 3- to 7-membered ring, which may optionally contain 1-4 heteroatoms selected from N, O, and S and be optionally substituted with 0-3 R 9a ;
- R 9 is independently hydrogen, alkyl, alkoxy, cycloalkyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl, wherein the alkyl, cycloalkyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl may be optionally substituted with 0-5 R 9a , and the heterocyclyl or heterocyclylalkyl contain 1-4 heteroatoms selected from N, O, and S; or
- R 9 's together with the nitrogen to which they are attached form a unsaturated, saturated or partially saturated cyclic ring system containing from 2-10 carbon atoms and from 0-4 additional heteroatoms selected from N, O, S, S(O) and S(O) 2 , wherein said ring system may be optionally substituted or fused with one or more R 9a 's;
- R 9a is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, halo, ⁇ O, —NH 2 , —CN, —NO 2 , —C( ⁇ O)OH, —C( ⁇ O)OR 14 , —OCF 3 , —OR 10 , —OH, —SH, —SR 14 , —C( ⁇ O)NR 14 R 14 , —NR 14 R 14 , —S(O) 2 NR 14 R 14 , —NR 14 S(O) 2 CF 3 , —C( ⁇ O)NR 14 S(O) 2 R 10 , —S(O) 2 NR 14 C( ⁇ O)OR 10 , —S(O) 2 NR 14 C( ⁇ O)NR 14 R 14 , —C( ⁇ O)
- R 10 is independently selected from alkyl, cycloalkyl, alkenyl, alkynyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl, wherein the alkyl, cycloalkyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl may be optionally substituted with 0-3 R 10a , and the heterocyclyl and heterocyclylalkyl contain 1-4 heteroatoms selected from N, O, and S;
- R 10a is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, halo, —NH 2 , —CN, —NO 2 , —C( ⁇ O)OH, —C( ⁇ O)OR 14 , —OCF 3 , —OR 14 , —OH, —SH, —SR 14 , —C( ⁇ O)NR 14 R 14 , —NR 14 R 14 , —S(O) 2 NR 14 R 14 , —NR 14 S(O) 2 CF 3 , —C( ⁇ O)NR 14 S(O) 2 R 14 , —S(O) 2 NR 14 C( ⁇ O)OR 14 , —S(O) 2 NR 14 C( ⁇ O)NR 14 R 14 , —C( ⁇ O)NR 14 S(S(O) 2 R
- R 14 is independently selected from hydrogen, alkyl, cycloalkyl, aryl or arylalkyl, wherein the alkyl, cycloalkyl, aryl or arylalkyl may be optionally substituted with 0-3 R 14a ;
- R 14a is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, halo, —NH 2 , —CN, —NO 2 , —C( ⁇ O)OH, —C( ⁇ O)OR 15 , —OCF 3 , —OR 15 , —OH, —SH, —SR 15 , —C( ⁇ O)NR 15 R 15 , —NR 15 R 15 , —S(O) 2 NR 15 R 15 , —NR 15 S(O) 2 CF 3 , —C( ⁇ O)NR 15 S(O) 2 R 15 , —S(O) 2 NR 15 C( ⁇ O)OR 15 , —S(O) 2 NR 15 C( ⁇ O)NR 15 R 15 , —C( ⁇ O)NR 15 S(S(O) 2 R
- R 15 is independently selected from hydrogen, alkyl, cycloalkyl, aryl or arylalkyl.
- compounds of formula I are those in which:
- A is a 7- to 14-membered non-aromatic bi-, tri- or polycyclic ring system optionally containing 1-3 heteroatoms selected from N, O, S, S(O) and S(O) 2 , which may be optionally substituted with one or more R 4 's;
- X is —C( ⁇ O)OH, —C( ⁇ O)NR 9 R 9 , or tetrazolyl
- W is absent, (—CR 8a R 8b —) m , —(CR 8a R 8b ) m —O— or alkenyl, wherein the alkenyl may be optionally substituted with one or more R 8a 's;
- n 1-2;
- Z is aryl, arylalkyl or heterocyclylalkyl, all of which may be optionally substituted with one or more R 4 's, and the heterocyclylalkyl contain 1-4 heteroatoms selected from N, O, and S;
- R 4 is independently selected from hydrogen, alkyl, aryl, alkenyl, cycloalkyl, heterocyclyl, halo, ⁇ O, —NH 2 , —CN, —NO 2 , —C( ⁇ O)OH, —C( ⁇ O)OR 10 , —OR 10 , —OH, —OCF 3 , —SH, —SR 10 , —C( ⁇ O)NR 9 R 9 , —NR 9 R 9 , —S(O) 2 NR 9 R 9 , —NR 9 S(O) 2 CF 3 , —C( ⁇ O)NR 9 S(O) 2 R 9 , —S(O) 2 NR 9 C( ⁇ O)OR 9 , —S(O) 2 NR 9 C( ⁇ O)NR 9 R 9 , —C( ⁇ O)NR 9 S(O) 2 CF 3 , —C( ⁇ O)R 10 , —NR 9 C( ⁇ O)R 10 ,
- R 5 is independently selected from hydrogen, alkyl, haloalkyl, aryl, alkenyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, halo, —NH 2 , —CN, —NO 2 , —C( ⁇ O)OH, —C( ⁇ O)OR 10 , —OCF 3 , —OR 10 , —OH, —SH, —SR 10 , —C( ⁇ O)NR 9 R 9 , —NR 9 R 9 , —S(O) 2 NR 9 R 9 , —NR 9 S(O) 2 CF 3 , —C( ⁇ O)NR 9 S(O) 2 R 9 , —S(O) 2 NR 9 C( ⁇ O)OR 9 , —S(O) 2 NR 9 C( ⁇ O)NR 9 R 9 , —C( ⁇ O)NR 9 S(O) 2 CF
- R 8 at each occurrence, is independently alkyl, aryl or heterocyclyl
- R 8a at each occurrence, is independently hydrogen, alkyl or aryl
- R 8b at each occurrence, is independently hydrogen, —C( ⁇ O)OH, alkyl, —OH, halo, —CN, —OR 10 , —C( ⁇ O)R 10 or —C( ⁇ O)NR 9 R 9 , wherein the alkyl may be optionally substituted with one or more R 9a 's; or
- R 8a and R 8b are taken together with the carbon to which both are attached to form a 3- to 7-membered ring, which may optionally contain 1-4 heteroatoms selected from N, O, and S and be optionally substituted with 0-3 R 9a ;
- R 9 is independently hydrogen, alkyl, alkoxy, cycloalkyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl, wherein the alkyl, cycloalkyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl may be optionally substituted with 0-5 R 9a , and the heterocyclyl or heterocyclylalkyl contain 1-4 heteroatoms selected from N, O, and S; or
- R 9 's together with the nitrogen to which they are attached form a unsaturated, saturated or partially saturated cyclic ring system containing from 2-10 carbon atoms and from 0-4 additional heteroatoms selected from N, O, S, S(O) and S(O) 2 , wherein said ring system may be optionally substituted or fused with one or more R 9a 's;
- R 9a is independently selected from alkyl, haloalkyl, aryl, alkenyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, halo, ⁇ O, —NH 2 , —CN, —NO 2 , —C( ⁇ O)OH, —C( ⁇ O)OR 14 , —OCF 3 , —OR 10 , —OH, —SH, —SR 14 , —C( ⁇ O)NR 14 R 14 , —NR 14 R 14 , —S(O) 2 NR 14 R 14 , —NR 14 S(O) 2 CF 3 , —C( ⁇ O)NR 14 S(O) 2 R 10 , —S(O) 2 NR 14 C( ⁇ O)OR 10 , —S(O) 2 NR 14 C( ⁇ O)NR 14 R 14 , —C( ⁇ O)NR 14 S(O)S(O) 2 R
- R 10 is independently selected from alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl, wherein the alkyl, cycloalkyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl may be optionally substituted with 0-3 R 10a , and the heterocyclyl and heterocyclylalkyl contain 1-4 heteroatoms selected from N, O, and S;
- R 10a is independently selected from alkyl, haloalkyl, aryl, alkenyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, halo, —NH 2 , —CN, —NO 2 , —C( ⁇ O)OH, —C( ⁇ O)OR 14 , —OCF 3 , —OR 14 , —OH, —SH, —SR 14 , —C( ⁇ O)NR 14 R 14 , —NR 14 R 14 , —S(O) 2 NR 14 R 14 , —NR 14 S(O) 2 CF 3 , —C( ⁇ O)NR 14 S(O) 2 R 14 , —S(O) 2 NR 14 C( ⁇ O)OR 14 , —S(O) 2 NR 14 C( ⁇ O)NR 14 R 14 , —C( ⁇ O)NR 14 S(O) 2 CF 3
- R 14 is independently selected from hydrogen, alkyl, cycloalkyl, aryl or arylalkyl, wherein the alkyl, cycloalkyl, aryl or arylalkyl may be optionally substituted with 0-3 R 14a ;
- R 14a is independently selected from alkyl, haloalkyl, aryl, alkenyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, halo, —NH 2 , —CN, —NO 2 , —C( ⁇ O)OH, —C( ⁇ O)OR 15 , —OCF 3 , —OR 15 , —OH, —SH, —SR 15 , —C( ⁇ O)NR 15 R 15 , —NR 15 R 15 , —S(O) 2 NR 15 R 15 , —NR 15 S(O) 2 CF 3 , —C( ⁇ O)NR 15 S(O) 2 R 15 , —S(O) 2 NR 15 C( ⁇ O)OR 15 , —S(O) 2 NR 15 C( ⁇ O)NR 15 R 15 , —C( ⁇ O)NR 15 S(O) 2 CF 3
- R 15 is independently selected from hydrogen, alkyl, cycloalkyl, aryl or arylalkyl.
- compounds of formula I are those in which:
- A is a 7- to 14-membered non-aromatic bi-, tri- or polycyclic ring system optionally containing 1-3 heteroatoms selected from N, O, S, S(O) and S(O) 2 , which may be optionally substituted with one or more R 4 's;
- X is —C( ⁇ O)OH, or —C( ⁇ O)NR 9 R 9 ;
- W is absent, (—CR 8a R 8b —) m , (—CR 8a R 8b ) m —O— or alkenyl, wherein the alkenyl may be optionally substituted with one or more R 8a 's;
- n 1-2;
- Z is aryl, arylalkyl or heterocyclylalkyl, all of which may be optionally substituted with one or more R 4 's, and the heterocyclylalkyl contain 1-4 heteroatoms selected from N, O, and S;
- R 4 is independently selected from hydrogen, alkyl, aryl, cycloalkyl, heterocyclyl, halo, ⁇ O, —NH 2 , —CN, —NO 2 , —C( ⁇ O)OH, —C( ⁇ O)OR 10 , —OR 10 , —OH, —OCF 3 , —SH, —SR 10 , —C( ⁇ O)NR 9 R 9 , —NR 9 R 9 , —S(O) 2 NR 9 R 9 , —NR 9 S(O) 2 CF 3 , —C( ⁇ O)NR 9 S(O) 2 R 9 , —S(O) 2 NR 9 C( ⁇ O)OR 9 , —S(O) 2 NR 9 C( ⁇ O)NR 9 R 9 , —C( ⁇ O)NR 9 S(O) 2 CF 3 , —C( ⁇ O)R 10 , —NR 9 C( ⁇ O)R 10 , —NR 9 C
- R 5 is independently selected from hydrogen, alkyl, haloalkyl, aryl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, halo, —NH 2 , —CN, —NO 2 , —C( ⁇ O)OH, —C( ⁇ O)OR 10 , —OCF 3 , —OR 10 , —OH, —SH, —SR 10 , —C( ⁇ O)NR 9 R 9 , —NR 9 R 9 , —S(O) 2 NR 9 R 9 , —NR 9 S(O) 2 CF 3 , —C( ⁇ O)NR 9 S(O) 2 R 9 , —S(O) 2 NR 9 C( ⁇ O)OR 9 , —S(O) 2 NR 9 C( ⁇ O)NR 9 R 9 , —C( ⁇ O)NR 9 S(O) 2 CF 3 , —S(O) 2
- R 8 at each occurrence, is independently alkyl, aryl or heterocyclyl
- R 8a at each occurrence, is independently hydrogen, alkyl or aryl
- R 8b at each occurrence, is independently hydrogen, —C( ⁇ O)OH, alkyl, —OH, halo, —CN, —OR 10 , —C( ⁇ O)R 10 or —C( ⁇ O)NR 9 R 9 , wherein the alkyl may be optionally substituted with one or more R 9a 's; or
- R 8a and R 8b are taken together with the carbon to which both are attached to form a 3- to 7-membered ring, which may optionally contain 1-4 heteroatoms selected from N, O, and S and be optionally substituted with 0-3 R 9a ;
- R 9 is independently hydrogen, alkyl, alkoxy, cycloalkyl, aryl, arylalkyl, or heterocyclyl, wherein the alkyl, cycloalkyl, aryl, arylalkyl or heterocyclyl may be optionally substituted with 0-5 R 9a , and the heterocyclyl contains 1-4 heteroatoms selected from N, O, and S; or
- R 9 's together with the nitrogen to which they are attached form a unsaturated, saturated or partially saturated cyclic ring system containing from 2-10 carbon atoms and from 0-4 additional heteroatoms selected from N, O, S, S(O) and S(O) 2 , wherein said ring system may be optionally substituted or fused with one or more R 9a 's;
- R 9a is independently selected from alkyl, haloalkyl, aryl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, halo, ⁇ O, —NH 2 , —CN, —NO 2 , —C( ⁇ O)OH, —C( ⁇ O)OR 14 , —OCF 3 , —OR 10 , —OH, —SH, —SR 14 , —C( ⁇ O)NR 14 R 14 , —NR 14 R 14 , —S(O) 2 NR 14 R 14 , —NR 14 S(O) 2 CF 3 , —C( ⁇ O)NR 14 S(O) 2 R 10 , —S(O) 2 NR 14 C( ⁇ O)OR 10 , —S(O) 2 NR 14 C( ⁇ O)NR 14 R 14 , —C( ⁇ O)NR 14 S(O) 2 R 14 ,
- R 10 is independently selected from alkyl, cycloalkyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl, wherein the alkyl, cycloalkyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl may be optionally substituted with 0-3 R 10a , and the heterocyclyl and heterocyclylalkyl contain 1-4 heteroatoms selected from N, O, and S;
- R 10a is independently selected from alkyl, haloalkyl, aryl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, halo, —NH 2 , —CN, —NO 2 , —C( ⁇ O)OH, —C( ⁇ O)OR 14 , —OCF 3 , —OR 14 , —OH, —SH, —SR 14 , —C( ⁇ O)NR 14 R 14 , —NR 14 R 14 , —S(O) 2 NR 14 R 14 , —NR 14 S(O) 2 CF 3 , —C( ⁇ O)NR 14 S(O) 2 R 14 , —S(O) 2 NR 14 C( ⁇ O)OR 14 , —S(O) 2 NR 14 C( ⁇ O)NR 14 R 14 , —C( ⁇ O)NR 14 S(O) 2 CF 3 , —C( ⁇ O)NR 14
- R 14 is independently selected from hydrogen, alkyl, cycloalkyl, aryl or arylalkyl, wherein the alkyl, cycloalkyl, aryl or arylalkyl may be optionally substituted with 0-3 R 14a ;
- R 14a is independently selected from alkyl, haloalkyl, aryl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, halo, —NH 2 , —CN, —NO 2 , —C( ⁇ O)OH, —C( ⁇ O)OR 15 , —OCF 3 , —OR 15 , —OH, —SH, —SR 15 , —C( ⁇ O)NR 15 R 15 , —NR 15 R 15 , —S(O) 2 NR 15 R 15 , —NR 15 S(O) 2 CF 3 , —C( ⁇ O)NR 15 S(O) 2 R 15 , —S(O) 2 NR 15 C( ⁇ O)OR 15 , —S(O) 2 NR 15 C( ⁇ O)NR 15 R 15 , —C( ⁇ O)NR 15 S(O) 2 CF 3 , —C( ⁇ O)NR 15
- R 15 is independently selected from hydrogen, alkyl, cycloalkyl, aryl or arylalkyl.
- compounds of formula I are those compounds in which:
- A is a 7- to 14-membered non-aromatic bi-, tri- or polycyclic ring system optionally containing 1-3 heteroatoms selected from N, O, S, S(O) and S(O) 2 , which may be optionally substituted with one or more R 4 's;
- X is —C( ⁇ O)OH, or —C( ⁇ O)NR 9 R 9 ;
- W is absent, (—CR 8a R 8b —) m or (—CR 8a R 8b ) m —O—;
- n 1-2;
- Z is aryl, arylalkyl or heterocyclylalkyl, all of which may be optionally substituted with one or more R 4 's, and the heterocyclylalkyl contain 1-4 heteroatoms selected from N, O, and S;
- R 4 is independently selected from hydrogen, alkyl, aryl, cycloalkyl, heterocyclyl, halo, ⁇ O, —NH 2 , —CN, —NO 2 , —C( ⁇ O)OH, —C( ⁇ O)OR 10 , —OR 10 , —OH, —OCF 3 , —SH, —SR 10 , —C( ⁇ O)NR 9 R 9 , —NR 9 R 9 , —S(O) 2 NR 9 R 9 , —NR 9 S(O) 2 CF 3 , —C( ⁇ O)NR 9 S(O) 2 R 9 , —S(O) 2 NR 9 C( ⁇ O)OR 9 , —S(O) 2 NR 9 C( ⁇ O)NR 9 R 9 , —C( ⁇ O)NR 9 S(O) 2 CF 3 , —C( ⁇ O)R 10 , —NR 9 C( ⁇ O)R 10 , —NR 9 C
- R 5 is independently selected from hydrogen, alkyl, haloalkyl, aryl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, halo, —NH 2 , —CN, —NO 2 , —C( ⁇ O)OH, —C( ⁇ O)OR 10 , —OCF 3 , —OR 10 , —OH, —SH, —SR 10 , —C( ⁇ O)NR 9 R 9 , —NR 9 R 9 , —S(O) 2 NR 9 R 9 , —NR 9 S(O) 2 CF 3 , —C( ⁇ O)NR 9 S(O) 2 R 9 , —S(O) 2 NR 9 C( ⁇ O)OR 9 , —S(O) 2 NR 9 C( ⁇ O)NR 9 R 9 , —C( ⁇ O)NR 9 S(O) 2 CF 3 , —S(O) 2
- R 8 at each occurrence, is independently alkyl, aryl or heterocyclyl
- R 8a at each occurrence, is independently hydrogen, alkyl or aryl
- R 8b at each occurrence, is independently hydrogen, —C( ⁇ O)OH, alkyl, —OH, halo, —CN, —OR 10 or —C( ⁇ O)NR 9 R 9 , wherein the alkyl may be optionally substituted with one or more R 9a 's; or
- R 9 is independently hydrogen, alkyl, alkoxy, cycloalkyl, aryl, arylalkyl, or heterocyclyl, wherein the alkyl, cycloalkyl, aryl, arylalkyl or heterocyclyl may be optionally substituted with 0-5 R 9a , and the heterocyclyl contains 1-4 heteroatoms selected from N, O, and S; or
- R 9 's together with the nitrogen to which they are attached form a unsaturated, saturated or partially saturated cyclic ring system containing from 2-10 carbon atoms and from 0-4 additional heteroatoms selected from N, O, S, S(O) and S(O) 2 , wherein said ring system may be optionally substituted or fused with one or more R 9a 's;
- R 9a is independently selected from alkyl, haloalkyl, aryl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, halo, ⁇ O, —NH 2 , —CN, —NO 2 , —C( ⁇ O)OH, —C( ⁇ O)OR 14 , —OCF 3 , —OR 10 , —OH, —SH, —SR 14 , —C( ⁇ O)NR 14 R 14 , —NR 14 R 14 , —S(O) 2 NR 14 R 14 , —NR 14 S(O) 2 CF 3 , —C( ⁇ O)NR 14 S(O) 2 R 10 , —S(O) 2 NR 14 C( ⁇ O)OR 10 , —S(O) 2 NR 14 C( ⁇ O)NR 14 R 14 , —C( ⁇ O)NR 14 S(O) 2 R 14 ,
- R 10 is independently selected from alkyl, cycloalkyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl, wherein the alkyl, cycloalkyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl may be optionally substituted with 0-3 R 10a , and the heterocyclyl and heterocyclylalkyl contain 1-4 heteroatoms selected from N, O, and S;
- R 10a is independently selected from alkyl, haloalkyl, aryl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, halo, —NH 2 , —CN, —NO 2 , —C( ⁇ O)OH, —C( ⁇ O)OR 14 , —OCF 3 , —OR 14 , —OH, —SH, —SR 14 , —C( ⁇ O)NR 14 R 14 , —NR 14 R 14 , —S(O) 2 NR 14 R 14 , —NR 14 S(O) 2 CF 3 , —C( ⁇ O)NR 14 S(O) 2 R 14 , —S(O) 2 NR 14 C( ⁇ O)OR 14 , —S(O) 2 NR 14 C( ⁇ O)NR 14 R 14 , —C( ⁇ O)NR 14 S(O) 2 CF 3 , —C( ⁇ O)NR 14
- R 14 at each occurrence, is independently selected from hydrogen, alkyl, cycloalkyl, or aryl, wherein the alkyl, cycloalkyl or aryl may be optionally substituted with 0-3 R 14a ;
- R 14a is independently selected from alkyl, haloalkyl, aryl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, halo, —NH 2 , —CN, —NO 2 , —C( ⁇ O)OH, —C( ⁇ O)OR 15 , —OCF 3 , —OR 15 , —OH, —SH, —SR 15 , —C( ⁇ O)NR 15 R 15 , —NR 15 R 15 , —S(O) 2 NR 15 R 15 , —NR 15 S(O) 2 CF 3 , —C( ⁇ O)NR 15 S(O) 2 R 15 , —S(O) 2 NR 15 C( ⁇ O)OR 15 , —S(O) 2 NR 15 C( ⁇ O)NR 15 R 15 , —C( ⁇ O)NR 15 S(O) 2 CF 3 , —C( ⁇ O)NR 15
- R 15 is independently selected from hydrogen, alkyl, cycloalkyl or aryl.
- compounds of formula I are those compounds in which:
- A is a 7- to 14-membered non-aromatic bi-, tri- or polycyclic ring system optionally containing 1-3 heteroatoms selected from N, O, S, S(O) and S(O) 2 , which may be optionally substituted with one or more R 4 's;
- X is —C( ⁇ O)OH, or —C( ⁇ O)NR 9 R 9 ;
- W is absent, (—CR 8a R 8b —) m or —(CR 8a R 8b ) m —O—;
- n 1-2;
- Z is aryl or arylalkyl, both of which may be optionally substituted with one or more R 4 's;
- R 4 is independently selected from hydrogen, alkyl, aryl, cycloalkyl, heterocyclyl, halo, ⁇ O, —NH 2 , —CN, —NO 2 , —C( ⁇ O)OH, —C( ⁇ O)OR 10 , —OR 10 , —OH, —OCF 3 , —SH, —SR 10 , —C( ⁇ O)NR 9 R 9 , —NR 9 R 9 , —S(O) 2 NR 9 R 9 , —NR 9 S(O) 2 CF 3 , —C( ⁇ O)NR 9 S(O) 2 R 9 , —S(O) 2 NR 9 C( ⁇ O)OR 9 , —S(O) 2 NR 9 C( ⁇ O)NR 9 R 9 , —C( ⁇ O)NR 9 S(O) 2 CF 3 , —C( ⁇ O)R 10 , —NR 9 C( ⁇ O)R 10 , —NR 9 C
- R 5 is independently selected from hydrogen, alkyl, haloalkyl, aryl, cycloalkyl, cycloalkylalkyl, heterocyclyl, halo, —NH 2 , —CN, —NO 2 , —C( ⁇ O)OH, —C( ⁇ O)OR 10 , —OCF 3 , —OR 10 , —OH, —SH, —SR 10 , —C( ⁇ O)NR 9 R 9 , —NR 9 R 9 , —S(O) 2 NR 9 R 9 , —NR 9 S(O) 2 CF 3 , —C( ⁇ O)NR 9 S(O) 2 R 9 , —S(O) 2 NR 9 C( ⁇ O)OR 9 , —S(O) 2 NR 9 C( ⁇ O)NR 9 R 9 , —C( ⁇ O)NR 9 S(O) 2 CF 3 , —C( ⁇ O)R 10 , —S(O
- R 8 at each occurrence, is independently alkyl, aryl or heterocyclyl
- R 8a at each occurrence, is independently hydrogen, alkyl or aryl
- R 8b at each occurrence, is independently hydrogen, —C( ⁇ O)OH, alkyl, —OH, halo, —CN, —OR 10 or —C( ⁇ O)NR 9 R 9 , wherein the alkyl may be optionally substituted with one or more R 9a 's; or
- R 9 is independently hydrogen, alkyl, alkoxy, cycloalkyl, aryl or heterocyclyl, wherein the alkyl, cycloalkyl, aryl or heterocyclyl may be optionally substituted with 0-5 R 9a , and the heterocyclyl contains 1-4 heteroatoms selected from N, O, and S; or
- R 9 's together with the nitrogen to which they are attached form a unsaturated, saturated or partially saturated cyclic ring system containing from 2-10 carbon atoms and from 0-4 additional heteroatoms selected from N, O, S, S(O) and S(O) 2 , wherein said ring system may be optionally substituted or fused with one or more R 9a 's;
- R 9a is independently selected from alkyl, haloalkyl, aryl, cycloalkyl, cycloalkylalkyl, heterocyclyl, halo, ⁇ O, —NH 2 , —CN, —NO 2 , —C( ⁇ O)OH, —C( ⁇ O)OR 14 , —OCF 3 , —OR 10 , —OH, —SH, —SR 14 , —C( ⁇ O)NR 14 R 14 , —NR 14 R 14 , —S(O) 2 NR 14 R 14 , —NR 14 S(O) 2 CF 3 , —C( ⁇ O)NR 14 S(O) 2 R 10 , —S(O) 2 NR 14 C( ⁇ O)OR 10 , —S(O) 2 NR 14 C( ⁇ O)NR 14 R 14 , —C( ⁇ O)NR 14 S(O) 2 R 14 , —C( ⁇ O)R
- R 10 is independently selected from alkyl, cycloalkyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl, wherein the alkyl, cycloalkyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl may be optionally substituted with 0-3 R 10a , and the heterocyclyl and heterocyclylalkyl contain 1-4 heteroatoms selected from N, O, and S;
- R 10a is independently selected from alkyl, haloalkyl, aryl, cycloalkyl, cycloalkylalkyl, heterocyclyl, halo, —NH 2 , —CN, —NO 2 , —C( ⁇ O)OH, —C( ⁇ O)OR 14 , —OCF 3 , —OR 14 , —OH, —SH, —SR 14 , —C( ⁇ O)NR 14 R 14 , —NR 14 R 14 , —S(O) 2 NR 14 R 14 , —NR 14 S(O) 2 CF 3 , —C( ⁇ O)NR 14 S(O) 2 R 14 , —S(O) 2 NR 14 C( ⁇ O)OR 14 , —S(O) 2 NR 14 C( ⁇ O)NR 14 R 14 , —C( ⁇ O)NR 14 S(O) 2 CF 3 , —C( ⁇ O)R 14 ,
- R 14 at each occurrence, is independently selected from hydrogen, alkyl, cycloalkyl, or aryl, wherein the alkyl, cycloalkyl or aryl may be optionally substituted with 0-3 R 14a ;
- R 14a is independently selected from alkyl, haloalkyl, aryl, cycloalkyl, cycloalkylalkyl, heterocyclyl, halo, —NH 2 , —CN, —NO 2 , —C( ⁇ O)OH, —C( ⁇ O)OR 15 , —OCF 3 , —OR 15 , —OH, —SH, —SR 15 , —C( ⁇ O)NR 15 R 15 , —NR 15 R 15 , —S(O) 2 NR 15 R 15 , —NR 15 S(O) 2 CF 3 , —C( ⁇ O)NR 15 S(O) 2 R 15 , —S(O) 2 NR 15 C( ⁇ O)OR 15 , —S(O) 2 NR 15 C( ⁇ O)NR 15 R 15 , —C( ⁇ O)NR 15 S(O) 2 CF 3 , —C( ⁇ O)R 15 ,
- R 15 is independently selected from hydrogen, alkyl, cycloalkyl or aryl.
- compounds of formula I are those compounds in which:
- A is a 7- to 14-membered non-aromatic bi-, tri- or polycyclic ring system optionally containing 1-3 heteroatoms selected from N, O, S, S(O) and S(O) 2 , which may be optionally substituted with one or more R 4 's;
- X is —C( ⁇ O)NR 9 R 9 ;
- W is absent, (—CR 8a R 8b —) m or —(CR 8a R 8b ) m —O—;
- n 1-2;
- Z is aryl or arylalkyl, both of which may be optionally substituted with one or more R 4 's;
- R 4 is independently selected from hydrogen, alkyl, aryl, cycloalkyl, heterocyclyl, halo, ⁇ O, —NH 2 , —CN, —NO 2 , —C( ⁇ O)OH, —C( ⁇ O)OR 10 , —OR 10 , —OH, —OCF 3 , —SH, —SR 10 , —C( ⁇ O)NR 9 R 9 , —NR 9 R 9 , —S(O) 2 NR 9 R 9 , —NR 9 S(O) 2 CF 3 , —C( ⁇ O)NR 9 S(O) 2 R 9 , —S(O) 2 NR 9 C( ⁇ O)OR 9 , —S(O) 2 NR 9 C( ⁇ O)NR 9 R 9 , —C( ⁇ O)NR 9 S(O) 2 CF 3 , —C( ⁇ O)R 10 , —NR 9 C( ⁇ O)R 10 , —NR 9 C
- R 5 is independently selected from hydrogen, alkyl, haloalkyl, aryl, cycloalkyl, heterocyclyl, halo, —NH 2 , —CN, —NO 2 , —C( ⁇ O)OH, —C( ⁇ O)OR 10 , —OCF 3 , —OR 10 , —OH, —SH, —SR 10 , —C( ⁇ O)NR 9 R 9 , —NR 9 R 9 , —S(O) 2 NR 9 R 9 , —NR 9 S(O) 2 CF 3 , —C( ⁇ O)NR 9 S(O) 2 R 9 , —S(O) 2 NR 9 C( ⁇ O)OR 9 , —S(O) 2 NR 9 C( ⁇ O)NR 9 R 9 , —C( ⁇ O)NR 9 S(O) 2 CF 3 , —C( ⁇ O)R 10 , —NR 9 C( ⁇ O)R 10 , —
- R 8 at each occurrence, is independently alkyl, aryl or heterocyclyl
- R 8a at each occurrence, is independently hydrogen, alkyl or aryl
- R 8b at each occurrence, is independently hydrogen, —C( ⁇ O)OH, alkyl, —OH, halo, —CN, —OR 10 or —C( ⁇ O)NR 9 R 9 , wherein the alkyl may be optionally substituted with one or more R 9a 's; or
- R 9 is independently hydrogen, alkyl, alkoxy, cycloalkyl, aryl or heterocyclyl, wherein the alkyl, cycloalkyl, aryl or heterocyclyl may be optionally substituted with 0-5 R 9a , and the heterocyclyl contains 1-4 heteroatoms selected from N, O, and S; or
- R 9 's together with the nitrogen to which they are attached form a unsaturated, saturated or partially saturated cyclic ring system containing from 2-10 carbon atoms and from 0-4 additional heteroatoms selected from N, O, S, S(O) and S(O) 2 , wherein said ring system may be optionally substituted or fused with one or more R 9a 's;
- R 9a is independently selected from alkyl, haloalkyl, aryl, cycloalkyl, heterocyclyl, halo, ⁇ O, —NH 2 , —CN, —NO 2 , —C( ⁇ O)OH, —C( ⁇ O)OR 14 , —OCF 3 , —OR 10 , —OH, —SH, —SR 14 , —C( ⁇ O)NR 14 R 14 , —NR 14 R 14 , —S(O) 2 NR 14 R 14 , —NR 14 S(O) 2 CF 3 , —C( ⁇ O)NR 14 S(O) 2 R 10 , —S(O) 2 NR 14 C( ⁇ O)OR 10 , —S(O) 2 NR 14 C( ⁇ O)NR 14 R 14 , —C( ⁇ O)NR 14 S(O) 2 R 14 , —C( ⁇ O)R 14 , —NR 14 C( ⁇ O)OR 10 ,
- R 10 is independently selected from alkyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl, wherein the alkyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl may be optionally substituted with 0-3 R 10a , and the heterocyclyl and heterocyclylalkyl contain 1-4 heteroatoms selected from N, O, and S;
- R 10a is independently selected from alkyl, haloalkyl, aryl, cycloalkyl, heterocyclyl, halo, —NH 2 , —CN, —NO 2 , —C( ⁇ O)OH, —C( ⁇ O)OR 14 , —OCF 3 , —OR 14 , —OH, —SH, —SR 14 , —C( ⁇ O)NR 14 R 14 , —NR 14 R 14 , —S(O) 2 NR 14 R 14 , —NR 14 S(O) 2 CF 3 , —C( ⁇ O)NR 14 S(O) 2 R 14 , —S(O) 2 NR 14 C( ⁇ O)OR 14 , —S(O) 2 NR 14 C( ⁇ O)NR 14 R 14 , —C( ⁇ O)NR 14 S(O) 2 CF 3 , —C( ⁇ O)R 14 , —NR 14 C( ⁇ O)R 14 , —NR
- R 14 is independently selected from hydrogen, alkyl, cycloalkyl or aryl, wherein the alkyl, cycloalkyl or aryl may be optionally substituted with 0-3 R 14a ;
- R 14a is independently selected from alkyl, haloalkyl, aryl, cycloalkyl, heterocyclyl, halo, —NH 2 , —CN, —NO 2 , —C( ⁇ O)OH, —C( ⁇ O)OR 15 , —OCF 3 , —OR 15 , —OH, —SH, —SR 15 , —C( ⁇ O)NR 15 R 15 , —NR 15 R 15 , —S(O) 2 NR 15 R 15 , —NR 15 S(O) 2 CF 3 , —C( ⁇ O)NR 15 S(O) 2 R 15 , —S(O) 2 NR 15 C( ⁇ O)OR 15 , —S(O) 2 NR 15 C( ⁇ O)NR 15 R 15 , —C( ⁇ O)NR 15 S(O) 2 CF 3 , —C( ⁇ O)R 15 , —NR 15 C( ⁇ O)R 15 , —NR
- R 15 is independently selected from hydrogen, alkyl, cycloalkyl or aryl.
- compounds of formula I are those compounds in which:
- A is a 7- to 12-membered non-aromatic bi-, tri- or polycyclic ring system optionally containing 1-3 heteroatoms selected from N, O, S, S(O) and S(O) 2 , which is substituted with one or more R 4 's;
- X is —C( ⁇ O)NR 9 R 9 ;
- W is absent or (—CR 8a R 8b —) m ;
- n 1-2;
- Z is aryl or arylalkyl, both of which may be optionally substituted with one or more R 4 's;
- R 4 is independently selected from hydrogen, alkyl, aryl, cycloalkyl, heterocyclyl, halo, ⁇ O, —NH 2 , —CN, —NO 2 , —C( ⁇ O)OH, —C( ⁇ O)OR 10 , —OR 10 , —OH, —OCF 3 , —SH, —SR 10 , —C( ⁇ O)NR 9 R 9 , —NR 9 R 9 , —S(O) 2 NR 9 R 9 , —NR 9 S(O) 2 CF 3 , —C( ⁇ O)NR 9 S(O) 2 R 9 , —S(O) 2 NR 9 C( ⁇ O)OR 9 , —S(O) 2 NR 9 C( ⁇ O)NR 9 R 9 , —C( ⁇ O)NR 9 S(O) 2 CF 3 , —C( ⁇ O)R 10 , —NR 9 C( ⁇ O)R 10 , —NR 9 C
- R 5 is independently selected from hydrogen, alkyl, haloalkyl, aryl, cycloalkyl, heterocyclyl, halo, —NH 2 , —CN, —NO 2 , —C( ⁇ O)OH, —C( ⁇ O)OR 10 , —OCF 3 , —OR 10 , —OH, —SH, —SR 10 , —C( ⁇ O)NR 9 R 9 , —NR 9 R 9 , —S(O) 2 NR 9 R 9 , —NR 9 S(O) 2 CF 3 , —C( ⁇ O)NR 9 S(O) 2 R 9 , —S(O) 2 NR 9 C( ⁇ O)OR 9 , —S(O) 2 NR 9 C( ⁇ O)NR 9 R 9 , —C( ⁇ O)NR 9 S(O) 2 CF 3 , —C( ⁇ O)R 10 , —NR 9 C( ⁇ O)R 10 , —
- R 8 at each occurrence, is independently alkyl, aryl or heterocyclyl
- R 8a at each occurrence, is independently hydrogen or alkyl
- R 8b at each occurrence, is independently hydrogen, —C( ⁇ O)OH, alkyl, —OH, halo, —CN, —OR 10 or —C( ⁇ O)NR 9 R 9 , wherein the alkyl may be optionally substituted with one or more R 9a 's; or
- R 9 is independently hydrogen, alkyl, alkoxy, cycloalkyl, aryl or heterocyclyl, wherein the alkyl, cycloalkyl, aryl or heterocyclyl may be optionally substituted with 0-5 R 9a , and the heterocyclyl contains 1-4 heteroatoms selected from N, O, and S; or
- R 9 's together with the nitrogen to which they are attached form a unsaturated, saturated or partially saturated cyclic ring system containing from 2-10 carbon atoms and from 0-4 additional heteroatoms selected from N, O, S, S(O) and S(O) 2 , wherein said ring system may be optionally substituted or fused with one or more R 9a 's;
- R 9a is independently selected from alkyl, haloalkyl, aryl, cycloalkyl, heterocyclyl, halo, ⁇ O, —NH 2 , —CN, —NO 2 , —C( ⁇ O)OH, —C( ⁇ O)OR 14 , —OCF 3 , —OR 10 , —OH, —SH, —SR 14 , —C( ⁇ O)NR 14 R 14 , —NR 14 R 14 , —S(O) 2 NR 14 R 14 , —NR 14 S(O) 2 CF 3 , —C( ⁇ O)NR 14 S(O) 2 R 10 , —S(O) 2 NR 14 C( ⁇ O)OR 10 , —S(O) 2 NR 14 C( ⁇ O)NR 14 R 14 , —C( ⁇ O)NR 14 S(O) 2 R 14 , —C( ⁇ O)R 14 , —NR 14 C( ⁇ O)OR 10 ,
- R 10 is independently selected from alkyl, aryl, arylalkyl or heterocyclyl, wherein the alkyl, aryl, arylalkyl or heterocyclyl may be optionally substituted with 0-3 R 10a , and the heterocyclyl contains 1-4 heteroatoms selected from N, O, and S;
- R 10a is independently selected from alkyl, haloalkyl, aryl, cycloalkyl, heterocyclyl, halo, —NH 2 , —CN, —NO 2 , —C( ⁇ O)OH, —C( ⁇ O)OR 14 , —OCF 3 , —OR 14 , —OH, —SH, —SR 14 , —C( ⁇ O)NR 14 R 14 , —NR 14 R 14 , —S(O) 2 NR 14 R 14 , —NR 14 S(O) 2 CF 3 , —C( ⁇ O)NR 14 S(O) 2 R 14 , —S(O) 2 NR 14 C( ⁇ O)OR 14 , —S(O) 2 NR 14 C( ⁇ O)NR 14 R 14 , —C( ⁇ O)NR 14 S(O) 2 CF 3 , —C( ⁇ O)R 14 , —NR 14 C( ⁇ O)R 14 , —NR
- R 14 is independently selected from hydrogen, alkyl, cycloalkyl or aryl, wherein the alkyl, cycloalkyl or aryl may be optionally substituted with 0-3 R 14a ;
- R 14a is independently selected from alkyl, haloalkyl, aryl, cycloalkyl, heterocyclyl, halo, —NH 2 , —CN, —NO 2 , —C( ⁇ O)OH, —C( ⁇ O)OR 15 , —OCF 3 , —OR 15 , —OH, —SH, —SR 15 , —C( ⁇ O)NR 15 R 15 , —NR 15 R 15 , —S(O) 2 NR 15 R 15 , —NR 15 S(O) 2 CF 3 , —C( ⁇ O)NR 15 S(O) 2 R 15 , —S(O) 2 NR 15 C( ⁇ O)OR 15 , —S(O) 2 NR 15 C( ⁇ O)NR 15 R 15 , —C( ⁇ O)NR 15 S(O) 2 CF 3 , —C( ⁇ O)R 15 , —NR 15 C( ⁇ O)R 15 , —NR
- R 15 is independently selected from hydrogen, alkyl, cycloalkyl or aryl.
- compounds of formula I are those compounds in which:
- A is a 7- to 12-membered non-aromatic bi-, tri- or polycyclic ring system optionally containing 1-3 heteroatoms selected from N, O, S, S(O) and S(O) 2 , which is substituted with one or more R 4 's;
- X is —C( ⁇ O)NR 9 R 9 ;
- W is absent or (—CR 8a R 8b —) m ;
- n 1;
- Z is aryl or arylalkyl, both of which may be optionally substituted with one or more R 4 's;
- R 4 is independently selected from hydrogen, alkyl, aryl, cycloalkyl, heterocyclyl, halo, ⁇ O, —NH 2 , —CN, —NO 2 , —C( ⁇ O)OH, —C( ⁇ O)OR 10 , —OR 10 , —OH, —OCF 3 , —SH, —SR 10 , —C( ⁇ O)NR 9 R 9 , —NR 9 R 9 , —S(O) 2 NR 9 R 9 , —NR 9 S(O) 2 CF 3 , —C( ⁇ O)NR 9 S(O) 2 R 9 , —S(O) 2 NR 9 C( ⁇ O)OR 9 , —S(O) 2 NR 9 C( ⁇ O)NR 9 R 9 , —C( ⁇ O)NR 9 S(O) 2 CF 3 , —C( ⁇ O)R 10 , —NR 9 C( ⁇ O)R 10 , —NR 9 C
- R 5 is independently selected from hydrogen, alkyl, haloalkyl, aryl, cycloalkyl, heterocyclyl, halo, —NH 2 , —CN, —NO 2 , —C( ⁇ O)OH, —C( ⁇ O)OR 10 , —OCF 3 , —OR 10 , —OH, —SH, —SR 10 , —C( ⁇ O)NR 9 R 9 , —NR 9 R 9 , —S(O) 2 NR 9 R 9 , —NR 9 S(O) 2 CF 3 , —C( ⁇ O)NR 9 S(O) 2 R 9 , —S(O) 2 NR 9 C( ⁇ O)OR 9 , —S(O) 2 NR 9 C( ⁇ O)NR 9 R 9 , —C( ⁇ O)NR 9 S(O) 2 CF 3 , —C( ⁇ O)R 10 , —NR 9 C( ⁇ O)R 10 , —
- R 8 at each occurrence, is independently alkyl or aryl
- R 8a at each occurrence, is independently hydrogen or alkyl
- R 8b at each occurrence, is independently hydrogen, —C( ⁇ O)OH, alkyl, —OH, halo, —CN or —OR 10 , wherein the alkyl may be optionally substituted with one or more R 9a 's; or
- R 9 is independently hydrogen, alkyl, alkoxy, aryl or heterocyclyl, wherein the alkyl, aryl or heterocyclyl may be optionally substituted with 0-5 R 9a , and the heterocyclyl contains 1-4 heteroatoms selected from N, O, and S; or
- R 9 's together with the nitrogen to which they are attached form a unsaturated, saturated or partially saturated cyclic ring system containing from 2-10 carbon atoms and from 0-4 additional heteroatoms selected from N, O, S, S(O) and S(O) 2 , wherein said ring system may be optionally substituted or fused with one or more R 9a 's;
- R 9a is independently selected from alkyl, haloalkyl, aryl, cycloalkyl, heterocyclyl, halo, ⁇ O, —NH 2 , —CN, —NO 2 , —C( ⁇ O)OH, —C( ⁇ O)OR 14 , —OCF 3 , —OR 10 , —OH, —SH, —SR 14 , —C( ⁇ O)NR 14 R 14 , —NR 14 R 14 , —S(O) 2 NR 14 R 14 , —NR 14 S(O) 2 CF 3 , —C( ⁇ O)NR 14 S(O) 2 R 10 , —S(O) 2 NR 14 C( ⁇ O)OR 10 , —S(O) 2 NR 14 C( ⁇ O)NR 14 R 14 , —C( ⁇ O)NR 14 S(O) 2 R 14 , —C( ⁇ O)R 14 , —NR 14 C( ⁇ O)OR 10 ,
- R 10 is independently selected from alkyl, aryl or heterocyclyl, wherein the alkyl, aryl or heterocyclyl may be optionally substituted with 0-3 R 10a , and the heterocyclyl and heterocyclylalkyl contain 1-4 heteroatoms selected from N, O, and S;
- R 10a is independently selected from alkyl, haloalkyl, aryl, cycloalkyl, heterocyclyl, halo, —NH 2 , —CN, —NO 2 , —C( ⁇ O)OH, —C( ⁇ O)OR 14 , —OCF 3 , —OR 14 , —OH, —SH, —SR 14 , —C( ⁇ O)NR 14 R 14 , —NR 14 R 14 , —S(O) 2 NR 14 R 14 , —NR 14 S(O) 2 CF 3 , —C( ⁇ O)NR 14 S(O) 2 R 14 , —S(O) 2 NR 14 C( ⁇ O)OR 14 , —S(O) 2 NR 14 C( ⁇ O)NR 14 R 14 , —C( ⁇ O)NR 14 S(O) 2 CF 3 , —C( ⁇ O)R 14 , —NR 14 C( ⁇ O)R 14 , —NR
- R 14 is independently selected from hydrogen, alkyl or aryl, wherein the alkyl or aryl may be optionally substituted with 0-3 R 14a ;
- R 14a is independently selected from alkyl, haloalkyl, aryl, cycloalkyl, heterocyclyl, halo, —NH 2 , —CN, —NO 2 , —C( ⁇ O)OH, —C( ⁇ O)OR 15 , —OCF 3 , —OR 15 , —OH, —SH, —SR 15 , —C( ⁇ O)NR 15 R 15 , —NR 15 R 15 , —S(O) 2 NR 15 R 15 , —NR 15 S(O) 2 CF 3 , —C( ⁇ O)NR 15 S(O) 2 R 15 , —S(O) 2 NR 15 C( ⁇ O)OR 15 , —S(O) 2 NR 15 C( ⁇ O)NR 15 R 15 , —C( ⁇ O)NR 15 S(O) 2 CF 3 , —C( ⁇ O)R 15 , —NR 15 C( ⁇ O)R 15 , —NR
- R 15 is independently selected from hydrogen, alkyl or aryl.
- compounds of formula I are those compounds in which:
- A is a 7- to 10-membered non-aromatic bi-, tri- or polycyclic ring system optionally containing 1-3 heteroatoms selected from N, O, S, S(O) and S(O) 2 , which is substituted with one or more R 4 's;
- X is —C( ⁇ O)NR 9 R 9 ;
- W is absent or (—CR 8a R 8b —) m ;
- n 1;
- Z is aryl or arylalkyl, both of which may be optionally substituted with one or more R 4 's;
- R 4 is independently selected from hydrogen, alkyl, aryl, cycloalkyl, heterocyclyl, halo, ⁇ O, —NH 2 , —CN, —NO 2 , —C( ⁇ O)OH, —C( ⁇ O)OR 10 , —OR 10 , —OH, —OCF 3 , —SH, —SR 10 , —C( ⁇ O)NR 9 R 9 , —NR 9 R 9 , —S(O) 2 NR 9 R 9 , —NR 9 S(O) 2 CF 3 , —C( ⁇ O)NR 9 S(O) 2 R 9 , —S(O) 2 NR 9 C( ⁇ O)OR 9 , —S(O) 2 NR 9 C( ⁇ O)NR 9 R 9 , —C( ⁇ O)NR 9 S(O) 2 CF 3 , —C( ⁇ O)R 10 , —NR 9 C( ⁇ O)R 10 , —NR 9 C
- R 5 is independently selected from hydrogen, alkyl, haloalkyl, aryl, cycloalkyl, heterocyclyl, halo, —NH 2 , —CN, —NO 2 , —C( ⁇ O)OH, —C( ⁇ O)OR 10 , —OCF 3 , —OR 10 , —OH, —SH, —SR 10 , —C( ⁇ O)NR 9 R 9 , —NR 9 R 9 , —S(O) 2 NR 9 R 9 , —NR 9 S(O) 2 CF 3 , —C( ⁇ O)NR 9 S(O) 2 R 9 , —S(O) 2 NR 9 C( ⁇ O)OR 9 , —S(O) 2 NR 9 C( ⁇ O)NR 9 R 9 , —C( ⁇ O)NR 9 S(O) 2 CF 3 , —C( ⁇ O)R 10 , —NR 9 C( ⁇ O)R 10 , —
- R 8 at each occurrence, is independently alkyl or aryl
- R 8a at each occurrence, is independently hydrogen or alkyl
- R 8b at each occurrence, is independently hydrogen, —C( ⁇ O)OH, alkyl, —OH, halo, —CN, or —OR 10 ;
- R 9 is independently hydrogen, alkyl, alkoxy or aryl, wherein the alkyl or aryl may be optionally substituted with 0-5 R 9a ; or
- R 9 's together with the nitrogen to which they are attached form a unsaturated, saturated or partially saturated cyclic ring system containing from 2-10 carbon atoms and from 0-4 additional heteroatoms selected from N, O, S, S(O) and S(O) 2 , wherein said ring system may be optionally substituted or fused with one or more R 9a 's;
- R 9a is independently selected from alkyl, haloalkyl, aryl, cycloalkyl, heterocyclyl, halo, ⁇ O, —NH 2 , —CN, —NO 2 , —C( ⁇ O)OH, —C( ⁇ O)OR 14 , —OCF 3 , —OR 10 , —OH, —SH, —SR 14 , —C( ⁇ O)NR 14 R 14 , —NR 14 R 14 , —S(O) 2 NR 14 R 14 , —NR 14 S(O) 2 CF 3 , —C( ⁇ O)NR 14 S(O) 2 R 10 , —S(O) 2 NR 14 C( ⁇ O)OR 10 , —S(O) 2 NR 14 C( ⁇ O)NR 14 R 14 , —C( ⁇ O)NR 14 S(O) 2 R 14 , —C( ⁇ O)R 14 , —NR 14 C( ⁇ O)OR 10 ,
- R 10 at each occurrence, is independently selected from alkyl or aryl, wherein the alkyl or aryl may be optionally substituted with 0-3 R 10a ;
- R 10a is independently selected from alkyl, haloalkyl, aryl, cycloalkyl, heterocyclyl, halo, —NH 2 , —CN, —NO 2 , —C( ⁇ O)OH, —C( ⁇ O)OR 14 , —OCF 3 , —OR 14 , —OH, —SH, —SR 14 , —C( ⁇ O)NR 14 R 14 , —NR 14 R 14 , —S(O) 2 NR 14 R 14 , —NR 14 S(O) 2 CF 3 , —C( ⁇ O)NR 14 S(O) 2 R 14 , —S(O) 2 NR 14 C( ⁇ O)OR 14 , —S(O) 2 NR 14 C( ⁇ O)NR 14 R 14 , —C( ⁇ O)NR 14 S(O) 2 CF 3 , —C( ⁇ O)R 14 , —NR 14 C( ⁇ O)R 14 , —NR
- R 14 is independently selected from hydrogen, alkyl or aryl, wherein the alkyl or aryl may be optionally substituted with 0-3 R 14a ;
- R 14a is independently selected from alkyl, haloalkyl, aryl, cycloalkyl, heterocyclyl, halo, —NH 2 , —CN, —NO 2 , —C( ⁇ O)OH, —C( ⁇ O)OR 15 , —OCF 3 , —OR 15 , —OH, —SH, —SR 15 , —C( ⁇ O)NR 15 R 15 , —NR 15 R 15 , —S(O) 2 NR 15 R 15 , —NR 15 S(O) 2 CF 3 , —C( ⁇ O)NR 15 S(O) 2 R 15 , —S(O) 2 NR 15 C( ⁇ O)OR 15 , —S(O) 2 NR 15 C( ⁇ O)NR 15 R 15 , —C( ⁇ O)NR 15 S(O) 2 CF 3 , —C( ⁇ O)R 15 , —NR 15 C( ⁇ O)R 15 , —NR
- R 15 at each occurrence, is independently selected from hydrogen or alkyl.
- compounds of the present invention are selected from the compounds exemplified in the examples.
- the present invention relates to pharmaceutical compositions comprised of a therapeutically effective amount of a compound of the present invention, alone or, optionally, in combination with a pharmaceutically acceptable carrier and/or one or more other agent(s).
- the present invention relates to methods of inhibiting the activity of the enzyme 11-beta-hydroxysteroid dehydrogenase type I comprising administering to a mammalian patient, for example, a human patient, in need thereof a therapeutically effective amount of a compound of the present invention, alone, or optionally, in combination with another compound of the present invention and/or at least one other type of therapeutic agent.
- the present invention relates to a method for preventing, inhibiting, or treating the progression or onset of diseases or disorders associated with the activity of the enzyme 11-beta-hydroxysteroid dehydrogenase type I comprising administering to a mammalian patient, for example, a human patient, in need of prevention, inhibition, or treatment a therapeutically effective amount of a compound of the present invention, alone, or, optionally, in combination with another compound of the present invention and/or at least one other type of therapeutic agent.
- diseases or disorders associated with the activity of the enzyme 11-beta-hydroxysteroid dehydrogenase type I that can be prevented, inhibited, or treated according to the present invention include, but are not limited to, diabetes, hyperglycemia, impaired glucose tolerance, insulin resistance, hyperinsulinemia, retinopathy, neuropathy, nephropathy, delayed wound healing, atherosclerosis, acute coronary syndrome, myocardial infarction, angina pectoris, peripheral vascular disease, intermitant claudication, abnormal heart function, myocardial ischemia, stroke, Metabolic Syndrome, hypertension, obesity, dislipidemia, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, low HDL, high LDL, non-cardiac ischemia, infection, cancer, vascular restenosis, pancreatitis, neurodegenerative disease, lipid disorders, cognitive impairment and dementia, bone disease, HIV protease associated lipodystrophy, glaucoma, rheumatoid arthritis, Cushing'
- the present invention relates to a method for preventing, inhibiting, or treating the progression or onset of diabetes, hyperglycemia, obesity, dislipidemia, hypertension, cognitive impairment, rheumatoid arthritis, osteoarthritis, glaucoma, Cushing's Disease and Metabolic Syndrome comprising administering to a mammalian patient, for example, a human patient, in need of prevention, inhibition, or treatment a therapeutically effective amount of a compound of the present invention, alone, or, optionally, in combination with another compound of the present invention and/or at least one other type of therapeutic agent.
- the present invention relates to a method for preventing, inhibiting, or treating the progression or onset of diabetes, comprising administering to a mammalian patient, for example, a human patient, in need of prevention, inhibition, or treatment a therapeutically effective amount of a compound of the present invention, alone, or, optionally, in combination with another compound of the present invention and/or at least one other type of therapeutic agent.
- the present invention relates to a method for preventing, inhibiting, or treating the progression or onset of hyperglycemia comprising administering to a mammalian patient, for example, a human patient, in need of prevention, inhibition, or treatment a therapeutically effective amount of a compound of the present invention, alone, or, optionally, in combination with another compound of the present invention and/or at least one other type of therapeutic agent.
- the present invention relates to a method for preventing, inhibiting, or treating the progression or onset of obesity comprising administering to a mammalian patient, for example, a human patient, in need of prevention, inhibition, or treatment a therapeutically effective amount of a compound of the present invention, alone, or, optionally, in combination with another compound of the present invention and/or at least one other type of therapeutic agent.
- the present invention relates to a method for preventing, inhibiting, or treating the progression or onset of dislipidemia comprising administering to a mammalian patient, for example, a human patient, in need of prevention, inhibition, or treatment a therapeutically effective amount of a compound of the present invention, alone, or, optionally, in combination with another compound of the present invention and/or at least one other type of therapeutic agent.
- the present invention relates to a method for preventing, inhibiting, or treating the progression or onset of hypertension comprising administering to a mammalian patient, for example, a human patient, in need of prevention, inhibition, or treatment a therapeutically effective amount of a compound of the present invention, alone, or, optionally, in combination with another compound of the present invention and/or at least one other type of therapeutic agent.
- the present invention relates to a method for preventing, inhibiting, or treating the progression or onset of cognitive impairment comprising administering to a mammalian patient, for example, a human patient, in need of prevention, inhibition, or treatment a therapeutically effective amount of a compound of the present invention, alone, or, optionally, in combination with another compound of the present invention and/or at least one other type of therapeutic agent.
- the present invention relates to a method for preventing, inhibiting, or treating the progression or onset of rheumatoid arthritis comprising administering to a mammalian patient, for example, a human patient, in need of prevention, inhibition, or treatment a therapeutically effective amount of a compound of the present invention, alone, or, optionally, in combination with another compound of the present invention and/or at least one other type of therapeutic agent.
- the present invention relates to a method for preventing, inhibiting, or treating the progression or onset of osteoarthritis comprising administering to a mammalian patient, for example, a human patient, in need of prevention, inhibition, or treatment a therapeutically effective amount of a compound of the present invention, alone, or, optionally, in combination with another compound of the present invention and/or at least one other type of therapeutic agent.
- the present invention relates to a method for preventing, inhibiting, or treating the progression or onset of Metabolic Syndrome comprising administering to a mammalian patient, for example, a human patient, in need of prevention, inhibition, or treatment a therapeutically effective amount of a compound of the present invention, alone, or, optionally, in combination with another compound of the present invention and/or at least one other type of therapeutic agent.
- the present invention relates to a method for preventing, inhibiting, or treating the progression or onset of glaucoma comprising administering to a mammalian patient, for example, a human patient, in need of prevention, inhibition, or treatment a therapeutically effective amount of a compound of the present invention, alone, or, optionally, in combination with another compound of the present invention and/or at least one other type of therapeutic agent.
- the present invention relates to a method for preventing, inhibiting, or treating the progression or onset of Cushing's Disease comprising administering to a mammalian patient, for example, a human patient, in need of prevention, inhibition, or treatment a therapeutically effective amount of a compound of the present invention, alone, or, optionally, in combination with another compound of the present invention and/or at least one other type of therapeutic agent.
- the present invention provides a process for the preparation of a compound of Formula Ih or Ii
- an enzymatic reductase such as a ketoreductase, produced by a microorganism from the group consisting of Pichia, Hansenula, Candida or Rhodotorula.
- the strain of Pichia is Pichia membranafaciens, Pichia anomala, Pichia ciferrii or Pichia silvicola .
- the strain of Hansenula is Hansenula fabiani or Hansenula polymorpha .
- the strain of Candida is Candida utilis or Candida boidini .
- the strain of Rhodotorula is Rhodotorula glutinis.
- processes for preparing compounds of formula Ih or Ii are provided wherein the amount of the ketone compound of formula If added to the reaction mixture is up to about 50 g/L of the reaction mixture.
- processes for preparing compounds of formula Ih or Ii are provided wherein an enzyme is isolated and optionally purified.
- processes for preparing compounds of formula Ih or Ii wherein the reduction by an enzyme is carried out by reacting the ketone compound of formula If with the enzyme that was previously isolated and optionally purified before contacting with the ketone compound.
- processes for preparing compounds of formula Ih or Ii are provided wherein the enzyme is derived from cell extracts.
- processes for preparing compounds of formula Ih or Ii are provided wherein the enzyme is obtained from Hansenula fabiani .
- the enzyme is obtained from Hansenula fabiani strain SC13894 (ATCC 58045).
- processes for preparing compounds of formula Ih or Ii are provided wherein the enzyme provides a reaction yield of greater than 60% by weight of the compound of formula Ih or Ii, based on the weight of the ketone input.
- processes for preparing compounds of formula Ih or Ii are provided wherein the process provides the compounds of formula Ih or Ii in an enantiomeric excess greater than 95%.
- processes for preparing compounds of formula Ih or Ii are provided wherein the reduction by an enzyme is carried out at a pH of between about 5.0 and about 9.0.
- the present invention provides processes for the preparation of an enzyme for the preparation of compounds of formula Ih or Ii from a compound of formula If comprising:
- processes for the preparation of an enzyme for the preparation of compounds of formula Ih or Ii wherein the process of extracting the enzyme comprises lysing the cells of the microorganism and isolating the enzyme.
- processes for the preparation of an enzyme for the preparation of compounds of formula Ih or Ii wherein the processes of purifying the enzyme comprises ion-exchange, hydrophobic, and hydroxyapatite chromatography.
- the present invention provides processes for preparing a compound of formula Ih which comprises reacting a compound of the formula If with NADP or NADPH, glucose dehydrogenase, glucose, and a ketoreductase to afford Compound Ih or Ii.
- the compounds herein described may have asymmetric centers.
- One enantiomer of a compound of Formula I may display superior activity compared with the other. Thus, all of the stereochemistries are considered to be a part of the present invention.
- separation of the racemic material can be achieved by HPLC using a chiral column or by a resolution using a resolving agent such as camphonic chloride as in Steven D. Young et al., Antimicrobial Agents and Chemotherapy, 2602-2605 (1995).
- substituted means that any one or more hydrogens on the designated atom or ring is replaced with a selection from the indicated group, provided that the designated atom's or ring atom's normal valency is not exceeded, and that the substitution results in a stable compound.
- a substituent is keto (i.e., ⁇ O)
- 2 hydrogens on the atom are replaced.
- any variable e.g., R 4
- its definition at each occurrence is independent of its definition at every other occurrence.
- R 4 e.g., R 4
- R 4 at each occurrence is selected independently from the definition of R 4 .
- combinations of substituents and/or variables are permissible only if such combinations result in stable compounds.
- alkyl is intended to include both branched and straight-chain saturated aliphatic hydrocarbon groups containing 1 to 20 carbons, preferably 1 to 10 carbons, more preferably 1 to 8 carbons, in the normal chain, such as methyl, ethyl, propyl, isopropyl, butyl, t-butyl, isobutyl, pentyl, hexyl, isohexyl, heptyl, 4,4-dimethylpentyl, octyl, 2,2,4-trimethyl-pentyl, nonyl, decyl, undecyl, dodecyl, the various branched chain isomers thereof, and the like as well as such groups may optionally include 1 to 4 substituents such as halo, for example F, Br, Cl, or I, or CF 3 , alkyl, alkoxy, aryl, aryloxy, aryl(aryl) or diaryl, aryl
- alkenyl refers to straight or branched chain radicals of 2 to 20 carbons, preferably 2 to 12 carbons, and more preferably 1 to 8 carbons in the normal chain, which include one to six double bonds in the normal chain, such as vinyl, 2-propenyl, 3-butenyl, 2-butenyl, 4-pentenyl, 3-pentenyl, 2-hexenyl, 3-hexenyl, 2-heptenyl, 3-heptenyl, 4-heptenyl, 3-octenyl, 3-nonenyl, 4-decenyl, 3-undecenyl, 4-dodecenyl, 4,8,12-tetradecatrienyl, and the like, and which may be optionally substituted with 1 to 4 substituents, namely, halogen, haloalkyl, alkyl, alkoxy, alkenyl, alkynyl, aryl, ary
- alkynyl refers to straight or branched chain radicals of 2 to 20 carbons, preferably 2 to 12 carbons and more preferably 2 to 8 carbons in the normal chain, which include one triple bond in the normal chain, such as 2-propynyl, 3-butynyl, 2-butynyl, 4-pentynyl, 3-pentynyl, 2-hexynyl, 3-hexynyl, 2-heptynyl, 3-heptynyl, 4-heptynyl, 3-octynyl, 3-nonynyl, 4-decynyl, 3-undecynyl, 4-dodecynyl, and the like, and which may be optionally substituted with 1 to 4 substituents, namely, halogen, haloalkyl, alkyl, alkoxy, alkenyl, alkynyl, aryl,
- cycloalkyl as employed herein alone or as part of another group includes saturated or partially unsaturated (containing 1 or 2 double bonds) cyclic hydrocarbon groups containing 1 to 10 rings, preferably 1 to 3 rings, including monocyclic alkyl, bicyclic alkyl (or bicycloalkyl) and tricyclic alkyl, containing a total of 3 to 20 carbons forming the ring, preferably 3 to 15 carbons, more preferably 3 to 10 carbons, forming the ring and which may be fused to 1 or 2 aromatic rings as described for aryl, which includes cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclodecyl, cyclododecyl, cyclohexenyl,
- any of which groups may be optionally substituted with 1 to 4 substituents such as halogen, alkyl, alkoxy, hydroxy, aryl, aryloxy, arylalkyl, cycloalkyl, alkylamido, alkanoylamino, oxo, acyl, arylcarbonylamino, amino, nitro, cyano, thiol, and/or alkylthio, and/or any of the substituents for alkyl.
- substituents such as halogen, alkyl, alkoxy, hydroxy, aryl, aryloxy, arylalkyl, cycloalkyl, alkylamido, alkanoylamino, oxo, acyl, arylcarbonylamino, amino, nitro, cyano, thiol, and/or alkylthio, and/or any of the substituents for alkyl.
- alkyl groups as defined above have single bonds for attachment to other groups at two different carbon atoms, they are termed “alkylene” groups and may optionally be substituted as defined above for “alkyl”.
- alkenyl groups as defined above and alkynyl groups as defined above, respectively, have single bonds for attachment at two different carbon atoms, they are termed “alkenylene groups” and “alkynylene groups”, respectively, and may optionally be substituted as defined above for “alkenyl” and “alkynyl”.
- aryl refers to monocyclic and bicyclic aromatic groups containing 6 to 10 carbons in the ring portion (such as phenyl or naphthyl, including 1-naphthyl and 2-naphthyl) and may optionally include 1 to 3 additional rings fused to a carbocyclic ring or a heterocyclic ring (such as aryl, cycloalkyl, heteroaryl, or cycloheteroalkyl rings
- substituents for example, hydrogen, halo, haloalkyl, alkyl, haloalkyl, alkoxy, haloalkoxy, alkenyl, trifluoromethyl, trifluoromethoxy, alkynyl, cycloalkyl-alkyl, cycloheteroalkyl, cycloheteroalkylalkyl, aryl, heteroaryl, arylalkyl, aryloxy, aryloxyalkyl, arylalkoxy, arylthio, arylazo, heteroarylalkyl, heteroarylalkenyl, heteroarylheteroaryl, heteroaryloxy, hydroxy, nitro, cyano, amino, substituted amino wherein the amino includes 1 or 2 substituents (which are alkyl, aryl, or any of the other aryl compounds mentioned in the definitions), thiol, alkylthio
- lower alkoxy as employed herein alone or as part of another group includes any of the above alkyl, aralkyl, or aryl groups linked to an oxygen atom.
- amino as employed herein alone or as part of another group refers to amino that may be substituted with one or two substituents, which may be the same or different, such as alkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloheteroalkyl, cycloheteroalkylalkyl, cycloalkyl, cycloalkylalkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, or thioalkyl.
- substituents may be further substituted with a carboxylic acid and/or any of the R 1 groups or substituents for R 1 as set out above.
- amino substituents may be taken together with the nitrogen atom to which they are attached to form 1-pyrrolidinyl, 1-piperidinyl, 1-azepinyl, 4-morpholinyl, 4-thiamorpholinyl, 1-piperazinyl, 4-alkyl-1-piperazinyl, 4-arylalkyl-1-piperazinyl, 4-diarylalkyl-1-piperazinyl, 1-pyrrolidinyl, 1-piperidinyl, or 1-azepinyl, optionally substituted with alkyl, alkoxy, alkylthio, halo, trifluoromethyl, or hydroxy.
- lower alkylthio “alkylthio,” “arylthio,” or “aralkylthio” as employed herein alone or as part of another group includes any of the above alkyl, aralkyl, or aryl groups linked to a sulfur atom.
- lower alkylamino “alkylamino,” “arylamino,” or “arylalkylamino” as employed herein alone or as part of another group includes any of the above alkyl, aryl, or arylalkyl groups linked to a nitrogen atom.
- heterocyclyl As used herein, the term “heterocyclyl”, “heterocyclic system” or “heterocyclic ring” is intended to mean a stable 3- to 14-membered monocyclic, bicyclic or tricyclic heterocyclic ring which is saturated, partially unsaturated or unsaturated (aromatic), and which consists of carbon atoms and 1, 2, 3, or 4 heteroatoms independently selected from the group consisting of N, NH, O and S and including any bicyclic group in which any of the above-defined heterocyclic rings is fused to a benzene ring.
- the nitrogen and sulfur heteroatoms may optionally be oxidized.
- the heterocyclic ring may be attached to its pendant group at any heteroatom or carbon atom, which results in a stable structure.
- heterocyclic rings described herein may be substituted on carbon or on a nitrogen atom if the resulting compound is stable. If specifically noted, a nitrogen in the heterocycle may optionally be quaternized. It is preferred that when the total number of S and O atoms in the heterocycle exceeds 1, then these heteroatoms are not adjacent to one another.
- aromatic heterocyclic system or “heteroaryl” is intended to mean a stable 5- to 7-membered monocyclic or bicyclic or 7- to 10-membered bicyclic heterocyclic aromatic ring which consists of carbon atoms and from 1 to 4 heteroatoms independently selected from the group consisting of N, O and S and is aromatic in nature.
- heterocycles include, but are not limited to, 1H-indazole, 2-pyrrolidonyl, 2H,6H-1,5,2-dithiazinyl, 2H-pyrrolyl, 1H-indolyl, 4-piperidonyl, 4aH-carbazole, 4H-quinolizinyl, 6H-1,2,5-thiadiazinyl, acridinyl, azocinyl, benzimidazolyl, benzofuranyl, benzothiofuranyl, benzothiophenyl, benzoxazolyl, benzthiazolyl, benztriazolyl, benztetrazolyl, benzisoxazolyl, benzisothiazolyl, benzimidazalonyl, carbazolyl, 4aH-carbazolyl, ⁇ -carbolinyl, chromanyl, chromenyl, cinnolinyl, decahydroquinolinyl,
- the heterocycles include, but are not limited to, pyridinyl, thiophenyl, furanyl, indazolyl, benzothiazolyl, benzimidazolyl, benzothiaphenyl, benzofuranyl, benzoxazolyl, benzisoxazolyl, quinolinyl, isoquinolinyl, imidazolyl, indolyl, isoindolyl, piperidinyl, piperidonyl, 4-piperidonyl, piperonyl, pyrazolyl, 1,2,4-triazolyl, 1,2,3-triazolyl, tetrazolyl, thiazolyl, oxazolyl, pyrazinyl, and pyrimidinyl. Also included are fused ring and spiro compounds containing, for example, the above heterocycles.
- heteroaryls are 1H-indazole, 2H,6H-1,5,2-dithiazinyl, indolyl, 4aH-carbazole, 4H-quinolizinyl, 6H-1,2,5-thiadiazinyl, acridinyl, azocinyl, benzimidazolyl, benzofuranyl, benzothiofuranyl, benzothiophenyl, benzoxazolyl, benzthiazolyl, benztriazolyl, benztetrazolyl, benzisoxazolyl, benzisothiazolyl, benzimidazalonyl, carbazolyl, 4aH-carbazolyl, ⁇ -carbolinyl, chromanyl, chromenyl, cinnolinyl, decahydroquinolinyl, 2H,6H-1,5,2-dithiazinyl, dihydrofuro[2,3-b]tetra
- heteroaryls are indolyl, benzimidazolyl, benzofuranyl, benzothiofuranyl, benzoxazolyl, benzthiazolyl, benztriazolyl, benztetrazolyl, benzisoxazolyl, benzisothiazolyl, benzimidazalonyl, cinnolinyl, furanyl, imidazolyl, indazolyl, indolyl, isoquinolinyl isothiazolyl, isoxazolyl, oxazolyl, pyrazinyl, pyrazolyl, pyrazolotriazinyl, pyridazinyl, pyridyl, pyridinyl, pyrimidinyl, pyrrolyl, quinazolinyl, quinolinyl, thiazolyl, thienyl, and tetrazolyl.
- heterocyclylalkyl or “heterocyclyl” as used herein alone or as part of another group refers to heterocyclyl groups as defined above linked through a C atom or heteroatom to an alkyl chain.
- heteroarylalkyl or “heteroarylalkenyl” as used herein alone or as part of another group refers to a heteroaryl group as defined above linked through a C atom or heteroatom to an alkyl chain, alkylene, or alkenylene as defined above.
- cyano refers to a —CN group.
- nitro refers to an —NO 2 group.
- hydroxy refers to an OH group.
- phrases “pharmaceutically acceptable” is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
- pharmaceutically acceptable salts refer to derivatives of the disclosed compounds wherein the parent compound is modified by making acid or base salts thereof.
- examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like.
- the pharmaceutically acceptable salts include the conventional non-toxic salts or the quaternary ammonium salts of the parent compound formed, for example, from non-toxic inorganic or organic acids.
- such conventional non-toxic salts include those derived from inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, nitric and the like; and the salts prepared from organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, pamoic, maleic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicylic, sulfanilic, 2-acetoxybenzoic, fumaric, toluenesulfonic, methanesulfonic, ethane disulfonic, oxalic, isethionic, and the like.
- inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, nitric and the like
- organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic,
- the pharmaceutically acceptable salts of the present invention can be synthesized from the parent compound which contains a basic or acidic moiety by conventional chemical methods.
- such salts can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two; generally, nonaqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are preferred.
- Lists of suitable salts are found in Remington's Pharmaceutical Sciences, 17th ed., Mack Publishing Company, Easton, Pa., p. 1418, (1985), the disclosure of which is hereby incorporated by reference.
- any compound that can be converted in vivo to provide the bioactive agent i.e., the compound of formula I
- prodrugs as employed herein includes esters and carbonates formed by reacting one or more hydroxyls of compounds of formula I with alkyl, alkoxy, or aryl substituted acylating agents employing procedures known to those skilled in the art to generate acetates, pivalates, methylcarbonates, benzoates, and the like.
- compounds of the formula I are, subsequent to their preparation, preferably isolated and purified to obtain a composition containing an amount by weight equal to or greater than 99% formula I compound (“substantially pure” compound I), which is then used or formulated as described herein. Such “substantially pure” compounds of the formula I are also contemplated herein as part of the present invention.
- All stereoisomers of the compounds of the instant invention are contemplated, either in admixture or in pure or substantially pure form.
- the compounds of the present invention can have asymmetric centers at any of the carbon atoms including any one of the R substituents and/or exhibit polymorphism. Consequently, compounds of formula I can exist in enantiomeric, or diastereomeric forms, or in mixtures thereof.
- the processes for preparation can utilize racemates, enantiomers, or diastereomers as starting materials. When diastereomeric or enantiomeric products are prepared, they can be separated by conventional methods for example, chromatographic or fractional crystallization.
- the compounds of formula I may exist in tautomeric form. Such tautomeric forms of the formula I are also contemplated herein as part of the present invention.
- “Stable compound” and “stable structure” are meant to indicate a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into an efficacious therapeutic agent.
- the present invention is intended to embody stable compounds.
- “Therapeutically effective amount” is intended to include an amount of a compound of the present invention alone or an amount of the combination of compounds claimed or an amount of a compound of the present invention in combination with other active ingredients effective to inhibit MIP-1 ⁇ or effective to treat or prevent inflammatory disorders.
- treating cover the treatment of a disease-state in a mammal, particularly in a human, and include: (a) preventing the disease-state from occurring in a mammal, in particular, when such mammal is predisposed to the disease-state but has not yet been diagnosed as having it; (b) inhibiting the disease-state, i.e., arresting it development; and/or (c) relieving the disease-state, i.e., causing regression of the disease state.
- Scheme I describes a method for preparing compounds of formula IB (a subset of compounds of formula I).
- a ketone intermediate II can be obtained commercially, prepared by methods known in the literature or by other methods known to one skilled in the art.
- the reaction of ketone II with Meldrum's acid, commonly known as a Knoevenagel condensation can be carried out in anhydrous pyridine in the presence of a catalytic amount of piperidine (Baty, J. D., Jones, G., Moore, C., J. Org. Chem., 34:3295-3302 (1969)) or molecular sieves (Vogt, P. F., Molino, B. F., Robichaud, A. J., Synth.
- the disubstituted Meldrum's acid alkylidene III can be purified by recrystallization from alcohols such as ethanol or methanol, or via flash column chromatography.
- nucleophiles such alkyl or aryl Grignard's reagents (Haslego, M. L., Smith, F. X., Synth. Commun., 10:421-427 (1980)) or other organometallic reagents can be carried out in the presence or in the absence of Cu + salts (such as CuBr, CuCN etc.) at room temperature or at 40° C.
- Cu + salts such as CuBr, CuCN etc.
- the isopropylidene malonate (IV) can be converted to compounds IB via deprotection and subsequent decarboxylation in wet organic solvent at 100 to 110° C. ( J. Am. Chem. Soc., 125:6054-6055 (2003)).
- Knoevenagel condensation of ketone II with malononitrile in the presence of a wide range of catalysts such as NH 4 OAc or amino acids provides alkylidene III-B, which can be easily purified by recrystallization and/or via flash column chromatography.
- the 1,4-conjugate addition of nucleophiles such alkyl or aryl Grignard's reagents can be carried out in the absence of Cu + salts at 0° C. to room temperature to facilitate the adducts IV-B, which can be easily converted to compounds IB via standard nitrile hydrolysis and subsequent decarboxylation.
- Scheme II describes a method for preparing compounds of formula IC (a subset of compounds of formula I) from compounds of formula IB.
- the alcohol V obtained from the reduction of IB, for example, with LAH or diborane, can be converted to the corresponding mesylate or halide VI, followed by the subsequent elimination under basic condition to afford the olefin VII.
- the compounds IC Upon oxidative cleavage of the C ⁇ C bond and further oxidation of the resulting aldehyde VIII, the compounds IC can be obtained.
- Scheme III describes methods for preparing compounds of formula ID (a subset of compounds of formula IC, exemplified here where Z is adamantane or substituted adamantane).
- Z is benzyl, substituted benzyl, or other heteroaryl methyl
- the direct alkylation of the dianion of compound IX (generated for example with LiN(TMS) 2 or LDA) with the alkyl halide Z-X gives ID.
- compound ID can be synthesized by converting compound I ⁇ to the corresponding ester IX-B, ⁇ -alkylation of IX-B to IX-C, followed by ester hydrolysis to provide compound ID.
- ketone X can be reacted with nucleophiles such as organolithium reagents (ZCH 2 Li) or Grignard reagents (ZCH 2 Mghalide) to afford the tertiary alcohol XI, which can be converted to aldehyde XII via acid-catalyzed rearrangement. Further oxidation of aldehyde XII gives compounds ID.
- nucleophiles such as organolithium reagents (ZCH 2 Li) or Grignard reagents (ZCH 2 Mghalide)
- Scheme IV describes a method for preparing compounds of formula IF and IF′ (subsets of compounds of formula I).
- Aldehyde VIII (see Scheme II for the synthesis) can be reacted with triethyl phosphoryl acetate to give ⁇ , ⁇ -unsaturated ester XIII, which may be subsequently converted to ester XIV by metal-catalyzed hydrogenation (for example Pd/C or Pt in the presence of H 2 ).
- metal-catalyzed hydrogenation for example Pd/C or Pt in the presence of H 2 .
- Hydrolysis of the ester in basic condition gives the carboxylic acid IF′.
- XIII may be hydrolyzed to provide the corresponding acid IF directly.
- the carboxylic acid XV (see Scheme I to IV) can be reacted with (cyanomethylene)triphenylphosphorane in the presence of coupling reagents such as EDCI to form cyano keto phosphoranes XVI, which can be oxidatively cleaved to form ⁇ -keto esters XVII. Further hydrolysis of ester XVII gives compounds IG (Wasserman, H., J. Org. Chem., 59:4364 (1994)).
- Scheme VI describes a method for preparing compounds of formula IH (a subset of compounds of formula I).
- Ketone II reacts with Grignard reagent ZMgX or organolithium to give the tertiary alcohol XVIII.
- the O-allylation with an allyl halide can be carried out in the presence of bases such as NaH in reflux condition to give XIX, which can be further converted to IH via oxidative cleavage of the C ⁇ C bond.
- Scheme VII describes a method for preparing compounds of formula IJ, formula XX, and formula IK (subsets of compounds of formula I).
- the enolate anions obtained by treating carboxylic acid XV with bases such as LDA/DMPU, can react with a variety of electrophilic hydroxylating agents, such as oxygen (Wassermann, H. H. et al., Tetrahedron Lett., 1731 (1975)), molybdenum peroxide-pyridine-hexamethylphosphoramide (Vedejs, E., J. Am. Chem. Soc., 96:5944 (1974)), 2-sulfonyloxaziridine (Davis, F. A. et al., J. Org.
- Scheme VIII describes a method for preparing compounds of formula IL (subset of compounds of formula I) from readily accessible material XXI (see Scheme I to III for the synthesis of XXI).
- Phenol XXII obtained from demethylation of XXI (when R ⁇ OMe) using BBr 3 or HBr in acetic acid, can be converted to the corresponding trifluoromethanesulphonate (triflate) or nonaflate XXIII by treatment with corresponding sulfonyl halide or sulphonic anhydride.
- Subsequent displacement of TfO or NfO with —CN can be catalyzed by transition metals such as palladium(0) or nickel(0), yielding compound IL.
- Compound XXIII may also be useful for the incorporating of a variety of R 4 groups via Pd or Ni catalyzed coupling conditions well known in the literature.
- Scheme IX describes a method of preparing compounds of formula IM (subset of compounds of formula I).
- the alkylation of phenol XXII (see Scheme VIII) can be carried out in the presence of base such as NaH, to form XXIV.
- base such as NaH
- IM Upon the hydrolysis of the ester, IM can be obtained.
- Scheme X describes a method for preparing compounds of formula IO (subset of compounds of formula I, when A represents adamantane).
- the oxidation of compounds XXV can be carried out under a wide variety of oxidative conditions such as dimethyldioxirane, potassium permanganate, ferrous iron-molecular oxygen, etc.
- the products and their yields are depended on the reaction conditions. These products can be separated by preparative HPLC, and their structures can be fully elucidated by 2D NMR technique.
- Scheme XI describes a method of preparing compounds of formula IP (subset of compounds of formula I, when A represents adamantane).
- Compounds IP can be readily synthesized using Scheme I, II, and III.
- Scheme XII describes a method of preparing compounds of formula IQa and IQb (subsets of compounds of formula I, when A represents adamantane).
- Ketone XXIX (see Scheme X and XI) reacts with reducing agents such as NaBH 4 , LiBH 4 , or reductases or other nucleophiles such as organo magnesium halides or organolithiums to form compounds IQa.
- reducing agents such as NaBH 4 , LiBH 4 , or reductases or other nucleophiles such as organo magnesium halides or organolithiums
- Ketone XXIX can react with TOSMIC under basic condition to afford IQb.
- Scheme XIII describes a method for preparing compounds of formula IR (subset of compounds of formula I when Z represents adamantane).
- Compounds IP and IO can react with alkyl halides in the presence of a base such as NaH to form the O-alkylation product, which can be hydrolyzed to form compounds IR.
- Scheme XIV describes a method of preparing compounds of formula IS (a subset of compound of formula I).
- the acids XXV (see Scheme I to III) can be converted to the corresponding acyl halides using a wide variety of reagents such as thionyl chloride, sulfuryl chloride, oxalyl chloride, and phosphorus trichloride, or alkyl or aryl chloroformate, etc.
- the acyl halide can react with ammonium hydroxide to form the amide XXX, which can be further converted to nitrile XXXI by treating with dehydration reagents such as acetic anhydride, acyl halide, POCl 3 , chloroformate, etc.
- the nitrites XXXI can react with azide such as sodium azide, Me 3 SnN 3 , etc to form the tetrazole IS.
- Scheme XV describes a method of preparing compounds of formula IT (a subset of compounds of formula I).
- the acid XXV can readily react with amine HNR 9 R 9 or its salt to form amide IT in the presence of a wide variety of peptide coupling reagents, such as carbodiimide type reagents (DCC, EDAC, DIC etc.), imidazolium type reagents (CDI, CBMIT, BOI, CMBI etc.), phosphonium type reagents (such as BOP, PyBOP etc.), uronium type reagents (HBTU, TBTU etc).
- the acid XXV can be converted to acyl chloride XXXII, which reacts with amine HNR 9 R 9 in the presence of base such as i-Pr 2 NEt, Et 3 N to form compound IT.
- Scheme XVI describes a method of preparing compounds of formula IU (a subset of compounds of formula I).
- the acid XXV can readily react with sulfonamide H 2 NSO 2 R 9 to form acyl sulfonamide IU in the presence of a wide variety peptide coupling reagents, such as EDAC.
- Scheme XVII describes a method of preparing compounds of formula IW (a subset of compounds of formula I). Exemplified in this scheme is the synthesis of a variety of cyclic amines such as compounds XXXV, XXXVII, and XXXIX, but not limited to these structures.
- XXXIII can react with isocyanate to form the corresponding carbamate.
- XXXIII can be converted to corresponding chloroformate by reacting with phosgene, then to carbamate by further reacting to appropriate amines.
- Compound IW can be synthesized by reacting acid XXV with appropriate amines XXXV or XXXVII or XXXIX using the protocol described in Scheme XV.
- HPLC refers to a Shimadzu high performance liquid chromatography with one of following methods:
- UV ultra violet
- UV ultra violet
- UV ultra violet
- Prep HPLC refers to an automated Shimadzu HPLC system using a mixture of solvent A (10% MeOH/90% H 2 O/0.2% TFA) and solvent B (90% MeOH/10% H 2 O/0.2% TFA).
- solvent A 10% MeOH/90% H 2 O/0.2% TFA
- solvent B 90% MeOH/10% H 2 O/0.2% TFA.
- the preparative columns were packed with YMC or Phenomenex Luna C18 5 micron resin or equivalent.
- This material is commercially available from the Aldrich Company. It can also be synthesized using the following procedure: A solution of 2-adamantanone (1.5 g, 10 mmol), Meldrum's acid (1.73 g, 12 mmol), and a catalytic amount of piperidine (5 drops) in anhydrous pyridine (10 mL) was stirred under argon for 5 days. After this time, the solution was poured into ice water (30 mL), and the resulting mixture was stirred at room temperature for 20 min. At the conclusion of this period, the resulting precipitate was collected by filtration and washed with cold water (15 mL). The resulting solid was dried in vacuo to provide compound 1A (2.43 g, 88% yield) as a white solid.
- reaction mixture was quenched with NH 4 Cl (saturated aqueous solution, 20 mL) and then extracted with CH 2 Cl 2 (3 ⁇ 30 mL). The combined organic layers were dried over Na 2 SO 4 and filtered. The filtrate was concentrated under reduced pressure to provide a crude product.
- the crude product was purified via column chromatography (SiO 2 , 10% EtOAc/n-Hexane) to provide compound 1B (0.75 g, 76% yield) as a white solid.
- Example 1 was isolate in the manner described above in 80% yield.
- Example 2 To a solution of Example 2 (33 mg, 0.114 mmol) in dry THF (1 mL) at ⁇ 40° C. under argon was slowly added LDA (0.13 mL, 0.267 mmol), followed by DMPU (15.3 ⁇ L, 0.124 mmol). Upon completion of addition, the reaction mixture was gradually warmed to RT, where it stirred for 1 hour. At the conclusion of this period, the reaction mixture was cooled to 0° C., and benzyl chloromethyl ether (17.2 mL, 0.124 mmol) was added. The resulting mixture was warmed to RT in 2 hours and then aqueous HCl (1 mL, 1 N) was added to quench the reaction.
- Example 8 was prepared in a similar manner as described in Example 4, utilizing compound 8C and the other appropriate reagents.
- 1 H NMR 400 MHz, CDCl 3 ) ⁇ ppm 7.38-7.49 (m, 2H), 6.97-7.16 (m, 2H), 3.59 (s, 2H), 2.63 (s, 2H), 2.23 (s, 2H), 1.94 (s, 1H), 1.56-1.84 (m, 10H);
- Example 1 To a solution of potassium hydroxide (106.6 mg, 1.618 mmol) in water (3.2 mL) was added KMnO 4 (290 mg, 1.78 mmol). The resulting solution was warmed in an oil bath (about. 50° C.) and then Example 1 (460 mg, 1.618 mmol) was added portionwise. After the addition was complete, the reaction mixture was allowed to warm to a gentle reflux, where it stirred until all of the KMnO 4 was consumed (about 1.5 h). Once the KMnO 4 was completely consumed, the reaction mixture was cooled to RT, and then acidified with 6 N HCl (aq.). Sodium metabisulfite was added to remove MnO 2 (until all the brown color became white). The resulting solid was collected by filtration and then subjected to Prep HPLC to provide Examples 11 to 16. Some Example 1 starting material was also recovered (260 mg, white solid).
- Example 11 (45.6 mg, white solid, 21.6% yield based on the recovery of starting material).
- Example 12 (70.5 mg, white solid, 33.4% yield based on the recovery of starting material).
- Example 13 (10 mg, white solid, 4.7% yield based on the recovery of starting material).
- Example 15 (15 mg, white solid, 7.1% yield based on the recovery of starting material).
- HPLC Rt (Method B): 7.665 min; LC/MS (m/z) 303.2 (M ⁇ H) ⁇ ;
- Example 12 To a suspension of NaH (21 mg, 0.831 mmol, 95%) in anhydrous THF (2 mL) was added Example 12 (25.8 mg, 0.085 mmol). Upon completion of addition, the reaction mixture was heated to reflux under argon where it stirred for 1 h and then iodomethane was added (0.1 mL). Upon completion of addition, the resulting mixture was heated at reflux for about 16 h. After this time, the solvent was removed under reduced pressure to yield a residue. The residue was dissolved in THF (1 mL) and saturated LiOH (0.5 mL, aqueous). The resulting mixture was heated to 67° C., where it stirred for about 16 h.
- Example 13 To a stirred solution of Example 13 (14.4 mg, 0.047 mmol) in dry THF (1.0 mL) at RT under argon was added methyl magnesium bromide (0.4 mL, 0.56 mmol, 1.4 M in THF). Upon completion of addition, the reaction mixture was heated to 65° C., where it stirred for 1 h. After this time, the solvent was removed under reduced pressure to yield a residue. The residue was purified via Prep HPLC to provide Example 18 (7.2 mg, 48% yield) as a white solid.
- Example 1 To a stirred solution of Example 1 (120 mg, 0.42 mmol) in CH 2 Cl 2 (2 mL) at 0° C. was added triethylamine (71 ⁇ L, 0.5 mmol), followed by i-butyl chlorformate (57 ⁇ L, 0.44 mmol). Upon completion of addition, the reaction mixture was stirred at 0° C. for 45 min. At the conclusion of this period, NH 4 OH (2.0 mL) was added, and the resulting mixture was warmed to RT where it stirred for about 16 hours. After this time, water was added, and the resulting mixture was extracted with CH 2 Cl 2 (3 ⁇ 5 mL).
- Example 1 To a stirred suspension of Example 1 (30 mg, 0.1 mmol), EDAC (28 mg, 0.15 mmol), HOBT (20 mg, 0.15 mmol), and 3-hydroxyazetidine hydrochloride (16 mg, 0.15 mmol) in CH 2 Cl 2 (1.5 mL) was added N,N-diisopropylethylamine (20 mg, 0.15 mmol). Upon completion of addition, the reaction mixture was stirred at RT for about 16 hours, and then the solvent was removed under reduced pressure to yield a residue. The residue was purified via Prep HPLC to provide Example 21 (15 mg, 43% yield) as a white solid.
- Compound 23A can be prepared from 3-methylenebicyclo[3.3.1]nonan-9-one (reference: Buono, F., Tenaglia, A., J. Org. Chem., 65:3869-3874 (2000)) and Meldrum's acid by following the procedure in Example 1 and 2.
- reaction mixture was quenched with NH 4 Cl (saturated aqueous solution, 20 mL) and then extracted with EtOAc (3 ⁇ 30 mL). The combined organic layers were dried over Na 2 SO 4 and filtered. The filtrate was concentrated under reduced pressure to provide compound 23B and its regioisomer as yellow oil.
- Example 24 was synthesized from compound 24B and 3-hydroxyazetidine hydrochloride via standard peptide coupling reaction (see procedure in Example 23). Yield: 59%.
- Compound 25C was synthesized from compound 25A and Meldrum's acid according to the procedure described in Example 1.
- compounds 25H and 25I can be prepared according to the following enzymatic conversions:
- reaction mixture (350 mL, pH 7.56) was then acidified to pH 3.0 with 5M H 2 SO 4 (4.75 g) and extracted with ethylacetate (2 ⁇ 250 mL). The combined ethylacetate phases were washed with 100 mL of 15% NaCl, dried over MgSO 4 for 2 h, and filtered. Solvent removal of the filtrate gave a white solid, which was further dried in a vacuum oven at room temperature overnight to give 745 mg of crude compound 25H (Yield 108%, AP 94, e.e. 96.1%).
- Yeast strains were screened for reduction of Compound 25F in a similar manner as described above. Strains giving the most enantioselective reduction are set forth in the Table 25-4 below.
- Example 25 was synthesized from compound 25H and 3-hydroxyazetidine hydrochloride according to the procedure in Example 21.
- Chiral analytic HPLC Chiralpak AD, 250 ⁇ 4.6 mm ID; 10 ⁇ m, room temperature, mobile phase: CO 2 /MeOH/(80/20), Flow rate: 2 mL/min, UV Detection: 220 nm, Retention Time (min): 10.64. e.e>99.9%.
- Example 26 was synthesized from compound 26A by following the procedures described in Example 25.
- HPLC Rt (Method C): 7.89 min; LC/MS (m/z) 342 (M+H) + ; 1 H NMR (400 MHz, CD 3 OD) ⁇ ppm 7.27 (br.
- Potassium tert-butoxide (39.5 mg, 0.352 mmol) was added in a small portion to a well stirred, moisture-protected suspension of compound 25F (21.3 mg, 0.070 mmol), TOSMIC (19.26 mg, 0.099 mmol), and ethanol (6.89 ⁇ L) in 1,2-dimethoxyethane (403 ⁇ L) at 0° C. (ice water bath). After completion, the mixture was warmed to room temperature, then placed in a 37° C. oil bath and stirred for 1 hour. LCMS showed the reaction was completed. The reaction was quenched with HOAc (0.1 mL). Solvent was removed under reduced pressure.
- Example 27 was synthesized from compound 27A and 3-hydroxyazetidine hydrochloride via standard peptide coupling reaction (see procedure in Example 23). Yield: 62.3%.
- HPLC Rt (Method C): 6.741 min; LC/MS (m/z) 369 (M+H) + ; 1 H NMR (400 MHz, CD 3 OD) ⁇ ppm 7.38 (br.
- Example 28 was synthesized from compound 28D and the corresponding carboxylic acid 26A by following the procedures described in Example 26.
- HPLC Rt (Method B): 6.450 min; LC/MS (m/z) 408 (M+H) + ;
- Example 29 was synthesized from compound 29B and 3-hydroxyazetidine hydrochloride via standard peptide coupling reaction (see procedure in Example 23). Yield: 64.8%.
- Example 30 was synthesized from compound 30B and 30D via standard peptide coupling reaction (see procedure in Example 23).
- LC/MS (m/z) 382 (M+H) + ;
- Compound 31A was synthesized from 4-oxo-1-adamantanecarboxylic acid and Meldrum's acid via the procedure described in Example 25.
- 1 H NMR 400 MHz, CD 3 OD
- ppm 4.06 br. s., 2H
- 2.00-2.26 m, 9H
- 1.86-1.99 m, 2H
- 1.75 s, 3H
- 1.74 s, 3H
- 13 C NMR 101 MHz, CD 3 OD
- Compound 31B and its regioisomer 31C were synthesized from compound 31A and 4-fluorophenyl magnesium bromide via cuprate addition reaction and decarboxylation reaction using the procedures described in Example 25.
- the ratio of 31B:31C is about 2.3:1.
- Example 31 was synthesized from compound 31G and 3-hydroxyazetidine hydrochloride via standard peptide coupling reaction (see procedure in Example 23).
- Example 32 was synthesized from compound 32A and 32C via standard peptide coupling reaction (see procedure in Example 23).
- LC/MS (m/z) 444 (M+H) + ;
- 1 H NMR (400 MHz, CDCl 3 ) ⁇ ppm 7.26 (dd, J 8.6, 5.6 Hz, 2H), 7.00 (br. s., 2H), 6.53 (br. s., 1H), 5.86 (br.
- Example 33 was synthesized from compound 33A and 3-hydroxyazetidine hydrochloride via standard peptide coupling reaction (see the procedure described in Example 23).
- Example 35 was synthesized from compound 26A and compound 35C via standard peptide coupling reaction (see procedure in Example 23).
- HPLC Rt (Method B): 5.550 min; LC/MS (m/z) 275 (M+H) + .
- Example 36 was synthesized from compound 26A and compound 36B via standard peptide coupling reaction (see procedure in Example 23).
- HPLC Rt (Method B): 6.25 min; LC/MS (m/z) 438 (M+H) + .
- compound 38C was synthesized via the stepwise procedures described in Example 25.
- Example 38 was synthesized from compound 38C and 3-hydroxyazetidine hydrochloride via standard peptide coupling reaction (see procedure in Example 23). 38: white solid; Yield 23%.
- HPLC Rt (Method C): 6.380 min; LC/MS (m/z) 390 (M+H) + .
- 1 H NMR (400 MHz, CDCl 3 ): ⁇ ppm 7.20 (br. s., 2H), 7.14 (br. s., 1H), 7.06 (br. s., 1H), 4.59 (d, J 3.52 Hz, 1H), 4.27 (br.
- Examples 39 to 386 in Table 1 were synthesized according to the procedures described in Examples 1 to 38, the schemes, or by other similar methods known to one skilled in the art, with other appropriate reagents.
- the “—O” attached to an adjacent carbon atom substituted with ⁇ O is used to denote an “—OH” group.
- the “N” attached to an adjacent carbon atom substituted with ⁇ O is used to denote an “NH” moiety.
- the compounds set forth in Table 1 below are racemic, achiral or diastereomeric unless indicated to the contrary.
- [ 3 H]-Cortisone with a specific radioactivity of 50 Ci/mmol was from American Radiolabeled Chemicals, Inc. (St Louis, Mo.); monoclonal ab to Cortisol (P01-9294M-P, Lot: L-28) was from East Coast Bio., (North Berwick, Me.); Protein A-yttrium silicate, type-1, SPA bead NJ® (RPN-143) was from Amersham LifeSciences, (Piscataway, N.J.); 384 well-Optiplate384 (#6007299) was from PerkinElmer (Boston, Mass.); DPBS, pH 7.4 (14040) is from GIBCO, (Grand Island, N.Y.); carbenoxolone (C4790) is from Sigma, (St Louis, Mo.).
- Full length recombinant human 11 ⁇ -HSD-1 cDNAs and the cDNA encoding human 11 ⁇ -HSD-2 were expressed stably in HEK 293 EBNA cells.
- Cells were grown in DMEM (high glucose) containing MEM non-essential amino acids, L-glutamine, hygromycin B (200 ⁇ g/ml), and G-418(200 ⁇ g/ml) in the presence of 10% FBS.
- Human 11 ⁇ -HSD-1 transfected HEK 293 EBNA cells were grown to 80% confluency and the cell pellet was quick frozen and stored at ⁇ 80° C. before purification.
- Cell paste 40 g from ⁇ 80° C. storage, was thawed in water and then 100 ml of homogenization buffer H (0.01 M sodium phosphate pH 6.5 containing 0.25 M sucrose and protease inhibitor cocktail (Roche #1836145 1 tablet per 50 ml) were added to completely thaw the paste.
- the cell paste suspension was homogenized using a Polytron for 20 seconds to create a homogeneous mixture.
- Additional buffer H was added to a volume of 300 ml and cells were broken open using a N2-bomb (at 4° C.) in two batches by treating at 500 psi.
- the extract was centrifuged at 750 ⁇ g for 30 min.
- the supernatant was centrifuged at 20,000 ⁇ g for 30 min.
- the supernatant was further centrifuged at 105,000 ⁇ g for 60 min.
- the 105,000 ⁇ g pellet was resuspended in buffer H and centrifuged at 105,000 ⁇ g for 60 min.
- the microsome pellet was scraped from the bottom of tube and resuspended in 0.01M phosphate buffer, pH 6.5 containing protease inhibitors (Roche #1836145, 1 tablet per 50 ml). Aliquots were stored at ⁇ 80° C. until needed.
- the protein concentration was measured by the BioRad method using BSA standard.
- 11 ⁇ -HSD-1 was assayed by Scintillation Proximity assay in a 384-well Perkin Elmer white plate.
- the dose response of the compounds was determined using 11 half-log dilutions of compound in DMSO in duplicate. To each well, 0.5 ⁇ l of compound dilution in DMSO were added. 15 ⁇ l of assay buffer (for blanks) or 15 ⁇ l of human microsomes in assay buffer were added next and the plates were incubated for 10 min at room temperature. The final microsomal protein concentration was 1.1 ⁇ g/assay. Duplicates were in the same plate one row below the other.
- mice were fed a 60% fat diet (Research Diets D12492) soon after weaning and kept on this diet for 24 weeks. These mice were individually housed. All mice were housed under controlled temperature (23° C.) and lighting (12 hours of light between 6 am to 6 pm, 12 hours of dark) with free access to water. The animals continued on this diet and were utilized for experimentation at 30 to 32 weeks of age, at which time these mice weighed 45 to 55 grams.
- DIO diet induced obese mice obtained from Jackson Laboratory (ME, USA). These mice were fed a 60% fat diet (Research Diets D12492) soon after weaning and kept on this diet for 24 weeks. These mice were individually housed. All mice were housed under controlled temperature (23° C.) and lighting (12 hours of light between 6 am to 6 pm, 12 hours of dark) with free access to water. The animals continued on this diet and were utilized for experimentation at 30 to 32 weeks of age, at which time these mice weighed 45 to 55 grams.
- DHC 11-dehydrocorticosterone
- mice were bled again via the tail tip and dosed orally (7.5 ml/kg) with DHC 10 mg/kg. All animals were subsequently bled at 30, 60 and 120 minutes post DHC dosing. Thirty-five microliters of whole blood are collected per time point in microvette tubes coated with EDTA (Sarstedt Tubes Microvette CB 300/Haematology Potassium EDTA # 16.444.300) and kept on ice. Samples were centrifuged at 4° C. in a Beckman Coulter centrifuge for 10 minutes at 2500 RPM. Plasma was separated and collected and immediately frozen at ⁇ 20° C. until corticosterone analysis could be assessed.
- EDTA Sest Tubes Microvette CB 300/Haematology Potassium EDTA # 16.444.300
- Plasma Corticosterone was measured using an EIA (IDS AC-14F1). Samples were measured at (1:2) for the ⁇ 30 (or ⁇ 60 minute) and 0 time point and (1:10) for the 30, 60 and 120 minutes time points. AUC was calculated using Graphpad and the zero timepoint was used as the baseline. One way ANOVA was calculated using Sigmastat. A p value of less that 0.05 via post hoc analysis with Dunnett's was used to determine statistical significance.
- the vehicle utilized for the suspension of the compounds was 0.5% methocel; 0.1% tween 80 in water.
- Methocel Cellulose (M-0262) was purchased from Sigma-Aldrich, St Louis, Mo. 6.
- Tween 80 (274364) was purchased from Sigma-Aldrich, St Louis, Mo.
- Compounds were administered in 7.5 ml/kg volumes at final dosages of 0.1 to 300 mg/kg depending on the study and compound evaluated.
- the compounds of the present invention possess activity as inhibitors of the enzyme 11-beta-hydroxysteroid dehydrogenase type I, and, therefore, may be used in the treatment of diseases associated with 11-beta-hydroxysteroid dehydrogenase type I activity.
- the compounds of the present invention may preferably be employed to inhibit or modulate glucocorticoid production, thereby interrupting or modulating cortisone or cortisol production.
- the compounds of the present invention can be administered to mammals, preferably humans, for the treatment of a variety of conditions and disorders, including, but not limited to, treating, preventing, or slowing the progression of diabetes and related conditions, microvascular complications associated with diabetes, macrovascular complications associated with diabetes, cardiovascular diseases, Metabolic Syndrome and its component conditions, inflammatory diseases and other maladies.
- the compounds of the present invention may be used in preventing, inhibiting, or treating diabetes, hyperglycemia, impaired glucose tolerance, insulin resistance, hyperinsulinemia, retinopathy, neuropathy, nephropathy, delayed wound healing, atherosclerosis and its sequelae (acute coronary syndrome, myocardial infarction, angina pectoris, peripheral vascular disease, intermitant claudication), abnormal heart function, myocardial ischemia, stroke, Metabolic Syndrome, hypertension, obesity, dislipidemia, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, low HDL, high LDL, non-cardiac ischemia, infection, cancer, vascular restenosis, pancreatitis, neurodegenerative disease, lipid disorders, cognitive impairment and dementia, bone disease, HIV protease associated lipodystrophy, glaucoma and inflammatory diseases, such as, rheumatoid arthritis, Cushing's Disease, Alzheimer's Disease and osteoarthritis.
- diabetes hyperglycemia
- the present invention includes within its scope pharmaceutical compositions comprising, as an active ingredient, a therapeutically effective amount of at least one of the compounds of formula I, alone or in combination with a pharmaceutical carrier or diluent.
- compounds of the present invention can be used alone, in combination with other compounds of the invention, or in combination with one or more other therapeutic agent(s), e.g., an antidiabetic agent or other pharmaceutically active material.
- the compounds of the present invention may be employed in combination with other 11-beta-hydroxysteroid dehydrogenase type I inhibitors or one or more other suitable therapeutic agents useful in the treatment of the aforementioned disorders including: anti-diabetic agents, anti-hyperglycemic agents, anti-hyperinsulinemic agents, anti-retinopathic agents, anti-neuropathic agents, anti-nephropathic agents, anti-atherosclerotic agents, anti-ischemic agents, anti-hypertensive agents, anti-obesity agents, anti-dislipidemic agents, anti-dyslipidemic agents, anti-hyperlipidemic agents, anti-hypertriglyceridemic agents, anti-hypercholesterolemic agents, anti-restenotic agents, anti-pancreatic agents, lipid lowering agents, appetite suppressants, memory enhancing agents, cognition promoting agents and anti-inflammatory agents.
- anti-diabetic agents anti-hyperglycemic agents, anti-hyperinsulinemic
- Suitable anti-diabetic agents for use in combination with the compounds of the present invention include insulin and insulin analogs: LysPro insulin, inhaled formulations comprising insulin; glucagon-like peptides; sulfonylureas and analogs: chlorpropamide, glibenclamide, tolbutamide, tolazamide, acetohexamide, glypizide, glyburide, glimepiride, repaglinide, meglitinide; biguanides: metformin, phenformin, buformin; alpha2-antagonists and imidazolines: midaglizole, isaglidole, deriglidole, idazoxan, efaroxan, fluparoxan; other insulin secretagogues: linogliride, insulinotropin, exendin-4, BTS-67582, A-4166; thiazolidinediones: ciglitazone, pioglitazone,
- Suitable thiazolidinediones include Mitsubishi's MCC-555 (disclosed in U.S. Pat. No. 5,594,016), Glaxo-Wellcome's GL-262570, englitazone (CP-68722, Pfizer), or darglitazone (CP-86325, Pfizer, isaglitazone (MIT/J&J), JTT-501 (JPNT/P&U), L-895645 (Merck), R-119702 (Sankyo/WL), N,N-2344 (Dr. Reddy/NN), or YM-440 (Yamanouchi).
- Suitable PPAR alpha/gamma dual agonists include AR-HO39242 (Astra/Zeneca), GW-409544 (Glaxo-Wellcome), KRP297 (Kyorin Merck), as well as those disclosed by Murakami et al., “A Novel Insulin Sensitizer Acts As a Coligand for Peroxisome Proliferation—Activated Receptor Alpha (PPAR alpha) and PPAR gamma; Effect of PPAR alpha Activation on Abnormal Lipid Metabolism in Liver of Zucker Fatty Rats”, Diabetes, 47:1841-1847 (1998), and WO 01/21602, the disclosure of which is incorporated herein by reference, employing dosages as set out therein, which compounds designated as preferred are preferred for use herein.
- Suitable alpha2 antagonists also include those disclosed in WO 00/59506, employing dosages as set out herein.
- Suitable SGLT2 inhibitors include T-1095, phlorizin, WAY-123783, and those described in WO 01/27128.
- Suitable DPP4 inhibitors include saxagliptan, sitagliptan, vildagliptan, and denagliptan.
- Suitable aldose reductase inhibitors include those disclosed in WO 99/26659.
- Suitable meglitinides include nateglinide (Novartis) or KAD1229 (PF/Kissei).
- GLP-1 receptor agonists examples include
- Exenatide (ByettaTM), NN2211 (Liraglutide, Novo Nordisk), AVE0010 (Sanofi-Aventis), R1583 (Roche/Ipsen), SUN E7001 (Daiichi/Santory), GSK-716155 (GSK/Human Genome Sciences) and Exendin-4 (PC-DACTM).
- anti-diabetic agents that can be used in combination with compounds of the invention include ergoset and D-chiroinositol.
- Suitable anti-ischemic agents include, but are not limited to, those described in the Physician's Desk Reference and NHE inhibitors, including those disclosed in WO 99/43663.
- MTP inhibitors HMG CoA reductase inhibitors
- squalene synthetase inhibitors fibric acid derivatives
- ACAT inhibitors lipoxygenase inhibitors
- cholesterol absorption inhibitors ileal Na + /bile acid cotransporter inhibitors
- upregulators of LDL receptor activity e.g., CP-529414 (Pfizer)
- MTP inhibitors which may be employed as described above include those disclosed in U.S. Pat. No. 5,595,872, U.S. Pat. No. 5,739,135, U.S. Pat. No. 5,712,279, U.S. Pat. No. 5,760,246, U.S. Pat. No. 5,827,875, U.S. Pat. No. 5,885,983, and U.S. Pat. No. 5,962,440.
- HMG CoA reductase inhibitors which may be employed in combination with one or more compounds of formula I include mevastatin and related compounds, as disclosed in U.S. Pat. No. 3,983,140, lovastatin, (mevinolin) and related compounds, as disclosed in U.S. Pat. No. 4,231,938, pravastatin, and related compounds, such as disclosed in U.S. Pat. No. 4,346,227, simvastatin, and related compounds, as disclosed in U.S. Pat. Nos. 4,448,784 and 4,450,171.
- Other HMG CoA reductase inhibitors which may be employed herein include, but are not limited to, fluvastatin, disclosed in U.S. Pat. No.
- Preferred hypolipidemic agents are pravastatin, lovastatin, simvastatin, atorvastatin, fluvastatin, cerivastatin, atavastatin, and ZD-4522.
- fibric acid derivatives which may be employed in combination with one or more compounds of formula I include fenofibrate, gemfibrozil, clofibrate, bezafibrate, ciprofibrate, clinofibrate, and the like, probucol, and related compounds, as disclosed in U.S. Pat. No.
- bile acid sequestrants such as cholestyramine, colestipol and DEAE-Sephadex (Secholex®, policexide®), as well as lipostabil (Rhone-Poulenc), Eisai E-5050 (an N-substituted ethanolamine derivative), imanixil (HOE-402), tetrahydrolipstatin (THL), istigmastanylphosphorylcholine (SPC, Roche), aminocyclodextrin (Tanabe Seiyoku), Ajinomoto AJ-814 (azulene derivative), melinamide (Sumitomo), Sandoz 58-035, American Cyanamid CL-277,082 and CL-283,546 (disubstituted urea derivatives), nicotinic acid, acipimox, acifran, neomycin, p-aminosalicylic acid, as
- the ACAT inhibitor which may be employed in combination with one or more compounds of formula I include those disclosed in Drugs of the Future 24:9-15 (1999), (Avasimibe); “The ACAT inhibitor, C1-1011 is effective in the prevention and regression of aortic fatty streak area in hamsters”, Nicolosi et al., Atherosclerosis (Shannon, Irel)., 137(1):77-85 (1998); “The pharmacological profile of FCE 27677: a novel ACAT inhibitor with potent hypolipidemic activity mediated by selective suppression of the hepatic secretion of ApoB 100-containing lipoprotein”, Ghiselli, Giancarlo, Cardiovasc.
- the hypolipidemic agent may be an upregulator of LDL receptor activity, such as MD-700 (Taisho Pharmaceutical Co. Ltd) and LY295427 (Eli Lilly).
- Suitable cholesterol absorption inhibitors for use in combination with the compounds of the invention include ezetimibe (Zetia®).
- ileal Na + /bile acid cotransporter inhibitors for use in combination with the compounds of the invention include compounds as disclosed in Drugs of the Future, 24:425-430 (1999).
- the lipoxygenase inhibitors which may be employed in combination with one or more compounds of formula I include 15-lipoxygenase (15-LO) inhibitors, such as benzimidazole derivatives, as disclosed in WO 97/12615, 15-LO inhibitors, as disclosed in WO 97/12613, isothiazolones, as disclosed in WO 96/38144, and 15-LO inhibitors, as disclosed by Sendobry et al., “Attenuation of diet-induced atherosclerosis in rabbits with a highly selective 15-lipoxygenase inhibitor lacking significant antioxidant properties”, Brit. J. Pharmacology, 120:1199-1206 (1997), and Cornicelli et al., “15-Lipoxygenase and its Inhibition: A Novel Therapeutic Target for Vascular Disease”, Current Pharmaceutical Design, 5:11-20 (1999).
- 15-LO 15-lipoxygenase
- 15-LO 15-lipoxygenase
- benzimidazole derivatives as
- Suitable anti-hypertensive agents for use in combination with the compounds of the present invention include beta adrenergic blockers, calcium channel blockers (L-type and T-type; e.g. diltiazem, verapamil, nifedipine, amlodipine and mybefradil), diuretics (e.g., chlorothiazide, hydrochlorothiazide, flumethiazide, hydroflumethiazide, bendroflumethiazide, methylchlorothiazide, trichloromethiazide, polythiazide, benzthiazide, ethacrynic acid tricrynafen, chlorthalidone, furosemide, musolimine, bumetanide, triamtrenene, amiloride, spironolactone), renin inhibitors (e.g., aliskiren), ACE inhibitors (e.g., captopril, z
- Dual ET/AII antagonist e.g., compounds disclosed in WO 00/01389
- neutral endopeptidase (NEP) inhibitors neutral endopeptidase (NEP) inhibitors
- vasopepsidase inhibitors dual NEP-ACE inhibitors
- omapatrilat and gemopatrilat e.g., omapatrilat and gemopatrilat
- Suitable anti-obesity agents for use in combination with the compounds of the present invention include a cannabinoid receptor 1 antagonist or inverse agonist, a beta 3 adrenergic agonist, a lipase inhibitor, a serotonin (and dopamine) reuptake inhibitor, a thyroid receptor beta drug, and/or an anorectic agent.
- Cannabinoid receptor 1 antagonists and inverse agonists which may be optionally employed in combination with compounds of the present invention include rimonabant, SLV 319, CP-945598 (Pfizer), SR-147778 (Sanofi-Aventis), MK0364 (Merck) and those discussed in D. L. Hertzog, Expert Opin. Ther. Patents, 14:1435-1452 (2004).
- beta 3 adrenergic agonists which may be optionally employed in combination with compounds of the present invention include AJ9677 (Takeda/Dainippon), L750355 (Merck), or CP331648 (Pfizer) or other known beta 3 agonists, as disclosed in U.S. Pat. Nos. 5,541,204, 5,770,615, 5,491,134, 5,776,983, and 5,488,064, with AJ9677, L750,355, and CP331648 being preferred.
- lipase inhibitors which may be optionally employed in combination with compounds of the present invention include orlistat or ATL-962 (Alizyme), with orlistat being preferred.
- the serotonin (and dopamine) reuptake inhibitor and/or modulator which may be optionally employed in combination with a compound of formula I may be sibutramine, topiramate (Johnson & Johnson), APD-356 (Arena) or axokine (Regeneron), with sibutramine and APD-356 being preferred.
- thyroid receptor beta compounds which may be optionally employed in combination with compounds of the present invention include thyroid receptor ligands, such as those disclosed in WO 97/21993 (U. Cal SF), WO 99/00353 (KaroBio), and WO 00/039077 (KaroBio), with compounds of the KaroBio applications being preferred.
- the anorectic agent which may be optionally employed in combination with compounds of the present invention include dexamphetamine, phentermine, phenylpropanolamine, or mazindol, with dexamphetamine being preferred.
- CCK receptor agonists e.g., SR-27895B
- MCHR1 antagonist e.g., GSK 856464
- galanin receptor antagonists e.g., MCR-4 antagonists
- leptin or mimetics e.g., urocortin mimetics
- CRF antagonists e.g., RU-486, urocortin
- CRF binding proteins e.g., RU-486, urocortin
- the compounds of the present invention may be used in combination with HIV protease inhibitors, including but not limited to Reyataz® and Kaletra®.
- Suitable memory enhancing agents, anti-dementia agents, or cognition promoting agents for use in combination with the compounds of the present invention include, but are not limited to, donepezil, rivastigmine, galantamine, memantine, tacrine, metrifonate, muscarine, xanomelline, deprenyl and physostigmine.
- Suitable anti-inflammatory agents for use in combination with the compounds of the present invention include, but are not limited to, prednisone, acetaminophen, aspirin, codeine, fentaynl, ibuprofen, indomethacin, ketorolac, morphine, naproxen, phenacetin, piroxicam, a steroidal analgesic, sufentanyl, sunlindac, interferon alpha, prednisolone, methylprednisolone, dexamethazone, flucatisone, betamethasone, hydrocortisone and beclomethasone.
- the compounds of formula I can be administered for any of the uses described herein by any suitable means, for example, orally, such as in the form of tablets, capsules, granules or powders; sublingually; bucally; parenterally, such as by subcutaneous, intravenous, intramuscular, or intrasternal injection, or infusion techniques (e.g., as sterile injectable aqueous or non-aqueous solutions or suspensions); nasally, including administration to the nasal membranes, such as by inhalation spray; topically, such as in the form of a cream or ointment; or rectally such as in the form of suppositories; in dosage unit formulations containing non-toxic, pharmaceutically acceptable vehicles or diluents.
- suitable means for example, orally, such as in the form of tablets, capsules, granules or powders; sublingually; bucally; parenterally, such as by subcutaneous, intravenous, intramuscular, or intrasternal injection, or infusion techniques (e
- a pharmaceutical composition will be employed containing the compounds of formula I, with or without other antidiabetic agent(s) and/or antihyperlipidemic agent(s) and/or other type therapeutic agents in association with a pharmaceutical vehicle or diluent.
- the pharmaceutical composition can be formulated employing conventional solid or liquid vehicles or diluents and pharmaceutical additives of a type appropriate to the mode of desired administration, such as pharmaceutically acceptable carriers, excipients, binders, and the like.
- the compounds can be administered to a mammalian patient, including humans, monkeys, dogs, etc. by an oral route, for example, in the form of tablets, capsules, beads, granules or powders.
- the dose for adults is preferably between 1 and 2,000 mg per day, which can be administered in a single dose or in the form of individual doses from 1-4 times per day.
- a typical capsule for oral administration contains compounds of structure I (250 mg), lactose (75 mg), and magnesium stearate (15 mg). The mixture is passed through a 60 mesh sieve and packed into a No. 1 gelatin capsule.
- a typical injectable preparation is produced by aseptically placing 250 mg of compounds of structure I into a vial, aseptically freeze-drying and sealing. For use, the contents of the vial are mixed with 2 mL of physiological saline, to produce an injectable preparation.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Communicable Diseases (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Child & Adolescent Psychology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
Novel compounds are provided which are 11-beta-hydroxysteroid dehydrogenase type I inhibitors. 11-Beta-hydroxysteroid dehydrogenase type I inhibitors are useful in treating, preventing, or slowing the progression of diseases requiring 11-beta-hydroxysteroid dehydrogenase type I inhibitor therapy. These novel compounds have the structure:
enantiomers, diastereomers, solvates, or salts thereof, wherein A, W, X and Z are defined herein.
Description
- This application is a Divisional Application of copending, prior application Ser. No. 11/843,015, filed on Aug. 22, 2007, which claims the benefit under Title 35 §119(e) of U.S. provisional Application No. 60/840,071, filed Aug. 24, 2006. The entirety of each of these applications is incorporated herein by reference.
- The steroid hormone cortisol is a key regulator of many physiological processes. However, an excess of cortisol, as occurs in Cushing's Disease, provokes severe metabolic abnormalities including: type 2 diabetes, cardiovascular disease, obesity, and osteoporosis. Many patients with these diseases, however, do not show significant increases in plasma cortisol levels. In addition to plasma cortisol, individual tissues can regulate their glucocorticoid tone via the in situ conversion of inactive cortisone to the active hormone cortisol. Indeed, the normally high plasma concentration of cortisone provides a ready supply of precursor for conversion to cortisol via the intracellular enzyme 11-beta-hydroxysteroid dehydrogenase type I (11beta-HSD1).
- 11beta-HSD1 is a member of the short chain dehydrogenase superfamily of enzymes. By catalyzing the conversion of cortisone to cortisol, 11beta-HSD1 controls the intracellular glucocorticoid tone according to its expression and activity levels. In this manner, 11beta-HSD1 can determine the overall metabolic status of the organ. 11beta-HSD1 is expressed at high levels in the liver and at lower levels in many metabolically active tissues including the adipose, the CNS, the pancreas, and the pituitary. Taking the example of the liver, it is predicted that high levels of 11beta-HSD1 activity will stimulate gluconeogenesis and overall glucose output. Conversely, reduction of 11beta-HSD1 activity will downregulate gluconeogenesis resulting in lower plasma glucose levels.
- Various studies have been conducted that support this hypothesis. For example, transgenic mice expressing 2× the normal level of 11beta-HSD1 in only the adipose tissue show abdominal obesity, hyperglycemia, and insulin resistance. (H. Masuzaki, J. Paterson, H. Shinyama, N. M. Morton, J. J. Mullins, J. R. Seckl, J. S. Flier, “A Transgenic Model of Visceral Obesity and the Metabolic Syndrome”, Science, 294:2166-2170 (2001). Conversely, when the 11beta-HSD1 gene is ablated by homologous recombination, the resulting mice are resistant to diet induced obesity and the accompanying dysregulation of glucose metabolism (N. M. Morton, J. M. Paterson, H. Masuzaki, M. C. Holmes, B. Staels, C. Fievet, B. R. Walker, J. S. Flier, J. J. Mullings, J. R. Seckl, “Novel Adipose Tissue-Mediated Resistance to Diet-induced Visceral Obesity in 11β-Hydroxysteroid Dehydrogenase Type 1-Deficient Mice”, Diabetes, 53:931-938 (2004). In addition, treatment of genetic mouse models of obesity and diabetes (ob/ob, db/db and KKAy mice) with a specific inhibitor of 11beta-HSD1 causes a decrease in glucose output from the liver and an overall increase in insulin sensitivity (P. Alberts, C. Nilsson, G. Selen, L. O. M. Engblom, N. H. M. Edling, S. Norling, G. Klingstrom, C. Larsson, M. Forsgren, M. Ashkzari, C. E. Nilsson, M. Fiedler, E. Bergqvist, B. Ohman, E. Bjorkstrand, L. B. Abrahmsen, “Selective Inhibition of 11β-Hydroxysteroid Dehydrogenase Type I Improves Hepatic Insuling Sensitivity in Hyperglycemic Mice Strains”, Endocrinology, 144:4755-4762 (2003)). Furthermore, inhibitors of 11beta-HSD1 have been shown to be effective in treating metabolic syndrome and atherosclerosis in high fat fed mice (Hermanowski-Vosatka et al., J. Exp. Med., 202(4):517-527 (2002)). Based in part on these studies, it is believed that local control of cortisol levels is important in metabolic diseases in these model systems. In addition, the results of these studies also suggest that inhibition of 11beta-HSD1 will be a viable strategy for treating metabolic diseases such as type 2 diabetes, obesity, and the metabolic syndrome.
- Lending further support to this idea are the results of a series of preliminary clinical studies. For example, several reports have shown that adipose tissue from obese individuals has elevated levels of 11beta-HSD1 activity. In addition, studies with carbenoxolone, a natural product derived from licorice that inhibits both 11beta-HSD1 and 11beta-HSD2 (converts cortisol to cortisone in kidney) have shown promising results. A seven day, double blind, placebo controlled, cross over study with carbenoxolone in mildly overweight individuals with type 2 diabetes showed that patients treated with the inhibitor, but not the placebo group, displayed a decrease in hepatic glucose production (R. C. Andrews, O. Rooyackers, B. R. Walker, J. Clin. Endocrinol. Metab., 88:285-291 (2003)). This observation is consistent with the inhibition of 11beta-HSD1 in the liver. The results of these preclinical and early clinical studies strongly support the concept that treatment with a potent and selective inhibitor of 11beta-HSD1 will be an efficacious therapy in patients afflicted with type 2 diabetes, obesity, and the metabolic syndrome.
- In accordance with the present invention, compounds are provided that have the general structure of formula I:
- wherein m, A, X, W and Z are defined below.
- The compounds of the present invention inhibit the activity of the enzyme 11-beta-hydroxysteroid dehydrogenase type I. Consequently, the compounds of the present invention may be used in the treatment of multiple diseases or disorders associated with 11-beta-hydroxysteroid dehydrogenase type I, such as diabetes and related conditions, microvascular complications associated with diabetes, the macrovascular complications associated with diabetes, cardiovascular diseases, Metabolic Syndrome and its component conditions, inflammatory diseases and other maladies. Examples of diseases or disorders associated with the activity of the enzyme 11-beta-hydroxysteroid dehydrogenase type I that can be prevented, inhibited, or treated according to the present invention include, but are not limited to, diabetes, hyperglycemia, impaired glucose tolerance, insulin resistance, hyperinsulinemia, retinopathy, neuropathy, nephropathy, delayed wound healing, atherosclerosis and its sequelae (acute coronary syndrome, myocardial infarction, angina pectoris, peripheral vascular disease, intermitant claudication), abnormal heart function, myocardial ischemia, stroke, Metabolic Syndrome, hypertension, obesity, dislipidemia, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, low HDL, high LDL, non-cardiac ischemia, infection, cancer, vascular restenosis, pancreatitis, neurodegenerative disease, lipid disorders, cognitive impairment and dementia, bone disease, HIV protease associated lipodystrophy, glaucoma and inflammatory diseases, such as, rheumatoid arthritis, Cushing's Disease, Alzheimer's Disease and osteoarthritis.
- The present invention provides for compounds of formula I, pharmaceutical compositions employing such compounds, and for methods of using such compounds. In particular, the present invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of formula I, alone or in combination with a pharmaceutically acceptable carrier.
- Further, in accordance with the present invention, a method is provided for preventing, inhibiting, or treating the progression or onset of diseases or disorders associated with the activity of the enzyme 11-beta-hydroxysteroid dehydrogenase type I, such as defined above and hereinafter, wherein a therapeutically effective amount of a compound of formula I is administered to a mammalian, i.e., human, patient in need of treatment.
- The compounds of the invention can be used alone, in combination with other compounds of the present invention, or in combination with one or more other agent(s).
- Further, the present invention provides a method for preventing, inhibiting, or treating the diseases as defined above and hereinafter, wherein a therapeutically effective amount of a combination of a compound of formula I and another compound of formula I and/or at least one other type of therapeutic agent, is administered to a mammalian, i.e., human, patient in need of treatment.
- In accordance with the present invention, compounds of formula I are provided
- enantiomers, diastereomers, solvates, or salts thereof wherein:
- A is a 5- to 20-membered non-aromatic bi-, tri- or polycyclic ring system optionally containing 1-3 heteroatoms selected from N, O, S, S(O) and S(O)2, which may be optionally substituted with one or more R4's;
- X is —C(═O)OH, —C(═O)C(═O)OH, —C(═O)NR9R9, tetrazolyl, or —C(═O)NHS(O)2R9;
- W is absent, (—CR8aR8b—)m, (—CR8aR8b—)m—O—, (—CR8aR8b—)m—N(R14)—, C3-6 cycloalkyl, alkenyl or alkynyl, wherein the cycloalkyl or alkenyl may be optionally substituted with one or more R8a's;
- m is 1-3;
- Z is —CN, C3-10 alkyl, cycloalkyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl, all of which may be optionally substituted with one or more R4's, and the heterocyclyl and heterocyclylalkyl contain 1-4 heteroatoms selected from N, O, and S;
- provided that W and Z, or when W is absent, X and Z, are attached to the same carbon on Ring A;
- R4, at each occurrence, is independently selected from hydrogen, alkyl, aryl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, halo, ═O, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)OR10, —OR10, —OH, —OCF3, —SH, —SR10, —C(═O)NR9R9, —NR9R9, —S(O)2NR9R9, —NR9S(O)2CF3, —C(═O)NR9S(O)2R9, —S(O)2NR9C(═O)OR9, —S(O)2NR9C(═O)NR9R9, —C(═O)NR9S(O)2CF3, —C(═O)R10, —NR9C(═O)R10, —OC(═O)R10, —S(═O)R10, —S(O)2R10, —O—S(O)2R10, —NR9C(═O)OR8 or —NR9S(O2)R8, wherein the alkyl, aryl, alkenyl, alkynyl, cycloalkyl, or heterocyclyl may be optionally substituted with one or more R5's;
- R5, at each occurrence, is independently selected from hydrogen, alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, halo, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)OR10, —OCF3, —OR10, —OH, —SH, —SR10, —C(═O)NR9R9, —NR9R9, —S(O)2NR9R9, —NR9S(O)2CF3, —C(═O)NR9S(O)2R9, —S(O)2NR9C(═O)OR9, —S(O)2NR9C(═O)NR9R9, —C(═O)NR9S(O)2CF3, —C(═O)R10, —NR9C(═O)R10, —OC(═O)R10, —S(═O)R10, —S(O)2R10, —O—S(O)2R10, —NR9C(═O)OR8 or —NR9S(O2)R8;
- R8, at each occurrence, is independently alkyl, aryl or heterocyclyl;
- R8a, at each occurrence, is independently hydrogen, alkyl or aryl;
- R8b, at each occurrence, is independently hydrogen, —C(═O)OH, alkyl, —OH, halo, —CN, —OR10, —C(═O)R10 or —C(═O)NR9R9, wherein the alkyl may be optionally substituted with one or more R9a's; or
- R8a and R8b are taken together with the carbon to which both are attached to form a 3- to 7-membered ring, which may optionally contain 1-4 heteroatoms selected from N, O, and S and be optionally substituted with 0-3 R9a;
- R9, at each occurrence, is independently hydrogen, alkyl, alkoxy, cycloalkyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl, wherein the alkyl, cycloalkyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl may be optionally substituted with 0-5 R9a, and the heterocyclyl or heterocyclylalkyl contain 1-4 heteroatoms selected from N, O, and S; or
- two R9's together with the nitrogen to which they are attached form a unsaturated, saturated or partially saturated cyclic ring system containing from 2-10 carbon atoms and from 0-4 additional heteroatoms selected from N, O, S, S(O) and S(O)2, wherein said ring system may be optionally substituted or fused with one or more R9a's;
- R9a, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, halo, ═O, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)OR14, —OCF3, —OR10, —OH, —OCF3, —SH, —SR14,
- —C(═O)NR14R14, —NR14R14, —S(O)2NR14R14, —NR14S(O)2CF3, —C(═O)NR14S(O)2R10, —S(O)2NR14C(═O)OR10, —S(O)2NR14C(═O)NR14R14, —C(═O)NR14S(O)2R14, —C(═O)R14, —NR14C(═O)R14, —OC(═O)R14, —C(═NR14)NR14R14, —NHC(═NR14)NR14R14, —S(═O)R14, —S(O)2R14, —OS(O)2R14, —NR14C(═O)OR10, —NR14S(O2)R8, —C(═O)R10, —OC(═O)NR14R14, —NR14C(═O)NR14R14 or arylalkyl, wherein the alkyl, aryl, cycloalkyl, cycloalkylalkyl, heterocyclyl, and heterocyclylalkyl may be optionally substituted with 0-3 R10a;
- R10, at each occurrence, is independently selected from alkyl, cycloalkyl, alkenyl, alkynyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl, wherein the alkyl, cycloalkyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl may be optionally substituted with 0-3 R10a, and the heterocyclyl and heterocyclylalkyl contain 1-4 heteroatoms selected from N, O, and S;
- R10a, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, halo, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)OR14, —OCF3, —OR14, —OH, —SH, —SR14, —C(═O)NR14R14, —NR14R14, —S(O)2NR14R14, —NR14S(O)2CF3, —C(═O)NR14S(O)2R14, —S(O)2NR14C(═O)OR14, —S(O)2NR14C(═O)NR14R14, —C(═O)NR14S(O)2CF3, —C(═O)R14, —NR14C(═O)R14, —OC(═O)R14, —C(═NR14)NR14R14, —NHC(═NR14)NR14R14, —S(═O)R14, —S(O)2R14, —NR14C(═O)OR8, —NR14S(O2)R8 or arylalkyl;
- R14, at each occurrence, is independently selected from hydrogen, alkyl, cycloalkyl, aryl or arylalkyl, wherein the alkyl, cycloalkyl, aryl or arylalkyl may be optionally substituted with 0-3 R14a;
- R14a, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, halo, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)OR15, —OCF3, —OR15, —OH, —SH, —SR15, —C(═O)NR15R15, —NR15R15, —S(O)2NR15R15, —NR15S(O)2CF3, —C(═O)NR15S(O)2R15, —S(O)2NR15C(═O)OR15, —S(O)2NR15C(═O)NR15R15, —C(═O)NR15S(O)2CF3, —C(═O)R15, —NR15C(═O)R15, —OC(═O)R15, —C(═NR15)NR15R15, —NHC(═NR15)NR15R15, —S(═O)R15, —S(O)2R15, —NR15C(═O)OR8, —NR15S(O2)R8 or arylalkyl;
- R15, at each occurrence, is independently selected from hydrogen, alkyl, cycloalkyl, aryl or arylalkyl; and
- provided that:
- (i) when W is absent, Z is phenyl, X is —C(═O)OH, lower alkyl or tetrazolyl, A is not bicyclo(2,2,1)heptanyl, bicyclo(2,2,1)heptenyl, bicyclo(2,2,2)octanyl, or bicyclo(2,2,2)octenyl;
- (ii) when W is absent, Z is optionally substituted phenyl, or heterocyclyl, X is —C(═O)OH or —C(═O)NR9R9 and R9 is hydrogen or lower alkyl, A is not 8-azabicyclo(3.2.1)octanyl;
- (iii) the compound is not a compound of the following structure:
- wherein R is optionally substituted phenyl;
- (iv) the compound is not a compound of the following structure:
- (v) the compound is not a compound of the following structure:
- (vi) the compound is not a compound of the following structure:
- and
- (vii) the compound is not a compound of the following structure:
- In another embodiment, compounds of formula I are those in which A is a 5- to 20-membered non-aromatic bi-, tri- or polycyclic ring system optionally containing 1-3 heteroatoms selected from N, O, S, S(O) and S(O)2, which is substituted with at least one R4.
- In another embodiment, compounds of formula I are those in which:
- A is a 6- to 15-membered non-aromatic bi-, tri- or polycyclic ring system optionally containing 1-3 heteroatoms selected from N, O, S, S(O) and S(O)2, which may be optionally substituted with one or more R4's;
- X is —C(═O)OH, —C(═O)C(═O)OH, —C(═O)NR9R9, or tetrazolyl;
- W is absent, (—CR8aR8b—)m, (—CR8aR8b—)m—O—, (—CR8aR8b—)m—N(R14)—, or alkenyl, wherein the alkenyl may be optionally substituted with one or more R8a's;
- m is 1-3;
- Z is CN, C3-10 alkyl, cycloalkyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl, all of which may be optionally substituted with one or more R4's, and the heterocyclyl and heterocyclylalkyl contain 1-4 heteroatoms selected from N, O, and S;
- provided that W and Z, or when W is absent, X and Z, are attached to the same carbon on Ring A;
- R4, at each occurrence, is independently selected from hydrogen, alkyl, aryl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, halo, ═O, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)OR10, —OR10, —OH, —OCF3, —SH, —SR10, —C(═O)NR9R9, —NR9R9, —S(O)2NR9R9, —NR9S(O)2CF3, —C(═O)NR9S(O)2R9, —S(O)2NR9C(═O)OR9, —S(O)2NR9C(═O)NR9R9, —C(═O)NR9S(O)2CF3, —C(═O)R10, —NR9C(═O)R10, —OC(═O)R10, —S(═O)R10, —S(O)2R10, —O—S(O)2R10, —NR9C(═O)OR8 or —NR9S(O2)R8, wherein the alkyl, aryl, alkenyl, alkynyl, cycloalkyl, or heterocyclyl may be optionally substituted with one or more R5's;
- R5, at each occurrence, is independently selected from hydrogen, alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, halo, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)OR10, —OCF3, —OR10, —OH, —SH, —SR10, —C(═O)NR9R9, —NR9R9, —S(O)2NR9R9, —NR9S(O)2CF3, —C(═O)NR9S(O)2R9, —S(O)2NR9C(═O)OR9, —S(O)2NR9C(═O)NR9R9, —C(═O)NR9S(O)2CF3, —C(═O)R10, —NR9C(═O)R10, —OC(═O)R10, —S(═O)R10, —S(O)2R10, —O—S(O)2R10, —NR9C(═O)OR8 or —NR9S(O2)R8;
- R8, at each occurrence, is independently alkyl, aryl or heterocyclyl;
- R8a, at each occurrence, is independently hydrogen, alkyl or aryl;
- R8b, at each occurrence, is independently hydrogen, —C(═O)OH, alkyl, —OH, halo, —CN, —OR10, —C(═O)R10 or —C(═O)NR9R9, wherein the alkyl may be optionally substituted with one or more R9a's; or
- R8a and R8b are taken together with the carbon to which both are attached to form a 3- to 7-membered ring, which may optionally contain 1-4 heteroatoms selected from N, O, and S and be optionally substituted with 0-3 R9a;
- R9, at each occurrence, is independently hydrogen, alkyl, alkoxy, cycloalkyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl, wherein the alkyl, cycloalkyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl may be optionally substituted with 0-5 R9a, and the heterocyclyl or heterocyclylalkyl contain 1-4 heteroatoms selected from N, O, and S; or
- two R9's together with the nitrogen to which they are attached form a unsaturated, saturated or partially saturated cyclic ring system containing from 2-10 carbon atoms and from 0-4 additional heteroatoms selected from N, O, S, S(O) and S(O)2, wherein said ring system may be optionally substituted or fused with one or more R9a's;
- R9a, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, halo, ═O, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)OR14, —OCF3, —OR10, —OH, —SH, —SR14, —C(═O)NR14R14, —NR14R14, —S(O)2NR14R14, —NR14S(O)2CF3, —C(═O)NR14S(O)2R10, —S(O)2NR14C(═O)OR10, —S(O)2NR14C(═O)NR14R14, —C(═O)NR14S(O)2R14, —C(═O)R14, —NR14C(═O)R14, —OC(═O)R14, —S(═O)R14, —S(O)2R14, —OS(O)2R14, —NR14C(═O)OR10, —NR14S(O2)R8, —C(═O)R10, —OC(═O)NR14R14, —NR14C(═O)NR14R14 or arylalkyl, wherein the alkyl, aryl, cycloalkyl, cycloalkylalkyl, heterocyclyl, and heterocyclylalkyl may be optionally substituted with 0-3 R10a;
- R10, at each occurrence, is independently selected from alkyl, cycloalkyl, alkenyl, alkynyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl, wherein the alkyl, cycloalkyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl may be optionally substituted with 0-3 R10a, and the heterocyclyl and heterocyclylalkyl contain 1-4 heteroatoms selected from N, O, and S;
- R10a, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, halo, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)OR14, —OCF3, —OR14, —OH, —SH, —SR14, —C(═O)NR14R14, —NR14R14, —S(O)2NR14R14, —NR14S(O)2CF3, —C(═O)NR14S(O)2R14, —S(O)2NR14C(═O)OR14, —S(O)2NR14C(═O)NR14R14, —C(═O)NR14S(O)2CF3, —C(═O)R14, —NR14C(═O)R14, —OC(═O)R14, —S(═O)R14, —S(O)2R14, —NR14C(═O)OR8, —NR14S(O2)R8 or arylalkyl;
- R14, at each occurrence, is independently selected from hydrogen, alkyl, cycloalkyl, aryl or arylalkyl, wherein the alkyl, cycloalkyl, aryl or arylalkyl may be optionally substituted with 0-3 R14a;
- R14a, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, halo, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)OR15, —OCF3, —OR15, —OH, —SH, —SR15, —C(═O)NR15R15, —NR15R15, —S(O)2NR15R15, —NR15S(O)2CF3, —C(═O)NR15S(O)2R15, —S(O)2NR15C(═O)OR15, —S(O)2NR15C(═O)NR15R15, —C(═O)NR15S(O)2CF3, —C(═O)R15, —NR15C(═O)R15, —OC(═O)R15, —S(═O)R15, —S(O)2R15, —NR15C(═O)OR8, —NR15S(O2)R8 or arylalkyl; and
- R15, at each occurrence, is independently selected from hydrogen, alkyl, cycloalkyl, aryl or arylalkyl.
- In yet another embodiment, compounds of formula I are those in which:
- A is a 7- to 14-membered non-aromatic bi-, tri- or polycyclic ring system optionally containing 1-3 heteroatoms selected from N, O, S, S(O) and S(O)2, which may be optionally substituted with one or more R4's;
- X is —C(═O)OH, —C(═O)NR9R9, or tetrazolyl;
- W is absent, (—CR8aR8b—)m, (—CR8aR8b—)m—O— or alkenyl, wherein the alkenyl may be optionally substituted with one or more R8a's;
- m is 1-2;
- Z is CN, C3-10 alkyl, cycloalkyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl, all of which may be optionally substituted with one or more R4's, and the heterocyclyl and heterocyclylalkyl contain 1-4 heteroatoms selected from N, O, and S;
- provided that W and Z, or when W is absent, X and Z, are attached to the same carbon on Ring A;
- R4, at each occurrence, is independently selected from hydrogen, alkyl, aryl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, halo, ═O, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)OR10, —OR10, —OH, —OCF3, —SH, —SR10, —C(═O)NR9R9, —NR9R9, —S(O)2NR9R9, —NR9S(O)2CF3, —C(═O)NR9S(O)2R9, —S(O)2NR9C(═O)OR9, —S(O)2NR9C(═O)NR9R9, —C(═O)NR9S(O)2CF3, —C(═O)R10, —NR9C(═O)R10, —OC(═O)R10, —S(═O)R10, —S(O)2R10, —O—S(O)2R10, —NR9C(═O)OR8 or —NR9S(O2)R8, wherein the alkyl, aryl, alkenyl, alkynyl, cycloalkyl, or heterocyclyl may be optionally substituted with one or more R5's;
- R5, at each occurrence, is independently selected from hydrogen, alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, halo, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)OR10, —OCF3, —OR10, —OH, —SH, —SR10, —C(═O)NR9R9, —NR9R9, —S(O)2NR9R9, —NR9S(O)2CF3, —C(═O)NR9S(O)2R9, —S(O)2NR9C(═O)OR9, —S(O)2NR9C(═O)NR9R9, —C(═O)NR9S(O)2CF3, —C(═O)R10, —NR9C(═O)R10, —OC(═O)R10, —S(═O)R10, —S(O)2R10, —O—S(O)2R10, —NR9C(═O)OR8 or —NR9S(O2)R8;
- R8, at each occurrence, is independently alkyl, aryl or heterocyclyl;
- R8a, at each occurrence, is independently hydrogen, alkyl or aryl;
- R8b, at each occurrence, is independently hydrogen, —C(═O)OH, alkyl, —OH, halo, —CN, —OR10, —C(═O)R10 or —C(═O)NR9R9, wherein the alkyl may be optionally substituted with one or more R9a's; or
- R8a and R8b are taken together with the carbon to which both are attached to form a 3- to 7-membered ring, which may optionally contain 1-4 heteroatoms selected from N, O, and S and be optionally substituted with 0-3 R9a;
- R9, at each occurrence, is independently hydrogen, alkyl, alkoxy, cycloalkyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl, wherein the alkyl, cycloalkyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl may be optionally substituted with 0-5 R9a, and the heterocyclyl or heterocyclylalkyl contain 1-4 heteroatoms selected from N, O, and S; or
- two R9's together with the nitrogen to which they are attached form a unsaturated, saturated or partially saturated cyclic ring system containing from 2-10 carbon atoms and from 0-4 additional heteroatoms selected from N, O, S, S(O) and S(O)2, wherein said ring system may be optionally substituted or fused with one or more R9a's;
- R9a, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, halo, ═O, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)OR14, —OCF3, —OR10, —OH, —SH, —SR14, —C(═O)NR14R14, —NR14R14, —S(O)2NR14R14, —NR14S(O)2CF3, —C(═O)NR14S(O)2R10, —S(O)2NR14C(═O)OR10, —S(O)2NR14C(═O)NR14R14, —C(═O)NR14S(O)2R14, —C(═O)R14, —NR14C(═O)R14, —OC(═O)R14, —S(═O)R14, —S(O)2R14, —OS(O)2R14, —NR14C(═O)OR10, —NR14S(O2)R8, —C(═O)R10, —OC(═O)NR14R14, —NR14C(═O)NR14R14 or arylalkyl, wherein the alkyl, aryl, cycloalkyl, cycloalkylalkyl, heterocyclyl, and heterocyclylalkyl may be optionally substituted with 0-3 R10a;
- R10, at each occurrence, is independently selected from alkyl, cycloalkyl, alkenyl, alkynyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl, wherein the alkyl, cycloalkyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl may be optionally substituted with 0-3 R10a, and the heterocyclyl and heterocyclylalkyl contain 1-4 heteroatoms selected from N, O, and S;
- R10a, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, halo, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)OR14, —OCF3, —OR14, —OH, —SH, —SR14, —C(═O)NR14R14, —NR14R14, —S(O)2NR14R14, —NR14S(O)2CF3, —C(═O)NR14S(O)2R14, —S(O)2NR14C(═O)OR14, —S(O)2NR14C(═O)NR14R14, —C(═O)NR14S(O)2CF3, —C(═O)R14, —NR14C(═O)R14, —OC(═O)R14, —S(═O)R14, —S(O)2R14, —NR14C(═O)OR8, —NR14S(O2)R8 or arylalkyl;
- R14, at each occurrence, is independently selected from hydrogen, alkyl, cycloalkyl, aryl or arylalkyl, wherein the alkyl, cycloalkyl, aryl or arylalkyl may be optionally substituted with 0-3 R14a;
- R14a, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, halo, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)OR15, —OCF3, —OR15, —OH, —SH, —SR15, —C(═O)NR15R15, —NR15R15, —S(O)2NR15R15, —NR15S(O)2CF3, —C(═O)NR15S(O)2R15, —S(O)2NR15C(═O)OR15, —S(O)2NR15C(═O)NR15R15, —C(═O)NR15S(O)2CF3, —C(═O)R15, —NR15C(═O)R15, —OC(═O)R15, —S(═O)R15, —S(O)2R15, —NR15C(═O)OR8, —NR15S(O2)R8 or arylalkyl; and
- R15, at each occurrence, is independently selected from hydrogen, alkyl, cycloalkyl, aryl or arylalkyl.
- In another embodiment, compounds of formula I are those in which:
- A is a 7- to 14-membered non-aromatic bi-, tri- or polycyclic ring system optionally containing 1-3 heteroatoms selected from N, O, S, S(O) and S(O)2, which may be optionally substituted with one or more R4's;
- X is —C(═O)OH, —C(═O)NR9R9, or tetrazolyl;
- W is absent, (—CR8aR8b—)m, (—CR8aR8b)m—O— or alkenyl, wherein the alkenyl may be optionally substituted with one or more R8a's;
- m is 1-2;
- Z is cycloalkyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl, all of which may be optionally substituted with one or more R4's, and the heterocyclyl and heterocyclylalkyl contain 1-4 heteroatoms selected from N, O, and S;
- provided that W and Z, or when W is absent, X and Z, are attached to the same carbon on Ring A;
- R4, at each occurrence, is independently selected from hydrogen, alkyl, aryl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, halo, ═O, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)OR10, —OR10, —OH, —OCF3, —SH, —SR10, —C(═O)NR9R9, —NR9R9, —S(O)2NR9R9, —NR9S(O)2CF3, —C(═O)NR9S(O)2R9, —S(O)2NR9C(═O)OR9, —S(O)2NR9C(═O)NR9R9, —C(═O)NR9S(O)2CF3, —C(═O)R10, —NR9C(═O)R10, —OC(═O)R10, —S(═O)R10, —S(O)2R10, —O—S(O)2R10, —NR9C(═O)OR8 or —NR9S(O2)R8, wherein the alkyl, aryl, alkenyl, alkynyl, cycloalkyl, or heterocyclyl may be optionally substituted with one or more R5's;
- R5, at each occurrence, is independently selected from hydrogen, alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, halo, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)OR10, —OCF3, —OR10, —OH, —SH, —SR10, —C(═O)NR9R9, —NR9R9, —S(O)2NR9R9, —NR9S(O)2CF3, —C(═O)NR9S(O)2R9, —S(O)2NR9C(═O)OR9, —S(O)2NR9C(═O)NR9R9, —C(═O)NR9S(O)2CF3, —C(═O)R10, —NR9C(═O)R10, —OC(═O)R10, —S(═O)R10, —S(O)2R10, —O—S(O)2R10, —NR9C(═O)OR8 or —NR9S(O2)R8;
- R8, at each occurrence, is independently alkyl, aryl or heterocyclyl;
- R8a, at each occurrence, is independently hydrogen, alkyl or aryl;
- R8b, at each occurrence, is independently hydrogen, —C(═O)OH, alkyl, —OH, halo, —CN, —OR10, —C(═O)R10 or —C(═O)NR9R9, wherein the alkyl may be optionally substituted with one or more R9a's; or
- R8a and R8b are taken together with the carbon to which both are attached to form a 3- to 7-membered ring, which may optionally contain 1-4 heteroatoms selected from N, O, and S and be optionally substituted with 0-3 R9a;
- R9, at each occurrence, is independently hydrogen, alkyl, alkoxy, cycloalkyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl, wherein the alkyl, cycloalkyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl may be optionally substituted with 0-5 R9a, and the heterocyclyl or heterocyclylalkyl contain 1-4 heteroatoms selected from N, O, and S; or
- two R9's together with the nitrogen to which they are attached form a unsaturated, saturated or partially saturated cyclic ring system containing from 2-10 carbon atoms and from 0-4 additional heteroatoms selected from N, O, S, S(O) and S(O)2, wherein said ring system may be optionally substituted or fused with one or more R9a's;
- R9a, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, halo, ═O, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)OR14, —OCF3, —OR10, —OH, —SH, —SR14, —C(═O)NR14R14, —NR14R14, —S(O)2NR14R14, —NR14S(O)2CF3, —C(═O)NR14S(O)2R10, —S(O)2NR14C(═O)OR10, —S(O)2NR14C(═O)NR14R14, —C(═O)NR14S(O)2R14, —C(═O)R14, —NR14C(═O)R14, —OC(═O)R14, —S(═O)R14, —S(O)2R14, —OS(O)2R14, —NR14C(═O)OR10, —NR14S(O2)R8, —C(═O)R10, —OC(═O)NR14R14, —NR14C(═O)NR14R14 or arylalkyl, wherein the alkyl, aryl, cycloalkyl, cycloalkylalkyl, heterocyclyl, and heterocyclylalkyl may be optionally substituted with 0-3 R10a;
- R10, at each occurrence, is independently selected from alkyl, cycloalkyl, alkenyl, alkynyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl, wherein the alkyl, cycloalkyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl may be optionally substituted with 0-3 R10a, and the heterocyclyl and heterocyclylalkyl contain 1-4 heteroatoms selected from N, O, and S;
- R10a, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, halo, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)OR14, —OCF3, —OR14, —OH, —SH, —SR14, —C(═O)NR14R14, —NR14R14, —S(O)2NR14R14, —NR14S(O)2CF3, —C(═O)NR14S(O)2R14, —S(O)2NR14C(═O)OR14, —S(O)2NR14C(═O)NR14R14, —C(═O)NR14S(O)2CF3, —C(═O)R14, —NR14C(═O)R14, —OC(═O)R14, —S(═O)R14, —S(O)2R14, —NR14C(═O)OR8, —NR14S(O2)R8 or arylalkyl;
- R14, at each occurrence, is independently selected from hydrogen, alkyl, cycloalkyl, aryl or arylalkyl, wherein the alkyl, cycloalkyl, aryl or arylalkyl may be optionally substituted with 0-3 R14a;
- R14a, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, halo, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)OR15, —OCF3, —OR15, —OH, —SH, —SR15, —C(═O)NR15R15, —NR15R15, —S(O)2NR15R15, —NR15S(O)2CF3, —C(═O)NR15S(O)2R15, —S(O)2NR15C(═O)OR15, —S(O)2NR15C(═O)NR15R15, —C(═O)NR15S(O)2CF3, —C(═O)R15, —NR15C(═O)R15, —OC(═O)R15, —S(═O)R15, —S(O)2R15, —NR15C(═O)OR8, —NR15S(O2)R8 or arylalkyl; and
- R15, at each occurrence, is independently selected from hydrogen, alkyl, cycloalkyl, aryl or arylalkyl.
- In still yet another embodiment, compounds of formula I are those in which:
- A is a 7- to 14-membered non-aromatic bi-, tri- or polycyclic ring system optionally containing 1-3 heteroatoms selected from N, O, S, S(O) and S(O)2, which may be optionally substituted with one or more R4's;
- X is —C(═O)OH, —C(═O)NR9R9, or tetrazolyl;
- W is absent, (—CR8aR8b—)m, (—CR8aR8b)m—O— or alkenyl, wherein the alkenyl may be optionally substituted with one or more R8a's;
- m is 1-2;
- Z is aryl, arylalkyl, heterocyclyl or heterocyclylalkyl, all of which may be optionally substituted with one or more R4's, and the heterocyclyl and heterocyclylalkyl contain 1-4 heteroatoms selected from N, O, and S;
- provided that W and Z, or when W is absent, X and Z, are attached to the same carbon on Ring A;
- R4, at each occurrence, is independently selected from hydrogen, alkyl, aryl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, halo, ═O, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)OR10, —OR10, —OH, —OCF3, —SH, —SR10, —C(═O)NR9R9, —NR9R9, —S(O)2NR9R9, —NR9S(O)2CF3, —C(═O)NR9S(O)2R9, —S(O)2NR9C(═O)OR9, —S(O)2NR9C(═O)NR9R9, —C(═O)NR9S(O)2CF3, —C(═O)R10, —NR9C(═O)R10, —OC(═O)R10, —S(═O)R10, —S(O)2R10, —O—S(O)2R10, —NR9C(═O)OR8 or —NR9S(O2)R8, wherein the alkyl, aryl, alkenyl, alkynyl, cycloalkyl, or heterocyclyl may be optionally substituted with one or more R5's;
- R5, at each occurrence, is independently selected from hydrogen, alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, halo, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)OR10, —OCF3, —OR10, —OH, —SH, —SR10, —C(═O)NR9R9, —NR9R9, —S(O)2NR9R9, —NR9S(O)2CF3, —C(═O)NR9S(O)2R9, —S(O)2NR9C(═O)OR9, —S(O)2NR9C(═O)NR9R9, —C(═O)NR9S(O)2CF3, —C(═O)R10, —NR9C(═O)R10, —OC(═O)R10, —S(═O)R10, —S(O)2R10, —O—S(O)2R10, —NR9C(═O)OR8 or —NR9S(O2)R8;
- R8, at each occurrence, is independently alkyl, aryl or heterocyclyl;
- R8a, at each occurrence, is independently hydrogen, alkyl or aryl;
- R8b, at each occurrence, is independently hydrogen, —C(═O)OH, alkyl, —OH, halo, —CN, —OR10, —C(═O)R10 or —C(═O)NR9R9, wherein the alkyl may be optionally substituted with one or more R9a's; or
- R8a and R8b are taken together with the carbon to which both are attached to form a 3- to 7-membered ring, which may optionally contain 1-4 heteroatoms selected from N, O, and S and be optionally substituted with 0-3 R9a;
- R9, at each occurrence, is independently hydrogen, alkyl, alkoxy, cycloalkyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl, wherein the alkyl, cycloalkyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl may be optionally substituted with 0-5 R9a, and the heterocyclyl or heterocyclylalkyl contain 1-4 heteroatoms selected from N, O, and S; or
- two R9's together with the nitrogen to which they are attached form a unsaturated, saturated or partially saturated cyclic ring system containing from 2-10 carbon atoms and from 0-4 additional heteroatoms selected from N, O, S, S(O) and S(O)2, wherein said ring system may be optionally substituted or fused with one or more R9a's;
- R9a, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, halo, ═O, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)OR14, —OCF3, —OR10, —OH, —SH, —SR14, —C(═O)NR14R14, —NR14R14, —S(O)2NR14R14, —NR14S(O)2CF3, —C(═O)NR14S(O)2R10, —S(O)2NR14C(═O)OR10, —S(O)2NR14C(═O)NR14R14, —C(═O)NR14S(O)2R14, —C(═O)R14, —NR14C(═O)R14, —OC(═O)R14, —S(═O)R14, —S(O)2R14, —OS(O)2R14, —NR14C(═O)OR10, —NR14S(O2)R8, —C(═O)R10, —OC(═O)NR14R14, —NR14C(═O)NR14R14 or arylalkyl, wherein the alkyl, aryl, cycloalkyl, cycloalkylalkyl, heterocyclyl, and heterocyclylalkyl may be optionally substituted with 0-3 R10a;
- R10, at each occurrence, is independently selected from alkyl, cycloalkyl, alkenyl, alkynyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl, wherein the alkyl, cycloalkyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl may be optionally substituted with 0-3 R10a, and the heterocyclyl and heterocyclylalkyl contain 1-4 heteroatoms selected from N, O, and S;
- R10a, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, halo, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)OR14, —OCF3, —OR14, —OH, —SH, —SR14, —C(═O)NR14R14, —NR14R14, —S(O)2NR14R14, —NR14S(O)2CF3, —C(═O)NR14S(O)2R14, —S(O)2NR14C(═O)OR14, —S(O)2NR14C(═O)NR14R14, —C(═O)NR14S(O)2CF3, —C(═O)R14, —NR14C(═O)R14, —OC(═O)R14, —S(═O)R14, —S(O)2R14, —NR14C(═O)OR8, —NR14S(O2)R8 or arylalkyl;
- R14, at each occurrence, is independently selected from hydrogen, alkyl, cycloalkyl, aryl or arylalkyl, wherein the alkyl, cycloalkyl, aryl or arylalkyl may be optionally substituted with 0-3 R14a;
- R14a, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, halo, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)OR15, —OCF3, —OR15, —OH, —SH, —SR15, —C(═O)NR15R15, —NR15R15, —S(O)2NR15R15, —NR15S(O)2CF3, —C(═O)NR15S(O)2R15, —S(O)2NR15C(═O)OR15, —S(O)2NR15C(═O)NR15R15, —C(═O)NR15S(O)2CF3, —C(═O)R15, —NR15C(═O)R15, —OC(═O)R15, —S(═O)R15, —S(O)2R15, —NR15C(═O)OR8, —NR15S(O2)R8 or arylalkyl; and
- R15, at each occurrence, is independently selected from hydrogen, alkyl, cycloalkyl, aryl or arylalkyl.
- In one embodiment, compounds of formula I are those in which:
- A is a 7- to 14-membered non-aromatic bi-, tri- or polycyclic ring system optionally containing 1-3 heteroatoms selected from N, O, S, S(O) and S(O)2, which may be optionally substituted with one or more R4's;
- X is —C(═O)OH, —C(═O)NR9R9, or tetrazolyl;
- W is absent, (—CR8aR8b—)m, —(CR8aR8b)m—O— or alkenyl, wherein the alkenyl may be optionally substituted with one or more R8a's;
- m is 1-2;
- Z is aryl, arylalkyl or heterocyclylalkyl, all of which may be optionally substituted with one or more R4's, and the heterocyclylalkyl contain 1-4 heteroatoms selected from N, O, and S;
- provided that W and Z, or when W is absent, X and Z, are attached to the same carbon on Ring A;
- R4, at each occurrence, is independently selected from hydrogen, alkyl, aryl, alkenyl, cycloalkyl, heterocyclyl, halo, ═O, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)OR10, —OR10, —OH, —OCF3, —SH, —SR10, —C(═O)NR9R9, —NR9R9, —S(O)2NR9R9, —NR9S(O)2CF3, —C(═O)NR9S(O)2R9, —S(O)2NR9C(═O)OR9, —S(O)2NR9C(═O)NR9R9, —C(═O)NR9S(O)2CF3, —C(═O)R10, —NR9C(═O)R10, —OC(═O)R10, —S(═O)R10, —S(O)2R10, —O—S(O)2R10, —NR9C(═O)OR8 or —NR9S(O2)R8, wherein the alkyl, aryl, alkenyl, cycloalkyl, or heterocyclyl may be optionally substituted with one or more R5's;
- R5, at each occurrence, is independently selected from hydrogen, alkyl, haloalkyl, aryl, alkenyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, halo, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)OR10, —OCF3, —OR10, —OH, —SH, —SR10, —C(═O)NR9R9, —NR9R9, —S(O)2NR9R9, —NR9S(O)2CF3, —C(═O)NR9S(O)2R9, —S(O)2NR9C(═O)OR9, —S(O)2NR9C(═O)NR9R9, —C(═O)NR9S(O)2CF3, —C(═O)R10, —NR9C(═O)R10, —OC(═O)R10, —S(═O)R10, —S(O)2R10, —O—S(O)2R10, —NR9C(═O)OR8 or —NR9S(O2)R8;
- R8, at each occurrence, is independently alkyl, aryl or heterocyclyl;
- R8a, at each occurrence, is independently hydrogen, alkyl or aryl;
- R8b, at each occurrence, is independently hydrogen, —C(═O)OH, alkyl, —OH, halo, —CN, —OR10, —C(═O)R10 or —C(═O)NR9R9, wherein the alkyl may be optionally substituted with one or more R9a's; or
- R8a and R8b are taken together with the carbon to which both are attached to form a 3- to 7-membered ring, which may optionally contain 1-4 heteroatoms selected from N, O, and S and be optionally substituted with 0-3 R9a;
- R9, at each occurrence, is independently hydrogen, alkyl, alkoxy, cycloalkyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl, wherein the alkyl, cycloalkyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl may be optionally substituted with 0-5 R9a, and the heterocyclyl or heterocyclylalkyl contain 1-4 heteroatoms selected from N, O, and S; or
- two R9's together with the nitrogen to which they are attached form a unsaturated, saturated or partially saturated cyclic ring system containing from 2-10 carbon atoms and from 0-4 additional heteroatoms selected from N, O, S, S(O) and S(O)2, wherein said ring system may be optionally substituted or fused with one or more R9a's;
- R9a, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, halo, ═O, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)OR14, —OCF3, —OR10, —OH, —SH, —SR14, —C(═O)NR14R14, —NR14R14, —S(O)2NR14R14, —NR14S(O)2CF3, —C(═O)NR14S(O)2R10, —S(O)2NR14C(═O)OR10, —S(O)2NR14C(═O)NR14R14, —C(═O)NR14S(O)2R14, —C(═O)R14, —NR14C(═O)R14, —OC(═O)R14, —S(═O)R14, —S(O)2R14, —OS(O)2R14, —NR14C(═O)OR10, —NR14S(O2)R8, —C(═O)R10, —OC(═O)NR14R14, —NR14C(═O)NR14R14 or arylalkyl, wherein the alkyl, aryl, cycloalkyl, cycloalkylalkyl, heterocyclyl, and heterocyclylalkyl may be optionally substituted with 0-3 R10a;
- R10, at each occurrence, is independently selected from alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl, wherein the alkyl, cycloalkyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl may be optionally substituted with 0-3 R10a, and the heterocyclyl and heterocyclylalkyl contain 1-4 heteroatoms selected from N, O, and S;
- R10a, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, halo, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)OR14, —OCF3, —OR14, —OH, —SH, —SR14, —C(═O)NR14R14, —NR14R14, —S(O)2NR14R14, —NR14S(O)2CF3, —C(═O)NR14S(O)2R14, —S(O)2NR14C(═O)OR14, —S(O)2NR14C(═O)NR14R14, —C(═O)NR14S(O)2CF3, —C(═O)R14, —NR14C(═O)R14, —OC(═O)R14, —S(═O)R14, —S(O)2R14, —NR14C(═O)OR8, —NR14S(O2)R8 or arylalkyl;
- R14, at each occurrence, is independently selected from hydrogen, alkyl, cycloalkyl, aryl or arylalkyl, wherein the alkyl, cycloalkyl, aryl or arylalkyl may be optionally substituted with 0-3 R14a;
- R14a, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, halo, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)OR15, —OCF3, —OR15, —OH, —SH, —SR15, —C(═O)NR15R15, —NR15R15, —S(O)2NR15R15, —NR15S(O)2CF3, —C(═O)NR15S(O)2R15, —S(O)2NR15C(═O)OR15, —S(O)2NR15C(═O)NR15R15, —C(═O)NR15S(O)2CF3, —C(═O)R15, —NR15C(═O)R15, —OC(═O)R15, —S(═O)R15, —S(O)2R15, —NR15C(═O)OR8, —NR15S(O2)R8 or arylalkyl; and
- R15, at each occurrence, is independently selected from hydrogen, alkyl, cycloalkyl, aryl or arylalkyl.
- In still yet another embodiment, compounds of formula I are those in which:
- A is a 7- to 14-membered non-aromatic bi-, tri- or polycyclic ring system optionally containing 1-3 heteroatoms selected from N, O, S, S(O) and S(O)2, which may be optionally substituted with one or more R4's;
- X is —C(═O)OH, or —C(═O)NR9R9;
- W is absent, (—CR8aR8b—)m, (—CR8aR8b)m—O— or alkenyl, wherein the alkenyl may be optionally substituted with one or more R8a's;
- m is 1-2;
- Z is aryl, arylalkyl or heterocyclylalkyl, all of which may be optionally substituted with one or more R4's, and the heterocyclylalkyl contain 1-4 heteroatoms selected from N, O, and S;
- provided that W and Z, or when W is absent, X and Z, are attached to the same carbon on Ring A;
- R4, at each occurrence, is independently selected from hydrogen, alkyl, aryl, cycloalkyl, heterocyclyl, halo, ═O, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)OR10, —OR10, —OH, —OCF3, —SH, —SR10, —C(═O)NR9R9, —NR9R9, —S(O)2NR9R9, —NR9S(O)2CF3, —C(═O)NR9S(O)2R9, —S(O)2NR9C(═O)OR9, —S(O)2NR9C(═O)NR9R9, —C(═O)NR9S(O)2CF3, —C(═O)R10, —NR9C(═O)R10, —OC(═O)R10, —S(═O)R10, —S(O)2R10, —O—S(O)2R10, —NR9C(═O)OR8 or —NR9S(O2)R8, wherein the alkyl, aryl, cycloalkyl or heterocyclyl may be optionally substituted with one or more R5's;
- R5, at each occurrence, is independently selected from hydrogen, alkyl, haloalkyl, aryl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, halo, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)OR10, —OCF3, —OR10, —OH, —SH, —SR10, —C(═O)NR9R9, —NR9R9, —S(O)2NR9R9, —NR9S(O)2CF3, —C(═O)NR9S(O)2R9, —S(O)2NR9C(═O)OR9, —S(O)2NR9C(═O)NR9R9, —C(═O)NR9S(O)2CF3, —C(═O)R10, —NR9C(═O)R10, —OC(═O)R10, —S(═O)R10, —S(O)2R10, —O—S(O)2R10, —NR9C(═O)OR8 or —NR9S(O2)R8;
- R8, at each occurrence, is independently alkyl, aryl or heterocyclyl;
- R8a, at each occurrence, is independently hydrogen, alkyl or aryl;
- R8b, at each occurrence, is independently hydrogen, —C(═O)OH, alkyl, —OH, halo, —CN, —OR10, —C(═O)R10 or —C(═O)NR9R9, wherein the alkyl may be optionally substituted with one or more R9a's; or
- R8a and R8b are taken together with the carbon to which both are attached to form a 3- to 7-membered ring, which may optionally contain 1-4 heteroatoms selected from N, O, and S and be optionally substituted with 0-3 R9a;
- R9, at each occurrence, is independently hydrogen, alkyl, alkoxy, cycloalkyl, aryl, arylalkyl, or heterocyclyl, wherein the alkyl, cycloalkyl, aryl, arylalkyl or heterocyclyl may be optionally substituted with 0-5 R9a, and the heterocyclyl contains 1-4 heteroatoms selected from N, O, and S; or
- two R9's together with the nitrogen to which they are attached form a unsaturated, saturated or partially saturated cyclic ring system containing from 2-10 carbon atoms and from 0-4 additional heteroatoms selected from N, O, S, S(O) and S(O)2, wherein said ring system may be optionally substituted or fused with one or more R9a's;
- R9a, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, halo, ═O, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)OR14, —OCF3, —OR10, —OH, —SH, —SR14, —C(═O)NR14R14, —NR14R14, —S(O)2NR14R14, —NR14S(O)2CF3, —C(═O)NR14S(O)2R10, —S(O)2NR14C(═O)OR10, —S(O)2NR14C(═O)NR14R14, —C(═O)NR14S(O)2R14, —C(═O)R14, —NR14C(═O)R14, —OC(═O)R14, —S(═O)R14, —S(O)2R14, —OS(O)2R14, —NR14C(═O)OR10, —NR14S(O2)R8, —C(═O)R10, —OC(═O)NR14R14, —NR14C(═O)NR14R14 or arylalkyl, wherein the alkyl, aryl, cycloalkyl, cycloalkylalkyl, heterocyclyl, and heterocyclylalkyl may be optionally substituted with 0-3 R10a;
- R10, at each occurrence, is independently selected from alkyl, cycloalkyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl, wherein the alkyl, cycloalkyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl may be optionally substituted with 0-3 R10a, and the heterocyclyl and heterocyclylalkyl contain 1-4 heteroatoms selected from N, O, and S;
- R10a, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, halo, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)OR14, —OCF3, —OR14, —OH, —SH, —SR14, —C(═O)NR14R14, —NR14R14, —S(O)2NR14R14, —NR14S(O)2CF3, —C(═O)NR14S(O)2R14, —S(O)2NR14C(═O)OR14, —S(O)2NR14C(═O)NR14R14, —C(═O)NR14S(O)2CF3, —C(═O)R14, —NR14C(═O)R14, —OC(═O)R14, —S(═O)R14, —S(O)2R14, —NR14C(═O)OR8, —NR14S(O2)R8 or arylalkyl;
- R14, at each occurrence, is independently selected from hydrogen, alkyl, cycloalkyl, aryl or arylalkyl, wherein the alkyl, cycloalkyl, aryl or arylalkyl may be optionally substituted with 0-3 R14a;
- R14a, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, halo, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)OR15, —OCF3, —OR15, —OH, —SH, —SR15, —C(═O)NR15R15, —NR15R15, —S(O)2NR15R15, —NR15S(O)2CF3, —C(═O)NR15S(O)2R15, —S(O)2NR15C(═O)OR15, —S(O)2NR15C(═O)NR15R15, —C(═O)NR15S(O)2CF3, —C(═O)R15, —NR15C(═O)R15, —OC(═O)R15, —S(═O)R15, —S(O)2R15, —NR15C(═O)OR8, —NR15S(O2)R8 or arylalkyl; and
- R15, at each occurrence, is independently selected from hydrogen, alkyl, cycloalkyl, aryl or arylalkyl.
- In another embodiment, compounds of formula I are those compounds in which:
- A is a 7- to 14-membered non-aromatic bi-, tri- or polycyclic ring system optionally containing 1-3 heteroatoms selected from N, O, S, S(O) and S(O)2, which may be optionally substituted with one or more R4's;
- X is —C(═O)OH, or —C(═O)NR9R9;
- W is absent, (—CR8aR8b—)m or (—CR8aR8b)m—O—;
- m is 1-2;
- Z is aryl, arylalkyl or heterocyclylalkyl, all of which may be optionally substituted with one or more R4's, and the heterocyclylalkyl contain 1-4 heteroatoms selected from N, O, and S;
- provided that W and Z, or when W is absent, X and Z, are attached to the same carbon on Ring A;
- R4, at each occurrence, is independently selected from hydrogen, alkyl, aryl, cycloalkyl, heterocyclyl, halo, ═O, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)OR10, —OR10, —OH, —OCF3, —SH, —SR10, —C(═O)NR9R9, —NR9R9, —S(O)2NR9R9, —NR9S(O)2CF3, —C(═O)NR9S(O)2R9, —S(O)2NR9C(═O)OR9, —S(O)2NR9C(═O)NR9R9, —C(═O)NR9S(O)2CF3, —C(═O)R10, —NR9C(═O)R10, —OC(═O)R10, —S(═O)R10, —S(O)2R10, —O—S(O)2R10, —NR9C(═O)OR8 or —NR9S(O2)R8, wherein the alkyl, aryl, cycloalkyl, or heterocyclyl may be optionally substituted with one or more R5's;
- R5, at each occurrence, is independently selected from hydrogen, alkyl, haloalkyl, aryl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, halo, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)OR10, —OCF3, —OR10, —OH, —SH, —SR10, —C(═O)NR9R9, —NR9R9, —S(O)2NR9R9, —NR9S(O)2CF3, —C(═O)NR9S(O)2R9, —S(O)2NR9C(═O)OR9, —S(O)2NR9C(═O)NR9R9, —C(═O)NR9S(O)2CF3, —C(═O)R10, —NR9C(═O)R10, —OC(═O)R10, —S(═O)R10, —S(O)2R10, —O—S(O)2R10, —NR9C(═O)OR8 or —NR9S(O2)R8;
- R8, at each occurrence, is independently alkyl, aryl or heterocyclyl;
- R8a, at each occurrence, is independently hydrogen, alkyl or aryl;
- R8b, at each occurrence, is independently hydrogen, —C(═O)OH, alkyl, —OH, halo, —CN, —OR10 or —C(═O)NR9R9, wherein the alkyl may be optionally substituted with one or more R9a's; or
- R9, at each occurrence, is independently hydrogen, alkyl, alkoxy, cycloalkyl, aryl, arylalkyl, or heterocyclyl, wherein the alkyl, cycloalkyl, aryl, arylalkyl or heterocyclyl may be optionally substituted with 0-5 R9a, and the heterocyclyl contains 1-4 heteroatoms selected from N, O, and S; or
- two R9's together with the nitrogen to which they are attached form a unsaturated, saturated or partially saturated cyclic ring system containing from 2-10 carbon atoms and from 0-4 additional heteroatoms selected from N, O, S, S(O) and S(O)2, wherein said ring system may be optionally substituted or fused with one or more R9a's;
- R9a, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, halo, ═O, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)OR14, —OCF3, —OR10, —OH, —SH, —SR14, —C(═O)NR14R14, —NR14R14, —S(O)2NR14R14, —NR14S(O)2CF3, —C(═O)NR14S(O)2R10, —S(O)2NR14C(═O)OR10, —S(O)2NR14C(═O)NR14R14, —C(═O)NR14S(O)2R14, —C(═O)R14, —NR14C(═O)R14, —OC(═O)R14, —S(═O)R14, —S(O)2R14, —OS(O)2R14, —NR14C(═O)OR10, —NR14S(O2)R8, —C(═O)R10, —OC(═O)NR14R14, —NR14C(═O)NR14R14 or arylalkyl, wherein the alkyl, aryl, cycloalkyl, cycloalkylalkyl, heterocyclyl and heterocyclylalkyl may be optionally substituted with 0-3 R10a;
- R10, at each occurrence, is independently selected from alkyl, cycloalkyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl, wherein the alkyl, cycloalkyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl may be optionally substituted with 0-3 R10a, and the heterocyclyl and heterocyclylalkyl contain 1-4 heteroatoms selected from N, O, and S;
- R10a, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, halo, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)OR14, —OCF3, —OR14, —OH, —SH, —SR14, —C(═O)NR14R14, —NR14R14, —S(O)2NR14R14, —NR14S(O)2CF3, —C(═O)NR14S(O)2R14, —S(O)2NR14C(═O)OR14, —S(O)2NR14C(═O)NR14R14, —C(═O)NR14S(O)2CF3, —C(═O)R14, —NR14C(═O)R14, —OC(═O)R14, —S(═O)R14, —S(O)2R14, —NR14C(═O)OR8, —NR14S(O2)R8 or arylalkyl;
- R14, at each occurrence, is independently selected from hydrogen, alkyl, cycloalkyl, or aryl, wherein the alkyl, cycloalkyl or aryl may be optionally substituted with 0-3 R14a;
- R14a, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, halo, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)OR15, —OCF3, —OR15, —OH, —SH, —SR15, —C(═O)NR15R15, —NR15R15, —S(O)2NR15R15, —NR15S(O)2CF3, —C(═O)NR15S(O)2R15, —S(O)2NR15C(═O)OR15, —S(O)2NR15C(═O)NR15R15, —C(═O)NR15S(O)2CF3, —C(═O)R15, —NR15C(═O)R15, —OC(═O)R15, —S(═O)R15, —S(O)2R15, —NR15C(═O)OR8, —NR15S(O2)R8 or arylalkyl; and
- R15, at each occurrence, is independently selected from hydrogen, alkyl, cycloalkyl or aryl.
- In another embodiment, compounds of formula I are those compounds in which:
- A is a 7- to 14-membered non-aromatic bi-, tri- or polycyclic ring system optionally containing 1-3 heteroatoms selected from N, O, S, S(O) and S(O)2, which may be optionally substituted with one or more R4's;
- X is —C(═O)OH, or —C(═O)NR9R9;
- W is absent, (—CR8aR8b—)m or —(CR8aR8b)m—O—;
- m is 1-2;
- Z is aryl or arylalkyl, both of which may be optionally substituted with one or more R4's;
- provided that W and Z, or when W is absent, X and Z, are attached to the same carbon on Ring A;
- R4, at each occurrence, is independently selected from hydrogen, alkyl, aryl, cycloalkyl, heterocyclyl, halo, ═O, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)OR10, —OR10, —OH, —OCF3, —SH, —SR10, —C(═O)NR9R9, —NR9R9, —S(O)2NR9R9, —NR9S(O)2CF3, —C(═O)NR9S(O)2R9, —S(O)2NR9C(═O)OR9, —S(O)2NR9C(═O)NR9R9, —C(═O)NR9S(O)2CF3, —C(═O)R10, —NR9C(═O)R10, —OC(═O)R10, —S(═O)R10, —S(O)2R10, —O—S(O)2R10, —NR9C(═O)OR8 or —NR9S(O2)R8, wherein the alkyl, aryl, cycloalkyl, or heterocyclyl may be optionally substituted with one or more R5's;
- R5, at each occurrence, is independently selected from hydrogen, alkyl, haloalkyl, aryl, cycloalkyl, cycloalkylalkyl, heterocyclyl, halo, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)OR10, —OCF3, —OR10, —OH, —SH, —SR10, —C(═O)NR9R9, —NR9R9, —S(O)2NR9R9, —NR9S(O)2CF3, —C(═O)NR9S(O)2R9, —S(O)2NR9C(═O)OR9, —S(O)2NR9C(═O)NR9R9, —C(═O)NR9S(O)2CF3, —C(═O)R10, —NR9C(═O)R10, —OC(═O)R10, —S(═O)R10, —S(O)2R10, —O—S(O)2R10, —NR9C(═O)OR8 or —NR9S(O2)R8;
- R8, at each occurrence, is independently alkyl, aryl or heterocyclyl;
- R8a, at each occurrence, is independently hydrogen, alkyl or aryl;
- R8b, at each occurrence, is independently hydrogen, —C(═O)OH, alkyl, —OH, halo, —CN, —OR10 or —C(═O)NR9R9, wherein the alkyl may be optionally substituted with one or more R9a's; or
- R9, at each occurrence, is independently hydrogen, alkyl, alkoxy, cycloalkyl, aryl or heterocyclyl, wherein the alkyl, cycloalkyl, aryl or heterocyclyl may be optionally substituted with 0-5 R9a, and the heterocyclyl contains 1-4 heteroatoms selected from N, O, and S; or
- two R9's together with the nitrogen to which they are attached form a unsaturated, saturated or partially saturated cyclic ring system containing from 2-10 carbon atoms and from 0-4 additional heteroatoms selected from N, O, S, S(O) and S(O)2, wherein said ring system may be optionally substituted or fused with one or more R9a's;
- R9a, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, cycloalkyl, cycloalkylalkyl, heterocyclyl, halo, ═O, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)OR14, —OCF3, —OR10, —OH, —SH, —SR14, —C(═O)NR14R14, —NR14R14, —S(O)2NR14R14, —NR14S(O)2CF3, —C(═O)NR14S(O)2R10, —S(O)2NR14C(═O)OR10, —S(O)2NR14C(═O)NR14R14, —C(═O)NR14S(O)2R14, —C(═O)R14, —NR14C(═O)R14, —OC(═O)R14, —S(═O)R14, —S(O)2R14, —OS(O)2R14, —NR14C(═O)OR10, —NR14S(O2)R8, —C(═O)R10, —OC(═O)NR14R14, —NR14C(═O)NR14R14 or arylalkyl, wherein the alkyl, aryl, cycloalkyl, cycloalkylalkyl and heterocyclyl may be optionally substituted with 0-3 R10a;
- R10, at each occurrence, is independently selected from alkyl, cycloalkyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl, wherein the alkyl, cycloalkyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl may be optionally substituted with 0-3 R10a, and the heterocyclyl and heterocyclylalkyl contain 1-4 heteroatoms selected from N, O, and S;
- R10a, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, cycloalkyl, cycloalkylalkyl, heterocyclyl, halo, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)OR14, —OCF3, —OR14, —OH, —SH, —SR14, —C(═O)NR14R14, —NR14R14, —S(O)2NR14R14, —NR14S(O)2CF3, —C(═O)NR14S(O)2R14, —S(O)2NR14C(═O)OR14, —S(O)2NR14C(═O)NR14R14, —C(═O)NR14S(O)2CF3, —C(═O)R14, —NR14C(═O)R14, —OC(═O)R14, —S(═O)R14, —S(O)2R14, —NR14C(═O)OR8, —NR14S(O2)R8 or arylalkyl;
- R14, at each occurrence, is independently selected from hydrogen, alkyl, cycloalkyl, or aryl, wherein the alkyl, cycloalkyl or aryl may be optionally substituted with 0-3 R14a;
- R14a, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, cycloalkyl, cycloalkylalkyl, heterocyclyl, halo, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)OR15, —OCF3, —OR15, —OH, —SH, —SR15, —C(═O)NR15R15, —NR15R15, —S(O)2NR15R15, —NR15S(O)2CF3, —C(═O)NR15S(O)2R15, —S(O)2NR15C(═O)OR15, —S(O)2NR15C(═O)NR15R15, —C(═O)NR15S(O)2CF3, —C(═O)R15, —NR15C(═O)R15, —OC(═O)R15, —S(═O)R15, —S(O)2R15, —NR15C(═O)OR8, —NR15S(O2)R8 or arylalkyl; and
- R15, at each occurrence, is independently selected from hydrogen, alkyl, cycloalkyl or aryl.
- In another embodiment, compounds of formula I are those compounds in which:
- A is a 7- to 14-membered non-aromatic bi-, tri- or polycyclic ring system optionally containing 1-3 heteroatoms selected from N, O, S, S(O) and S(O)2, which may be optionally substituted with one or more R4's;
- X is —C(═O)NR9R9;
- W is absent, (—CR8aR8b—)m or —(CR8aR8b)m—O—;
- m is 1-2;
- Z is aryl or arylalkyl, both of which may be optionally substituted with one or more R4's;
- provided that W and Z, or when W is absent, X and Z, are attached to the same carbon on Ring A;
- R4, at each occurrence, is independently selected from hydrogen, alkyl, aryl, cycloalkyl, heterocyclyl, halo, ═O, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)OR10, —OR10, —OH, —OCF3, —SH, —SR10, —C(═O)NR9R9, —NR9R9, —S(O)2NR9R9, —NR9S(O)2CF3, —C(═O)NR9S(O)2R9, —S(O)2NR9C(═O)OR9, —S(O)2NR9C(═O)NR9R9, —C(═O)NR9S(O)2CF3, —C(═O)R10, —NR9C(═O)R10, —OC(═O)R10, —S(═O)R10, —S(O)2R10, —O—S(O)2R10, —NR9C(═O)OR8 or —NR9S(O2)R8, wherein the alkyl, aryl, cycloalkyl or heterocyclyl may be optionally substituted with one or more R5's;
- R5, at each occurrence, is independently selected from hydrogen, alkyl, haloalkyl, aryl, cycloalkyl, heterocyclyl, halo, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)OR10, —OCF3, —OR10, —OH, —SH, —SR10, —C(═O)NR9R9, —NR9R9, —S(O)2NR9R9, —NR9S(O)2CF3, —C(═O)NR9S(O)2R9, —S(O)2NR9C(═O)OR9, —S(O)2NR9C(═O)NR9R9, —C(═O)NR9S(O)2CF3, —C(═O)R10, —NR9C(═O)R10, —OC(═O)R10, —S(═O)R10, —S(O)2R10, —O—S(O)2R10, —NR9C(═O)OR8 or —NR9S(O2)R8;
- R8, at each occurrence, is independently alkyl, aryl or heterocyclyl;
- R8a, at each occurrence, is independently hydrogen, alkyl or aryl;
- R8b, at each occurrence, is independently hydrogen, —C(═O)OH, alkyl, —OH, halo, —CN, —OR10 or —C(═O)NR9R9, wherein the alkyl may be optionally substituted with one or more R9a's; or
- R9, at each occurrence, is independently hydrogen, alkyl, alkoxy, cycloalkyl, aryl or heterocyclyl, wherein the alkyl, cycloalkyl, aryl or heterocyclyl may be optionally substituted with 0-5 R9a, and the heterocyclyl contains 1-4 heteroatoms selected from N, O, and S; or
- two R9's together with the nitrogen to which they are attached form a unsaturated, saturated or partially saturated cyclic ring system containing from 2-10 carbon atoms and from 0-4 additional heteroatoms selected from N, O, S, S(O) and S(O)2, wherein said ring system may be optionally substituted or fused with one or more R9a's;
- R9a, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, cycloalkyl, heterocyclyl, halo, ═O, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)OR14, —OCF3, —OR10, —OH, —SH, —SR14, —C(═O)NR14R14, —NR14R14, —S(O)2NR14R14, —NR14S(O)2CF3, —C(═O)NR14S(O)2R10, —S(O)2NR14C(═O)OR10, —S(O)2NR14C(═O)NR14R14, —C(═O)NR14S(O)2R14, —C(═O)R14, —NR14C(═O)R14, —OC(═O)R14, —S(═O)R14, —S(O)2R14, —OS(O)2R14, —NR14C(═O)OR10, —NR14S(O2)R8, —C(═O)R10, —OC(═O)NR14R14, —NR14C(═O)NR14R14 or arylalkyl, wherein the alkyl, aryl, cycloalkyl and heterocyclyl may be optionally substituted with 0-3 R10a;
- R10, at each occurrence, is independently selected from alkyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl, wherein the alkyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl may be optionally substituted with 0-3 R10a, and the heterocyclyl and heterocyclylalkyl contain 1-4 heteroatoms selected from N, O, and S;
- R10a, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, cycloalkyl, heterocyclyl, halo, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)OR14, —OCF3, —OR14, —OH, —SH, —SR14, —C(═O)NR14R14, —NR14R14, —S(O)2NR14R14, —NR14S(O)2CF3, —C(═O)NR14S(O)2R14, —S(O)2NR14C(═O)OR14, —S(O)2NR14C(═O)NR14R14, —C(═O)NR14S(O)2CF3, —C(═O)R14, —NR14C(═O)R14, —OC(═O)R14, —S(═O)R14, —S(O)2R14, —NR14C(═O)OR8, —NR14S(O2)R8 or arylalkyl;
- R14, at each occurrence, is independently selected from hydrogen, alkyl, cycloalkyl or aryl, wherein the alkyl, cycloalkyl or aryl may be optionally substituted with 0-3 R14a;
- R14a, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, cycloalkyl, heterocyclyl, halo, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)OR15, —OCF3, —OR15, —OH, —SH, —SR15, —C(═O)NR15R15, —NR15R15, —S(O)2NR15R15, —NR15S(O)2CF3, —C(═O)NR15S(O)2R15, —S(O)2NR15C(═O)OR15, —S(O)2NR15C(═O)NR15R15, —C(═O)NR15S(O)2CF3, —C(═O)R15, —NR15C(═O)R15, —OC(═O)R15, —S(═O)R15, —S(O)2R15, —NR15C(═O)OR8, —NR15S(O2)R8 or arylalkyl; and
- R15, at each occurrence, is independently selected from hydrogen, alkyl, cycloalkyl or aryl.
- In another embodiment, compounds of formula I are those compounds in which:
- A is a 7- to 12-membered non-aromatic bi-, tri- or polycyclic ring system optionally containing 1-3 heteroatoms selected from N, O, S, S(O) and S(O)2, which is substituted with one or more R4's;
- X is —C(═O)NR9R9;
- W is absent or (—CR8aR8b—)m;
- m is 1-2;
- Z is aryl or arylalkyl, both of which may be optionally substituted with one or more R4's;
- provided that W and Z, or when W is absent, X and Z, are attached to the same carbon on Ring A;
- R4, at each occurrence, is independently selected from hydrogen, alkyl, aryl, cycloalkyl, heterocyclyl, halo, ═O, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)OR10, —OR10, —OH, —OCF3, —SH, —SR10, —C(═O)NR9R9, —NR9R9, —S(O)2NR9R9, —NR9S(O)2CF3, —C(═O)NR9S(O)2R9, —S(O)2NR9C(═O)OR9, —S(O)2NR9C(═O)NR9R9, —C(═O)NR9S(O)2CF3, —C(═O)R10, —NR9C(═O)R10, —OC(═O)R10, —S(═O)R10, —S(O)2R10, —O—S(O)2R10, —NR9C(═O)OR8 or —NR9S(O2)R8, wherein the alkyl, aryl, cycloalkyl, or heterocyclyl may be optionally substituted with one or more R5's;
- R5, at each occurrence, is independently selected from hydrogen, alkyl, haloalkyl, aryl, cycloalkyl, heterocyclyl, halo, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)OR10, —OCF3, —OR10, —OH, —SH, —SR10, —C(═O)NR9R9, —NR9R9, —S(O)2NR9R9, —NR9S(O)2CF3, —C(═O)NR9S(O)2R9, —S(O)2NR9C(═O)OR9, —S(O)2NR9C(═O)NR9R9, —C(═O)NR9S(O)2CF3, —C(═O)R10, —NR9C(═O)R10, —OC(═O)R10, —S(═O)R10, —S(O)2R10, —O—S(O)2R10, —NR9C(═O)OR8 or —NR9S(O2)R8;
- R8, at each occurrence, is independently alkyl, aryl or heterocyclyl;
- R8a, at each occurrence, is independently hydrogen or alkyl;
- R8b, at each occurrence, is independently hydrogen, —C(═O)OH, alkyl, —OH, halo, —CN, —OR10 or —C(═O)NR9R9, wherein the alkyl may be optionally substituted with one or more R9a's; or
- R9, at each occurrence, is independently hydrogen, alkyl, alkoxy, cycloalkyl, aryl or heterocyclyl, wherein the alkyl, cycloalkyl, aryl or heterocyclyl may be optionally substituted with 0-5 R9a, and the heterocyclyl contains 1-4 heteroatoms selected from N, O, and S; or
- two R9's together with the nitrogen to which they are attached form a unsaturated, saturated or partially saturated cyclic ring system containing from 2-10 carbon atoms and from 0-4 additional heteroatoms selected from N, O, S, S(O) and S(O)2, wherein said ring system may be optionally substituted or fused with one or more R9a's;
- R9a, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, cycloalkyl, heterocyclyl, halo, ═O, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)OR14, —OCF3, —OR10, —OH, —SH, —SR14, —C(═O)NR14R14, —NR14R14, —S(O)2NR14R14, —NR14S(O)2CF3, —C(═O)NR14S(O)2R10, —S(O)2NR14C(═O)OR10, —S(O)2NR14C(═O)NR14R14, —C(═O)NR14S(O)2R14, —C(═O)R14, —NR14C(═O)R14, —OC(═O)R14, —S(═O)R14, —S(O)2R14, —OS(O)2R14, —NR14C(═O)OR10, —NR14S(O2)R8, —C(═O)R10, —OC(═O)NR14R14, —NR14C(═O)NR14R14 or arylalkyl, wherein the alkyl, aryl, cycloalkyl and heterocyclyl may be optionally substituted with 0-3 R10a;
- R10, at each occurrence, is independently selected from alkyl, aryl, arylalkyl or heterocyclyl, wherein the alkyl, aryl, arylalkyl or heterocyclyl may be optionally substituted with 0-3 R10a, and the heterocyclyl contains 1-4 heteroatoms selected from N, O, and S;
- R10a, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, cycloalkyl, heterocyclyl, halo, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)OR14, —OCF3, —OR14, —OH, —SH, —SR14, —C(═O)NR14R14, —NR14R14, —S(O)2NR14R14, —NR14S(O)2CF3, —C(═O)NR14S(O)2R14, —S(O)2NR14C(═O)OR14, —S(O)2NR14C(═O)NR14R14, —C(═O)NR14S(O)2CF3, —C(═O)R14, —NR14C(═O)R14, —OC(═O)R14, —S(═O)R14, —S(O)2R14, —NR14C(═O)OR8, —NR14S(O2)R8 or arylalkyl;
- R14, at each occurrence, is independently selected from hydrogen, alkyl, cycloalkyl or aryl, wherein the alkyl, cycloalkyl or aryl may be optionally substituted with 0-3 R14a;
- R14a, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, cycloalkyl, heterocyclyl, halo, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)OR15, —OCF3, —OR15, —OH, —SH, —SR15, —C(═O)NR15R15, —NR15R15, —S(O)2NR15R15, —NR15S(O)2CF3, —C(═O)NR15S(O)2R15, —S(O)2NR15C(═O)OR15, —S(O)2NR15C(═O)NR15R15, —C(═O)NR15S(O)2CF3, —C(═O)R15, —NR15C(═O)R15, —OC(═O)R15, —S(═O)R15, —S(O)2R15, —NR15C(═O)OR8, —NR15S(O2)R8 or arylalkyl; and
- R15, at each occurrence, is independently selected from hydrogen, alkyl, cycloalkyl or aryl.
- In another embodiment, compounds of formula I are those compounds in which:
- A is a 7- to 12-membered non-aromatic bi-, tri- or polycyclic ring system optionally containing 1-3 heteroatoms selected from N, O, S, S(O) and S(O)2, which is substituted with one or more R4's;
- X is —C(═O)NR9R9;
- W is absent or (—CR8aR8b—)m;
- m is 1;
- Z is aryl or arylalkyl, both of which may be optionally substituted with one or more R4's;
- provided that W and Z, or when W is absent, X and Z, are attached to the same carbon on Ring A;
- R4, at each occurrence, is independently selected from hydrogen, alkyl, aryl, cycloalkyl, heterocyclyl, halo, ═O, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)OR10, —OR10, —OH, —OCF3, —SH, —SR10, —C(═O)NR9R9, —NR9R9, —S(O)2NR9R9, —NR9S(O)2CF3, —C(═O)NR9S(O)2R9, —S(O)2NR9C(═O)OR9, —S(O)2NR9C(═O)NR9R9, —C(═O)NR9S(O)2CF3, —C(═O)R10, —NR9C(═O)R10, —OC(═O)R10, —S(═O)R10, —S(O)2R10, —O—S(O)2R10, —NR9C(═O)OR8 or —NR9S(O2)R8, wherein the alkyl, aryl, cycloalkyl or heterocyclyl may be optionally substituted with one or more R5's;
- R5, at each occurrence, is independently selected from hydrogen, alkyl, haloalkyl, aryl, cycloalkyl, heterocyclyl, halo, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)OR10, —OCF3, —OR10, —OH, —SH, —SR10, —C(═O)NR9R9, —NR9R9, —S(O)2NR9R9, —NR9S(O)2CF3, —C(═O)NR9S(O)2R9, —S(O)2NR9C(═O)OR9, —S(O)2NR9C(═O)NR9R9, —C(═O)NR9S(O)2CF3, —C(═O)R10, —NR9C(═O)R10, —OC(═O)R10, —S(═O)R10, —S(O)2R10, —O—S(O)2R10, —NR9C(═O)OR8 or —NR9S(O2)R8;
- R8, at each occurrence, is independently alkyl or aryl;
- R8a, at each occurrence, is independently hydrogen or alkyl;
- R8b, at each occurrence, is independently hydrogen, —C(═O)OH, alkyl, —OH, halo, —CN or —OR10, wherein the alkyl may be optionally substituted with one or more R9a's; or
- R9, at each occurrence, is independently hydrogen, alkyl, alkoxy, aryl or heterocyclyl, wherein the alkyl, aryl or heterocyclyl may be optionally substituted with 0-5 R9a, and the heterocyclyl contains 1-4 heteroatoms selected from N, O, and S; or
- two R9's together with the nitrogen to which they are attached form a unsaturated, saturated or partially saturated cyclic ring system containing from 2-10 carbon atoms and from 0-4 additional heteroatoms selected from N, O, S, S(O) and S(O)2, wherein said ring system may be optionally substituted or fused with one or more R9a's;
- R9a, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, cycloalkyl, heterocyclyl, halo, ═O, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)OR14, —OCF3, —OR10, —OH, —SH, —SR14, —C(═O)NR14R14, —NR14R14, —S(O)2NR14R14, —NR14S(O)2CF3, —C(═O)NR14S(O)2R10, —S(O)2NR14C(═O)OR10, —S(O)2NR14C(═O)NR14R14, —C(═O)NR14S(O)2R14, —C(═O)R14, —NR14C(═O)R14, —OC(═O)R14, —S(═O)R14, —S(O)2R14, —OS(O)2R14, —NR14C(═O)OR10, —NR14S(O2)R8, —C(═O)R10, —OC(═O)NR14R14, or —NR14C(═O)NR14R14, wherein the alkyl, aryl, cycloalkyl and heterocyclyl may be optionally substituted with 0-3 R10a;
- R10, at each occurrence, is independently selected from alkyl, aryl or heterocyclyl, wherein the alkyl, aryl or heterocyclyl may be optionally substituted with 0-3 R10a, and the heterocyclyl and heterocyclylalkyl contain 1-4 heteroatoms selected from N, O, and S;
- R10a, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, cycloalkyl, heterocyclyl, halo, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)OR14, —OCF3, —OR14, —OH, —SH, —SR14, —C(═O)NR14R14, —NR14R14, —S(O)2NR14R14, —NR14S(O)2CF3, —C(═O)NR14S(O)2R14, —S(O)2NR14C(═O)OR14, —S(O)2NR14C(═O)NR14R14, —C(═O)NR14S(O)2CF3, —C(═O)R14, —NR14C(═O)R14, —OC(═O)R14, —S(═O)R14, —S(O)2R14, —NR14C(═O)OR8, or —NR14S(O2)R8;
- R14, at each occurrence, is independently selected from hydrogen, alkyl or aryl, wherein the alkyl or aryl may be optionally substituted with 0-3 R14a;
- R14a, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, cycloalkyl, heterocyclyl, halo, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)OR15, —OCF3, —OR15, —OH, —SH, —SR15, —C(═O)NR15R15, —NR15R15, —S(O)2NR15R15, —NR15S(O)2CF3, —C(═O)NR15S(O)2R15, —S(O)2NR15C(═O)OR15, —S(O)2NR15C(═O)NR15R15, —C(═O)NR15S(O)2CF3, —C(═O)R15, —NR15C(═O)R15, —OC(═O)R15, —S(═O)R15, —S(O)2R15, —NR15C(═O)OR8, or —NR15S(O2)R8; and
- R15, at each occurrence, is independently selected from hydrogen, alkyl or aryl.
- In another embodiment, compounds of formula I are those compounds in which:
- A is a 7- to 10-membered non-aromatic bi-, tri- or polycyclic ring system optionally containing 1-3 heteroatoms selected from N, O, S, S(O) and S(O)2, which is substituted with one or more R4's;
- X is —C(═O)NR9R9;
- W is absent or (—CR8aR8b—)m;
- m is 1;
- Z is aryl or arylalkyl, both of which may be optionally substituted with one or more R4's;
- provided that W and Z, or when W is absent, X and Z, are attached to the same carbon on Ring A;
- R4, at each occurrence, is independently selected from hydrogen, alkyl, aryl, cycloalkyl, heterocyclyl, halo, ═O, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)OR10, —OR10, —OH, —OCF3, —SH, —SR10, —C(═O)NR9R9, —NR9R9, —S(O)2NR9R9, —NR9S(O)2CF3, —C(═O)NR9S(O)2R9, —S(O)2NR9C(═O)OR9, —S(O)2NR9C(═O)NR9R9, —C(═O)NR9S(O)2CF3, —C(═O)R10, —NR9C(═O)R10, —OC(═O)R10, —S(═O)R10, —S(O)2R10, —O—S(O)2R10, —NR9C(═O)OR8 or —NR9S(O2)R8, wherein the alkyl, aryl, cycloalkyl or heterocyclyl may be optionally substituted with one or more R5's;
- R5, at each occurrence, is independently selected from hydrogen, alkyl, haloalkyl, aryl, cycloalkyl, heterocyclyl, halo, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)OR10, —OCF3, —OR10, —OH, —SH, —SR10, —C(═O)NR9R9, —NR9R9, —S(O)2NR9R9, —NR9S(O)2CF3, —C(═O)NR9S(O)2R9, —S(O)2NR9C(═O)OR9, —S(O)2NR9C(═O)NR9R9, —C(═O)NR9S(O)2CF3, —C(═O)R10, —NR9C(═O)R10, —OC(═O)R10, —S(═O)R10, —S(O)2R10, —O—S(O)2R10, —NR9C(═O)OR8 or —NR9S(O2)R8;
- R8, at each occurrence, is independently alkyl or aryl;
- R8a, at each occurrence, is independently hydrogen or alkyl;
- R8b, at each occurrence, is independently hydrogen, —C(═O)OH, alkyl, —OH, halo, —CN, or —OR10;
- R9, at each occurrence, is independently hydrogen, alkyl, alkoxy or aryl, wherein the alkyl or aryl may be optionally substituted with 0-5 R9a; or
- two R9's together with the nitrogen to which they are attached form a unsaturated, saturated or partially saturated cyclic ring system containing from 2-10 carbon atoms and from 0-4 additional heteroatoms selected from N, O, S, S(O) and S(O)2, wherein said ring system may be optionally substituted or fused with one or more R9a's;
- R9a, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, cycloalkyl, heterocyclyl, halo, ═O, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)OR14, —OCF3, —OR10, —OH, —SH, —SR14, —C(═O)NR14R14, —NR14R14, —S(O)2NR14R14, —NR14S(O)2CF3, —C(═O)NR14S(O)2R10, —S(O)2NR14C(═O)OR10, —S(O)2NR14C(═O)NR14R14, —C(═O)NR14S(O)2R14, —C(═O)R14, —NR14C(═O)R14, —OC(═O)R14, —S(═O)R14, —S(O)2R14, —OS(O)2R14, —NR14C(═O)OR10, —NR14S(O2)R8, —C(═O)R10, —OC(═O)NR14R14, or —NR14C(═O)NR14R14, wherein the alkyl, aryl, cycloalkyl and heterocyclyl may be optionally substituted with 0-3 R10a;
- R10, at each occurrence, is independently selected from alkyl or aryl, wherein the alkyl or aryl may be optionally substituted with 0-3 R10a;
- R10a, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, cycloalkyl, heterocyclyl, halo, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)OR14, —OCF3, —OR14, —OH, —SH, —SR14, —C(═O)NR14R14, —NR14R14, —S(O)2NR14R14, —NR14S(O)2CF3, —C(═O)NR14S(O)2R14, —S(O)2NR14C(═O)OR14, —S(O)2NR14C(═O)NR14R14, —C(═O)NR14S(O)2CF3, —C(═O)R14, —NR14C(═O)R14, —OC(═O)R14, —S(═O)R14, —S(O)2R14, —NR14C(═O)OR8, or —NR14S(O2)R8;
- R14, at each occurrence, is independently selected from hydrogen, alkyl or aryl, wherein the alkyl or aryl may be optionally substituted with 0-3 R14a;
- R14a, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, cycloalkyl, heterocyclyl, halo, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)OR15, —OCF3, —OR15, —OH, —SH, —SR15, —C(═O)NR15R15, —NR15R15, —S(O)2NR15R15, —NR15S(O)2CF3, —C(═O)NR15S(O)2R15, —S(O)2NR15C(═O)OR15, —S(O)2NR15C(═O)NR15R15, —C(═O)NR15S(O)2CF3, —C(═O)R15, —NR15C(═O)R15, —OC(═O)R15, —S(═O)R15, —S(O)2R15, —NR15C(═O)OR8, or —NR15S(O2)R8; and
- R15, at each occurrence, is independently selected from hydrogen or alkyl.
- In another embodiment, compounds of the present invention are selected from the compounds exemplified in the examples.
- In another embodiment, the present invention relates to pharmaceutical compositions comprised of a therapeutically effective amount of a compound of the present invention, alone or, optionally, in combination with a pharmaceutically acceptable carrier and/or one or more other agent(s).
- In another embodiment, the present invention relates to methods of inhibiting the activity of the enzyme 11-beta-hydroxysteroid dehydrogenase type I comprising administering to a mammalian patient, for example, a human patient, in need thereof a therapeutically effective amount of a compound of the present invention, alone, or optionally, in combination with another compound of the present invention and/or at least one other type of therapeutic agent.
- In another embodiment, the present invention relates to a method for preventing, inhibiting, or treating the progression or onset of diseases or disorders associated with the activity of the enzyme 11-beta-hydroxysteroid dehydrogenase type I comprising administering to a mammalian patient, for example, a human patient, in need of prevention, inhibition, or treatment a therapeutically effective amount of a compound of the present invention, alone, or, optionally, in combination with another compound of the present invention and/or at least one other type of therapeutic agent.
- Examples of diseases or disorders associated with the activity of the enzyme 11-beta-hydroxysteroid dehydrogenase type I that can be prevented, inhibited, or treated according to the present invention include, but are not limited to, diabetes, hyperglycemia, impaired glucose tolerance, insulin resistance, hyperinsulinemia, retinopathy, neuropathy, nephropathy, delayed wound healing, atherosclerosis, acute coronary syndrome, myocardial infarction, angina pectoris, peripheral vascular disease, intermitant claudication, abnormal heart function, myocardial ischemia, stroke, Metabolic Syndrome, hypertension, obesity, dislipidemia, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, low HDL, high LDL, non-cardiac ischemia, infection, cancer, vascular restenosis, pancreatitis, neurodegenerative disease, lipid disorders, cognitive impairment and dementia, bone disease, HIV protease associated lipodystrophy, glaucoma, rheumatoid arthritis, Cushing's Disease, Alzheimer's Disease and osteoarthritis.
- In another embodiment, the present invention relates to a method for preventing, inhibiting, or treating the progression or onset of diabetes, hyperglycemia, obesity, dislipidemia, hypertension, cognitive impairment, rheumatoid arthritis, osteoarthritis, glaucoma, Cushing's Disease and Metabolic Syndrome comprising administering to a mammalian patient, for example, a human patient, in need of prevention, inhibition, or treatment a therapeutically effective amount of a compound of the present invention, alone, or, optionally, in combination with another compound of the present invention and/or at least one other type of therapeutic agent.
- In still another embodiment, the present invention relates to a method for preventing, inhibiting, or treating the progression or onset of diabetes, comprising administering to a mammalian patient, for example, a human patient, in need of prevention, inhibition, or treatment a therapeutically effective amount of a compound of the present invention, alone, or, optionally, in combination with another compound of the present invention and/or at least one other type of therapeutic agent.
- In yet still another embodiment, the present invention relates to a method for preventing, inhibiting, or treating the progression or onset of hyperglycemia comprising administering to a mammalian patient, for example, a human patient, in need of prevention, inhibition, or treatment a therapeutically effective amount of a compound of the present invention, alone, or, optionally, in combination with another compound of the present invention and/or at least one other type of therapeutic agent.
- In another embodiment, the present invention relates to a method for preventing, inhibiting, or treating the progression or onset of obesity comprising administering to a mammalian patient, for example, a human patient, in need of prevention, inhibition, or treatment a therapeutically effective amount of a compound of the present invention, alone, or, optionally, in combination with another compound of the present invention and/or at least one other type of therapeutic agent.
- In one embodiment, the present invention relates to a method for preventing, inhibiting, or treating the progression or onset of dislipidemia comprising administering to a mammalian patient, for example, a human patient, in need of prevention, inhibition, or treatment a therapeutically effective amount of a compound of the present invention, alone, or, optionally, in combination with another compound of the present invention and/or at least one other type of therapeutic agent.
- In another embodiment, the present invention relates to a method for preventing, inhibiting, or treating the progression or onset of hypertension comprising administering to a mammalian patient, for example, a human patient, in need of prevention, inhibition, or treatment a therapeutically effective amount of a compound of the present invention, alone, or, optionally, in combination with another compound of the present invention and/or at least one other type of therapeutic agent.
- In another embodiment, the present invention relates to a method for preventing, inhibiting, or treating the progression or onset of cognitive impairment comprising administering to a mammalian patient, for example, a human patient, in need of prevention, inhibition, or treatment a therapeutically effective amount of a compound of the present invention, alone, or, optionally, in combination with another compound of the present invention and/or at least one other type of therapeutic agent.
- In another embodiment, the present invention relates to a method for preventing, inhibiting, or treating the progression or onset of rheumatoid arthritis comprising administering to a mammalian patient, for example, a human patient, in need of prevention, inhibition, or treatment a therapeutically effective amount of a compound of the present invention, alone, or, optionally, in combination with another compound of the present invention and/or at least one other type of therapeutic agent.
- In another embodiment, the present invention relates to a method for preventing, inhibiting, or treating the progression or onset of osteoarthritis comprising administering to a mammalian patient, for example, a human patient, in need of prevention, inhibition, or treatment a therapeutically effective amount of a compound of the present invention, alone, or, optionally, in combination with another compound of the present invention and/or at least one other type of therapeutic agent.
- In another embodiment, the present invention relates to a method for preventing, inhibiting, or treating the progression or onset of Metabolic Syndrome comprising administering to a mammalian patient, for example, a human patient, in need of prevention, inhibition, or treatment a therapeutically effective amount of a compound of the present invention, alone, or, optionally, in combination with another compound of the present invention and/or at least one other type of therapeutic agent.
- In another embodiment, the present invention relates to a method for preventing, inhibiting, or treating the progression or onset of glaucoma comprising administering to a mammalian patient, for example, a human patient, in need of prevention, inhibition, or treatment a therapeutically effective amount of a compound of the present invention, alone, or, optionally, in combination with another compound of the present invention and/or at least one other type of therapeutic agent.
- In another embodiment, the present invention relates to a method for preventing, inhibiting, or treating the progression or onset of Cushing's Disease comprising administering to a mammalian patient, for example, a human patient, in need of prevention, inhibition, or treatment a therapeutically effective amount of a compound of the present invention, alone, or, optionally, in combination with another compound of the present invention and/or at least one other type of therapeutic agent.
- In one embodiment, the present invention provides a process for the preparation of a compound of Formula Ih or Ii
- wherein A, X, W and Z are as defined above;
comprising reducing a racemic compound of Formula If - with an enzymatic reductase, such as a ketoreductase, produced by a microorganism from the group consisting of Pichia, Hansenula, Candida or Rhodotorula.
- In one embodiment, the strain of Pichia is Pichia membranafaciens, Pichia anomala, Pichia ciferrii or Pichia silvicola. In another embodiment, the strain of Hansenula is Hansenula fabiani or Hansenula polymorpha. In a further embodiment, the strain of Candida is Candida utilis or Candida boidini. In yet a further embodiment, the strain of Rhodotorula is Rhodotorula glutinis.
- In another embodiment, processes for preparing compounds of formula Ih or Ii are provided wherein the reduction with an enzyme is carried out either by:
- introducing a ketone compound of formula If into a medium in which the microorganism is being fermented to form a reaction mixture in which the enzyme is concurrently being formed and reduces the racemic compound; or
- fermenting the microorganism until sufficient growth is realized, and
- introducing the racemic compound to the microorganism in which the ketone compound of formula If is reduced with the enzyme.
- In still another embodiment, processes for preparing compounds of formula Ih or Ii are provided wherein the amount of the ketone compound of formula If added to the reaction mixture is up to about 50 g/L of the reaction mixture.
- In still yet another embodiment, processes for preparing compounds of formula Ih or Ii are provided wherein an enzyme is isolated and optionally purified.
- In one embodiment, processes for preparing compounds of formula Ih or Ii are provided wherein the reduction by an enzyme is carried out by reacting the ketone compound of formula If with the enzyme that was previously isolated and optionally purified before contacting with the ketone compound.
- In another embodiment, processes for preparing compounds of formula Ih or Ii are provided wherein the enzyme is derived from cell extracts.
- In still yet another embodiment, processes for preparing compounds of formula Ih or Ii are provided wherein the enzyme is obtained from Hansenula fabiani. In one embodiment, the enzyme is obtained from Hansenula fabiani strain SC13894 (ATCC 58045).
- In another embodiment, processes for preparing compounds of formula Ih or Ii are provided wherein the enzyme provides a reaction yield of greater than 60% by weight of the compound of formula Ih or Ii, based on the weight of the ketone input.
- In still another embodiment, processes for preparing compounds of formula Ih or Ii are provided wherein the process provides the compounds of formula Ih or Ii in an enantiomeric excess greater than 95%.
- In yet another embodiment, processes for preparing compounds of formula Ih or Ii are provided wherein the reduction by an enzyme is carried out at a pH of between about 5.0 and about 9.0.
- In one embodiment, the present invention provides processes for the preparation of an enzyme for the preparation of compounds of formula Ih or Ii from a compound of formula If comprising:
- (a) either
-
- (i) providing a microorganism selected from the group consisting of Pichia, Hansenula, Candida or Rhodotorula in a growth medium under conditions which allow for expression of an enzyme, or
- (ii) introducing a gene which encodes for the enzyme into a host microorganism for recombinant expression, introducing the host microorganism in a growth medium under conditions which allow for expression of the enzyme and allowing it to grow and express the enzyme;
- (b) optionally, extracting the enzyme from the growth medium; and
- (c) optionally, purifying the enzyme.
- In another embodiment, processes for the preparation of an enzyme for the preparation of compounds of formula Ih or Ii are provided wherein the process of extracting the enzyme comprises lysing the cells of the microorganism and isolating the enzyme.
- In still another embodiment, processes for the preparation of an enzyme for the preparation of compounds of formula Ih or Ii are provided wherein the processes of purifying the enzyme comprises ion-exchange, hydrophobic, and hydroxyapatite chromatography.
- In one embodiment, processes for preparing compounds of formula Ih or Ii are provided wherein
- (a) either
-
- (i) providing a microorganism in a growth medium under conditions which allow for expression of an enzyme, or
- (ii) introducing a gene which encodes for the enzyme into a host microorganism for recombinant expression, introducing the host microorganism in a growth medium under conditions which allow for expression of the enzyme and allowing it to grow and express the enzyme; and
- (b) reacting the enzyme with a compound of formula If to produce the desired compounds.
- In another embodiment, the present invention provides processes for preparing a compound of formula Ih which comprises reacting a compound of the formula If with NADP or NADPH, glucose dehydrogenase, glucose, and a ketoreductase to afford Compound Ih or Ii.
- The invention may be embodied in other specific forms without departing from the spirit or essential attributes thereof. This invention also encompasses all combinations of alternative aspects of the invention noted herein. It is understood that any and all embodiments of the present invention may be taken in conjunction with any other embodiment to describe additional embodiments of the present invention. Furthermore, any elements of an embodiment may be combined with any and all other elements from any of the embodiments to describe additional embodiments.
- The compounds herein described may have asymmetric centers. Compounds of the present invention containing an asymmetrically substituted atom may be isolated in optically active or racemic forms. It is well known in the art how to prepare optically active forms, such as by resolution of racemic forms or by synthesis from optically active starting materials. Many geometric isomers of olefins, C═N double bonds, and the like can also be present in the compounds described herein, and all such stable isomers are contemplated in the present invention. Cis and trans geometric isomers of the compounds of the present invention are described and may be isolated as a mixture of isomers or as separated isomeric forms. All chiral, diastereomeric, racemic forms and all geometric isomeric forms of a structure are intended, unless the specific stereochemistry or isomeric form is specifically indicated.
- One enantiomer of a compound of Formula I may display superior activity compared with the other. Thus, all of the stereochemistries are considered to be a part of the present invention. When required, separation of the racemic material can be achieved by HPLC using a chiral column or by a resolution using a resolving agent such as camphonic chloride as in Steven D. Young et al., Antimicrobial Agents and Chemotherapy, 2602-2605 (1995).
- To the extent that compounds of the formula I, and salts thereof, may exist in their tautomeric form, all such tautomeric forms are contemplated herein as part of the present invention.
- The term “substituted,” as used herein, means that any one or more hydrogens on the designated atom or ring is replaced with a selection from the indicated group, provided that the designated atom's or ring atom's normal valency is not exceeded, and that the substitution results in a stable compound. When a substituent is keto (i.e., ═O), then 2 hydrogens on the atom are replaced.
- When any variable (e.g., R4) occurs more than one time in any constituent or formula for a compound, its definition at each occurrence is independent of its definition at every other occurrence. Thus, for example, if a group is shown to be substituted with (R4)m and m is 0-3, then said group may optionally be substituted with up to three R4 groups and R4 at each occurrence is selected independently from the definition of R4. Also, combinations of substituents and/or variables are permissible only if such combinations result in stable compounds.
- When a bond to a substituent is shown to cross a bond connecting two atoms in a ring, then such substituent may be bonded to any atom on the ring. When a substituent is listed without indicating the atom via which such substituent is bonded to the rest of the compound of a given formula, then such substituent may be bonded via any atom in such substituent. Combinations of substituents and/or variables are permissible only if such combinations result in stable compounds.
- As used herein, “alkyl” is intended to include both branched and straight-chain saturated aliphatic hydrocarbon groups containing 1 to 20 carbons, preferably 1 to 10 carbons, more preferably 1 to 8 carbons, in the normal chain, such as methyl, ethyl, propyl, isopropyl, butyl, t-butyl, isobutyl, pentyl, hexyl, isohexyl, heptyl, 4,4-dimethylpentyl, octyl, 2,2,4-trimethyl-pentyl, nonyl, decyl, undecyl, dodecyl, the various branched chain isomers thereof, and the like as well as such groups may optionally include 1 to 4 substituents such as halo, for example F, Br, Cl, or I, or CF3, alkyl, alkoxy, aryl, aryloxy, aryl(aryl) or diaryl, arylalkyl, arylalkyloxy, alkenyl, cycloalkyl, cycloalkylalkyl, cycloalkylalkyloxy, amino, hydroxy, hydroxyalkyl, acyl, heteroaryl, heteroaryloxy, heteroarylalkyl, heteroarylalkoxy, aryloxyalkyl, alkylthio, arylalkylthio, aryloxyaryl, alkylamido, alkanoylamino, arylcarbonylamino, nitro, cyano, thiol, haloalkyl, trihaloalkyl, and/or alkylthio.
- Unless otherwise indicated, the term “alkenyl” as used herein by itself or as part of another group refers to straight or branched chain radicals of 2 to 20 carbons, preferably 2 to 12 carbons, and more preferably 1 to 8 carbons in the normal chain, which include one to six double bonds in the normal chain, such as vinyl, 2-propenyl, 3-butenyl, 2-butenyl, 4-pentenyl, 3-pentenyl, 2-hexenyl, 3-hexenyl, 2-heptenyl, 3-heptenyl, 4-heptenyl, 3-octenyl, 3-nonenyl, 4-decenyl, 3-undecenyl, 4-dodecenyl, 4,8,12-tetradecatrienyl, and the like, and which may be optionally substituted with 1 to 4 substituents, namely, halogen, haloalkyl, alkyl, alkoxy, alkenyl, alkynyl, aryl, arylalkyl, cycloalkyl, amino, hydroxy, heteroaryl, cycloheteroalkyl, alkanoylamino, alkylamido, arylcarbonyl-amino, nitro, cyano, thiol, alkylthio, and/or any of the alkyl substituents set out herein.
- Unless otherwise indicated, the term “alkynyl” as used herein by itself or as part of another group refers to straight or branched chain radicals of 2 to 20 carbons, preferably 2 to 12 carbons and more preferably 2 to 8 carbons in the normal chain, which include one triple bond in the normal chain, such as 2-propynyl, 3-butynyl, 2-butynyl, 4-pentynyl, 3-pentynyl, 2-hexynyl, 3-hexynyl, 2-heptynyl, 3-heptynyl, 4-heptynyl, 3-octynyl, 3-nonynyl, 4-decynyl, 3-undecynyl, 4-dodecynyl, and the like, and which may be optionally substituted with 1 to 4 substituents, namely, halogen, haloalkyl, alkyl, alkoxy, alkenyl, alkynyl, aryl, arylalkyl, cycloalkyl, amino, heteroaryl, cycloheteroalkyl, hydroxy, alkanoylamino, alkylamido, arylcarbonylamino, nitro, cyano, thiol, and/or alkylthio, and/or any of the alkyl substituents set out herein.
- Unless otherwise indicated, the term “cycloalkyl” as employed herein alone or as part of another group includes saturated or partially unsaturated (containing 1 or 2 double bonds) cyclic hydrocarbon groups containing 1 to 10 rings, preferably 1 to 3 rings, including monocyclic alkyl, bicyclic alkyl (or bicycloalkyl) and tricyclic alkyl, containing a total of 3 to 20 carbons forming the ring, preferably 3 to 15 carbons, more preferably 3 to 10 carbons, forming the ring and which may be fused to 1 or 2 aromatic rings as described for aryl, which includes cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclodecyl, cyclododecyl, cyclohexenyl,
- any of which groups may be optionally substituted with 1 to 4 substituents such as halogen, alkyl, alkoxy, hydroxy, aryl, aryloxy, arylalkyl, cycloalkyl, alkylamido, alkanoylamino, oxo, acyl, arylcarbonylamino, amino, nitro, cyano, thiol, and/or alkylthio, and/or any of the substituents for alkyl.
- Where alkyl groups as defined above have single bonds for attachment to other groups at two different carbon atoms, they are termed “alkylene” groups and may optionally be substituted as defined above for “alkyl”.
- Where alkenyl groups as defined above and alkynyl groups as defined above, respectively, have single bonds for attachment at two different carbon atoms, they are termed “alkenylene groups” and “alkynylene groups”, respectively, and may optionally be substituted as defined above for “alkenyl” and “alkynyl”.
- “Halo” or “halogen” as used herein refers to fluoro, chloro, bromo, and iodo; and “haloalkyl” is intended to include both branched and straight-chain saturated aliphatic hydrocarbon groups, for example CF3, having the specified number of carbon atoms, substituted with 1 or more halogen (for example —CvFw where v=1 to 3 and w=1 to (2v+1)).
- Unless otherwise indicated, the term “aryl” as employed herein alone or as part of another group refers to monocyclic and bicyclic aromatic groups containing 6 to 10 carbons in the ring portion (such as phenyl or naphthyl, including 1-naphthyl and 2-naphthyl) and may optionally include 1 to 3 additional rings fused to a carbocyclic ring or a heterocyclic ring (such as aryl, cycloalkyl, heteroaryl, or cycloheteroalkyl rings
- for example
- and may be optionally substituted through available carbon atoms with 1, 2, or 3 substituents, for example, hydrogen, halo, haloalkyl, alkyl, haloalkyl, alkoxy, haloalkoxy, alkenyl, trifluoromethyl, trifluoromethoxy, alkynyl, cycloalkyl-alkyl, cycloheteroalkyl, cycloheteroalkylalkyl, aryl, heteroaryl, arylalkyl, aryloxy, aryloxyalkyl, arylalkoxy, arylthio, arylazo, heteroarylalkyl, heteroarylalkenyl, heteroarylheteroaryl, heteroaryloxy, hydroxy, nitro, cyano, amino, substituted amino wherein the amino includes 1 or 2 substituents (which are alkyl, aryl, or any of the other aryl compounds mentioned in the definitions), thiol, alkylthio, arylthio, heteroarylthio, arylthioalkyl, alkoxyarylthio, alkylcarbonyl, arylcarbonyl, alkylaminocarbonyl, arylaminocarbonyl, alkoxycarbonyl, aminocarbonyl, alkylcarbonyloxy, arylcarbonyloxy, alkylcarbonylamino, arylcarbonylamino, arylsulfinyl, arylsulfinylalkyl, arylsulfonylamino, or arylsulfonaminocarbonyl, and/or any of the alkyl substituents set out herein.
- Unless otherwise indicated, the term “lower alkoxy”, “alkoxy”, “aryloxy” or “aralkoxy” as employed herein alone or as part of another group includes any of the above alkyl, aralkyl, or aryl groups linked to an oxygen atom.
- Unless otherwise indicated, the term “amino” as employed herein alone or as part of another group refers to amino that may be substituted with one or two substituents, which may be the same or different, such as alkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloheteroalkyl, cycloheteroalkylalkyl, cycloalkyl, cycloalkylalkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, or thioalkyl. These substituents may be further substituted with a carboxylic acid and/or any of the R1 groups or substituents for R1 as set out above. In addition, the amino substituents may be taken together with the nitrogen atom to which they are attached to form 1-pyrrolidinyl, 1-piperidinyl, 1-azepinyl, 4-morpholinyl, 4-thiamorpholinyl, 1-piperazinyl, 4-alkyl-1-piperazinyl, 4-arylalkyl-1-piperazinyl, 4-diarylalkyl-1-piperazinyl, 1-pyrrolidinyl, 1-piperidinyl, or 1-azepinyl, optionally substituted with alkyl, alkoxy, alkylthio, halo, trifluoromethyl, or hydroxy.
- Unless otherwise indicated, the term “lower alkylthio,” “alkylthio,” “arylthio,” or “aralkylthio” as employed herein alone or as part of another group includes any of the above alkyl, aralkyl, or aryl groups linked to a sulfur atom.
- Unless otherwise indicated, the term “lower alkylamino,” “alkylamino,” “arylamino,” or “arylalkylamino” as employed herein alone or as part of another group includes any of the above alkyl, aryl, or arylalkyl groups linked to a nitrogen atom.
- As used herein, the term “heterocyclyl”, “heterocyclic system” or “heterocyclic ring” is intended to mean a stable 3- to 14-membered monocyclic, bicyclic or tricyclic heterocyclic ring which is saturated, partially unsaturated or unsaturated (aromatic), and which consists of carbon atoms and 1, 2, 3, or 4 heteroatoms independently selected from the group consisting of N, NH, O and S and including any bicyclic group in which any of the above-defined heterocyclic rings is fused to a benzene ring. The nitrogen and sulfur heteroatoms may optionally be oxidized. The heterocyclic ring may be attached to its pendant group at any heteroatom or carbon atom, which results in a stable structure. The heterocyclic rings described herein may be substituted on carbon or on a nitrogen atom if the resulting compound is stable. If specifically noted, a nitrogen in the heterocycle may optionally be quaternized. It is preferred that when the total number of S and O atoms in the heterocycle exceeds 1, then these heteroatoms are not adjacent to one another. As used herein, the term “aromatic heterocyclic system” or “heteroaryl” is intended to mean a stable 5- to 7-membered monocyclic or bicyclic or 7- to 10-membered bicyclic heterocyclic aromatic ring which consists of carbon atoms and from 1 to 4 heteroatoms independently selected from the group consisting of N, O and S and is aromatic in nature.
- Examples of heterocycles include, but are not limited to, 1H-indazole, 2-pyrrolidonyl, 2H,6H-1,5,2-dithiazinyl, 2H-pyrrolyl, 1H-indolyl, 4-piperidonyl, 4aH-carbazole, 4H-quinolizinyl, 6H-1,2,5-thiadiazinyl, acridinyl, azocinyl, benzimidazolyl, benzofuranyl, benzothiofuranyl, benzothiophenyl, benzoxazolyl, benzthiazolyl, benztriazolyl, benztetrazolyl, benzisoxazolyl, benzisothiazolyl, benzimidazalonyl, carbazolyl, 4aH-carbazolyl, β-carbolinyl, chromanyl, chromenyl, cinnolinyl, decahydroquinolinyl, 2H,6H-1,5,2-dithiazinyl, dihydrofuro[2,3-b]tetrahydrofuran, furanyl, furazanyl, imidazolidinyl, imidazolinyl, imidazolyl, indazolyl, indolenyl, indolinyl, indolizinyl, indolyl, isobenzofuranyl, isochromanyl, isoindazolyl, isoindolinyl, isoindolyl, isoquinolinyl(benzimidazolyl), isothiazolyl, isoxazolyl, morpholinyl, naphthyridinyl, octahydroisoquinolinyl, oxadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, oxazolidinyl, oxazolyl, oxazolidinylperimidinyl, phenanthridinyl, phenanthrolinyl, phenarsazinyl, phenazinyl, phenothiazinyl, phenoxathiinyl, phenoxazinyl, phthalazinyl, piperazinyl, piperidinyl, pteridinyl, piperidonyl, 4-piperidonyl, pteridinyl, purinyl, pyranyl, pyrazinyl, pyrazolidinyl, pyrazolinyl, pyrazolyl, pyridazinyl, pyridooxazole, pyridoimidazole, pyridothiazole, pyridinyl, pyridyl, pyrimidinyl, pyrrolidinyl, pyrrolinyl, pyrrolyl, quinazolinyl, quinolinyl, 4H-quinolizinyl, quinoxalinyl, quinuclidinyl, carbolinyl, tetrahydrofuranyl, tetrahydroisoquinolinyl, tetrahydroquinolinyl, 6H-1,2,5-thiadiazinyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl, thianthrenyl, thiazolyl, thienyl, thienothiazolyl, thienooxazolyl, thienoimidazolyl, thiophenyl, triazinyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,5-triazolyl, 1,3,4-triazolyl, tetrazolyl, and xanthenyl. In another aspect of the invention, the heterocycles include, but are not limited to, pyridinyl, thiophenyl, furanyl, indazolyl, benzothiazolyl, benzimidazolyl, benzothiaphenyl, benzofuranyl, benzoxazolyl, benzisoxazolyl, quinolinyl, isoquinolinyl, imidazolyl, indolyl, isoindolyl, piperidinyl, piperidonyl, 4-piperidonyl, piperonyl, pyrazolyl, 1,2,4-triazolyl, 1,2,3-triazolyl, tetrazolyl, thiazolyl, oxazolyl, pyrazinyl, and pyrimidinyl. Also included are fused ring and spiro compounds containing, for example, the above heterocycles.
- Examples of heteroaryls are 1H-indazole, 2H,6H-1,5,2-dithiazinyl, indolyl, 4aH-carbazole, 4H-quinolizinyl, 6H-1,2,5-thiadiazinyl, acridinyl, azocinyl, benzimidazolyl, benzofuranyl, benzothiofuranyl, benzothiophenyl, benzoxazolyl, benzthiazolyl, benztriazolyl, benztetrazolyl, benzisoxazolyl, benzisothiazolyl, benzimidazalonyl, carbazolyl, 4aH-carbazolyl, β-carbolinyl, chromanyl, chromenyl, cinnolinyl, decahydroquinolinyl, 2H,6H-1,5,2-dithiazinyl, dihydrofuro[2,3-b]tetrahydrofuran, furanyl, furazanyl, imidazolidinyl, imidazolinyl, imidazolyl, indazolyl, indolenyl, indolinyl, indolizinyl, indolyl, isobenzofuranyl, isochromanyl, isoindazolyl, isoindolinyl, isoindolyl, isoquinolinyl(benzimidazolyl), isothiazolyl, isoxazolyl, morpholinyl, naphthyridinyl, octahydroisoquinolinyl, oxadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, oxazolidinyl, oxazolyl, oxazolidinylperimidinyl, phenanthridinyl, phenanthrolinyl, phenarsazinyl, phenazinyl, phenothiazinyl, phenoxathiinyl, phenoxazinyl, phthalazinyl, piperazinyl, piperidinyl, pteridinyl, piperidonyl, 4-piperidonyl, pteridinyl, purinyl, pyranyl, pyrazinyl, pyrazolidinyl, pyrazolinyl, pyrazolyl, pyrazolotriazinyl, pyridazinyl, pyridooxazole, pyridoimidazole, pyridothiazole, pyridinyl, pyridyl, pyrimidinyl, pyrrolidinyl, pyrrolinyl, pyrrolyl, quinazolinyl, quinolinyl, 4H-quinolizinyl, quinoxalinyl, quinuclidinyl, carbolinyl, tetrahydrofuranyl, tetrahydroisoquinolinyl, tetrahydroquinolinyl, 6H-1,2,5-thiadiazinyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl, thianthrenyl, thiazolyl, thienyl, thienothiazolyl, thienooxazolyl, thienoimidazolyl, thiophenyl, triazinyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,5-triazolyl, 1,3,4-triazolyl, tetrazolyl, and xanthenyl. In another aspect of the invention, examples of heteroaryls are indolyl, benzimidazolyl, benzofuranyl, benzothiofuranyl, benzoxazolyl, benzthiazolyl, benztriazolyl, benztetrazolyl, benzisoxazolyl, benzisothiazolyl, benzimidazalonyl, cinnolinyl, furanyl, imidazolyl, indazolyl, indolyl, isoquinolinyl isothiazolyl, isoxazolyl, oxazolyl, pyrazinyl, pyrazolyl, pyrazolotriazinyl, pyridazinyl, pyridyl, pyridinyl, pyrimidinyl, pyrrolyl, quinazolinyl, quinolinyl, thiazolyl, thienyl, and tetrazolyl.
- The term “heterocyclylalkyl” or “heterocyclyl” as used herein alone or as part of another group refers to heterocyclyl groups as defined above linked through a C atom or heteroatom to an alkyl chain.
- The term “heteroarylalkyl” or “heteroarylalkenyl” as used herein alone or as part of another group refers to a heteroaryl group as defined above linked through a C atom or heteroatom to an alkyl chain, alkylene, or alkenylene as defined above.
- The term “cyano” as used herein, refers to a —CN group.
- The term “nitro” as used herein, refers to an —NO2 group.
- The term “hydroxy” as used herein, refers to an OH group.
- The phrase “pharmaceutically acceptable” is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
- As used herein, “pharmaceutically acceptable salts” refer to derivatives of the disclosed compounds wherein the parent compound is modified by making acid or base salts thereof. Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like. The pharmaceutically acceptable salts include the conventional non-toxic salts or the quaternary ammonium salts of the parent compound formed, for example, from non-toxic inorganic or organic acids. For example, such conventional non-toxic salts include those derived from inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, nitric and the like; and the salts prepared from organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, pamoic, maleic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicylic, sulfanilic, 2-acetoxybenzoic, fumaric, toluenesulfonic, methanesulfonic, ethane disulfonic, oxalic, isethionic, and the like.
- The pharmaceutically acceptable salts of the present invention can be synthesized from the parent compound which contains a basic or acidic moiety by conventional chemical methods. Generally, such salts can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two; generally, nonaqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are preferred. Lists of suitable salts are found in Remington's Pharmaceutical Sciences, 17th ed., Mack Publishing Company, Easton, Pa., p. 1418, (1985), the disclosure of which is hereby incorporated by reference.
- Any compound that can be converted in vivo to provide the bioactive agent (i.e., the compound of formula I) is a prodrug within the scope and spirit of the invention.
- The term “prodrugs” as employed herein includes esters and carbonates formed by reacting one or more hydroxyls of compounds of formula I with alkyl, alkoxy, or aryl substituted acylating agents employing procedures known to those skilled in the art to generate acetates, pivalates, methylcarbonates, benzoates, and the like.
- Various forms of prodrugs are well known in the art and are described in:
- a) The Practice of Medicinal Chemistry, Camille G. Wermuth et al., Ch. 31, (Academic Press, 1996);
- b) Design of Prodrugs, edited by H. Bundgaard, (Elsevier, 1985);
- c) A Textbook of Drug Design and Development, P. Krogsgaard-Larson and H. Bundgaard, eds. Ch. 5, pp. 113-191 (Harwood Academic Publishers, 1991); and
- d) Hydrolysis in Drug and Prodrug Metabolism, Bernard Testa and Joachim M. Mayer, (Wiley-VCH, 2003).
Said references are incorporated herein by reference. - In addition, compounds of the formula I are, subsequent to their preparation, preferably isolated and purified to obtain a composition containing an amount by weight equal to or greater than 99% formula I compound (“substantially pure” compound I), which is then used or formulated as described herein. Such “substantially pure” compounds of the formula I are also contemplated herein as part of the present invention.
- All stereoisomers of the compounds of the instant invention are contemplated, either in admixture or in pure or substantially pure form. The compounds of the present invention can have asymmetric centers at any of the carbon atoms including any one of the R substituents and/or exhibit polymorphism. Consequently, compounds of formula I can exist in enantiomeric, or diastereomeric forms, or in mixtures thereof. The processes for preparation can utilize racemates, enantiomers, or diastereomers as starting materials. When diastereomeric or enantiomeric products are prepared, they can be separated by conventional methods for example, chromatographic or fractional crystallization. In addition, the compounds of formula I may exist in tautomeric form. Such tautomeric forms of the formula I are also contemplated herein as part of the present invention.
- “Stable compound” and “stable structure” are meant to indicate a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into an efficacious therapeutic agent. The present invention is intended to embody stable compounds.
- “Therapeutically effective amount” is intended to include an amount of a compound of the present invention alone or an amount of the combination of compounds claimed or an amount of a compound of the present invention in combination with other active ingredients effective to inhibit MIP-1α or effective to treat or prevent inflammatory disorders.
- As used herein, “treating” or “treatment” cover the treatment of a disease-state in a mammal, particularly in a human, and include: (a) preventing the disease-state from occurring in a mammal, in particular, when such mammal is predisposed to the disease-state but has not yet been diagnosed as having it; (b) inhibiting the disease-state, i.e., arresting it development; and/or (c) relieving the disease-state, i.e., causing regression of the disease state.
- Compounds of formula I may be prepared as shown in the following reaction schemes and description thereof, as well as relevant literature procedures that may be used by one skilled in the art. Exemplary reagents and procedures for these reactions appear hereinafter and in the working Examples.
- Scheme I describes a method for preparing compounds of formula IB (a subset of compounds of formula I). A ketone intermediate II can be obtained commercially, prepared by methods known in the literature or by other methods known to one skilled in the art. The reaction of ketone II with Meldrum's acid, commonly known as a Knoevenagel condensation, can be carried out in anhydrous pyridine in the presence of a catalytic amount of piperidine (Baty, J. D., Jones, G., Moore, C., J. Org. Chem., 34:3295-3302 (1969)) or molecular sieves (Vogt, P. F., Molino, B. F., Robichaud, A. J., Synth. Commun., 31:679-684 (2001)), or via dehydrative condensation with TiCl4 in CH2Cl2 (Brown, R. F. C., Coulston, K. J., Eastwood, F. W., Gatehouse, B. M., Guddatt, L. W., Luke, W., Pfenninger, M., Rainbow, I., Aust. J. Chem., 37:2509-2524 (1984)). The disubstituted Meldrum's acid alkylidene III can be purified by recrystallization from alcohols such as ethanol or methanol, or via flash column chromatography. The 1,4-conjugate addition of nucleophiles such alkyl or aryl Grignard's reagents (Haslego, M. L., Smith, F. X., Synth. Commun., 10:421-427 (1980)) or other organometallic reagents can be carried out in the presence or in the absence of Cu+ salts (such as CuBr, CuCN etc.) at room temperature or at 40° C. The isopropylidene malonate (IV) can be converted to compounds IB via deprotection and subsequent decarboxylation in wet organic solvent at 100 to 110° C. (J. Am. Chem. Soc., 125:6054-6055 (2003)). Alternatively, Knoevenagel condensation of ketone II with malononitrile in the presence of a wide range of catalysts such as NH4OAc or amino acids provides alkylidene III-B, which can be easily purified by recrystallization and/or via flash column chromatography. The 1,4-conjugate addition of nucleophiles such alkyl or aryl Grignard's reagents can be carried out in the absence of Cu+ salts at 0° C. to room temperature to facilitate the adducts IV-B, which can be easily converted to compounds IB via standard nitrile hydrolysis and subsequent decarboxylation.
- Scheme II describes a method for preparing compounds of formula IC (a subset of compounds of formula I) from compounds of formula IB. The alcohol V, obtained from the reduction of IB, for example, with LAH or diborane, can be converted to the corresponding mesylate or halide VI, followed by the subsequent elimination under basic condition to afford the olefin VII. Upon oxidative cleavage of the C═C bond and further oxidation of the resulting aldehyde VIII, the compounds IC can be obtained.
- Scheme III describes methods for preparing compounds of formula ID (a subset of compounds of formula IC, exemplified here where Z is adamantane or substituted adamantane). When Z is benzyl, substituted benzyl, or other heteroaryl methyl, the direct alkylation of the dianion of compound IX (generated for example with LiN(TMS)2 or LDA) with the alkyl halide Z-X gives ID. Alternatively, compound ID can be synthesized by converting compound I× to the corresponding ester IX-B, α-alkylation of IX-B to IX-C, followed by ester hydrolysis to provide compound ID. When Z is aryl, substituted aryl, heteroaryl or other aromatic groups, ketone X can be reacted with nucleophiles such as organolithium reagents (ZCH2Li) or Grignard reagents (ZCH2Mghalide) to afford the tertiary alcohol XI, which can be converted to aldehyde XII via acid-catalyzed rearrangement. Further oxidation of aldehyde XII gives compounds ID.
- Scheme IV describes a method for preparing compounds of formula IF and IF′ (subsets of compounds of formula I). Aldehyde VIII (see Scheme II for the synthesis) can be reacted with triethyl phosphoryl acetate to give α,β-unsaturated ester XIII, which may be subsequently converted to ester XIV by metal-catalyzed hydrogenation (for example Pd/C or Pt in the presence of H2). Hydrolysis of the ester in basic condition gives the carboxylic acid IF′. Alternatively, XIII may be hydrolyzed to provide the corresponding acid IF directly.
- There are numerous methods for the conversion of carboxylic acids to α-keto acids (see reviews: (a) Kovacs, L., Recl. Trav. Chim. Pays-Bas, 112:471 (1993); (b) Cooper, A., Chem. Rev., 83:321 (1983)). Scheme V exemplifies a method of using (cyanomethylene)phosphorane as a carbonyl synthon for preparing compounds of formula IG (a subset of compounds of formula I). Other methods known in the literature or known to one skilled in the art can also be applied. The carboxylic acid XV (see Scheme I to IV) can be reacted with (cyanomethylene)triphenylphosphorane in the presence of coupling reagents such as EDCI to form cyano keto phosphoranes XVI, which can be oxidatively cleaved to form α-keto esters XVII. Further hydrolysis of ester XVII gives compounds IG (Wasserman, H., J. Org. Chem., 59:4364 (1994)).
- Scheme VI describes a method for preparing compounds of formula IH (a subset of compounds of formula I). Ketone II reacts with Grignard reagent ZMgX or organolithium to give the tertiary alcohol XVIII. The O-allylation with an allyl halide can be carried out in the presence of bases such as NaH in reflux condition to give XIX, which can be further converted to IH via oxidative cleavage of the C═C bond.
- Scheme VII describes a method for preparing compounds of formula IJ, formula XX, and formula IK (subsets of compounds of formula I). The enolate anions, obtained by treating carboxylic acid XV with bases such as LDA/DMPU, can react with a variety of electrophilic hydroxylating agents, such as oxygen (Wassermann, H. H. et al., Tetrahedron Lett., 1731 (1975)), molybdenum peroxide-pyridine-hexamethylphosphoramide (Vedejs, E., J. Am. Chem. Soc., 96:5944 (1974)), 2-sulfonyloxaziridine (Davis, F. A. et al., J. Org. Chem., 49:3243 (1984)), dibenzyl peroxydicarbonate (Gore, M. P., Vederas, J. C., J. Org. Chem., 51:3700 (1986)), and bis(trimethylsilyl)peroxide (TMSOOTMS) (Pohmakotr, M., Winotai, C., Synthetic Communications, 18:2141-2146 (1988)) to form compound IJ. On the other hand, the enolate anions can react with chloromethyl benzyl ether to give XX. Upon the cleavage of benzyl group, the acid IK can be obtained.
- Scheme VIII describes a method for preparing compounds of formula IL (subset of compounds of formula I) from readily accessible material XXI (see Scheme I to III for the synthesis of XXI). Phenol XXII, obtained from demethylation of XXI (when R═OMe) using BBr3 or HBr in acetic acid, can be converted to the corresponding trifluoromethanesulphonate (triflate) or nonaflate XXIII by treatment with corresponding sulfonyl halide or sulphonic anhydride. Subsequent displacement of TfO or NfO with —CN can be catalyzed by transition metals such as palladium(0) or nickel(0), yielding compound IL. Compound XXIII may also be useful for the incorporating of a variety of R4 groups via Pd or Ni catalyzed coupling conditions well known in the literature. Alternatively, aryl halide XXI (when R=halo) can be converted to the corresponding nitrile IL through direct nucleophilic displacement catalyzed by transition metal such as Cu(I), Pd, Co, Ni (Ellis, G. P., Romney-Alexander, T. M., Chem. Rev., 87:779-794 (1987), Arvela, R., Leadbeater, N. E., J. Org. Chem., 68:9122-9125 (2003)).
- Scheme IX describes a method of preparing compounds of formula IM (subset of compounds of formula I). The alkylation of phenol XXII (see Scheme VIII) can be carried out in the presence of base such as NaH, to form XXIV. Upon the hydrolysis of the ester, IM can be obtained.
- Scheme X describes a method for preparing compounds of formula IO (subset of compounds of formula I, when A represents adamantane). The oxidation of compounds XXV (see Scheme I to III for synthesis) can be carried out under a wide variety of oxidative conditions such as dimethyldioxirane, potassium permanganate, ferrous iron-molecular oxygen, etc. The products and their yields are depended on the reaction conditions. These products can be separated by preparative HPLC, and their structures can be fully elucidated by 2D NMR technique.
- Scheme XI describes a method of preparing compounds of formula IP (subset of compounds of formula I, when A represents adamantane). Compounds IP can be readily synthesized using Scheme I, II, and III.
- Scheme XII describes a method of preparing compounds of formula IQa and IQb (subsets of compounds of formula I, when A represents adamantane). Ketone XXIX (see Scheme X and XI) reacts with reducing agents such as NaBH4, LiBH4, or reductases or other nucleophiles such as organo magnesium halides or organolithiums to form compounds IQa. On the other hand, Ketone XXIX can react with TOSMIC under basic condition to afford IQb.
- Scheme XIII describes a method for preparing compounds of formula IR (subset of compounds of formula I when Z represents adamantane). Compounds IP and IO (see Scheme IX for synthesis) can react with alkyl halides in the presence of a base such as NaH to form the O-alkylation product, which can be hydrolyzed to form compounds IR.
- Scheme XIV describes a method of preparing compounds of formula IS (a subset of compound of formula I). The acids XXV (see Scheme I to III) can be converted to the corresponding acyl halides using a wide variety of reagents such as thionyl chloride, sulfuryl chloride, oxalyl chloride, and phosphorus trichloride, or alkyl or aryl chloroformate, etc. The acyl halide can react with ammonium hydroxide to form the amide XXX, which can be further converted to nitrile XXXI by treating with dehydration reagents such as acetic anhydride, acyl halide, POCl3, chloroformate, etc. The nitrites XXXI can react with azide such as sodium azide, Me3SnN3, etc to form the tetrazole IS.
- Scheme XV describes a method of preparing compounds of formula IT (a subset of compounds of formula I). The acid XXV can readily react with amine HNR9R9 or its salt to form amide IT in the presence of a wide variety of peptide coupling reagents, such as carbodiimide type reagents (DCC, EDAC, DIC etc.), imidazolium type reagents (CDI, CBMIT, BOI, CMBI etc.), phosphonium type reagents (such as BOP, PyBOP etc.), uronium type reagents (HBTU, TBTU etc). Alternatively, the acid XXV can be converted to acyl chloride XXXII, which reacts with amine HNR9R9 in the presence of base such as i-Pr2NEt, Et3N to form compound IT.
- Scheme XVI describes a method of preparing compounds of formula IU (a subset of compounds of formula I). The acid XXV can readily react with sulfonamide H2NSO2R9 to form acyl sulfonamide IU in the presence of a wide variety peptide coupling reagents, such as EDAC.
- Scheme XVII describes a method of preparing compounds of formula IW (a subset of compounds of formula I). Exemplified in this scheme is the synthesis of a variety of cyclic amines such as compounds XXXV, XXXVII, and XXXIX, but not limited to these structures. For example, when X″=O, XXXIII can react with isocyanate to form the corresponding carbamate. Alternatively, XXXIII can be converted to corresponding chloroformate by reacting with phosgene, then to carbamate by further reacting to appropriate amines. On the other hand, when X″=CO2 (carboxylic acid), XXXV can be converted to heterocycles, such as oxazole, oxadiazole, etc. Alternatively, XXXV can be converted to nitrile, then to other heterocycles such as tetrazole etc. Compound IW can be synthesized by reacting acid XXV with appropriate amines XXXV or XXXVII or XXXIX using the protocol described in Scheme XV.
- The following working Examples serve to better illustrate, but not limit, some of the preferred embodiments of the present invention.
- The term HPLC refers to a Shimadzu high performance liquid chromatography with one of following methods:
- Method A: Zorbax SB C18 4.6×75 mm column, Gradient solvent system: from 50% A: 50% B to 0% A: 100% B (A=90% H2O/10% MeOH+0.2% H3PO4); (B=90% MeOH/10% H2O+0.2% H3PO4) for 8 min; with 2.5 mL/min flow rate and a 2 min. hold, an ultra violet (UV) detector set at 220 nm.
- Method B: Zorbax SB C18 4.6×75 mm column, Gradient solvent system: from 100% A: 0% B to 0% A: 100% B (A=90% H2O/10% MeOH+0.2% H3PO4); (B=90% MeOH/10% H2O+0.2% H3PO4) for 8 min; with 2.5 mL/min flow rate and a 2 min. hold, an ultra violet (UV) detector set at 220 nm.
- Method C: Sunfire 3.5×150 mm column, Gradient solvent system: from 90% A: 10% B to 0% A: 100% B (A=95% H2O/5% MeCN+0.05% TFA); (B=95% MeCN/5% H2O+0.05% TFA) for 10 min, with 2.5 mL/min flow rate and a 5 min. hold, an ultra violet (UV) detector set at 220 nm.
- The term Prep HPLC refers to an automated Shimadzu HPLC system using a mixture of solvent A (10% MeOH/90% H2O/0.2% TFA) and solvent B (90% MeOH/10% H2O/0.2% TFA). The preparative columns were packed with YMC or Phenomenex Luna C18 5 micron resin or equivalent.
- The following abbreviations are employed in the Examples and elsewhere herein:
- Ph=phenyl
- Bn=benzyl
- i-Bu=iso-butyl
- Me=methyl
- Et=ethyl
- Pr=propyl
- Bn=benzyl
- Bu=butyl
- Cbz=carbobenzyloxy or carbobenzoxy or benzyloxycarbonyl
- BOI=2-(1H-benzotriazol-1-yloxy)-4,5-dihydro-1,3-dimethyl-1H-Imidazolium
- BOP=2-(1H-Benzotriazol-1-yl)tris(dimethylamino)phosphonium hexafluorophosphate
- CBMIT=1,1′-Carbonylbis(3-methylimidazolium)triflate
- CDI=1,1′-Carbonyldiimidazole
- CMBI=2-chloro-1,3-dimethyl-1H-benzimidazolium hexafluorophosphate
- DCC=1,3-Dicyclohexylcarbodiimide
- DCM=dichloromethane
- DEAD=Diethyl azodicarboxylate
- DIAD=Diisopropyl azodicarboxylate
- DIC=1,3-Diisopropylcarbodiimide
- DIEA=N,N-diisopropylethylamine
- DMA=N,N-dimethylacetylamide
- DMAP=4-(Dimethylamino)pyridine
- DMPU=N,N′-Dimethyl-3,4,5,6-tetrahydro-2(1H)-pyrimidinone
- DMF=N,N-dimethylformamide
- DMSO=dimethylsulfoxide
- EtOAc=ethyl acetate
- EDC/EDCI/EDAC=3-ethyl-3′-(dimethylamino)propyl-carbodiimide hydrochloride
- (or 1-[(3-(dimethyl)amino)propyl])-3-ethylcarbodiimide hydrochloride)
- HBTU=1-[Bis(dimethylamino)methylene]-1H-benzotriazoliumhexa-fluorophosphate(1-) 3-oxide
- HOAc or AcOH=acetic acid
- HOAT=1-hydroxy-7-azabenzotriazole
- HOBT=1-hydroxybenzotriazole
- HRMS=high resolution mass spectrum
- LAH=lithium aluminum hydride
- LDA=lithium diisopropylamide
- LiN(TMS)2=lithium bis(trimethylsilyl)amide
- mCPBA=3-Chloroperoxybenzoic acid
- MsCl=Methanesulphonyl chloride
- Nf=Nonafluoro-1-butanesulfonyl
- Nf-F=Nonafluoro-1-butanesulfonyl fluoride
- NMP=N-Methylpyrrolidone
- NBS=N-Bromosuccinimide
- n-BuLi=n-butyllithium
- Pd/C=palladium on carbon
- PtO2=platinum oxide
- PyBOP=benzotriazol-1-yloxytrispyrrolidino phosphonium hexafluorophosphate
- SOCl2=Thionyl chloride
- TBAF=tetrabutylammonium fluoride
- TBS=tert-Butyldimethylsilyl
- TBTU=O-Benzotriazolyl tetramethylisouronium tetrafluoroborate
- Tf=Trifluoromethanesulfonyl
- TMS=trimethylsilyl
- TEA=triethylamine
- TFA=trifluoroacetic acid
- THF=tetrahydrofuran
- TOSMIC=Tosylmethyl isocyanide
- equiv=equivalent(s)
- min=minute(s)
- h or hr=hour(s)
- L=liter
- mL=milliliter
- μL=microliter
- g=gram(s)
- mg=milligram(s)
- mol=mole(s)
- mmol=millimole(s)
- meq=milliequivalent
- RT=room temperature
- sat or sat'd=saturated
- aq.=aqueous
- TLC=thin layer chromatography
- HPLC=high performance liquid chromatography
- HPLC Rt=HPLC retention time
- LC/MS=high performance liquid chromatography/mass spectrometry
- MS or Mass Spec=mass spectrometry
- NMR=nuclear magnetic resonance
-
-
- This material is commercially available from the Aldrich Company. It can also be synthesized using the following procedure: A solution of 2-adamantanone (1.5 g, 10 mmol), Meldrum's acid (1.73 g, 12 mmol), and a catalytic amount of piperidine (5 drops) in anhydrous pyridine (10 mL) was stirred under argon for 5 days. After this time, the solution was poured into ice water (30 mL), and the resulting mixture was stirred at room temperature for 20 min. At the conclusion of this period, the resulting precipitate was collected by filtration and washed with cold water (15 mL). The resulting solid was dried in vacuo to provide compound 1A (2.43 g, 88% yield) as a white solid.
-
- To a suspension of copper(I)bromide (1.14 g, 7.947 mmol) in dry THF (10 mL) at −2° C. under argon was added 4-fluorophenylmagnesium bromide (7.9 mL, 15.9 mmol, 2.0 M in THF) dropwise. Upon completion of addition, the resulting mixture was stirred at −2° C. for 10 min, and then a solution of compound 1A (0.732 g, 2.649 mmol) in THF (10 mL) was added through a cannula. The reaction mixture was then allowed to warm to RT where it was stirred under argon for about 16 hours. At the conclusion of this period, the reaction mixture was quenched with NH4Cl (saturated aqueous solution, 20 mL) and then extracted with CH2Cl2 (3×30 mL). The combined organic layers were dried over Na2SO4 and filtered. The filtrate was concentrated under reduced pressure to provide a crude product. The crude product was purified via column chromatography (SiO2, 10% EtOAc/n-Hexane) to provide compound 1B (0.75 g, 76% yield) as a white solid. 1H NMR (400 MHz, CDCl3) δ ppm 7.18-7.25 (m, 2H), 7.04 (t, J=8.79 Hz, 2H), 4.29 (s, 1H), 2.97 (s, 2H), 2.38 (d, J=14.06 Hz, 2H), 2.04 (s, 1H), 1.95 (d, J=13.18 Hz, 2H), 1.61-1.78 (m, 7H), 1.55 (s, 1H), 1.49 (s, 3H), 0.77 (s, 3H); 19F NMR (376 MHz, CDCl3) δ ppm −115.28; 13C NMR (101 MHz, CDCl3) δ ppm 164.6, 129.1, 129.0, 115.5, 115.3, 105.2, 52.3, 51.3, 38.3, 33.5, 33.2, 31.8, 30.6, 27.0, 26.7, 26.4; HPLC Rt (Method A): 7.38 min.
- A suspension of compound 1B (54.5 mg, 0.126 mmol) in a DMF-H2O mixture (v/v 10:1) (1.3 mL) was heated at 100° C. under argon in an oil bath for 6 h. After this time, the solvent was evaporated under reduced pressure to provide a residue. The residue was purified via Prep HPLC to yield Examples 1 (25.3 mg, 60% yield) and 2 (9.7 mg, 20% yield). Example 1: 1H NMR (400 MHz, CDCl3) δ ppm 7.27-7.31 (m, 2H), 6.95-7.02 (m, 2H), 2.69-2.73 (m, 2H), 2.54-2.61 (m, 2H), 2.20 (d, 2H), 1.91-1.99 (m, 1H), 1.78-1.87 (m, 4H), 1.68-1.76 (m, 3H), 1.58 (d, 2H); 19F NMR (376 MHz, CDCl3) δ ppm −117.16; HPLC Rt (Method A): 7.02 min; LC/MS (m/z)=287.3 (M−H)−. Example 2: 1H NMR (400 MHz, CDCl3) δ ppm 7.18-7.25 (m, 2H), 6.96-7.04 (m, 2H), 4.51-4.56 (m, 1H), 2.67-2.73 (m, 2H), 2.41 (d, 2H), 2.04 (s, 1H), 1.91 (d, 2H), 1.81 (d, 2H), 1.69-1.76 (m, 3H), 1.59-1.67 (m, 2H), 1.59 (none, 1H); 19F NMR (376 MHz, CDCl3) δ ppm −115.14; HPLC Rt (Method A): 6.18 min; LC/MS (m/z)=331.3 (M−H)−
- In an alternate experiment, a suspension of compound 1B in a DMF-H2O mixture was heated at 110° C. in an oil bath under argon for 12 h. After this time, Example 1 was isolate in the manner described above in 80% yield.
-
-
- A solution of 2-admantanone (5.0 g, 33 mmol) in THF (25 mL) was stirred at 0° C. and 4-F-benzylmagnesium bromide (132 mL, 33 mmol) was added slowly. Upon completion of addition, the reaction mixture was warmed to room temperature where it was stirred for 16 hours. At the conclusion of this period, the reaction mixture was cooled at 0° C., quenched with saturated NH4Cl solution (30 mL), and extracted with Et2O (3×30 mL). The combined organic layers were dried over MgSO4, filtered, and concentrated to provide compound 3A (8.0 g, 93%) as a yellow solid. LC/MS (m/z)=263 (M+H)+.
-
- To a stirred suspension of compound 3A (8.0 g, 30.7 mmol) in formic acid (32 mL) at 40° C. was added H2O2 (30% solution, 5.6 mL). Upon completion of addition, the reaction was heated at 40° C. in oil bath for about 16 hours. After this time, the reaction mixture was allowed to cool to RT. Once at the prescribed temperature, the reaction mixture was poured into ice, stirred for 10 min, and then extracted with Et2O (3×30 mL). The combined organic layers were washed with sat. NaHCO3, dried over MgSO4, and concentrated to yield a residue. The residue was purified via column chromatography (SiO2, 0-15% EtOAc in hexanes) to provide compound 3B (1.15 g, 14%) as a light yellow oil. LC/MS (m/z)=259 (M+H)+. 1H NMR (400 MHz, CDCl3) δ ppm 9.28 (s, 1H), 7.32 (dd, J=8.79, 5.27 Hz, 2H), 7.05 (t, J=8.57 Hz, 2H), 2.83 (s, 2H), 1.50-2.00 (m, 12H).
- To a solution of compound 3B (50 mg, 0.194 mmol) and 2-methyl-2-butene (2.0 mL) in a t-BuOH—H2O mixture (2.3 mL, v/v 3:1) was added NaH2PO4 (267.7 mg, 1.94 mmol), followed by sodium chlorite (131.6 mg, 1.16 mmol). Upon completion of addition, the reaction mixture was stirred at RT for 3 h. After this time, Na2SO3 (aq.) was added to quench the reaction, and the resulting mixture was extracted with EtOAc (3×5 mL). The combined organic layers were dried over MgSO4, filtered, and then concentrate to yield a crude product. The crude product was purified via Prep HPLC to provide Example 3 (21.2 mg, 40%). HPLC Rt (Method A): 6.686 min; HRMS (high resolution mass spectrum): Calculated for C17H18O2F: 273.1291, found: 273.1298. 1H NMR (400 MHz, CDCl3) δ ppm 7.42-7.49 (m, 2H), 6.98-7.07 (m, 2H), 2.91 (br. s., 2H), 2.03 (d, J=12.3 Hz, 2H), 1.82-1.94 (m, 3H), 1.65-1.79 (m, 6H), 1.59 (d, 2H). 19F NMR (376 MHz, CDCl3) δ ppm-115.67 (s).
-
-
- To a suspension of NaH (86 mg, 2.15 mmol) in THF (2 mL) was added triethyl phosphonoacetate (481 mg, 2.15 mmol) dropwise. Upon completion of addition, the mixture was stirred at RT for 1 h and then a solution of compound 3B (170 mg, 0.65 mmol, see Example 3) in THF (1.5 mL) was added dropwise. The reaction mixture was stirred at RT for about 16 hours and then the solvent was evaporated to dryness to yield a residue. The residue was purified via column chromatography (SiO2, 0-10% EtOAc in hexanes) to provide compound 4A (100 mg, 46%) as a colorless oil. LC/MS (m/z)=329 (M+H)+.
-
- To a solution of compound 4A (60 mg, 0.18 mmol) in MeOH (2.0 mL) was added Pd/C catalyst (12 mg, 20%). Upon completion of addition, the reaction mixture was charged with a H2 balloon for about 16 hours. After this time, the Pd/C catalyst was filtered off, and the filter cake was rinsed with MeOH. The solvent was evaporated to provide compound 4B (60 mg, 100%) as a colorless oil. LC/MS (m/z)=331 (M+H)+.
- To a solution of compound 4B (60 mg, 0.18 mmol) in THF (1.0 mL) was added saturated LiOH (1.0 mL, aqueous). Upon completion of addition, the reaction mixture was stirred at room temperature for three days during which time a few drops of MeOH were added. At the conclusion of the three day period, the reaction mixture was acidified with 1N HCl to pH=2. Once at the prescribed pH, the resulting mixture was extracted with EtOAc (3×5 mL). The combined organic layers were evaporated to dryness to yield a residue. The residue was purified via Prep HPLC to provide Example 4 (5.8 mg, 10% yield) as white solid. LC/MS (m/z)=301 (M−H)−. HPLC Rt (Method A): 7.62 min; 1H NMR (400 MHz, CDCl3) δ ppm 7.15 (dd, J=8.35, 5.71 Hz, 2H), 6.93 (t, J=8.35 Hz, 2H), 2.23 (s, 2H), 2.14 (d, J=12.30 Hz, 2H), 1.89-1.97 (m, 2H), 1.79-1.89 (m, 3H), 1.58-1.77 (m, 7H), 1.49 (d, J=12.74 Hz, 2H).
-
- To a stirred solution of 2-adamantane carboxylic acid (114.5 mg, 0.635 mmol) in dry THF (6 mL) at −40° C. under argon was slowly added LDA (0.79 mL, 1.588 mmol), followed by DMPU (93 μL, 0.688 mmol). Upon completion of addition, the mixture was gradually warmed to RT, where it stirred for 1 hour. After this time, the reaction mixture was cooled to 0° C., and benzyl bromide (83 μL, 0.699 mmol) was added. The resulting mixture was warmed to RT over a 2 hour period. Once at the prescribed temperature, aqueous HCl (1 mL, 1 N) was added to quench the reaction. The reaction mixture was extracted with EtOAc (3×5 mL), and the combined organic layers were dried (Na2SO4) and then concentrated to afford a crude product. The crude product was purified via column chromatography (SiO2, 2% MeOH in CH2Cl2, with 0.1% HOAc) to afford a less crude product. This less crude product was further purified via Prep HPLC to provide Example 5 (29 mg, 17% yield) as a white solid. HPLC Rt (Method A): 7.301 min; 1H NMR (400 MHz, CDCl3) δ ppm 7.17-7.26 (m, 3H), 7.09-7.15 (m, 2H), 3.08 (s, 2H), 2.27 (d, J=11.9 Hz, 2H), 2.14 (s, 2H), 1.83-1.98 (m, 4H), 1.69-1.79 (m, 6H).
-
-
- To a solution of Example 2 (33 mg, 0.114 mmol) in dry THF (1 mL) at −40° C. under argon was slowly added LDA (0.13 mL, 0.267 mmol), followed by DMPU (15.3 μL, 0.124 mmol). Upon completion of addition, the reaction mixture was gradually warmed to RT, where it stirred for 1 hour. At the conclusion of this period, the reaction mixture was cooled to 0° C., and benzyl chloromethyl ether (17.2 mL, 0.124 mmol) was added. The resulting mixture was warmed to RT in 2 hours and then aqueous HCl (1 mL, 1 N) was added to quench the reaction. The resulting mixture was extracted with EtOAc (3×5 mL). The combined organic layers were washed with 1 N HCl, brine, dried over Na2SO4 and concentrated to yield a crude product. The crude product was purified via Prep HPLC to afford compound 6A (15 mg, 32% yield) as a white solid. HRMS (high resolution mass spectrum): Calculated for C26H30O3F: 409.2179, found: 409.2176. 1H NMR (400 MHz, CDCl3) δ ppm 7.22-7.40 (m, 5H), 7.02-7.17 (m, 2H), 6.80-7.01 (m, 2H), 4.33-4.50 (m, 2H), 3.73 (dd, J=10.1, 3.5 Hz, 1H), 3.67 (dd, J=9.0, 3.7 Hz, 1H), 3.18-3.30 (m, 1H), 2.42-2.66 (m, 3H), 2.19 (d, J=12.3 Hz, 1H), 1.98 (br. s., 1H), 1.63-1.88 (m, 7H), 1.45-1.62 (m, 2H).
- Under argon, to a solution of compound 6A (12 mg, 0.029 mmol) in EtOH (0.5 mL) was added 10% Pd/C catalyst (5 mg). Upon completion of addition, the reaction mixture was charged with H2 balloon for 2 h. After this time, the Pd/C catalyst was filtered off, and the filter cake was rinsed with EtOH. The filtrate was concentrated under reduced pressure to afford a crude product. The crude product was purified via Prep HPLC to afford Example 6 (3.2 mg, 34% yield) as white solid. HPLC Rt (Method A): 5.935 min; LC/MS (m/z)=319 (M+H)+. 1H NMR (400 MHz, CDCl3) δ ppm 7.07-7.17 (m, 1H), 6.99-7.07 (m, 1H), 6.81-6.95 (m, 2H), 3.52-3.70 (m, 4H), 3.48 (dd, J=10.8, 3.3 Hz, 1H), 3.24-3.39 (m, 2H), 2.64 (br. s., 1H), 2.50 (br. s., 1H), 2.38 (br. s., 1H), 2.11 (br. s., 1H), 1.91 (br. s., 1H), 1.54-1.80 (m, 5H), 1.46 (d, 2H).
-
-
- To a solution of Example 1 (100 mg, 0.35 mmol), (Triphenylphosphoranylidene)acetonitrile (137 mg, 0.45 mmol), and DMAP (55 mg, 0.45 mmol) in CH2Cl2 (4.0 mL) was added EDC (86 mg, 0.45 mmol). Upon completion of addition, the reaction mixture was stirred at RT for about 16 hours. After this time, the solvent was removed under reduced pressure to yield a residue. The residue was purified via column chromatography (SiO2, 0-30% EtOAc in hexanes) to provide compound 7A (200 mg, 100%) as a colorless oil. LC/MS (m/z)=572 (M+H)+.
-
- To a solution of Compound 7A (200 mg, 0.35 mmol) in a CH2Cl2/MeOH (3.5 mL/1.5 mL) mixture at −78° C. was bubbled O3 gas until a light blue color appeared (about 10 min). Once at the prescribed color, the reaction mixture was aspirated with argon gas for about 10 min to remove any excess O3 and then a few drops of Me2S were added. Upon completion of addition, the reaction mixture was warmed to RT. Once at the prescribed temperature, the solvent was evaporated to yield a residue. The residue was purified via column chromatography (SiO2, 0-15% EtOAc in hexanes) to provide compound 7B (90 mg, 77%) as a white solid. LC/MS (m/z)=331 (M+H)+.
- To a solution of compound 7B (30 mg, 0.09 mmol) in THF (1.0 mL) was added a saturated LiOH solution (1.0 mL, aqueous). Upon completion of addition, the reaction mixture was stirred at room temperature for about 16 hours. At the conclusion of this period, the reaction mixture was acidified with 1 N HCl to a pH of less than 5. Once at the prescribed pH, the reaction mixture was extracted with CH2Cl2 (3×5 mL). The combined organic layers were dried over MgSO4 and concentrated to yield a crude product. The crude product was purified via Prep HPLC to provide Example 7 (14.4 mg, 50% yield) as a white solid. LC/MS (m/z)=315 (M−H)−. HPLC Rt (Method A): 6.85 min; 1H NMR (400 MHz, CDCl3) δ ppm 7.23 (dd, J=9.23, 5.27 Hz, 2H), 6.96 (t, J=8.57 Hz, 2H), 3.35 (s, 2H), 2.57 (s, 2H), 2.21 (d, J=11.86 Hz, 2H), 1.98 (s, 1H), 1.77-1.92 (m, 4H), 1.71 (s, 3H), 1.58 (m, 2H).
-
-
- To a solution of 2-adamantanone (1.214 g, 8.081 mmol) in THF (10 mL) at RT was slowly added 4-fluorophenyl magnesium bromide (4.45 mL, 8.89 mmol, 2.0 M in Et2O). The reaction mixture was heated to 65° C., where it stirred for 1 h. After this time, the reaction mixture was cooled to RT, quenched with NH4Cl (saturated aqueous solution, 10 mL), and then extracted with Et2O (2×20 mL). The combined organic layers were washed with H2O and brine, dried over Na2SO4 and filtered. The filtrate was concentrated under reduced pressure to yield compound 8A (1.59 g, 80%) as a lightly yellow solid.
-
- A suspension of NaH (44 mg, 1.741 mmol, 95%) and compound 8A (306 mg, 1.244 mmol) in THF (6 mL) was heated to 65° C. for 30 min. After this time, the reaction mixture was cooled to RT, and allyl bromide (0.155 mL, 1.74 mmol) was added. Upon completion of addition, the resulting mixture was heated at reflux for 2 h. At the conclusion of this period, the reaction mixture was analyzed by HPLC, which showed that the reaction was complete. The reaction mixture was cooled to RT, quenched with dilute HCl (aq.), and then extracted with CH2Cl2 (3×10 mL). The combined organic layers were washed with H2O and brine and then dried over Na2SO4. The solvent was evaporated to afford a crude product. The crude product was purified via column chromatography (SiO2, 5% EtOAc in Hexanes) to afford compound 8B (0.217 g, 61% yield). 1H NMR (400 MHz, CDCl3) δ ppm 7.39-7.50 (m, 2H), 6.96-7.08 (m, 2H), 5.61-5.79 (m, 1H), 4.90-5.20 (m, 2H), 3.40 (dd, J=3.5, 1.5 Hz, 2H), 2.60 (s, 2H), 2.37 (d, J=10.9 Hz, 2H), 1.88 (s, J=2.8 Hz, 1H), 1.59-1.80 (m, 9H); 19F NMR (376 MHz, CDCl3) δ ppm −116.01.
-
- Ozone (ca. 5% in O2) was bubbled into a well-stirred solution of compound 8B (0.217 g, 0.757 mmol) in CH2Cl2 (7.5 mL) at −78° C. After a pale blue color appeared, the gas flow was stopped and Me2S (6 drops) was added. The reaction mixture was allowed to warm to RT, where it stirred for 3 h. After this time, the solvent was removed under reduced vacuum to yield a residue. The residue was purified via column chromatography (SiO2, 5% EtOAc in n-hexane) to provide compound 8C (46 mg, 21% yield). 1H NMR (400 MHz, CDCl3) δ ppm 9.42 (s, 1H), 7.37-7.57 (m, 2H), 6.94-7.14 (m, 2H), 3.53 (d, J=1.0 Hz, 2H), 2.61 (s, 2H), 2.33 (d, J=11.9 Hz, 2H), 1.91 (d, J=2.5 Hz, 1H), 1.57-1.82 (m, 9H); 19F NMR (376 MHz, CDCl3) δ ppm −114.84.
- Example 8 was prepared in a similar manner as described in Example 4, utilizing compound 8C and the other appropriate reagents. 1H NMR (400 MHz, CDCl3) δ ppm 7.38-7.49 (m, 2H), 6.97-7.16 (m, 2H), 3.59 (s, 2H), 2.63 (s, 2H), 2.23 (s, 2H), 1.94 (s, 1H), 1.56-1.84 (m, 10H); HRMS (ESI): Calculated for C18H20O3F: 303.1396, found: 303.1401.
-
-
- To a solution of 2-(3′-methoxyphenyl)-tricyclo[3.3.1.13,7]decane-2-acetic acid (199 mg, 0.667 mmol, as prepared following the procedure described in Example 1) in CH2Cl2 (5 mL) at −78° C. under argon was added BBr3 (1.33 mL, 1.33 mmol, 1 M solution in CH2Cl2). The mixture was carefully warmed to RT, and then stirred at RT for 2 h. Upon completion of this period, the reaction mixture was quenched with saturated NaHCO3 (aq. 1 mL) and then the solvent was evaporated to dryness to provide a residue. The residue was purified via Prep HPLC to provide compound 9A (152.7 mg, 80% yield) as a white solid. HPLC Rt (Method A): 5.480 min; 1H NMR (400 MHz, CDCl3) δ ppm 7.11 (t, J=7.9 Hz, 1H), 6.84 (d, J=8.8 Hz, 1H), 6.74-6.80 (m, 1H), 6.60 (dd, J=7.9, 1.8 Hz, 1H), 3.04 (br. 1H), 2.37-2.65 (m, J=31.2 Hz, 3H), 2.14 (s, 2H), 1.83-1.96 (m, 3H), 1.77 (d, J=13.6 Hz, 3H), 1.62-1.72 (m, 4H), 1.53 (d, J=12.3 Hz, 2H).
-
- To a solution of compound 9A (30 mg, 0.105 mmol) in DMF (1.2 mL) at −10° C. was added Et3N (45 μL, 0.325 mmol) followed by Nf-F (40 μL, 0.2199 mmol). Upon completion of addition, the reaction mixture was warmed to RT, where it stirred for 3 h. After this time, the solvent was evaporated to provide a residue. The residue was purified via Prep HPLC to afford compound 9B (51 mg, 86% yield) as a white solid. LC/MS (m/z)=567.0 (M−H)−.
- To a solution of compound 9B (51 mg, 0.09 mmol) and Zn(CN)2 (21.1 mg, 0.18 mmol) in anhydrous DMF (2 mL) under argon was added Pd(PPh3)4 (20.8 mg, 0.018 mmol). Upon completion of addition, the reaction mixture was stirred in an 85° C. oil bath for 8 h. At the conclusion of this period, the solvent was removed under reduced pressure to provide a residue. The residue was purified via Prep HPLC to afford Example 9 (7.3 mg, 27% yield) as a white solid. HPLC Rt (Method A): 6.023 min; 1H NMR (400 MHz, CDCl3) δ ppm 7.62 (s, 1H), 7.58 (d, J=7.9 Hz, 1H), 7.46-7.52 (m, 1H), 7.41 (t, J=7.7 Hz, 1H), 2.73 (s, 2H), 2.58 (s, 2H), 2.21 (d, J=13.6 Hz, 2H), 1.99 (s, 1H), 1.85 (d, J=13.6 Hz, 2H), 1.67-1.79 (m, 5H), 1.54-1.67 (m, 2H).
-
- A mixture of compound 9A (24 mg, 0.084 mmol), K2CO3 (24.8 mg, 0.251 mmol), and ethyl iodoacetate (20 μL, 0.168 mmol) in THF (1 mL) was refluxed under argon for 3 h. At the conclusion of this period, the reaction mixture was cooled to RT, neutralized with 1 N HCl (aq.) to a pH=3, and then extracted with EtOAc (3×5 mL). The combined organic layers were evaporated to dryness and then THF (1 mL) and saturated LiOH (aq., 0.5 mL) were added. The resulting mixture was heat to 70° C., where it stirred for about 16 h. After this time, the mixture was neutralized with 1 N HCl (aq.) to a pH=1, and then extracted with EtOAc (3×5 mL). The combined organic layers were evaporated to dryness to yield a residue. The residue was purified via Prep HPLC to provide Example 10 (7.8 mg, 27% yield). HPLC Rt (Method A): 5.703 min; HRMS (ESI): Calculated for C20H23O5: 343.1545, found: 343.1540; 1H NMR (400 MHz, CD3OD) δ ppm 7.22 (t, J=8.1 Hz, 1H), 7.00 (d, J=7.8 Hz, 1H), 6.96 (s, 1H), 6.74 (dd, J=8.2, 1.9 Hz, 1H), 4.61 (s, 2H), 2.56-2.76 (m, 4H), 2.30 (d, J=13.4 Hz, 2H), 1.93 (s, 3H), 1.84 (d, J=13.4 Hz, 2H), 1.75 (s, 2H), 1.69 (s, 1H), 1.61 (d, J=12.4 Hz, 2H).
-
- To a solution of potassium hydroxide (106.6 mg, 1.618 mmol) in water (3.2 mL) was added KMnO4 (290 mg, 1.78 mmol). The resulting solution was warmed in an oil bath (about. 50° C.) and then Example 1 (460 mg, 1.618 mmol) was added portionwise. After the addition was complete, the reaction mixture was allowed to warm to a gentle reflux, where it stirred until all of the KMnO4 was consumed (about 1.5 h). Once the KMnO4 was completely consumed, the reaction mixture was cooled to RT, and then acidified with 6 N HCl (aq.). Sodium metabisulfite was added to remove MnO2 (until all the brown color became white). The resulting solid was collected by filtration and then subjected to Prep HPLC to provide Examples 11 to 16. Some Example 1 starting material was also recovered (260 mg, white solid).
- Example 11 (45.6 mg, white solid, 21.6% yield based on the recovery of starting material). HPLC Rt (Method B): 5.933 min; HRMS (ESI): Calculated for C18H20O3F: 303.1396, found: 303.1401; 1H NMR (400 MHz, CDCl3) δ ppm 7.28-7.38 (m, 2H), 7.00 (t, J=8.8 Hz, 2H), 2.84 (br. s., 2H), 2.66 (s, 2H), 2.08-2.29 (m, 4H), 1.80 (d, J=11.9 Hz, 2H), 1.63-1.74 (m, 4H), 1.53 (d, 2H). 19F NMR (376 MHz, CDCl3) δ ppm −117.60.
- Example 12 (70.5 mg, white solid, 33.4% yield based on the recovery of starting material). HPLC Rt (Method B): 6.986 min; 1H NMR (400 MHz, DMSO-d6) δ ppm 11.56 (br. s., 1H), 7.34 (dd, J=8.6, 5.6 Hz, 2H), 7.09 (t, J=8.8 Hz, 2H), 3.31 (br. s, 3H), 2.75 (br. s, 2H), 2.43-2.63 (m, 2H), 2.09 (d, J=12.4 Hz, 2H), 1.87 (br. s., 1H), 1.46-1.68 (m, 2H), 1.36 (d, J=12.6 Hz, 2H); 19F NMR (376 MHz, DMSO-d6) δ ppm −118.4; HRMS (ESI): Calculated for C18H20O3F: 303.1396, found: 303.1396.
- Example 13 (10 mg, white solid, 4.7% yield based on the recovery of starting material). HPLC Rt (Method B): 6.638 min; HRMS (ESI): Calculated for C18H18O3F: 301.1240, found: 301.1241; 1H NMR (500 MHz, CD3OD) δ ppm 7.39 (dd, J=9.1, 5.2 Hz, 2H), 6.98 (t, J=8.8 Hz, 2H), 3.55 (br. s., 1H), 3.23 (d, J=13.7 Hz, 1H), 2.61-2.70 (m, 2H), 2.55 (br. s., 1H), 2.39-2.48 (m, 1H), 2.27 (br. s., 1H), 2.08-2.17 (m, J=12.6, 3.2, 3.2, 3.0 Hz, 1H), 1.96-2.06 (m, 2H), 1.89-1.96 (m, 2H), 1.78-1.86 (m, 1H), 1.67-1.75 (m, 1H).
- Example 14 (15 mg, white solid, 7.1% yield based on the recovery of starting material). HRMS (ESI): Calculated for C18H18O3F: 301.1240, found: 301.1231.
- Example 15 (15 mg, white solid, 7.1% yield based on the recovery of starting material). HPLC Rt (Method B): 7.665 min; LC/MS (m/z)=303.2 (M−H)−; HRMS (ESI): Calculated for C18H20O3F: 303.1396, found: 303.1391; 1H NMR (500 MHz, CD3OD) δ ppm 7.81-8.01 (m, 2H), 6.95 (t, J=9.1 Hz, 2H), 3.25 (d, J=14.3 Hz, 1H), 2.77 (d, J=14.3 Hz, 2H), 2.29-2.39 (m, 2H), 2.09-2.20 (m, 2H), 1.91-1.98 (m, 1H), 1.63-1.74 (m, 5H), 1.61 (d, J=12.1 Hz, 1H), 1.45 (dd, J=12.9, 2.5 Hz, 1H).
- Example 16 (3 mg, white solid) LC/MS (m/z)=319.3 (M−H)−.
-
- To a suspension of NaH (21 mg, 0.831 mmol, 95%) in anhydrous THF (2 mL) was added Example 12 (25.8 mg, 0.085 mmol). Upon completion of addition, the reaction mixture was heated to reflux under argon where it stirred for 1 h and then iodomethane was added (0.1 mL). Upon completion of addition, the resulting mixture was heated at reflux for about 16 h. After this time, the solvent was removed under reduced pressure to yield a residue. The residue was dissolved in THF (1 mL) and saturated LiOH (0.5 mL, aqueous). The resulting mixture was heated to 67° C., where it stirred for about 16 h. At the conclusion of this period, the mixture was cooled to RT, acidified with 1 N HCl to pH=1, and then extracted with a EtOAc-MeOH solution (8:2, v/v) (5×5 mL). The combined organic layers were evaporated to dryness to yield a residue. The residue was purified via Prep HPLC to provide Example 17 (15.2 mg, 56% yield) as a white solid. HPLC Rt (Method B): 7.753 min; HRMS (ESI): Calculated for C19H22O3F: 317.1553, found: 317.1541; 1H NMR (400 MHz, CDCl3) δ ppm 7.26-7.39 (m, 2H), 6.99 (t, J=8.7 Hz, 2H), 3.29 (s, 3H), 2.86 (s, 2H), 2.67 (s, 2H), 2.21 (d, J=12.4 Hz, 2H), 2.03 (s, 1H), 1.69-1.87 (m, 6H), 1.45 (d, J=12.9 Hz, 2H); 19F NMR (376 MHz, CDCl3) δ ppm −118.23.
-
- To a stirred solution of Example 13 (14.4 mg, 0.047 mmol) in dry THF (1.0 mL) at RT under argon was added methyl magnesium bromide (0.4 mL, 0.56 mmol, 1.4 M in THF). Upon completion of addition, the reaction mixture was heated to 65° C., where it stirred for 1 h. After this time, the solvent was removed under reduced pressure to yield a residue. The residue was purified via Prep HPLC to provide Example 18 (7.2 mg, 48% yield) as a white solid. HPLC Rt (Method B): 7.00 min; HRMS (ESI): Calculated for C19H22O3F: 317.1553, found: 317.1544; 1H NMR (400 MHz, CD3OD) δ ppm 7.41-7.56 (m, 1H), 7.19-7.32 (m, 1H), 6.83-7.04 (m, 2H), 3.11 (d, J=13.6 Hz, 1H), 2.76-2.91 (m, 1H), 2.39-2.52 (m, 3H), 2.32 (d, J=13.6 Hz, 1H), 2.19 (dd, J=14.3, 2.7 Hz, 1H), 1.81-2.03 (m, 3H), 1.70-1.81 (m, 2H), 1.57-1.67 (m, 1H), 1.51 (s, 1H), 1.35 (s, 3H).
-
-
- To a stirred solution of Example 1 (120 mg, 0.42 mmol) in CH2Cl2 (2 mL) at 0° C. was added triethylamine (71 μL, 0.5 mmol), followed by i-butyl chlorformate (57 μL, 0.44 mmol). Upon completion of addition, the reaction mixture was stirred at 0° C. for 45 min. At the conclusion of this period, NH4OH (2.0 mL) was added, and the resulting mixture was warmed to RT where it stirred for about 16 hours. After this time, water was added, and the resulting mixture was extracted with CH2Cl2 (3×5 mL). The combined organic layers were dried over MgSO4 and concentrated to provide compound 19A (150 mg, 100%) as a light yellow solid. LC/MS (m/z)=288 (M+H)+. 1H NMR (400 MHz, CD3CN) δ ppm 7.26-7.38 (m, 2H), 6.94-7.07 (m, 2H), 5.14-5.40 (m, 2H), 2.58 (br. s., 2H), 2.51 (s, 2H), 2.26 (d, J=11.4 Hz, 2H), 1.85-1.95 (m, 1H), 1.76 (d, J=13.6 Hz, 4H), 1.63-1.71 (m, 3H), 1.56 (d, 2H). 19F NMR (376 MHz, Solvent) δ ppm −121.40.
-
- To a stirred solution of compound 19A (150 mg, 0.4 mmol) in pyridine (2.5 mL) was slowly added MsCl (316 μL, 4.0 mmol). Upon completion of addition, the reaction mixture was stirred at room temperature for about 16 h. After this time, the reaction mixture was quenched with water (1 mL), and then extracted with EtOAc (3×5 mL). The combined organic layers were washed with water, dried over MgSO4, and concentrated to yield a residue. The residue was purified via column chromatography (SiO2, 0-10% EtOAc in hexanes) to afford compound 19B (90 mg, 83%) as a white solid. LC/MS (m/z)=270 (M+H)+.
- To a stirred solution of compound 19B (80 mg, 0.29 mmol) in toluene (3.0 mL) was added azidotrimethyltin (103 mg, 0.49 mmol). Upon completion of addition, the resulting mixture was heated to 100° C. where it stirred for 18 hr. After this time, the solvent was removed under reduced pressure to yield a residue. The residue was purified via Prep HPLC to afford Example 19 (7.6 mg, 8.3% yield) as a white solid. LC/MS (m/z)=313 (M+H)+. 1H NMR (400 MHz, CD3OD) δ ppm 6.98-7.05 (m, 2H), 6.95 (t, J=9.0 Hz, 2H), 2.45-2.56 (m, 4H), 2.09-2.24 (m, 5H), 2.02 (br. s., 1H), 1.74 (d, J=19.8 Hz, 5H), 1.59-1.67 (m, 2H). 19F NMR (376 MHz, CD3OD) δ ppm-118.87 (s).
-
-
- A mixture of compound 3B (400 mg, 1.55 mmol), sodium acetate (500 mg), and hydroxylamine hydrochloride (400 mg) in acetic acid (45 mL) was heated at 50° C. for 2 h. After this time, the reaction mixture was allowed to cool to RT, where it stirred for about 16 hours. At the conclusion of this period, the solvent was evaporated under reduced pressure to yield a residue. The residue was dissolved in water (3 mL) and then extracted with CH2Cl2 (3×5 mL). The combined organic layers were washed (saturated NaHCO3 aqueous solution), dried over MgSO4, and concentrated to yield compound 20A (360 mg, 85% yield) as a lightly yellow oil. LC/MS (m/z)=274 (M+H)+.
-
- A stirred solution of compound 20A (360 mg, 1.3 mmol) in acetic anhydride (8.0 mL) was heated at reflux for 1 h. At the conclusion of this period, the reaction mixture was allowed to cool to RT, where it stirred for about 16 hours. After this time, MeOH (8 mL) and a few drops of concentrated H2SO4 were added to the reaction mixture. The resulting mixture was diluted with H2O (20 mL) and extracted with Et2O (3×10 mL). The combined organic layers were dried over MgSO4 and concentrated to yield a residue. The residue was purified via column chromatography (SiO2, 0-10% EtOAc in hexanes) to yield compound 20B (110 mg, 33%) as a lightly yellow oil. LC/MS (m/z)=256 (M+H)+.
- A mixture of compound 20B (110 mg, 0.43 mmol) and azidotrimethyltin (205 mg, 0.86 mmol) in toluene (3.0 mL) was heated at 100° C. for 2 days. At the conclusion of this period, the solvent was removed under reduced pressure to yield a residue. The residue was purified via Prep HPLC to provide Example 20 (10 mg, 7.8% yield) as a white solid. LC/MS (m/z)=299 (M+H)+. 1H NMR (400 MHz, CDCl3) δ ppm 7.53 (dd, J=9.0, 5.1 Hz, 2H), 6.98 (t, J=8.6 Hz, 2H), 3.32 (br. s., 2H), 2.01 (d, J=12.7 Hz, 2H), 1.81-1.97 (m, 6H), 1.76 (br. s., 4H). 13C NMR (101 MHz, CDCl3) δ ppm 163.21, 160.75, 134.45, 128.34, 128.26, 123.66, 116.15, 115.93, 45.43, 37.18, 34.94, 33.33, 31.13, 26.79, 26.27.
-
- To a stirred suspension of Example 1 (30 mg, 0.1 mmol), EDAC (28 mg, 0.15 mmol), HOBT (20 mg, 0.15 mmol), and 3-hydroxyazetidine hydrochloride (16 mg, 0.15 mmol) in CH2Cl2 (1.5 mL) was added N,N-diisopropylethylamine (20 mg, 0.15 mmol). Upon completion of addition, the reaction mixture was stirred at RT for about 16 hours, and then the solvent was removed under reduced pressure to yield a residue. The residue was purified via Prep HPLC to provide Example 21 (15 mg, 43% yield) as a white solid. LC/MS (m/z)=344 (M+H)+; 1H NMR (400 MHz, CDCl3) δ ppm 7.36 (dd, J=9.1, 5.2 Hz, 2H), 6.97-7.12 (m, 2H), 4.10-4.23 (m, 1H), 3.92 (dd, J=11.5, 6.0 Hz, 1H), 3.49 (dd, J=10.7, 4.1 Hz, 1H), 3.22-3.33 (m, 1H), 2.91 (dd, J=9.1, 4.1 Hz, 1H), 2.64 (br. s., 2H), 2.36-2.50 (m, 2H), 2.32 (d, J=12.6 Hz, 2H), 1.97 (br. s., 1H), 1.82 (t, J=12.1 Hz, 2H), 1.64-1.75 (m, 2H), 1.50-1.63 (m, 1H).
-
- Example 1 (50 mg, 0.17 mmol), EDCI (42 mg, 0.22 mmol), DMAP (27 mg, 0.22 mmol), and methanesulfonamide (21 mg, 0.22 mmol) were dissolved in CH2Cl2 (1.5 mL). The resulting mixture was stirred at RT for about 16 h. After this time, the solvent was evaporated under reduced pressure to provide a residue. The residue was purified via PrepHPLC to provide Example 22 as a white solid (54 mg, 67% yield). LC/MS (m/z)=366 (M+H)+. 1H NMR (400 MHz, CDCl3) δ ppm 7.30 (dd, J=9.01, 5.49 Hz, 2H), 7.17 (s, 1H), 7.04 (t, J=8.57 Hz, 2H), 2.93 (s, 3H), 2.62 (s, 2H), 2.43-2.57 (m, 2H), 2.09-2.29 (m, 2H), 1.90-2.02 (m, 1H), 1.49-1.89 (m, 9H).
-
-
- Compound 23A can be prepared from 3-methylenebicyclo[3.3.1]nonan-9-one (reference: Buono, F., Tenaglia, A., J. Org. Chem., 65:3869-3874 (2000)) and Meldrum's acid by following the procedure in Example 1 and 2. 1H NMR (400 MHz, CDCl3) δ ppm 4.82 (t, J=2.1 Hz, 2H), 4.06 (s, 2H), 2.56-2.77 (m, 4H), 2.33-2.55 (m, 1H), 1.98-2.14 (m, 2H), 1.80-1.95 (m, 2H), 1.77 (s, 3H), 1.80 (s, 3H), 1.29-1.40 (m, 1H).
-
- To a suspension of copper(I)bromide (0.416 g, 2.90 mmol) in dry THF (15 mL) at −2° C. under argon was added 4-fluorophenylmagnesium bromide (6.4 mL, 6.37 mmol, 1.0 M in THF) dropwise. Upon completion of addition, the resulting mixture was stirred at −2° C. for 10 min, and then a solution of compound 23A (0.8 g, 2.90 mmol) in THF (15 mL) was added through a cannula. The reaction mixture was then allowed to warm to RT where it was stirred under argon for about 16 hours. At the conclusion of this period, the reaction mixture was quenched with NH4Cl (saturated aqueous solution, 20 mL) and then extracted with EtOAc (3×30 mL). The combined organic layers were dried over Na2SO4 and filtered. The filtrate was concentrated under reduced pressure to provide compound 23B and its regioisomer as yellow oil.
-
- Compound 23B and its regioisomer in DMF-H2O (5 mL, 10:1 v/v) were heated in 110° C. oil bath for 12 hours. Solvent was removed and the residue was purified via PrepHPLC to provide 23C as a lightly yellow solid (59 mg, 7.1% yield), along with its regioisomer 23D as white solid (186 mg, 22.3% yield). 1H NMR of 23C suggests that it contains about 32% of its regioisomer (as the structure shown above). 23D (Regioisomer of 23C): 1H NMR (400 MHz, CD3OD) δ ppm 7.32-7.38 (m, 2H), 7.00 (t, J=8.6 Hz, 2H), 4.55 (t, J=2.6 Hz, 2H), 2.76 (s, 2H), 2.69 (s, 2H), 2.62 (d, J=12.7 Hz, 2H), 2.19-2.26 (m, 3H), 2.05-2.19 (m, 2H), 1.71-1.81 (m, 2H), 1.37-1.47 (m, 1H). LC/MS (m/z)=287 (M−H)+
-
- To a solution of compound 23C (59 mg, 0.205 mmol) in MeOH (3 mL) and CH2Cl2 (3 mL) at −78° C. was bubbled O3/O2 until a light blue color persisted for 10 minutes. Nitrogen gas was bubbled into the above solution to get rid of excess O3. Then 2 mL of Me2S was added in one portion. The mixture was gradually warmed to room temperature overnight. Solvent was removed under reduced pressure. The residue was purified via Prep HPLC to afford compound 23E as white solid (21 mg, 35% yield). LC/MS (m/z)=289 (M−H)+; 1H NMR (400 MHz, CDCl3) δ ppm 7.33-7.41 (m, 2H), 6.99-7.09 (m, 2H), 3.03 (s, 2H), 2.88-2.99 (m, 2H), 2.67 (s, 2H), 2.51 (d, J=18.9 Hz, 2H), 1.73-1.89 (m, 2H), 1.48 (dd, J=13.8, 2.4 Hz, 2H), 1.30-1.42 (m, 2H).
-
- To a solution of compound 23E (20 mg, 0.069 mmol) in dry THF (0.7 mL) at −78° C. under nitrogen was added L-selectride (0.17 mL, 1 M in THF, 0.17 mmol) dropwise. The mixture was stirred at this temperature for 5 hours, then at −20° C. overnight. It was quenched with 20 μL of H2O2 (30% aqueous), acidified with HOAc (30 μL). Solvent was evaporated and the residue was purified via Prep HPLC to afford compound 23F as white solid (16 mg, 80% yield). HPLC Rt (Method B): 6.705 min; HRMS (ESI): Calculated for C17H21FO3: 292.1474, found: 291.1406 (M−H)−. 1H NMR (400 MHz, CDCl3) δ ppm 7.30-7.35 (m, 2H), 6.93-7.10 (m, 2H), 4.26 (t, J=7.5 Hz, 1H), 3.75 (br., 1H, —OH), 3.34-3.40 (m, 1H), 2.86-3.10 (m, 1H), 2.57-2.71 (m, 3H), 2.45-2.56 (m, 1H), 2.43 (s, 2H), 1.63-1.80 (m, 3H), 1.30-1.53 (m, 2H), 1.07-1.21 (m, 1H).
- To a suspension of compound 23F (17 mg, 0.058 mmol), 3-hydroxyazetidine hydrochloride salt (9.6 mg, 0.087 mmol), EDAC (16.7 mg, 0.087 mmol), HOBt (11.8 mg, 0.087 mmol) in CH2Cl2 (1 mL) was added i-Pr2NEt (15.2 μL, 0.087 mmol). The mixture was stirred at room temperature overnight. Solvent was removed under reduced pressure and the residue was purified via Prep HPLC to afford example 23 as white solid (11 mg, 54% yield). HPLC Rt (Method B): 6.320 min; LC/MS (m/z)=348 (M−H)+; 1H NMR (400 MHz, CDCl3) δ ppm 7.19-7.34 (m, 2H), 6.97 (t, J=8.6 Hz, 2H), 4.18 (t, J=8.0 Hz, 1H), 3.98 (tt, J=6.8, 4.5 Hz, 1H), 3.66-3.83 (m, 1H), 3.39 (dd, J=10.9, 5.3 Hz, 1H), 3.21-3.34 (m, 1H), 2.80-3.12 (m, 6H), 2.30-2.78 (m, 4H), 2.07-2.30 (m, 1H), 1.86-2.07 (m, 1H), 1.54-1.73 (m, 2H), 1.22-1.40 (m, 2H), 0.97-1.20 (m, 1H).
-
-
- Compound 24A was synthesized via ozonolysis of compound 23D, followed by L-selectride reduction (see the procedure described in Example 23). Yield 34% (two steps). HPLC Rt (Method B): 5.906 min; LC/MS (m/z)=291 (M−H)−, 1H NMR (400 MHz, CDCl3) δ ppm 7.30-7.39 (m, 2H), 6.93-7.05 (m, 2H), 3.24 (quin, J=7.8 Hz, 1H), 2.77 (d, J=9.3 Hz, 2H), 2.63 (s, 2H), 2.21-2.34 (m, 2H), 2.01-2.14 (m, 2H), 1.86-2.00 (m, 2H), 1.47-1.60 (m, 3H), 1.25-1.38 (m, 2H).
-
- To a solution of KOH (aqueous, prepared from 5.0 g of KOH and 7.6 mL of H2O) and Et2O (8 mL) at 0° C. was added 1-methyl-3-nitro-1-nitrosoguanidine (MNNG, 460 mg) in portion. The ether layer turned to yellow. After 5 minutes, the flask was cooled to −78° C. The ether layer was added dropwise to a solution of compound 24A (89.6 mg, 0.307 mmol) in CH2Cl2 (4 mL) at 0° C., until the yellow color remained for 10 minutes. Solvent was removed and the residue was purified in column chromatography (SiO2, 45% EtOAc in n-hexane) to provide compound 24B as white solid (93 mg, 99% yield). HPLC Rt (Method B): 7.011 min; LC/MS (m/z)=307 (M+H)+, 1H NMR (400 MHz, CDCl3) δ ppm 7.29-7.36 (m, 2H), 6.91-7.06 (m, 2H), 3.30 (s, 3H), 3.16-3.28 (m, 1H), 2.76 (d, J=9.1 Hz, 2H), 2.61 (s, 2H), 2.21-2.34 (m, 2H), 1.89-2.14 (m, 3H), 1.47-1.60 (m, 2H), 1.23-1.40 (m, 3H).
-
- Compound 24B (46.5 mg, 0.152 mmol), iodobenzene diacetate (IBD, 58.7 mg, 0.182 mmol), and iodine (38.6 mg, 0.152 mmol) in cyclohexane (2.5 mL) was heated to 50-65° C. for 4 hours, under the irradiation of a 100 W normal light bulb. A solution of sodium sulfite (saturated aqueous, 4 mL) was added to remove excess I2. It was extracted with Et2O (3×5 mL). Combined organic layers were concentrated to dryness. The residue and Bu3SnH (0.1 mL) in Benzene (3 mL) was heated to reflux for 4 hours. Solvent was removed. The resulting residue was heated in THF (0.5 mL) and LiOH (saturated aqueous, 0.5 mL) at 70° C. overnight. It was acidified with HOAc (0.4 mL) and the solvent was then removed. The residue was purified via Prep HPLC to afford compound 24C as white solid (20 mg, 45% yield). HPLC Rt (Method B): 6.460 min; LC/MS (m/z)=289 (M−H)−, 1H NMR (400 MHz, CD3OD) δ ppm 7.30-7.37 (m, 2H), 6.98-7.06 (m, 2H), 4.05 (br. s., 1H), 3.83 (br. s., 1H), 2.79 (br. s., 2H), 2.70 (s, 2H), 2.15-2.25 (m, 2H), 2.10 (m, 2H), 1.96 (d, J=12.6 Hz, 2H), 1.70 (m, 2H).
- Example 24 was synthesized from compound 24B and 3-hydroxyazetidine hydrochloride via standard peptide coupling reaction (see procedure in Example 23). Yield: 59%. HPLC Rt (Method B): 5.918 min; LC/MS (m/z)=346 (M+H)+, 1H NMR (400 MHz, CDCl3) δ ppm 7.37 (dd, J=8.7, 5.4 Hz, 2H), 7.07 (t, J=7.8 Hz, 2H), 4.18 (tt, J=6.7, 4.3 Hz, 1H), 4.05 (br. s., 1H), 3.88-3.98 (m, 1H), 3.82 (br. s., 1H), 3.52 (dd, J=10.9, 3.5 Hz, 1H), 3.22-3.30 (m, 1H), 2.95 (dd, J=8.7, 3.7 Hz, 1H), 2.81 (d, J=14.9 Hz, 2H), 2.32-2.49 (m, 2H), 2.09-2.25 (m, 4H), 1.95 (d, J=12.4 Hz, 2H), 1.53-1.68 (m, 2H).
-
-
- A solution of 2,6-adamantanedione (9.5 g, 57.85 mmol), ethylene glycol (3.22 mL), and TsOH monohydrate (1.099 g, 5.785 mmol) in dry CH2Cl2 (870 mL) was stirred at room temperature overnight. Solvent was removed under reduced pressure and the residue was purified via column chromatography (SiO2, 300 g ISCO cartridge, 25% EtOAc in n-Hexane) to provide compound 25A as white solid (8.688 g, 72% yield), along with compound 25B as white solid (1.868 g, 12.8% yield). 25A: 1H NMR (400 MHz, CDCl3) δ ppm 3.72 (s, 4H), 2.12 (br. s., 2H), 1.95-2.08 (m, 4H), 1.54-1.68 (m, 6H).
-
- Compound 25C was synthesized from compound 25A and Meldrum's acid according to the procedure described in Example 1. 1H NMR (400 MHz, CDCl3) δ ppm 4.00 (s, 4H), 3.97 (br. s., 2H), 2.32 (d, J=12.1 Hz, 4H), 1.91 (br. s., 2H), 1.84 (d, J=12.6 Hz, 4H), 1.76 (s, 6H).
-
- Compound 25D was synthesized from compound 25C and 4-fluorophenyl magnesium bromide according to the procedure described in Example 1. Yield 87%. HPLC Rt (Method B): 5.66 min; LC/MS (m/z)=429 (M−H)−, 1H NMR (400 MHz, CDCl3) δ ppm 7.20-7.25 (m, 2H), 7.01-7.09 (m, 2H), 4.28 (s, 1H), 3.88-4.00 (m, 4H), 2.91 (br. s., 2H), 2.13-2.34 (m, 4H), 1.90 (d, J=12.4 Hz, 3H), 1.67 (br. s., 2H), 1.53-1.60 (m, 1H), 1.49 (s, 3H), 0.79 (s, 3H).
-
- Compound 25E was synthesized from compound 25D via decarboxylation in DMF-H2O at 110° C. according to the procedure described in Example 1. HPLC Rt (Method B): 4.60 min; LC/MS (m/z)=345 (M−H)−; 1H NMR (400 MHz, CDCl3) δ ppm 7.30 (dd, J=8.8, 5.3 Hz, 2H), 7.00 (t, J=8.8 Hz, 2H), 3.89-3.99 (m, 4H), 2.72 (s, 2H), 2.51 (br. s, 2H), 2.02-2.18 (m, 4H), 1.71-1.89 (m, 5H), 1.62 (br. s., 1H).
-
- A solution of compound 25E (73.7 mg, 0.213 mmol) and TsOH monohydrate (4.81 mg, 0.025 mmol) in 70% acetone-water (1.2 mL) was heated in a 50° C. oil bath for 12 hours. Solvent was removed and the residue was purified via Prep HPLC to provide compound 25F as white solid (49.4 mg, 77% yield). HPLC Rt (Method A): 2.333 min; LC/MS (m/z)=301 (M−H)−; 1H NMR (400 MHz, CDCl3) δ ppm 7.29-7.37 (m, 2H), 7.04 (t, J=8.7 Hz, 2H), 2.84 (s, 2H), 2.75 (br. s., 2H), 2.61 (br. s., 1H), 2.45-2.57 (m, 2H), 2.38 (br. s., 1H), 2.19 (d, J=13.1 Hz, 2H), 2.06 (d, J=14.1 Hz, 2H), 1.84 (d, J=13.6 Hz, 2H).
-
- To a solution of compound 25F (20 mg, 0.066 mmol) in THF (0.5 mL) was added sodium borohydride (25 mg, 0.66 mmol) slowly. The mixture was stirred at room temperature for 30 minutes. It was quenched with HOAc (0.1 mL). Solvent was removed and the residue was purified via Prep HPLC to provide compound 25G as white solid (17 mg, 84% yield). HPLC Rt (Method A): 2.260 min; LC/MS (m/z)=303 (M−H)−; 1H NMR (400 MHz, CDCl3) δ ppm 7.22-7.33 (m, 2H), 6.99 (t, J=8.8 Hz, 2H), 3.81 (br. s., 1H), 2.62-2.70 (dd, 2H), 2.40-2.58 (m, 2H), 2.29 (dd, J=13.6, 3.1 Hz, 1H), 2.11-2.23 (m, 1H), 1.82-1.99 (m, 4H), 1.66-1.80 (m, 2H), 1.60 (dd, J=13.0, 2.4 Hz, 1H), 1.52 (dd, J=13.2, 2.2 Hz, 1H).
-
- Racemic 25G (2.0 g) was subjected to chiral SFC purification (Chiralpak AD-H, 250×30 mm ID; 5 μm, Mobile Phase: CO2/MeOH (70/30), Flow rate: 65 ml/min; UV Detection: 220 nm; Injection volume: 2 ml of 76 mg/ml in methanol) to provide compound 25H (retention time=15.2 minutes) and compound 25I (retention time=6.1 minutes). HPLC Rt (Method A): 2.260 min; LC/MS (m/z)=303 (M−H)−; NMR spectra of 25H and 25I are identical to that of 25G.
- 25H: [α]D=+30.6° (c=3.6 mg/mL, pyridine, t=25.5° C.). Chiral analytic HPLC: Chiralpak AD, 250×4.6 mm ID; 10 μm, room temperature, mobile phase: CO2/MeOH/(80/20), Flow rate: 2 mL/min, UV Detection: 220 nm, Retention Time (min): 6.4. e.e>99.9%.
- 25I: [α]D=−26.5° (c=3.34 mg/mL, pyridine, t=25.5° C.). Chiral analytic HPLC: Chiralpak AD, 250×4.6 mm ID; 10 μm, room temperature, mobile phase: CO2/MeOH/(80/20), Flow rate: 2 mL/min, UV Detection: 220 nm, Retention Time (min): 3.3. e.e>99.9%.
- Alternatively, compounds 25H and 25I can be prepared according to the following enzymatic conversions:
- One mL of a solution containing 50 mM potassium phosphate buffer pH 7, 0.1 M KCl, 0.5 mM dithiothreitol, 5 mg/mL NADPH tetrasodium salt (6 mM), and compound 25F (1 mg/mL, 3.307 mM) was added to a microfuge tube or well of a 24-well plate containing about 1 to 5 mg of ketoreductase (available from Biocatalytics Inc.). The solutions were incubated for 15 to 17 h at 28° C. and then analyzed by HPLC. Enzymes that gave the most enantioselective reduction are set forth in Table 25-1 below.
-
TABLE 25-1 Time Compound 25F Alcohol Compound 25H Ketoreductase hrs mg/mL mg/mL % e.e. KRED 106 15 0.716 0.389 95.49 KRED c1q 15 0.844 0.186 95.03 KRED A1Y 16 0.806 0.200 94.84 KRED 125 17 0.869 0.214 94.14 KRED 102 15 0.034 1.039 93.27 KRED A1K 17 0.316 0.716 93.22 KRED C1K 15 0.930 0.092 91.42 KRED A1O 17 0.780 0.273 90.41 KRED EXP-A1X 16 0.195 0.760 80.81 KRED A1L (c1) 17 0.807 0.256 80.45 KRED EXP-B1N 16 0.088 0.875 76.34 KRED b1y 15 0.048 0.886 75.73 KRED A1P (c5) 17 1.032 0.026 75.58 KRED A1H (b3) 17 1.017 0.027 68.62 KRED EXP-A1U 16 0.104 0.830 65.18 KRED b1t 15 0.991 0.028 62.76 KREDEXP-B1G 16 0.373 0.649 61.19 - Two mL F7 medium (1% malt extract, 1% yeast extract, 0.1% peptone and 2% dextrose adjusted to pH 7) was added to each well of 24-well plates containing 69 frozen yeast cultures (0.1 mL broth with 20% glycerol) for screening for reduction of compound 25F. The plates were incubated for 21 h at 28° C. and 600 rpm, then 10 μL of 100 mg/mL compound 25F slurried in methanol was added to each well. Incubation was continued for 48 h before analysis by HPLC as described above. Strains that gave the most enantioselective reduction are set forth in Table 25-2 below.
-
TABLE 25-2 Compound 25F Compound 25H Strain SC # ATCC # mg/mL Alcohol mg/mL % e.e. Pichia membranafaciens 13859 20101 0.399 0.010 100.00 Pichia anomala 16139 8168 0.323 0.009 100.00 Pichia anomala 16140 20029 0.350 0.010 100.00 Pichia anomala 16141 36995 0.395 0.020 100.00 Pichia anomala 16143 66346 0.489 0.022 100.00 Pichia anomala 16145 20144 0.448 0.013 100.00 Pichia ciferrii 16170 14091 0.234 0.031 100.00 Hansenula fabianii 13894 58045 0.074 0.516 100.00 Candida utilis 16524 42181 0.213 0.108 100.00 Candida boidini 13821 0.300 0.082 100.00 Pichia silvicola 16160 16768 0.180 0.110 69.79 Rhodotorula glutinis 16293 201718 0.206 0.225 69.35 Hansenula polymorpha 13896 62809 0.268 0.315 51.54 - Enzymatic Conversion of Compound 25F to Compound 25H
- A 350 mL reaction mixture containing 0.1 M potassium phosphate buffer pH 8, 0.1 M KCl, 1 mM dithiothreitol, 1 mM NADP, glucose dehydrogenase (35 mg, 1540 U from Amano), glucose (3.5 g, 1.389 mmoles), ketoreductase KRED-102 (70 mg, 511 U from Biocatalytics) and compound 25F (700 mg, 0.165 mmoles) was incubated at 28° C. HPLC analysis after 17 h showed there was no remaining compound 25F.
- The reaction mixture (350 mL, pH 7.56) was then acidified to pH 3.0 with 5M H2SO4 (4.75 g) and extracted with ethylacetate (2×250 mL). The combined ethylacetate phases were washed with 100 mL of 15% NaCl, dried over MgSO4 for 2 h, and filtered. Solvent removal of the filtrate gave a white solid, which was further dried in a vacuum oven at room temperature overnight to give 745 mg of crude compound 25H (Yield 108%, AP 94, e.e. 96.1%).
- Enzymatic Conversion of Ketone Compound 25F to Compound 25I
- One mL of a solution containing 50 mM potassium phosphate buffer pH 7, 0.1 M KCl, 0.5 mM dithiothreitol, 5 mg/mL NADPH tetrasodium salt (6 mM), and compound 25F (1 mg/mL, 3.307 mM) was added to a microfuge tube or well of a 24-well plate containing about 1 to 5 mg keto reductase (available from Biocatalytics Inc.). The solutions were incubated for 15 to 17 h at 28° C. then analyzed by HPLC. Enzymes giving the most enantioselective reduction are shown in the Table 25-3 set forth below.
-
TABLE 25-3 Time Compound 25F Alcohol Compound 25I Ketoreductase hrs mg/mL mg/mL % e.e. KRED 101 15 0.570 0.537 93.08 KRED 103 15 0.668 0.447 92.82 KRED 112 15 0.725 0.391 92.39 KRED A1V 16 0.028 0.897 92.09 KRED 114 15 0.669 0.448 85.03 - Yeast strains were screened for reduction of Compound 25F in a similar manner as described above. Strains giving the most enantioselective reduction are set forth in the Table 25-4 below.
-
TABLE 25-4 Compound 25F Compound 25I Strain SC # ATCC # mg/mL Alcohol mg/mL % e.e. Pichia methanolica 13825 58403 0.070 0.245 100.00 Pichia methanolica 16413 58372 0.260 0.245 100.00 Pichia methanolica 16414 56508 0.237 0.408 100.00 Pichia methanolica 16415 56509 0.120 0.472 100.00 Pichia methanolica 16416 46071 0.097 0.320 100.00 Rhodotorula glutinis 16267 26207 0.277 0.086 100.00 Pichia methanolica 13860 0.107 0.302 100.00 Pichia methanolica 16413 0.166 0.175 100.00 Pichia methanolica 16116 56508 0.035 0.286 94.98 Pichia methanolica 13860 56510 0.023 0.303 94.95 - Example 25 was synthesized from compound 25H and 3-hydroxyazetidine hydrochloride according to the procedure in Example 21. HPLC Rt (Method C): 5.376 min; LC/MS (m/z)=360 (M−H)−; 1H NMR (400 MHz, CD3OD) δ ppm 7.38 (br. s, 2H), 7.09 (t, J=8.3 Hz, 2H), 3.99-4.13 (m, 1H), 3.77-3.87 (m, 1H), 3.74 (br. s, 1H), 3.40 (ddd, J=10.4, 5.1, 4.9 Hz, 1H), 3.20-3.36 (m, 1H), 2.98-3.14 (m, 1H), 2.33-2.68 (m, 5H), 2.21 (d, J=13.6 Hz, 1H), 1.82-2.12 (m, 4H), 1.75 (d, J=13.6 Hz, 1H), 1.66 (br. s., 1H), 1.46-1.60 (m, 2H). Chiral analytic HPLC: Chiralpak AD, 250×4.6 mm ID; 10 μm, room temperature, mobile phase: CO2/MeOH/(80/20), Flow rate: 2 mL/min, UV Detection: 220 nm, Retention Time (min): 10.64. e.e>99.9%.
-
-
- Compound 26A was synthesized from compound 25C by following the procedures described in Example 25. HPLC Rt (Method B): 6.263 min; LC/MS (m/z)=285 (M−H)−; 1H NMR (400 MHz, CDCl3) δ ppm 7.27-7.39 (m, 4H), 7.15-7.24 (m, 1H), 3.81 (br. s., 1H), 2.64-2.80 (m, 2H), 2.47-2.62 (m, 2H), 2.30 (dq, J=13.7, 3.3 Hz, 1H), 2.14-2.24 (m, 1H), 1.87-2.02 (m, 4H), 1.68-1.79 (m, 2H), 1.65 (dd, J=13.0, 2.7 Hz, 1H), 1.47-1.57 (m, 1H). 13C NMR (101 MHz, CDCl3) δ ppm 176.06, 144.22, 128.27, 126.41, 126.00, 74.25, 45.95, 44.86, 34.03, 33.38, 32.34, 32.26, 31.56, 31.44, 26.86, 26.26. Chiral analytic HPLC: Chiralpak AD, 250×4.6 mm ID; 10 μm, room temperature, mobile phase: CO2/MeOH/(70/30), Flow rate: 3 ml/min, UV Detection:220 nm, Retention Time (min): 6.9. e.e>99.9%.
- Example 26 was synthesized from compound 26A by following the procedures described in Example 25. HPLC Rt (Method C): 7.89 min; LC/MS (m/z)=342 (M+H)+; 1H NMR (400 MHz, CD3OD) δ ppm 7.27 (br. s., 4H), 7.11-7.21 (m, 1H), 3.78-3.93 (m, 1H), 3.60-3.75 (m, 2H), 3.24-3.34 (m, 1H), 3.02 (t, J=7.3 Hz, 0.5H), 2.92 (d, J=5.7 Hz, 1H), 2.83 (dd, J=9.0, 4.2 Hz, 0.5H), 2.49-2.63 (m, 2H), 2.17-2.49 (m, 3H), 2.06-2.17 (m, 1H), 1.75-2.06 (m, 4H), 1.66 (d, J=13.6 Hz, 1H), 1.38-1.59 (m, 3H).
-
-
- Potassium tert-butoxide (39.5 mg, 0.352 mmol) was added in a small portion to a well stirred, moisture-protected suspension of compound 25F (21.3 mg, 0.070 mmol), TOSMIC (19.26 mg, 0.099 mmol), and ethanol (6.89 μL) in 1,2-dimethoxyethane (403 μL) at 0° C. (ice water bath). After completion, the mixture was warmed to room temperature, then placed in a 37° C. oil bath and stirred for 1 hour. LCMS showed the reaction was completed. The reaction was quenched with HOAc (0.1 mL). Solvent was removed under reduced pressure. The residue was dissolved in MeOH, and purified via Prep HPLC (Phenomenex AXIA 5u C18 30×100 mm, Flow rate: 40 mL, Solvent A: 90% H2O and 10% MeOH with 0.1% TFA, Solvent B: 90% MeOH and 10% H2O with 0.1% TFA. 0% to 100% B in 12 min gradient, stop at 15 min, the product RT=11.146 min) to provide compound 27A as white solid (14.6 mg, 66% yield). HPLC Rt (Method B): 7.125 min; LC/MS (m/z)=312 (M−H)−; 1H NMR (400 MHz, CD3OD) δ ppm 7.37 (dd, J=8.7, 5.4 Hz, 2H), 7.03 (t, J=8.8 Hz, 2H), 3.03 (br. s., 1H), 2.63-2.79 (m, 4H), 2.42 (dd, J=13.9, 2.8 Hz, 1H), 2.32 (d, J=13.6 Hz, 1H), 2.09-2.26 (m, 2H), 1.90-2.01 (m, 3H), 1.80-1.90 (m, 2H), 1.60-1.69 (m, 1H).
- Example 27 was synthesized from compound 27A and 3-hydroxyazetidine hydrochloride via standard peptide coupling reaction (see procedure in Example 23). Yield: 62.3%. HPLC Rt (Method C): 6.741 min; LC/MS (m/z)=369 (M+H)+; 1H NMR (400 MHz, CD3OD) δ ppm 7.38 (br. s., 2H), 7.11 (t, J=8.8 Hz, 2H), 4.00-4.12 (m, 1H), 3.76-3.87 (m, 1H), 3.40 (dd, J=10.4, 4.5 Hz, 1H), 3.32-3.37 (m, 1H), 2.96-3.12 (m, 2H), 2.72 (br. s., 2H), 2.58 (dd, J=18.8, 13.3 Hz, 1H), 2.30-2.52 (m, 3H), 2.09-2.23 (m, 2H), 1.77-1.99 (m, 5H), 1.66 (d, J=2.8 Hz, 1H).
-
-
- Tert-butyl 3-cyanoazetidine-1-carboxylate (493.8 mg, 2.713 mmol) and azidotrimethyltin (920 mg, 4.34 mmol) in dry toluene (13 mL) were placed in sealed tube and heated in 100° C. oil bath for 18 hours. Solvent was removed under reduced pressure and the residue was purified via Prep HPLC to provide compound 28A as a light yellow oil (474 mg, 77.6% yield). 1H NMR (400 MHz, CDCl3) δ ppm 4.42-4.52 (m, 2H), 4.28-4.35 (m, 2H), 4.18-4.28 (m, 1H), 1.43-1.49 (s, 9H).
-
- Compound 28A (0.474 mg, 2.107 mmol) and K2CO3 (291 mg, 2.107 mmol) in acetone (4 mL) was heated to reflux for 2 hours under argon. Methyl iodide (138 μL, 2.21 mmol) was introduced. The resulting mixture was heated to reflux for another 6 hours. EtOAc (10 mL) was added to the cooled mixture, which was stirred for 5 minutes. Solid was filtered off and rinsed with EtOAc (3×5 mL). Organic solvent was evaporated. The residue was purified via column chromatography (SiO2, 40-60% EtOAc/n-Hexane) to provide compound 28B as colorless oil (228 mg, 45.3% yield), along with compound 28C as colorless oil (131 mg, 26% yield). 28B: 1H NMR (400 MHz, CDCl3) δ ppm 4.30-4.40 (m, 2H), 4.35 (s, 3H), 4.17-4.25 (m, 2H), 3.99-4.11 (m, 1H), 1.46 (s, 9H). 28C: 1H NMR (400 MHz, CDCl3) δ ppm 4.39 (t, J=8.6 Hz, 2H), 4.30 (br. s., 2H), 3.95-4.06 (m, 1H), 4.01 (s, 3H), 1.41-1.50 (m, 9H).
-
- To a solution of compound 28B (228 mg, 0.954 mmol) in MeOH (8.5 mL) was added 4 M HCl in dioxane (3.3 mL). The mixture was stirred at room temperature for 5 hours. Solvent was removed under reduced pressure to afford compound 28D as lightly yellow solid (198 mg, 100% yield).
- Example 28 was synthesized from compound 28D and the corresponding carboxylic acid 26A by following the procedures described in Example 26. HPLC Rt (Method B): 6.450 min; LC/MS (m/z)=408 (M+H)+; 1H NMR (400 MHz, CDCl3) δ ppm 7.28-7.45 (m, 4H), 7.09-7.22 (m, 1H), 4.31 (d, rotomers, 3H), 4.16-4.28 (m, 2H), 4.06-4.16 (m, 1H), 3.96-4.06 (m, 1H), 3.83 (br. s., 1H), 3.44-3.59 (m, rotomer, 1.5H), 3.21-3.36 (m, 1H), 3.05-3.15 (m, rotomer, 0.5H), 2.69-2.80 (m, 1H), 2.32-2.69 (m, 3H), 1.46-2.26 (m, 9H).
-
-
- Compound 29A was synthesized from compound 25C by following the procedures described in Example 25. HPLC Rt (Method C): 7.27 min; LC/MS (m/z)=319 (M−H)−; 1H NMR (400 MHz, CD3OD) δ ppm 7.31-7.40 (m, 2H), 7.24-7.31 (m, 2H), 3.75 (br. s., 1H), 2.63-2.79 (m, 2H), 2.47-2.61 (m, 2H), 2.31-2.42 (m, 1H), 2.22 (dd, J=13.5, 2.1 Hz, 1H), 1.95-2.06 (m, 2H), 1.85-1.95 (m, 2H), 1.75 (dd, J=13.6, 2.3 Hz, 1H), 1.67 (br. s., 1H), 1.56 (d, 2H).
-
- Compound 29A (56 mg, 0.175 mmol), nickel(II)bromide (275 mg, 1.257 mmol), sodium cyanide (25.7 mg, 0.524 mmol), and zinc cyanide (36.5 mg, 0.311 mmol) were placed in microwave vial under argon atmosphere. NMP (14 mL) was added. The reaction mixture was heated to 200° C. in microwave for 40 min. The resulting solid was filtered off and rinsed with MeOH. The filtrate was concentrated under reduced pressure to afford the crude product. The crude product was purified via Prep HPLC to provide compound 29B as a light brown oil (35 mg, 60.7% yield). LC/MS (m/z)=310 (M−H)−; 1H NMR (400 MHz, CD3OD) δ ppm 7.68 (t, J=8.6 Hz, 2H), 7.59 (t, J=8.1 Hz, 2H), 3.98 (s, 2H), 2.71-2.86 (m, 2H), 2.54-2.70 (m, 2H), 2.32-2.53 (m, 1H), 2.06-2.29 (m, 2H), 2.02 (dd, J=13.4, 2.5 Hz, 1H), 1.43-1.98 (m, 6H).
- Example 29 was synthesized from compound 29B and 3-hydroxyazetidine hydrochloride via standard peptide coupling reaction (see procedure in Example 23). Yield: 64.8%. HPLC Rt (Method C): 4.925 min; LC/MS (m/z)=367 (M+H)+; 1H NMR (400 MHz, CDCl3) δ ppm 7.67 (d, J=7.5 Hz, 2H), 7.52 (d, J=8.3 Hz, 2H), 4.15-4.27 (m, 1H), 3.84-3.97 (m, 1H), 3.82 (br. s., 1H), 3.75 (t, J=6.4 Hz, 1H), 3.50 (td, J=10.9, 4.2 Hz, 1H), 3.21-3.44 (m, 1H), 2.86-3.12 (m, 1H), 2.67 (d, J=15.4 Hz, 1H), 2.46-2.60 (m, 2H), 2.29-2.46 (m, 2H), 2.15-2.29 (m, 1H), 1.93-2.12 (m, 1H), 1.39-1.92 (m, 6H).
-
-
- To a solution of compound 25C (0.278 g, 0.831 mmol) in dry THF (5 mL) at −78° C. under argon was added methyl magnesium bromide (0.97 mL, 2.91 mmol, 3.0 M solution in THF) slowly. The mixture was stirred and gradually warmed to room temperature overnight. NH4Cl (saturated aqueous, 10 mL) was added to quench the reaction. It was extracted with EtOAc (3×15 mL). Combined organic layers were dried (Na2SO4), concentrated to afford white solid. A suspension of this solid in DMF-H2O (5 mL, 10:1 v/v) was heated in 110° C. oil bath for 12 hours. Solvent was removed under reduced pressure. The residue was purified via Prep HPLC to provide compound 30A as white solid (120 mg, 54.3% two steps).
-
- Compound 30B was synthesized from compound 30A via the procedure described in Example 25. Yield: 69% for two steps. LC/MS (m/z)=223 (M−H)−; 1H NMR (400 MHz, CD3OD) δ ppm 3.67-3.75 (m, 1H), 2.41-2.58 (m, 2H), 2.22 (ddd, J=13.6, 6.8, 3.4 Hz, 2H), 2.00 (dd, J=13.0, 1.6 Hz, 2H), 1.86 (br. s., 1H), 1.75-1.85 (m, 3H), 1.59 (br. s., 1H), 1.54 (br. s., 1H), 1.51 (br. s., 2H), 1.20 (s, 3H). 13C NMR (101 MHz, CD3OD) δ ppm 176.87, 75.69, 44.54, 39.36, 37.05, 36.10, 35.40, 35.16, 32.94, 32.90, 27.52, 23.89.
-
- To a suspension of NaH (114 mg, 95%, 4.51 mmol) in dry DMF (10 mL) at 0° C. was added tert-butyl 3-hydroxyazetidine-1-carboxylate (724.7 mg, 4.1 mmol) under argon. The mixture was heated in 40° C. oil bath for 1 hour. To the above mixture at room temperature was added 6-chloronicotinonitrile (638 mg, 4.51 mmol). After heating at 40° C. in an oil bath for 3 hours, the mixture was allowed to cool to room temperature overnight. It was quenched with water (50 mL) and then extracted with EtOAc (3×20 mL). The combined organic layers were dried (Na2SO4) and concentrated. The crude product was purified via column chromatography (SiO2, 25-30% EtOAc/n-Hexane) to provide compound 30C as a white solid (1.0 g, 88.6%). LC/MS (m/z)=276 (M+H)+; 1H NMR (400 MHz, CDCl3) δ ppm 8.45 (d, J=2.2 Hz, 1H), 7.84 (dd, J=8.8, 2.2 Hz, 1H), 6.89 (d, J=9.2 Hz, 1H), 5.30-5.42 (m, 1H), 4.34 (dd, J=11.0, 6.6 Hz, 2H), 3.98 (dd, J=11.2, 4.2 Hz, 2H), 1.46 (s, 9H). 13C NMR (101 MHz, CDCl3) δ ppm 164.26, 156.11, 151.86, 141.43, 116.88, 112.00, 103.38, 79.84, 65.78, 56.32, 28.35.
-
- Compound 30D was synthesized from compound 30C via the procedure described in Example 28. LC/MS (m/z)=176 (M+H)+.
- Example 30 was synthesized from compound 30B and 30D via standard peptide coupling reaction (see procedure in Example 23). LC/MS (m/z)=382 (M+H)+; 1H NMR (400 MHz, CDCl3) δ ppm 8.46 (d, J=2.2 Hz, 1H), 7.85 (dd, J=8.6, 2.4 Hz, 1H), 6.91 (d, J=8.3 Hz, 1H), 5.33-5.45 (m, 1H), 4.56 (dd, J=8.3, 6.6 Hz, 1H), 4.40 (dd, J=11.2, 6.8 Hz, 1H), 4.14 (dd, J=9.7, 4.0 Hz, 1H), 4.05 (dd, J=11.2, 4.2 Hz, 1H), 3.77 (br. s., 1H), 3.50 (s, 1H), 2.32-2.43 (m, 1H), 2.11-2.29 (m, 3H), 1.89-2.03 (m, 2H), 1.85 (br. s., 3H), 1.72 (br. s., 1H), 1.44-1.64 (m, 3H), 1.17 (s, 3H).
-
-
- Compound 31A was synthesized from 4-oxo-1-adamantanecarboxylic acid and Meldrum's acid via the procedure described in Example 25. 1H NMR (400 MHz, CD3OD) δ ppm 4.06 (br. s., 2H), 2.00-2.26 (m, 9H), 1.86-1.99 (m, 2H), 1.75 (s, 3H), 1.74 (s, 3H); 13C NMR (101 MHz, CD3OD) δ ppm 187.06, 162.36, 113.90, 105.28, 41.94, 40.86, 40.40, 38.89, 36.78, 28.72, 27.11, 26.93.
-
- Compound 31B and its regioisomer 31C were synthesized from compound 31A and 4-fluorophenyl magnesium bromide via cuprate addition reaction and decarboxylation reaction using the procedures described in Example 25. The ratio of 31B:31C is about 2.3:1.
- 31B: LC/MS (m/z)=331 (M−H)−; 1H NMR (400 MHz, CD3OD) δ ppm 7.33-7.44 (m, 2H), 7.02 (t, J=8.8 Hz, 2H), 2.77 (br. s., 2H), 2.72 (s, 2H), 2.30 (d, J=12.9 Hz, 2H), 2.08 (br. s., 1H), 1.98 (d, J=12.9 Hz, 2H), 1.87 (br. s., 2H), 1.66-1.82 (m, 4H)
- 31C: LC/MS (m/z)=331 (M−H)−; 1H NMR (400 MHz, CD3OD) δ ppm 7.35-7.42 (m, 2H), 6.98-7.06 (m, 2H), 2.73-2.81 (m, 2H), 2.68 (s, 2H), 2.43 (d, J=13.1 Hz, 2H), 1.94 (d, J=13.1 Hz, 2H), 1.79-1.90 (m, 6H), 1.57 (d, 2H).
-
- To a solution of Compound 31B (27.6 mg, 0.083 mmol), 2-(trimethylsilyl)ethanol (10.3 mg, 0.087 mmol), and DMAP (15.2 mg, 0.125 mmol) in dry CH2Cl2 at 0° C. was added EDAC (19.1 mg, 0.10 mmol), followed by i-Pr2NEt (17.4 μL, 0.10 mmol). The mixture was stirred and gradually warmed to room temperature overnight. Solvent was removed under reduced pressure; the residue was purified via Prep HPLC to provide compound 31D as white solid (25.3 mg, 70.4% yield). HPLC Rt (Method A): 6.335 min; 1H NMR (400 MHz, CDCl3) δ ppm 7.19-7.27 (m, 2H), 6.97 (t, J=8.5 Hz, 2H), 3.71-3.81 (m, 2H), 2.70 (br. s., 2H), 2.65 (s, 2H), 2.21 (d, J=12.6 Hz, 2H), 2.10 (br. s., 1H), 1.95 (d, J=12.6 Hz, 2H), 1.84 (br. s., 2H), 1.74 (t, J=14.6 Hz, 4H), 0.57-0.67 (m, 2H), −0.06 (s, 9H).
-
- A mixture of compound 31D (24 mg, 0.0556 mmol), HOBt (11.3 mg, 0.0834 mmol), NH4Cl (6 mg, 0.111 mmol), EDAC (16 mg, 0.0834 mmol), and i-Pr2NEt (34 μL, 0.195 mmol) in dry DMF (0.7 mL) was heated in 65° C. oil bath for 2 hours. Solvent was removed and the residue was purified via Prep HPLC to provide compound 31E as white solid (22.8 mg, 95% yield). HPLC Rt (Method A): 7.266 min; LC/MS (m/z)=432 (M+H)+; 1H NMR (400 MHz, CDCl3) δ ppm 7.26-7.36 (m, 2H), 7.00-7.11 (m, 2H), 6.82 (br. s., 1H), 5.76 (br. s., 1H), 3.78-3.88 (m, 2H), 2.82 (br. s, 2H), 2.72 (s, 2H), 2.30 (d, J=13.1 Hz, 2H), 2.21 (d, J=2.8 Hz, 1H), 2.00 (d, J=12.4 Hz, 2H), 1.90 (br. s., 2H), 1.72-1.88 (m, 4H), 0.62-0.74 (m, 2H), −0.03-0.04 (m, 9H). 13C NMR (101 MHz, CDCl3) δ ppm 182.45, 171.51, 162.27, 161.20, 159.83, 139.65, 139.62, 127.90, 127.81, 115.32, 115.11, 62.20, 45.38, 44.78, 40.36, 40.10, 34.80, 32.67, 31.65, 26.71, 17.06, −1.67.
-
- To a solution of compound 31E (22.8 mg, 0.0529 mmol) in pyridine (0.5 mL) at room temperature was added MsCl (16.4 mL, 0.211 mmol). The mixture was stirred at room temperature overnight. Solvent was removed and the residue was purified via Prep HPLC to provide compound 31F as white solid (16.7 mg, 76.4% yield). 1H NMR (400 MHz, CDCl3) δ ppm 7.25-7.34 (m, 2H), 7.08 (t, J=8.6 Hz, 2H), 3.79-3.88 (m, 2H), 2.79 (br. s., 2H), 2.70 (s, 2H), 2.14-2.34 (m, 4H), 2.07 (br. s., 2H), 1.80-1.99 (m, 4H), 1.75 (br. s., 1H), 0.63-0.73 (m, 2H), −0.04-0.04 (m, 9H).
-
- A solution of compound 31F (16.7 mg, 0.040 mmol) in TBAF-HOAc (0.25 mL, prepared from 1.0 M TBAF in THF and HOAc in equal molar ratio) was placed in sealed tube and heated in 70° C. oil bath for 48 hours. Solvent was removed and the residue was purified via Prep HPLC to provide compound 31G as white solid (10 mg, 79% yield). LC/MS (m/z)=312 (M−H)−; 1H NMR (400 MHz, CDCl3) δ ppm 7.24 (dd, J=8.8, 5.3 Hz, 2H), 7.03 (t, J=8.6 Hz, 2H), 2.73 (br. s., 2H), 2.69 (s, 2H), 2.08-2.24 (m, 5H), 2.03 (br. s., 2H), 1.88 (d, J=12.7 Hz, 2H), 1.81 (d, 2H).
- Example 31 was synthesized from compound 31G and 3-hydroxyazetidine hydrochloride via standard peptide coupling reaction (see procedure in Example 23). HRMS (ESI): Calculated for C22H25FN2O2: 368.1900, found: 369.1977 (M+1). LC/MS (m/z)=369 (M+H)+; 1H NMR (400 MHz, CDCl3) δ ppm 7.31 (dd, J=8.8, 5.3 Hz, 2H), 7.10 (d, J=6.2 Hz, 2H), 4.19 (d, J=4.0 Hz, 1H), 3.92 (dd, J=9.7, 7.0 Hz, 1H), 3.51 (dd, J=10.3, 3.7 Hz, 1H), 3.22-3.30 (m, 1H), 2.95 (dd, J=8.8, 3.5 Hz, 1H), 2.79 (d, J=18.9 Hz, 2H), 2.33-2.47 (m, 2H), 2.32 (dd, J=6.6, 3.5 Hz, 2H), 2.12 (d, J=9.7 Hz, 3H), 2.02 (br. s., 2H), 1.76-1.92 (m, 4H).
-
-
- Compound 32A was synthesized from compound 31C via the procedures described in Example 31. LC/MS (m/z)=330 (M+H)+; 1H NMR (400 MHz, CD3OD) δ ppm 7.31-7.34 (m, 2H), 6.96-7.07 (m, 2H), 3.39 (dt, J=3.3, 1.6 Hz, 2H), 2.76 (br. s., 2H), 2.68 (s, 2H), 2.39 (d, J=14.4 Hz, 2H), 1.80-1.96 (m, 6H), 1.55 (d, 2H).
-
- To a solution of tert-butyl 3-hydroxyazetidine-1-carboxylate (0.7 g, 4.041 mmol) and phosgene (2.2 mL, 1 M in PhMe, 4.243 mmol) in dry CH2Cl2 (10 mL) at −15° C. was added Et3N (0.62 mL, 4.445 mmol) slowly. The mixture was carefully warmed to room temperature overnight. Solvent was removed under reduced pressure. Et2O (15 mL) was added. The precipitate was filtered off and rinsed with Et2O (3×5 mL). The combined organic layers were evaporated to dryness to afford the crude chloroformate. To a mixture of methyl amine (1.04 mL, 12.123 mmol, 40% w/w aqueous) in THF (5 mL) and Na2CO3 (4 mL, saturated aqueous) was added slowly the above crude chloroformate. The mixture was stirred at room temperature for 40 minutes. The organic layer was separated and the aqueous layer was extracted with Et2O (3×5 mL). The combined organic layers were dried and evaporated. The residue was purified via column chromatography (SiO2, 35-40% EtOAc in n-hexane) to provide compound 32B as white solid (0.656 g, 70.5% yield). 1H NMR (400 MHz, CDCl3) δ ppm 5.20 (br. s., 1H), 5.11 (dd, J=6.2, 3.7 Hz, 1H), 4.15-4.29 (m, 2H), 3.81-3.97 (m, 2H), 2.79 (d, J=4.8 Hz, 3H), 1.39-1.51 (m, rotomer, 9H); 13C NMR (101 MHz, CDCl3) δ ppm 156.18, 156.01, 79.75, 63.34, 28.31, 27.39, 22.92.
-
- Compound 32C was synthesized from compound 32B via Boc-deprotection in 4 M HCl in dioxane followed the procedure described in Example 28.
- Example 32 was synthesized from compound 32A and 32C via standard peptide coupling reaction (see procedure in Example 23). LC/MS (m/z)=444 (M+H)+; 1H NMR (400 MHz, CDCl3) δ ppm 7.26 (dd, J=8.6, 5.6 Hz, 2H), 7.00 (br. s., 2H), 6.53 (br. s., 1H), 5.86 (br. s., 1H), 4.53-4.71 (m, 2H), 3.90 (dd, J=10.7, 7.5 Hz, 1H), 3.51 (d, J=7.6 Hz, 1H), 3.39-3.47 (m, 1H), 2.77-2.85 (m, 1H), 2.72-2.77 (m, 1H), 2.70 (d, J=4.8 Hz, 3H), 2.58-2.66 (m, 1H), 2.46 (d, J=13.1 Hz, 1H), 2.37-2.44 (m, 1H), 2.26-2.37 (m, 1H), 2.15 (d, 1H), 1.66-1.94 (m, 7H), 1.47 (dd, 2H).
-
-
- A mixture of Example 12 (30 mg, 0.10 mmol), acetonitrile (0.073 mL) and concentrated sulfuric acid (0.154 mL) was heated at 45° C. overnight. The mixture was poured onto ice (5 g) and warmed to room temperature. It was extracted with Et2O (2×10 mL). The combined organic phases were dried (MgSO4) and concentrated. The residue was purified via Prep-HPLC to provide compound 33A as a white solid (11.0 mg, 33% yield). HPLC Rt (Method A): 3.70 min; LC/MS (m/z)=344 (M−H)−. 1H NMR (400 MHz, CD3OD) δ ppm 7.53 (s, 1H), 7.37 (dd, J=8.79, 5.27 Hz, 2H), 7.00 (t, J=8.79 Hz, 2H), 2.76-2.84 (m, 3H), 2.73 (s, 3H), 1.83-1.95 (m, 8H), 1.79 (d, J=13.62 Hz, 2H), 1.54 (d, J=11.86 Hz, 2H).
- Example 33 was synthesized from compound 33A and 3-hydroxyazetidine hydrochloride via standard peptide coupling reaction (see the procedure described in Example 23). HRMS (ESI): Calculated for C23H29FN2O3: 400.2162, found: 401.2223 (M+1). HPLC Rt (Method B): 6.82 min; 1H NMR (400 MHz, CD3OD) δ ppm 7.38 (br. s., 2H), 7.09 (t, J=8.6 Hz, 2H), 4.01-4.12 (m, 1H), 3.81 (dd, J=9.9, 7.7 Hz, 1H), 3.39 (dd, J=10.5, 4.4 Hz, 1H), 3.31-3.37 (m, 2H), 3.09 (dd, J=8.6, 4.6 Hz, 1H), 2.70-2.90 (m, 4H), 2.61 (d, J=13.2 Hz, 1H), 2.45 (d, J=13.2 Hz, 1H), 1.83-1.98 (m, 7H), 1.76 (t, J=12.5 Hz, 2H), 1.53 (d, 2H).
-
-
- To a solution of 1-benzhydrylazetidine-3-carboxylic acid (2.097 g, 7.845 mmol) and acetohydrazine (0.967 g, 11.767 mmol) in DMF (40 mL) was added HOBt (1.59 g, 11.767 mmol) and EDAC (2.255 g, 11.767 mmol), followed by i-Pr2NEt (2.1 mL, 11.767 mmol). The mixture was stirred at room temperature overnight. Solvent was removed and the residue was purified via Prep HPLC to provide compound 34A as white solid (2.4 g, 95% yield). LC/MS (m/z)=324 (M+H)+. 1H NMR (400 MHz, CDCl3) δ ppm 7.48 (d, J=7.1 Hz, 4H), 7.28-7.42 (m, 6H), 5.40 (s, 1H), 4.30 (br. s., 2H), 3.84-4.10 (m, 3H), 1.84-2.07 (m, rotomer, 3H).
-
- To a solution of compound 34A (760 mg, 2.350 mmol) in acetonitrile (15 ml) was added i-Pr2NEt (2.372 ml, 13.58 mmol) and triphenylphosphine (1.091 g, 4.16 mmol). After stirring at RT for 5 mins, hexachloroethane (0.351 mL, 3.10 mmol) was added. The mixture was stirred at RT overnight. Solvent was evaporated off. The residue was partitioned between EtOAc (50 mL) and H2O (25 mL). Organic layer was separated; the aqueous layer was extracted with EtOAc (50 mL). The combined organic layers were dried (MgSO4), concentrated. The residue was purified first via column chromatography (0-15% EtOAc in n-hexane), then via Prep HPLC to provide compound 34B as a colorless oil (10 mg, 1.5% yield). LC/MS (m/z)=306 (M+H)+. 1H NMR (400 MHz, CD3OD) δ ppm 6.98-7.63 (m, 10H), 5.76 (s, 1H), 4.24-4.56 (m, 5H), 2.49-2.62 (m, 3H).
-
- To a solution of compound 34B (10 mg, 0.033 mmol) in MeOH (2.0 mL) was added Pd/C (3.0 mg, 10% activated). The reaction mixture was stirred at room temperature for 2.5 hours under an H2 atmosphere (balloon). The catalyst was filtered off and solvent was evaporated to provide compound 34C as a colorless oil (12 mg). LC/MS (m/z)=140 (M+H)+.
- Example 34 was synthesized from compound 26A and 34C via standard peptide coupling reaction (see the procedure described in Example 23). LC/MS (m/z)=408 (M+H)+. HPLC Rt (Method B): 6.08 min; 1H NMR (400 MHz, CDCl3) δ ppm 7.21-7.35 (m, 4H), 7.04-7.16 (m, 1H), 3.93-4.03 (m, 1H), 3.83-3.91 (m, 1H), 3.74 (br. s., 1H), 3.31-3.45 (m, 1H), 3.23-3.30 (m, 0.5H), 3.15 (t, J=8.6 Hz, 0.5H), 3.05-3.12 (m, 0.5H), 2.99 (t, J=8.8 Hz, 0.5H), 2.47-2.64 (m, 2H), 2.45 (two singlets, rotomers, 3H), 2.29-2.43 (m, 2H), 1.36-2.22 (m, 11H).
-
-
- To a solution of 1-(tert-butoxycarbonyl)azetidine-3-carboxylic acid (200 mg, 1.0 mmol) in THF (10 mL) at 0° C. was added Et3N (102 mg, 2.0 mmol), followed by ethyl chloroformate (130 mg, 1.3 mmol). After stirring at 0° C. for 30 minutes, a solution of 2-hydrazinylpyridine in THF (2.0 ml) was added. The mixture was warmed up and stirred at room temperature overnight. The precipitate was filtered off, the solvent was evaporated, and the resulting residue was purified via column chromatography (SiO2, 0-100% EtOAc in n-hexanes) to provide compound 35A as a yellow oil (189 mg, 64% yield). LC/MS (m/z)=294 (M+H)+. 1H NMR (400 MHz, CDCl3) δ ppm 7.87-8.23 (m, 1H), 7.30-7.70 (m, 1H), 6.70-6.93 (m, 1H), 6.65 (d, J=8.25 Hz, 1H), 4.05-4.16 (m, 2H), 4.02 (t, J=8.52 Hz, 2H), 3.94 (t, J=8.79 Hz, 1H), 1.32-1.45 (m, 9H).
-
- To a solution of compound 35A in CH2Cl2/CCl4 (12.0 mL/6.0 mL) at 0° C. was added i-Pr2NEt (838 mg, 6.5 mmol), followed by PEt3 (381 mg, 3.23 mmol). The mixture was warmed to room temperature and stirred overnight. The solvent was evaporated and the residue was purified via column chromatography (SiO2, 0-100% EtOAc in n-hexanes) to provide compound 35B as a yellow oil (158 mg). LC/MS (m/z)=275 (M+H)+. 1H NMR (400 MHz, CDCl3) δ ppm 7.88 (d, J=7.03 Hz, 1H), 7.77 (d, J=9.23 Hz, 1H), 7.25-7.30 (m, 1H), 6.87 (t, J=6.81 Hz, 1H), 4.44 (t, J=8.57 Hz, 4H), 4.12-4.27 (m, 1H), 1.44 (s, 9H).
-
- Compound 35C was synthesized from compound 35B via Boc-deprotection in 4 M HCl in dioxane following the procedure described in Example 28. LC/MS (m/z)=175 (M+H)+.
- Example 35 was synthesized from compound 26A and compound 35C via standard peptide coupling reaction (see procedure in Example 23). HPLC Rt (Method B): 5.550 min; LC/MS (m/z)=275 (M+H)+. 1H NMR (400 MHz, CD3OD) δ ppm 8.09-8.19 (m, 1H), 7.81-7.90 (m, 1H), 7.68-7.81 (m, 1H), 7.17-7.37 (m, 3H), 6.99-7.17 (m, 2H), 6.65-6.83 (m, 1H), 4.04-4.20 (m, 2H), 3.80-3.94 (m, 1H), 3.50-3.72 (m, 2H), 3.30-2.95 (m, 2H), 2.27-2.64 (m, 5H), 2.08-2.19 (m, 1H), 1.93-2.08 (m, 1H), 1.73-1.92 (m, 3H), 1.67 (d, J=13.6 Hz, 1H), 1.55 (br. s., 1H), 1.39-1.51 (m, 2H).
-
-
- To a solution of 1-Boc-3-(hydroxyl)azetidine (250 mg, 1.443 mmol) in THF (3 mL) at 0° C., was added NaH (75 mg, 1.876 mmol) in portions. The mixture was stirred at 0° C. for 0.5 hour, then at RT for 0.5 hour. To the above mixture was added a solution of 2-(Chloromethyl)-5-methyl-1,3,4-oxadiazole (191 mg, 1.443 mmol) in THF (3 mL) slowly. After stirring at RT overnight, the mixture was quenched with NH4Cl (10 mL, saturated aqueous), then extracted with EtOAc (3×30 mL). Combined organic layers were dried (MgSO4), concentrated, and purified via column chromatography (SiO2, 0-70% EtOAc in n-hexane) to provide compound 36A as colorless oil (100 mg, 25.7% yield). LC/MS (m/z)=270 (M+H)+. 1H NMR (400 MHz, CDCl3) δ ppm 4.60 (s, 2H), 4.29-4.39 (m, 1H), 4.04-4.10 (m, 2H), 3.81 (dd, J=9.67, 4.39 Hz, 2H), 2.55 (s, 3H), 1.38-1.42 (s, 9H).
-
- Compound 36B was synthesized from compound 36A via Boc-deprotection in 4 M HCl in dioxane followed the procedure described in Example 28. LC/MS (m/z)=170 (M+H)+.
- Example 36 was synthesized from compound 26A and compound 36B via standard peptide coupling reaction (see procedure in Example 23). HPLC Rt (Method B): 6.25 min; LC/MS (m/z)=438 (M+H)+. 1H NMR (400 MHz, CDCl3) δ ppm 7.22-7.33 (m, 4H), 7.12-7.20 (m, 1H), 4.29-4.39 (m, 2H), 3.70-3.86 (m, 3H), 3.42-3.53 (m, 1H), 2.97-3.05 (m, 0.5H), 2.80-2.93 (m, 1H), 2.70 (dd, J=9.9, 3.3 Hz, 0.5H), 2.19-2.62 (m, 9H), 2.11 (d, J=13.7 Hz, 1H), 1.77-2.04 (m, 4H), 1.60-1.72 (m, 2H), 1.49-1.60 (m, 1H), 1.44 (dd, 1H).
-
-
- Compound 37A was synthesized from 2-adamantane carboxylic acid via direct α-alkylation by following the procedure described in Example 5. Alternatively, compound 37A was synthesized via stepwise procedures described by Scheffer, John R. (Journal of the American Chemical Society, 126(11):3511-3520 (2004)). LC-MS (m/z)=303 (M−H)−.
- Compound 37A (15 mg, 0.05 mmol) in SOCl2 (0.5 ml) was heated at 60° C. under Ar overnight. Excess SOCl2 was evaporated off under reduced pressure to provide the corresponding acid chloride as a yellow oil. To a solution of above acid chloride in CH2Cl2 (2.0 mL) was added Et3N (15 mg, 0.15 mmol), followed by 3-hydroxyazetidine (8.0 mg, 0.075 mmol). The mixture was stirred at RT overnight. Solvent was evaporated. The residue was purified via Prep HPLC to provide Example 37 as a white solid (13 mg, 72% yield). HPLC Rt (Method A): 6.80 min; LC/MS (m/z)=360 (M+H)+. 1H NMR (400 MHz, CDCl3) δ ppm 7.11-7.45 (m, 4H), 4.15-4.42 (m, 1H), 4.01-4.15 (m, 1H), 3.97 (s, 2H), 3.63-3.79 (m, 2H), 3.44-3.64 (m, 3H), 3.15-3.30 (m, 1H), 2.81 (t, J=14.29 Hz, 2H), 2.63-2.73 (m, 1H), 2.38-2.59 (m, 2H), 2.33 (s, 2H), 2.10 (dd, J=29.41, 13.47 Hz, 3H), 1.59-1.97 (m, 2H).
-
-
- A mixture of compound 25A (1.84 g, 8.84 mmol), malononitrile (0.561 mL, 8.84 mmol), and ammonium acetate (0.068 g, 0.884 mmol) in EtOH (110 mL) was stirred at room temperature under argon for 6 hours. After evaporating the solvent, the residue was purified via column chromatography (SiO2, 0-60% EtOAc in n-hexane) to provide compound 38A (2.01 g, 89% yield) as a white solid. LC/MS (m/z)=257 (M+H)+. 1H NMR (400 MHz, CDCl3): δ ppm 4.00 (s, 4H), 3.17 (br. s., 2H), 2.37 (br. s., 2H), 2.34 (br. s., 2H), 1.93 (br. s., 2H), 1.82 (br. s., 2H), 1.79 (br. s., 2H).
-
- To a solution of 3-chlorobenzylmagnesium chloride (7.02 mL, 1.756 mmol) in THF (10 mL) at −5° C. under argon was added a solution of compound 38A (150 mg, 0.585 mmol) in THF (20 mL) dropwise while maintaining the temperature below 0° C. After stirring at this temperature for additional 1 hour, the mixture was warmed to room temperature over a period of 1 hour. The mixture was then diluted with saturated NH4Cl (50 mL) and extracted with ethyl acetate (50 mL). The organic layer was washed (brine), dried (Na2SO4), filtered and concentrated. The residue was purified via Prep HPLC provide compound 38B (200 mg, 0.522 mmol, 89% yield) as a white solid. LC/MS (m/z)=383 (M+H)+. 1H NMR (400 MHz, CDCl3): δ ppm 7.37-7.27 (m, 4H), 4.55 (s, 1H), 3.97 (s, 4H), 3.21 (s, 2H), 2.23-2.34 (m, 2H), 2.06-2.18 (m, 4H), 2.01 (br. s., 2H), 1.93 (br. s., 1H), 1.83 (br. s., 1H), 1.70 (br. s., 1H), 1.67 (br. s., 1H).
-
- A mixture of compound 38B (160 mg, 0.418 mmol), KOH (258 mg, 4.60 mmol), and ethylene glycol (2 mL) was placed in a 10 mL sealed tube reactor and heated at 205° C. oil bath for 18 hours. The mixture was cooled to room temperature, diluted with a solution of citric acid (50 mL, 10% w/v) and extracted with EtOAc (3×25 mL). The organic layer was washed (brine), dried (Na2SO4), filtered and concentrated. The residue was then diluted with HCl (aqueous, 10 mL, 2.0 M) and THF (10 mL) and heated at 60° C. for 6 hours. The THF was concentrated and the remaining aqueous phase was diluted with brine and extracted with ethyl acetate. The organic layer was washed (brine), dried (Na2SO4), filtered and concentrated. The residue was then dissolved in MeOH (20 mL) and sodium borohydride (47.4 mg, 1.25 mmol) was added in portions. The mixture was stirred for 1 hour and quenched with aqueous HCl (5 mL). The solvent was concentrated and the residue was purified via Prep HPLC (Gradient Solvent System: From 50% A: 50% B to 0% A: 100% B; [A=10% MeOH/90% H2O+0.1% TFA]; [B=90% MeOH/10% H2O+0.1% TFA]; detection at 220 nm: 10 min gradient; Phenomenex Luna AXIA 30×100 mm) to provide compound 38C (73 mg, 50% yield) as an off-white solid. LC/MS (m/z)=333 (M−H)−. 1H NMR (400 MHz, CDCl3) δ ppm 7.24-7.33 (m, 2H), 7.14-7.23 (m, 2H), 3.79-3.89 (m, 1H), 3.07-3.24 (m, 2H), 2.50 (d, J=7.03 Hz, 2H), 2.41-2.48 (m, 1H), 2.17 (dd, J=14.06, 3.52 Hz, 1H), 2.10 (d, J=2.64 Hz, 1H), 2.04 (dd, J=14.06, 2.20 Hz, 1H), 1.99 (br. s., 1H), 1.90 (br. s., 1H), 1.82 (d, J=14.50 Hz, 1H), 1.76 (br. s., 1H), 1.71 (br. s., 1H), 1.53-1.67 (m, 3H).
- Alternatively, compound 38C was synthesized via the stepwise procedures described in Example 25.
- Example 38 was synthesized from compound 38C and 3-hydroxyazetidine hydrochloride via standard peptide coupling reaction (see procedure in Example 23). 38: white solid; Yield 23%. HPLC Rt (Method C): 6.380 min; LC/MS (m/z)=390 (M+H)+. 1H NMR (400 MHz, CDCl3): δ ppm 7.20 (br. s., 2H), 7.14 (br. s., 1H), 7.06 (br. s., 1H), 4.59 (d, J=3.52 Hz, 1H), 4.27 (br. s., 1H), 3.76-3.93 (m, 3H), 3.49-3.66 (m, 1H), 3.05-3.33 (m, 2H), 2.40 (d, J=9.67 Hz, 1H), 2.27 (br. s., 3H), 1.93-2.16 (m, 5H), 1.82-1.91 (m, 2H), 1.69 (t, J=11.42 Hz, 1H), 1.58 (t, J=12.08 Hz, 2H).
- Examples 39 to 386 in Table 1 were synthesized according to the procedures described in Examples 1 to 38, the schemes, or by other similar methods known to one skilled in the art, with other appropriate reagents. In the structures set forth in Table 1, the “—O” attached to an adjacent carbon atom substituted with ═O is used to denote an “—OH” group. Similarly, in the structures set forth in Table 1, the “N” attached to an adjacent carbon atom substituted with ═O is used to denote an “NH” moiety. The compounds set forth in Table 1 below are racemic, achiral or diastereomeric unless indicated to the contrary.
-
TABLE 1 LC/MS Mass HPLC Example Structure [(M − H)−/(M + H)+] purity (%) 39 283 94.8 40 287 >95 41 313 >98 42 299 99 43 299 >97 44 275 >95 45 283 96 46 303 98.5 47 294 95.6 48 294 98 49 271 90 50 247 95 51 291 96 52 261 97 53 277 >90 54 303 >92 55 354 >99 56 366 96.7 57 366 95.7 58 345 94.9 59 301 96.8 60 317 >95 61 (chiral) 366 >95 62 (chiral) 366 95 63 303 >95 64 317 >95 65 331 >95 66 357 >95.6 67 343 >98 68 299 97 69 317 99.6 70 299 95 71 346 98 72 308 98.8 73 362 92.5 74 362 96.3 75 333 96.2 76 299 95 77 333 98.4 78 314 96 79 372 96.2 80 328 98 81 372 98 82 358 98 83 364 98 84 422 98 85 342 96 86 358 98 87 358 98 88 358 97.2 89 372 95 90 401 96 91 344 96.3 92 356 98 93 360 97 94 360 88 95 360 96 96 374 95 97 374 97 98 400 98 99 360 96.3 100 374 973 101 374 97.5 102 (chiral) 374 96.4 103 (chiral) 374 96.2 104 340 >96 105 368 96.8 106 451 97.4 107 388 99.4 108 388 98 109 353 98 110 369 98 111 385 98 112 360 98 113 383 97 114 374 96 115 369 97 116 374 98 117 400 95 118 414 96 119 351 98 120 360 95 121 356 98 122 356 98 123 299 95 124 297 >96 125 291 98.3 126 305 91 127 305 91 128 402 98.8 129 218 >90 130 (chiral) 319 99 131 (chiral) 319 99 132 287 98 133 287 97.2 134 273 98.2 135 289 >95 136 283 97 137 291 >95 138 275 >95 139 277 >98 140 288 98 141 301 98 142 317 >97 143 362 >92 144 319 98.1 145 317 97.8 146 333 99.3 147 333 >98 148 335 96 149 (chiral) 285 99 150 303 >97 151 (chiral) 299 98 152 (chiral) 303 98 153 (chiral) 299 98 154 (chiral) 303 98 155 299 >92 156 315 95.6 157 333 95.2 158 333 98.7 159 (chiral) 327 99 160 (chiral) 327 99 161 315 98 162 348 98 163 362 98 164 362 97 165 436 96 166 390 95 167 390 98.1 168 374 97.9 169 356 >96 170 304 98 171 354 >97 172 358 98 173 364 95 174 420 98 175 457 95 176 477 98 177 344 97 178 471 97.7 179 348 98 180 334 95 181 388 95 182 446 95 183 413 95 184 384 95 185 439 95 186 462 95 187 493 97 188 358 98 189 460 98 190 388 97 191 359 98 192 417 97 193 437 97.9 194 417 95 195 433 >95 196 388 >95 197 387 >95 198 383 >95 199 387 98 200 417 >95 201 417 98 202 369 95 203 374 95.3 204 399 98 205 399 >95 206 419 99 207 374 95 208 400 >96 209 342 97 210 444 96 211 390 >97 212 398 >97.3 213 374 98 214 390 98 215 376 >95 216 413 98 217 (chiral) 360 92 218 425 97 219 431 97 220 367 99 221 431 98 222 427 98 223 394 97.9 224 413 97 225 330 94 226 344 98 227 (chiral) 417 98 228 (chiral) 417 92 229 363 96 230 (chiral) 417 98 231 413 95 232 (chiral) 417 98 233 360 97 234 387 99 235 403 >97 236 403 95 237 397 96 238 (chiral) 342 >95 239 408 >95 240 417 95 241 (chiral) 399 98 242 (chiral) 399 97 243 457 95 244 360 97 245 417 98 246 (chiral) 356 96 247 358 97 248 (chiral) 408 >95 249 408 97 250 447 98 251 404 95 252 346 98 253 388 >95 254 390 >95 255 350 92 256 (chiral) 351 97 257 374 954 258 (chiral) 426 >98.6 259 (chiral) 467 98 260 (chiral) 399 97 261 405 97 262 356 99 263 330 96 264 387 98 265 (chiral) 356 96 266 376 99 267 387 95 268 (chiral) 358 90 269 330 95 270 (chiral) 358 95 271 362 95 272 374 98 273 (chiral) 356 98 274 (chiral) 370 97 275 (chiral) 356 >95 276 344 96 277 (chiral) 369 98 278 (chiral) 383 95 279 (chiral) 370 >96 280 418 >95 281 (chiral) 370 98 282 (chiral) 427 97 283 356 98 284 (chiral) 376 >99 285 (chiral) 376 >99 286 390 98.7 287 390 99.3 288 (chiral) 360 95 289 (chiral) 356 98 290 (chiral) 356 98 291 (chiral) 360 95 292 384 98 293 374 97.3 294 372 95 295 (chiral) 356 100 296 (chiral) 377 97.9 297 (chiral) 356 100 298 362 95 299 372 95.5 300 372 95.6 301 341 98 302 (chiral) 358 97 303 448 98 304 346 96 305 490 98 306 324 >98 307 362 93 308 328 97 309 283 99 310 331 98 311 330 98 312 381 94.2 313 399 98.3 314 399 97.8 315 406 99.3 316 444 99.0 317 377 100.0 318 430 100.0 319 356 91.7 320 343 99.2 321 404 99.2 322 392 100.0 323 358 100.0 324 402 95.3 325 342 91.2 326 465 97.9 327 446 90.9 328 342 97.1 329 459 100.0 330 432 98.4 331 397 96.4 332 370 97.0 333 404 100.0 334 390 100.0 335 433 98.4 336 411 100.0 337 449 99.1 338 394 97.9 339 370 97.5 340 390 95.5 341 469 98.3 342 433 99.3 343 394 100.0 344 377 100.0 345 384 99.3 346 369 100.0 347 325 100.0 348 330 100.0 349 431 96.4 350 406 98.9 351 344 96.5 352 371 100.0 353 390 100.0 354 402 100.0 355 340 97.2 356 (chiral) 457 99 357 (chiral) 358 96 358 387 96 359 390 99 360 376 97 361 374 99 362 383 99 363 399 96 364 419 100 365 460 100 366 460 100 367 376 100 368 342 100 369 357 99.3 370 413 98.6 371 399 100 372 328 99.1 373 356 100 374 465 100 375 465 100 376 358 100 377 371 100 378 444 100 379 384 100 380 445 99.3 381 459 100 382 425 100 383 370 98.3 384 454 99.5 385 420 98 386 388 97 - The in vitro inhibition of recombinant human 11beta-HSD1 was determined as follows.
- [3H]-Cortisone with a specific radioactivity of 50 Ci/mmol (ART 743, Lot: 050906) was from American Radiolabeled Chemicals, Inc. (St Louis, Mo.); monoclonal ab to Cortisol (P01-9294M-P, Lot: L-28) was from East Coast Bio., (North Berwick, Me.); Protein A-yttrium silicate, type-1, SPA bead NJ® (RPN-143) was from Amersham LifeSciences, (Piscataway, N.J.); 384 well-Optiplate384 (#6007299) was from PerkinElmer (Boston, Mass.); DPBS, pH 7.4 (14040) is from GIBCO, (Grand Island, N.Y.); carbenoxolone (C4790) is from Sigma, (St Louis, Mo.).
- Full length recombinant human 11β-HSD-1 cDNAs and the cDNA encoding human 11β-HSD-2 were expressed stably in HEK 293 EBNA cells. Cells were grown in DMEM (high glucose) containing MEM non-essential amino acids, L-glutamine, hygromycin B (200 μg/ml), and G-418(200 μg/ml) in the presence of 10% FBS.
- Human 11β-HSD-1 transfected HEK 293 EBNA cells were grown to 80% confluency and the cell pellet was quick frozen and stored at −80° C. before purification. Cell paste, 40 g from −80° C. storage, was thawed in water and then 100 ml of homogenization buffer H (0.01 M sodium phosphate pH 6.5 containing 0.25 M sucrose and protease inhibitor cocktail (Roche #1836145 1 tablet per 50 ml) were added to completely thaw the paste. The cell paste suspension was homogenized using a Polytron for 20 seconds to create a homogeneous mixture. Additional buffer H was added to a volume of 300 ml and cells were broken open using a N2-bomb (at 4° C.) in two batches by treating at 500 psi. The extract was centrifuged at 750×g for 30 min. The supernatant was centrifuged at 20,000×g for 30 min. The supernatant was further centrifuged at 105,000×g for 60 min. The 105,000×g pellet was resuspended in buffer H and centrifuged at 105,000×g for 60 min. The microsome pellet was scraped from the bottom of tube and resuspended in 0.01M phosphate buffer, pH 6.5 containing protease inhibitors (Roche #1836145, 1 tablet per 50 ml). Aliquots were stored at −80° C. until needed. The protein concentration was measured by the BioRad method using BSA standard.
- Compounds were dissolved in DMSO to obtain 10 mM stock concentrations. From the 10 mM stock, the compounds were diluted in DMSO to achieve the concentrations.
- 11β-HSD-1 was assayed by Scintillation Proximity assay in a 384-well Perkin Elmer white plate. The dose response of the compounds was determined using 11 half-log dilutions of compound in DMSO in duplicate. To each well, 0.5 μl of compound dilution in DMSO were added. 15 μl of assay buffer (for blanks) or 15 μl of human microsomes in assay buffer were added next and the plates were incubated for 10 min at room temperature. The final microsomal protein concentration was 1.1 μg/assay. Duplicates were in the same plate one row below the other. 10 μl of 3H-cortisone (final concentration 40 nM) was added to each well and the plate was spun down to mix and bring down the contents to the bottom of the wells. The plates were incubated at room temperature with gentle shaking for 4 hrs. The reaction was stopped with addition of 10 μl of 10 mM carbenoxolone. Then, 0.5 mg of yttrium silicate SPA beads coupled to anti-cortisol antibody in 20 μl were added to all the wells of plate, which were spun down once more and incubated at room temperature overnight. The plate was read in a TopCount® (1 min/well). Data were uploaded automatically to Tool Set, a Lead Evaluation informatics program for data capture and calculation. Graphs were generated with the Curve Master program.
- Compounds of the present invention were tested in the assay described immediately above and the results shown in the Table 2 below were obtained.
-
TABLE 2 h HSD1 Example Structure IC50 (nM) 4 234 8 633 20 10000 22 159 23 8.3 25 8.5 26 2.9 27 12 28 10 31 2.0 32 21 34 196 35 636 36 14 37 15 39 24 44 3.0 49 97 55 2982 64 21 79 81 98 1.6 103 10 106 457 117 90 122 253 124 2.2 126 13 127 14 132 15 134 30 136 1152 140 651 164 2.3 167 20 174 1.0 181 128 182 2.4 183 182 188 121 190 9121 195 105 199 6.9 210 316 212 127 213 44 216 5.1 235 520 236 274 240 67 242 8.8 243 16 247 3.0 250 1724 259 75 265 6.1 270 16 277 10000 279 260 281 175 292 2.8 301 0.3 302 2.4 303 4.7 304 25 305 28 306 30 307 383 308 10000 - The in vivo inhibition of recombinant human 11beta-HSD1 was determined as follows.
- Studies were conducted utilizing diet induced obese (DIO) mice obtained from Jackson Laboratory (ME, USA). These mice were fed a 60% fat diet (Research Diets D12492) soon after weaning and kept on this diet for 24 weeks. These mice were individually housed. All mice were housed under controlled temperature (23° C.) and lighting (12 hours of light between 6 am to 6 pm, 12 hours of dark) with free access to water. The animals continued on this diet and were utilized for experimentation at 30 to 32 weeks of age, at which time these mice weighed 45 to 55 grams.
- The basic model of 11-dehydrocorticosterone (DHC) administration to mice to produce corticosterone has been reported in the literature for clinical and preclinical evaluation of the activity of 11 β HSD. Essentially DHC (Steraloids INC, Newport R.I.), was suspended in the vehicle at a concentration of 10 mg/kg in a volume of 7.5 ml/kg of mouse body weight. For a typical study, non-fasting mice were weighed and separated into groups (n=6) where body weights are not statistically different from each other. Animals were bled via a tail knick, for a 0 time sample and then dosed orally (7.5 ml/kg) with vehicle or drug. At 60 minutes post administration of vehicle or compound, mice were bled again via the tail tip and dosed orally (7.5 ml/kg) with DHC 10 mg/kg. All animals were subsequently bled at 30, 60 and 120 minutes post DHC dosing. Thirty-five microliters of whole blood are collected per time point in microvette tubes coated with EDTA (Sarstedt Tubes Microvette CB 300/Haematology Potassium EDTA # 16.444.300) and kept on ice. Samples were centrifuged at 4° C. in a Beckman Coulter centrifuge for 10 minutes at 2500 RPM. Plasma was separated and collected and immediately frozen at −20° C. until corticosterone analysis could be assessed.
- Plasma Corticosterone was measured using an EIA (IDS AC-14F1). Samples were measured at (1:2) for the −30 (or −60 minute) and 0 time point and (1:10) for the 30, 60 and 120 minutes time points. AUC was calculated using Graphpad and the zero timepoint was used as the baseline. One way ANOVA was calculated using Sigmastat. A p value of less that 0.05 via post hoc analysis with Dunnett's was used to determine statistical significance.
- The vehicle utilized for the suspension of the compounds was 0.5% methocel; 0.1% tween 80 in water. Methocel Cellulose (M-0262) was purchased from Sigma-Aldrich, St Louis, Mo. 6. Tween 80 (274364) was purchased from Sigma-Aldrich, St Louis, Mo. Compounds were administered in 7.5 ml/kg volumes at final dosages of 0.1 to 300 mg/kg depending on the study and compound evaluated.
- Compounds of the present invention were tested in the assay described immediately above and the results shown in the Table 3 below were obtained.
-
TABLE 3 Example Dose % inhibition 25 30 mpK 74 26 30 mpK 57 217 30 mpK 67 242 30 mpK 65 - The compounds of the present invention possess activity as inhibitors of the enzyme 11-beta-hydroxysteroid dehydrogenase type I, and, therefore, may be used in the treatment of diseases associated with 11-beta-hydroxysteroid dehydrogenase type I activity. Via the inhibition of 11-beta-hydroxysteroid dehydrogenase type I, the compounds of the present invention may preferably be employed to inhibit or modulate glucocorticoid production, thereby interrupting or modulating cortisone or cortisol production.
- Accordingly, the compounds of the present invention can be administered to mammals, preferably humans, for the treatment of a variety of conditions and disorders, including, but not limited to, treating, preventing, or slowing the progression of diabetes and related conditions, microvascular complications associated with diabetes, macrovascular complications associated with diabetes, cardiovascular diseases, Metabolic Syndrome and its component conditions, inflammatory diseases and other maladies. Consequently, it is believed that the compounds of the present invention may be used in preventing, inhibiting, or treating diabetes, hyperglycemia, impaired glucose tolerance, insulin resistance, hyperinsulinemia, retinopathy, neuropathy, nephropathy, delayed wound healing, atherosclerosis and its sequelae (acute coronary syndrome, myocardial infarction, angina pectoris, peripheral vascular disease, intermitant claudication), abnormal heart function, myocardial ischemia, stroke, Metabolic Syndrome, hypertension, obesity, dislipidemia, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, low HDL, high LDL, non-cardiac ischemia, infection, cancer, vascular restenosis, pancreatitis, neurodegenerative disease, lipid disorders, cognitive impairment and dementia, bone disease, HIV protease associated lipodystrophy, glaucoma and inflammatory diseases, such as, rheumatoid arthritis, Cushing's Disease, Alzheimer's Disease and osteoarthritis.
- Metabolic Syndrome or “Syndrome X” is described in Ford et al., J. Am. Med. Assoc., 287:356-359 (2002) and Arbeeny et al., Curr. Med. Chem.—Imm., Endoc. & Metab. Agents, 1:1-24 (2001).
- The present invention includes within its scope pharmaceutical compositions comprising, as an active ingredient, a therapeutically effective amount of at least one of the compounds of formula I, alone or in combination with a pharmaceutical carrier or diluent. Optionally, compounds of the present invention can be used alone, in combination with other compounds of the invention, or in combination with one or more other therapeutic agent(s), e.g., an antidiabetic agent or other pharmaceutically active material.
- The compounds of the present invention may be employed in combination with other 11-beta-hydroxysteroid dehydrogenase type I inhibitors or one or more other suitable therapeutic agents useful in the treatment of the aforementioned disorders including: anti-diabetic agents, anti-hyperglycemic agents, anti-hyperinsulinemic agents, anti-retinopathic agents, anti-neuropathic agents, anti-nephropathic agents, anti-atherosclerotic agents, anti-ischemic agents, anti-hypertensive agents, anti-obesity agents, anti-dislipidemic agents, anti-dyslipidemic agents, anti-hyperlipidemic agents, anti-hypertriglyceridemic agents, anti-hypercholesterolemic agents, anti-restenotic agents, anti-pancreatic agents, lipid lowering agents, appetite suppressants, memory enhancing agents, cognition promoting agents and anti-inflammatory agents.
- Examples of suitable anti-diabetic agents for use in combination with the compounds of the present invention include insulin and insulin analogs: LysPro insulin, inhaled formulations comprising insulin; glucagon-like peptides; sulfonylureas and analogs: chlorpropamide, glibenclamide, tolbutamide, tolazamide, acetohexamide, glypizide, glyburide, glimepiride, repaglinide, meglitinide; biguanides: metformin, phenformin, buformin; alpha2-antagonists and imidazolines: midaglizole, isaglidole, deriglidole, idazoxan, efaroxan, fluparoxan; other insulin secretagogues: linogliride, insulinotropin, exendin-4, BTS-67582, A-4166; thiazolidinediones: ciglitazone, pioglitazone, troglitazone, rosiglitazone; PPAR-gamma agonists; PPAR-alpha agonists; PPAR alpha/gamma dual agonists; SGLT2 inhibitors; dipeptidyl peptidase-IV (DPP4) inhibitors; glucagon-like peptide-1 (GLP-1) receptor agonists; aldose reductase inhibitors; RXR agonists: JTT-501, MCC-555, MX-6054, DRF2593, GI-262570, KRP-297, LG100268; fatty acid oxidation inhibitors: clomoxir, etomoxir; α-glucosidase inhibitors: precose, acarbose, miglitol, emiglitate, voglibose, MDL-25,637, camiglibose, MDL-73,945; beta-agonists: BRL 35135, BRL 37344, Ro 16-8714, ICI D7114, CL 316,243, TAK-667, AZ40140; phosphodiesterase inhibitors, both cAMP and cGMP type: sildenafil, L686398: L-386,398; amylin antagonists: pramlintide, AC-137; lipoxygenase inhibitors: masoprocal; somatostatin analogs: BM-23014, seglitide, octreotide; glucagon antagonists: BAY 276-9955; insulin signaling agonists, insulin mimetics, PTP1B inhibitors: L-783281, TER17411, TER17529; gluconeogenesis inhibitors: GP3034; somatostatin analogs and antagonists; antilipolytic agents: nicotinic acid, acipimox, WAG 994; glucose transport stimulating agents: BM-130795; glucose synthase kinase inhibitors: lithium chloride, CT98014, CT98023; and galanin receptor agonists.
- Other suitable thiazolidinediones include Mitsubishi's MCC-555 (disclosed in U.S. Pat. No. 5,594,016), Glaxo-Wellcome's GL-262570, englitazone (CP-68722, Pfizer), or darglitazone (CP-86325, Pfizer, isaglitazone (MIT/J&J), JTT-501 (JPNT/P&U), L-895645 (Merck), R-119702 (Sankyo/WL), N,N-2344 (Dr. Reddy/NN), or YM-440 (Yamanouchi).
- Suitable PPAR alpha/gamma dual agonists include AR-HO39242 (Astra/Zeneca), GW-409544 (Glaxo-Wellcome), KRP297 (Kyorin Merck), as well as those disclosed by Murakami et al., “A Novel Insulin Sensitizer Acts As a Coligand for Peroxisome Proliferation—Activated Receptor Alpha (PPAR alpha) and PPAR gamma; Effect of PPAR alpha Activation on Abnormal Lipid Metabolism in Liver of Zucker Fatty Rats”, Diabetes, 47:1841-1847 (1998), and WO 01/21602, the disclosure of which is incorporated herein by reference, employing dosages as set out therein, which compounds designated as preferred are preferred for use herein.
- Suitable alpha2 antagonists also include those disclosed in WO 00/59506, employing dosages as set out herein.
- Suitable SGLT2 inhibitors include T-1095, phlorizin, WAY-123783, and those described in WO 01/27128.
- Suitable DPP4 inhibitors include saxagliptan, sitagliptan, vildagliptan, and denagliptan.
- Suitable aldose reductase inhibitors include those disclosed in WO 99/26659.
- Suitable meglitinides include nateglinide (Novartis) or KAD1229 (PF/Kissei).
- Examples of glucagon-like peptide-1 (GLP-1) receptor agonists include
- Exenatide (Byetta™), NN2211 (Liraglutide, Novo Nordisk), AVE0010 (Sanofi-Aventis), R1583 (Roche/Ipsen), SUN E7001 (Daiichi/Santory), GSK-716155 (GSK/Human Genome Sciences) and Exendin-4 (PC-DAC™).
- Other anti-diabetic agents that can be used in combination with compounds of the invention include ergoset and D-chiroinositol.
- Suitable anti-ischemic agents include, but are not limited to, those described in the Physician's Desk Reference and NHE inhibitors, including those disclosed in WO 99/43663.
- Examples of suitable lipid lowering agents for use in combination with the compounds of the present invention include one or more MTP inhibitors, HMG CoA reductase inhibitors, squalene synthetase inhibitors, fibric acid derivatives, ACAT inhibitors, lipoxygenase inhibitors, cholesterol absorption inhibitors, ileal Na+/bile acid cotransporter inhibitors, upregulators of LDL receptor activity, bile acid sequestrants, cholesterol ester transfer protein inhibitors (e.g., CP-529414 (Pfizer)), and/or nicotinic acid and derivatives thereof.
- MTP inhibitors which may be employed as described above include those disclosed in U.S. Pat. No. 5,595,872, U.S. Pat. No. 5,739,135, U.S. Pat. No. 5,712,279, U.S. Pat. No. 5,760,246, U.S. Pat. No. 5,827,875, U.S. Pat. No. 5,885,983, and U.S. Pat. No. 5,962,440.
- The HMG CoA reductase inhibitors which may be employed in combination with one or more compounds of formula I include mevastatin and related compounds, as disclosed in U.S. Pat. No. 3,983,140, lovastatin, (mevinolin) and related compounds, as disclosed in U.S. Pat. No. 4,231,938, pravastatin, and related compounds, such as disclosed in U.S. Pat. No. 4,346,227, simvastatin, and related compounds, as disclosed in U.S. Pat. Nos. 4,448,784 and 4,450,171. Other HMG CoA reductase inhibitors which may be employed herein include, but are not limited to, fluvastatin, disclosed in U.S. Pat. No. 5,354,772; cerivastatin, as disclosed in U.S. Pat. Nos. 5,006,530 and 5,177,080; atorvastatin, as disclosed in U.S. Pat. Nos. 4,681,893, 5,273,995, 5,385,929 and 5,686,104; atavastatin (Nissan/Sankyo's nisvastatin (NK-104)), as disclosed in U.S. Pat. No. 5,011,930; visastatin (Shionogi-Astra/Zeneca (ZD-4522)) as disclosed in U.S. Pat. No. 5,260,440.
- Preferred hypolipidemic agents are pravastatin, lovastatin, simvastatin, atorvastatin, fluvastatin, cerivastatin, atavastatin, and ZD-4522.
- The fibric acid derivatives which may be employed in combination with one or more compounds of formula I include fenofibrate, gemfibrozil, clofibrate, bezafibrate, ciprofibrate, clinofibrate, and the like, probucol, and related compounds, as disclosed in U.S. Pat. No. 3,674,836, fenofibrate and gemfibrozil being preferred, bile acid sequestrants, such as cholestyramine, colestipol and DEAE-Sephadex (Secholex®, Policexide®), as well as lipostabil (Rhone-Poulenc), Eisai E-5050 (an N-substituted ethanolamine derivative), imanixil (HOE-402), tetrahydrolipstatin (THL), istigmastanylphosphorylcholine (SPC, Roche), aminocyclodextrin (Tanabe Seiyoku), Ajinomoto AJ-814 (azulene derivative), melinamide (Sumitomo), Sandoz 58-035, American Cyanamid CL-277,082 and CL-283,546 (disubstituted urea derivatives), nicotinic acid, acipimox, acifran, neomycin, p-aminosalicylic acid, aspirin, poly(diallylmethylamine) derivatives, such as disclosed in U.S. Pat. No. 4,759,923, quaternary amine poly(diallyldimethylammonium chloride) and ionenes, such as disclosed in U.S. Pat. No. 4,027,009, and other known serum cholesterol lowering agents.
- The ACAT inhibitor which may be employed in combination with one or more compounds of formula I include those disclosed in Drugs of the Future 24:9-15 (1999), (Avasimibe); “The ACAT inhibitor, C1-1011 is effective in the prevention and regression of aortic fatty streak area in hamsters”, Nicolosi et al., Atherosclerosis (Shannon, Irel)., 137(1):77-85 (1998); “The pharmacological profile of FCE 27677: a novel ACAT inhibitor with potent hypolipidemic activity mediated by selective suppression of the hepatic secretion of ApoB 100-containing lipoprotein”, Ghiselli, Giancarlo, Cardiovasc. Drug Rev., 16(1):16-30 (1998); “RP 73163: a bioavailable alkylsulfinyl-diphenylimidazole ACAT inhibitor”, Smith, C. et al., Bioorg. Med. Chem. Lett., 6(1):47-50 (1996); “ACAT inhibitors: physiologic mechanisms for hypolipidemic and anti-atherosclerotic activities in experimental animals”, Krause et al, Editor(s): Ruffolo, Robert R., Jr.; Hollinger, Mannfred A., Inflammation: Mediators Pathways (1995), 173-98, Publisher: CRC, Boca Raton, Fla.; “ACAT inhibitors: potential anti-atherosclerotic agents”, Sliskovic et al., Curr. Med. Chem., 1(3), 204-25 (1994); “Inhibitors of acyl-CoA:cholesterol O-acyl transferase (ACAT) as hypocholesterolemic agents. 6. The first water-soluble ACAT inhibitor with lipid-regulating activity. Inhibitors of acyl-CoA:cholesterol acyltransferase (ACAT). 7. Development of a series of substituted N-phenyl-N′-[(1-phenylcyclopentyl)methyl]ureas with enhanced hypocholesterolemic activity”, Stout et al., Chemtracts: Org. Chem., 8(6):359-62 (1995), or TS-962 (Taisho Pharmaceutical Co. Ltd.).
- The hypolipidemic agent may be an upregulator of LDL receptor activity, such as MD-700 (Taisho Pharmaceutical Co. Ltd) and LY295427 (Eli Lilly).
- Examples of suitable cholesterol absorption inhibitors for use in combination with the compounds of the invention include ezetimibe (Zetia®).
- Examples of suitable ileal Na+/bile acid cotransporter inhibitors for use in combination with the compounds of the invention include compounds as disclosed in Drugs of the Future, 24:425-430 (1999).
- The lipoxygenase inhibitors which may be employed in combination with one or more compounds of formula I include 15-lipoxygenase (15-LO) inhibitors, such as benzimidazole derivatives, as disclosed in WO 97/12615, 15-LO inhibitors, as disclosed in WO 97/12613, isothiazolones, as disclosed in WO 96/38144, and 15-LO inhibitors, as disclosed by Sendobry et al., “Attenuation of diet-induced atherosclerosis in rabbits with a highly selective 15-lipoxygenase inhibitor lacking significant antioxidant properties”, Brit. J. Pharmacology, 120:1199-1206 (1997), and Cornicelli et al., “15-Lipoxygenase and its Inhibition: A Novel Therapeutic Target for Vascular Disease”, Current Pharmaceutical Design, 5:11-20 (1999).
- Examples of suitable anti-hypertensive agents for use in combination with the compounds of the present invention include beta adrenergic blockers, calcium channel blockers (L-type and T-type; e.g. diltiazem, verapamil, nifedipine, amlodipine and mybefradil), diuretics (e.g., chlorothiazide, hydrochlorothiazide, flumethiazide, hydroflumethiazide, bendroflumethiazide, methylchlorothiazide, trichloromethiazide, polythiazide, benzthiazide, ethacrynic acid tricrynafen, chlorthalidone, furosemide, musolimine, bumetanide, triamtrenene, amiloride, spironolactone), renin inhibitors (e.g., aliskiren), ACE inhibitors (e.g., captopril, zofenopril, fosinopril, enalapril, ceranopril, cilazopril, delapril, pentopril, quinapril, ramipril, lisinopril), AT-1 receptor antagonists (e.g., losartan, irbesartan, valsartan), ET receptor antagonists (e.g., sitaxsentan, atrsentan, and compounds disclosed in U.S. Pat. Nos. 5,612,359 and 6,043,265), Dual ET/AII antagonist (e.g., compounds disclosed in WO 00/01389), neutral endopeptidase (NEP) inhibitors, vasopepsidase inhibitors (dual NEP-ACE inhibitors) (e.g., omapatrilat and gemopatrilat), and nitrates.
- Examples of suitable anti-obesity agents for use in combination with the compounds of the present invention include a cannabinoid receptor 1 antagonist or inverse agonist, a beta 3 adrenergic agonist, a lipase inhibitor, a serotonin (and dopamine) reuptake inhibitor, a thyroid receptor beta drug, and/or an anorectic agent.
- Cannabinoid receptor 1 antagonists and inverse agonists which may be optionally employed in combination with compounds of the present invention include rimonabant, SLV 319, CP-945598 (Pfizer), SR-147778 (Sanofi-Aventis), MK0364 (Merck) and those discussed in D. L. Hertzog, Expert Opin. Ther. Patents, 14:1435-1452 (2004).
- The beta 3 adrenergic agonists which may be optionally employed in combination with compounds of the present invention include AJ9677 (Takeda/Dainippon), L750355 (Merck), or CP331648 (Pfizer) or other known beta 3 agonists, as disclosed in U.S. Pat. Nos. 5,541,204, 5,770,615, 5,491,134, 5,776,983, and 5,488,064, with AJ9677, L750,355, and CP331648 being preferred.
- Examples of lipase inhibitors which may be optionally employed in combination with compounds of the present invention include orlistat or ATL-962 (Alizyme), with orlistat being preferred.
- The serotonin (and dopamine) reuptake inhibitor and/or modulator which may be optionally employed in combination with a compound of formula I may be sibutramine, topiramate (Johnson & Johnson), APD-356 (Arena) or axokine (Regeneron), with sibutramine and APD-356 being preferred.
- Examples of thyroid receptor beta compounds which may be optionally employed in combination with compounds of the present invention include thyroid receptor ligands, such as those disclosed in WO 97/21993 (U. Cal SF), WO 99/00353 (KaroBio), and WO 00/039077 (KaroBio), with compounds of the KaroBio applications being preferred.
- The anorectic agent which may be optionally employed in combination with compounds of the present invention include dexamphetamine, phentermine, phenylpropanolamine, or mazindol, with dexamphetamine being preferred.
- Other compounds that can be used in combination with the compounds of the present invention include CCK receptor agonists (e.g., SR-27895B); MCHR1 antagonist (e.g., GSK 856464); galanin receptor antagonists; MCR-4 antagonists (e.g., HP-228); leptin or mimetics; urocortin mimetics, CRF antagonists, and CRF binding proteins (e.g., RU-486, urocortin).
- Further, the compounds of the present invention may be used in combination with HIV protease inhibitors, including but not limited to Reyataz® and Kaletra®.
- Examples of suitable memory enhancing agents, anti-dementia agents, or cognition promoting agents for use in combination with the compounds of the present invention include, but are not limited to, donepezil, rivastigmine, galantamine, memantine, tacrine, metrifonate, muscarine, xanomelline, deprenyl and physostigmine.
- Examples of suitable anti-inflammatory agents for use in combination with the compounds of the present invention include, but are not limited to, prednisone, acetaminophen, aspirin, codeine, fentaynl, ibuprofen, indomethacin, ketorolac, morphine, naproxen, phenacetin, piroxicam, a steroidal analgesic, sufentanyl, sunlindac, interferon alpha, prednisolone, methylprednisolone, dexamethazone, flucatisone, betamethasone, hydrocortisone and beclomethasone.
- The aforementioned patents and patent applications are incorporated herein by reference.
- The above other therapeutic agents, when employed in combination with the compounds of the present invention may be used, for example, in those amounts indicated in the Physicians' Desk Reference, as in the patents set out above, or as otherwise determined by one of ordinary skill in the art.
- The compounds of formula I can be administered for any of the uses described herein by any suitable means, for example, orally, such as in the form of tablets, capsules, granules or powders; sublingually; bucally; parenterally, such as by subcutaneous, intravenous, intramuscular, or intrasternal injection, or infusion techniques (e.g., as sterile injectable aqueous or non-aqueous solutions or suspensions); nasally, including administration to the nasal membranes, such as by inhalation spray; topically, such as in the form of a cream or ointment; or rectally such as in the form of suppositories; in dosage unit formulations containing non-toxic, pharmaceutically acceptable vehicles or diluents.
- In carrying out the method of the invention for treating diabetes and related diseases, a pharmaceutical composition will be employed containing the compounds of formula I, with or without other antidiabetic agent(s) and/or antihyperlipidemic agent(s) and/or other type therapeutic agents in association with a pharmaceutical vehicle or diluent. The pharmaceutical composition can be formulated employing conventional solid or liquid vehicles or diluents and pharmaceutical additives of a type appropriate to the mode of desired administration, such as pharmaceutically acceptable carriers, excipients, binders, and the like. The compounds can be administered to a mammalian patient, including humans, monkeys, dogs, etc. by an oral route, for example, in the form of tablets, capsules, beads, granules or powders. The dose for adults is preferably between 1 and 2,000 mg per day, which can be administered in a single dose or in the form of individual doses from 1-4 times per day.
- A typical capsule for oral administration contains compounds of structure I (250 mg), lactose (75 mg), and magnesium stearate (15 mg). The mixture is passed through a 60 mesh sieve and packed into a No. 1 gelatin capsule.
- A typical injectable preparation is produced by aseptically placing 250 mg of compounds of structure I into a vial, aseptically freeze-drying and sealing. For use, the contents of the vial are mixed with 2 mL of physiological saline, to produce an injectable preparation.
Claims (20)
1. A compound of formula (I)
enantiomers, diastereomers, solvates, or salts thereof wherein:
A is a 5- to 20-membered non-aromatic bi-, tri- or polycyclic ring system optionally containing 1-3 heteroatoms selected from N, O, S, S(O) and S(O)2, which may be optionally substituted with one or more R4's;
X is —C(═O)OH, —C(═O)C(═O)OH, —C(═O)NR9R9, tetrazolyl, or —C(═O)NHS(O)2R9;
W is absent, (—CR8aR8b—)m, (—CR8aR8b—)m—O—, (—CR8aR8b—)m—N(R14)—, C3-6 cycloalkyl, alkenyl or alkynyl, wherein the cycloalkyl or alkenyl may be optionally substituted with one or more R8a's;
m is 1-3;
Z is —CN, C3-10 alkyl, cycloalkyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl, all of which may be optionally substituted with one or more R4's, and the heterocyclyl and heterocyclylalkyl contain 1-4 heteroatoms selected from N, O, and S;
provided that W and Z, or when W is absent, X and Z, are attached to the same carbon on Ring A;
R4, at each occurrence, is independently selected from hydrogen, alkyl, aryl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, halo, ═O, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)OR10, —OR10, —OH, —OCF3, —SH, —SR10, —C(═O)NR9R9, —NR9R9, —S(O)2NR9R9, —NR9S(O)2CF3, —C(═O)NR9S(O)2R9, —S(O)2NR9C(═O)OR9, —S(O)2NR9C(═O)NR9R9, —C(═O)NR9S(O)2CF3, —C(═O)R10, —NR9C(═O)R10, —OC(═O)R10, —S(═O)R10, —S(O)2R10, —O—S(O)2R10, —NR9C(═O)OR8 or —NR9S(O2)R8, wherein the alkyl, aryl, alkenyl, alkynyl, cycloalkyl, or heterocyclyl may be optionally substituted with one or more R5's;
R5, at each occurrence, is independently selected from hydrogen, alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, halo, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)OR10, —OCF3, —OR10, —OH, —SH, —SR10, —C(═O)NR9R9, —NR9R9, —S(O)2NR9R9, —NR9S(O)2CF3, —C(═O)NR9S(O)2R9, —S(O)2NR9C(═O)OR9, —S(O)2NR9C(═O)NR9R9, —C(═O)NR9S(O)2CF3, —C(═O)R10, —NR9C(═O)R10, —OC(═O)R10, —S(═O)R10, —S(O)2R10, —O—S(O)2R10, —NR9C(═O)OR8 or —NR9S(O2)R8;
R8, at each occurrence, is independently alkyl, aryl or heterocyclyl;
R8a, at each occurrence, is independently hydrogen, alkyl or aryl;
R8b, at each occurrence, is independently hydrogen, —C(═O)OH, alkyl, —OH, halo, —CN, —OR10, —C(═O)R10 or —C(═O)NR9R9, wherein the alkyl may be optionally substituted with one or more R9a's; or
R8a and R8b are taken together with the carbon to which both are attached to form a 3- to 7-membered ring, which may optionally contain 1-4 heteroatoms selected from N, O, and S and be optionally substituted with 0-3 R9a;
R9, at each occurrence, is independently hydrogen, alkyl, alkoxy, cycloalkyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl, wherein the alkyl, cycloalkyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl may be optionally substituted with 0-5 R9a, and the heterocyclyl or heterocyclylalkyl contain 1-4 heteroatoms selected from N, O, and S; or
two R9's together with the nitrogen to which they are attached form a unsaturated, saturated or partially saturated cyclic ring system containing from 2-10 carbon atoms and from 0-4 additional heteroatoms selected from N, O, S, S(O) and S(O)2, wherein said ring system may be optionally substituted or fused with one or more R9a's;
R9a, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, halo, ═O, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)OR14, —OCF3, —OR10, —OH, —OCF3, —SH, —SR14, —C(═O)NR14R14, —NR14R14, —S(O)2NR14R14, —NR14S(O)2CF3, —C(═O)NR14S(O)2R10, —S(O)2NR14C(═O)OR10, —S(O)2NR14C(═O)NR14R14, —C(═O)NR14S(O)2R14, —C(═O)R14, —NR14C(═O)R14, —OC(═O)R14, —C(═NR14)NR14R14, —NHC(═NR14)NR14R14, —S(═O)R14, —S(O)2R14, —OS(O)2R14, —NR14C(═O)OR10, —NR14S(O2)R8, —C(═O)R10, —OC(═O)NR14R14, —NR14C(═O)NR14R14 or arylalkyl, wherein the alkyl, aryl, cycloalkyl, cycloalkylalkyl, heterocyclyl, and heterocyclylalkyl may be optionally substituted with 0-3 R10a;
R10, at each occurrence, is independently selected from alkyl, cycloalkyl, alkenyl, alkynyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl, wherein the alkyl, cycloalkyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl may be optionally substituted with 0-3 R10a, and the heterocyclyl and heterocyclylalkyl contain 1-4 heteroatoms selected from N, O, and S;
R10a, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, halo, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)OR14, —OCF3, —OR14, —OH, —SH, —SR14, —C(═O)NR14R14, —NR14R14, —S(O)2NR14R14, —NR14S(O)2CF3, —C(═O)NR14S(O)2R14, —S(O)2NR14C(═O)OR14, —S(O)2NR14C(═O)NR14R14, —C(═O)NR14S(O)2CF3, —C(═O)R14, —NR14C(═O)R14, —OC(═O)R14, —C(═NR14)NR14R14, —NHC(═NR14)NR14R14, —S(═O)R14, —S(O)2R14, —NR14C(═O)OR8, —NR14S(O2)R8 or arylalkyl;
R14, at each occurrence, is independently selected from hydrogen, alkyl, cycloalkyl, aryl or arylalkyl, wherein the alkyl, cycloalkyl, aryl or arylalkyl may be optionally substituted with 0-3 R14a;
R14a, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, halo, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)OR15, —OCF3, —OR15, —OH, —SH, —SR15, —C(═O)NR15R15, —NR15R15, —S(O)2NR15R15, —NR15S(O)2CF3, —C(═O)NR15S(O)2R15, —S(O)2NR15C(═O)OR15, —S(O)2NR15C(═O)NR15R15, —C(═O)NR15S(O)2CF3, —C(═O)R15, —NR15C(═O)R15, —OC(═O)R15, —C(═NR15)NR15R15, —NHC(═NR15)NR15R15, —S(═O)R15, —S(O)2R15, —NR15C(═O)OR8, —NR15S(O2)R8 or arylalkyl;
R15, at each occurrence, is independently selected from hydrogen, alkyl, cycloalkyl, aryl or arylalkyl; and
provided that:
(i) when W is absent, Z is phenyl, X is —C(═O)OH, lower alkyl or tetrazolyl, A is not bicyclo(2,2,1)heptanyl, bicyclo(2,2,1)heptenyl, bicyclo(2,2,2)octanyl, or bicyclo(2,2,2)octenyl;
(ii) when W is absent, Z is optionally substituted phenyl, or heterocyclyl, X is —C(═O)OH or —C(═O)NR9R9 and R9 is hydrogen or lower alkyl, A is not 8-azabicyclo(3.2.1)octanyl;
(iii) the compound is not a compound of the following structure:
wherein R is optionally substituted phenyl;
(iv) the compound is not a compound of the following structure:
and
(viii) when Z is —CN, optionally substituted C3-10 alkyl, optionally substituted cycloalkyl, optionally substituted aryl or optionally substituted arylalkyl, A is not
which is substituted with at least one R4 other than hydrogen; or
which may be optionally substituted with one or more R4's.
2. The compound of claim 1 , wherein A is a 5- to 20-membered non-aromatic bi-, tri- or polycyclic ring system optionally containing 1-3 heteroatoms selected from N, O, S, S(O) and S(O)2, which is substituted with at least one R4.
3. The compound of claim 1 , wherein:
A is a 6- to 15-membered non-aromatic bi-, tri- or polycyclic ring system optionally containing 1-3 heteroatoms selected from N, O, S, S(O) and S(O)2, which may be optionally substituted with one or more R4's;
X is —C(═O)OH, —C(═O)C(═O)OH, —C(═O)NR9R9, or tetrazolyl;
W is absent, (—CR8aR8b—)m, (—CR8aR8b—)m—O—, (—CR8aR8b—)m—N(R14)—, or alkenyl, wherein the alkenyl may be optionally substituted with one or more R8a's;
m is 1-3;
Z is CN, C3-10 alkyl, cycloalkyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl, all of which may be optionally substituted with one or more R4's, and the heterocyclyl and heterocyclylalkyl contain 1-4 heteroatoms selected from N, O, and S;
provided that W and Z, or when W is absent, X and Z, are attached to the same carbon on Ring A;
R4, at each occurrence, is independently selected from hydrogen, alkyl, aryl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, halo, ═O, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)OR10, —OR10, —OH, —OCF3, —SH, —SR10, —C(═O)NR9R9, —NR9R9, —S(O)2NR9R9, —NR9S(O)2CF3, —C(═O)NR9S(O)2R9, —S(O)2NR9C(═O)OR9, —S(O)2NR9C(═O)NR9R9, —C(═O)NR9S(O)2CF3, —C(═O)R10, —NR9C(═O)R10, —OC(═O)R10, —S(═O)R10, —S(O)2R10, —O—S(O)2R10, —NR9C(═O)OR8 or —NR9S(O2)R8, wherein the alkyl, aryl, alkenyl, alkynyl, cycloalkyl, or heterocyclyl may be optionally substituted with one or more R5's;
R5, at each occurrence, is independently selected from hydrogen, alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, halo, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)OR10, —OCF3, —OR10, —OH, —SH, —SR10, —C(═O)NR9R9, —NR9R9, —S(O)2NR9R9, —NR9S(O)2CF3, —C(═O)NR9S(O)2R9, —S(O)2NR9C(═O)OR9, —S(O)2NR9C(═O)NR9R9, —C(═O)NR9S(O)2CF3, —C(═O)R10, —NR9C(═O)R10, —OC(═O)R10, —S(═O)R10, —S(O)2R10, —O—S(O)2R10, —NR9C(═O)OR8 or —NR9S(O2)R8;
R8, at each occurrence, is independently alkyl, aryl or heterocyclyl;
R8a, at each occurrence, is independently hydrogen, alkyl or aryl;
R8b, at each occurrence, is independently hydrogen, —C(═O)OH, alkyl, —OH, halo, —CN, —OR10, —C(═O)R10 or —C(═O)NR9R9, wherein the alkyl may be optionally substituted with one or more R9a's; or
R8a and R8b are taken together with the carbon to which both are attached to form a 3- to 7-membered ring, which may optionally contain 1-4 heteroatoms selected from N, O, and S and be optionally substituted with 0-3 R9a;
R9, at each occurrence, is independently hydrogen, alkyl, alkoxy, cycloalkyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl, wherein the alkyl, cycloalkyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl may be optionally substituted with 0-5 R9a, and the heterocyclyl or heterocyclylalkyl contain 1-4 heteroatoms selected from N, O, and S; or
two R9's together with the nitrogen to which they are attached form a unsaturated, saturated or partially saturated cyclic ring system containing from 2-10 carbon atoms and from 0-4 additional heteroatoms selected from N, O, S, S(O) and S(O)2, wherein said ring system may be optionally substituted or fused with one or more R9a's;
R9a, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, halo, ═O, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)OR14, —OCF3, —OR10, —OH, —SH, —SR14, —C(═O)NR14R14, —NR14R14, —S(O)2NR14R14, —NR14S(O)2CF3, —C(═O)NR14S(O)2R10, —S(O)2NR14C(═O)OR10, —S(O)2NR14C(═O)NR14R14, —C(═O)NR14S(O)2R14, —C(═O)R14, —NR14C(═O)R14, —OC(═O)R14, —S(═O)R14, —S(O)2R14, —OS(O)2R14, —NR14C(═O)OR10, —NR14S(O2)R8, —C(═O)R10, —OC(═O)NR14R14, —NR14C(═O)NR14R14 or arylalkyl, wherein the alkyl, aryl, cycloalkyl, cycloalkylalkyl, heterocyclyl, and heterocyclylalkyl may be optionally substituted with 0-3 R10a;
R10, at each occurrence, is independently selected from alkyl, cycloalkyl, alkenyl, alkynyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl, wherein the alkyl, cycloalkyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl may be optionally substituted with 0-3 R10a, and the heterocyclyl and heterocyclylalkyl contain 1-4 heteroatoms selected from N, O, and S;
R10a, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, halo, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)OR14, —OCF3, —OR14, —OH, —SH, —SR14, —C(═O)NR14R14, —NR14R14, —S(O)2NR14R14, —NR14S(O)2CF3, —C(═O)NR14S(O)2R14, —S(O)2NR14C(═O)OR14, —S(O)2NR14C(═O)NR14R14, —C(═O)NR14S(O)2CF3, —C(═O)R14, —NR14C(═O)R14, —OC(═O)R14, —S(═O)R14, —S(O)2R14, —NR14C(═O)OR8, —NR14S(O2)R8 or arylalkyl;
R14, at each occurrence, is independently selected from hydrogen, alkyl, cycloalkyl, aryl or arylalkyl, wherein the alkyl, cycloalkyl, aryl or arylalkyl may be optionally substituted with 0-3 R14a;
R14a, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, halo, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)OR15, —OCF3, —OR15, —OH, —SH, —SR15, —C(═O)NR15R15, —NR15R15, —S(O)2NR15R15, —NR15S(O)2CF3, —C(═O)NR15S(O)2R15, —S(O)2NR15C(═O)OR15, —S(O)2NR15C(═O)NR15R15, —C(═O)NR15S(O)2CF3, —C(═O)R15, —NR15C(═O)R15, —OC(═O)R15, —S(═O)R15, —S(O)2R15, —NR15C(═O)OR8, —NR15S(O2)R8 or arylalkyl; and
R15, at each occurrence, is independently selected from hydrogen, alkyl, cycloalkyl, aryl or arylalkyl.
4. The compound of claim 1 , wherein:
A is a 7- to 14-membered non-aromatic bi-, tri- or polycyclic ring system optionally containing 1-3 heteroatoms selected from N, O, S, S(O) and S(O)2, which may be optionally substituted with one or more R4's;
X is —C(═O)OH, —C(═O)NR9R9, or tetrazolyl;
W is absent, (—CR8aR8b—)m, (—CR8aR8b—)m—O— or alkenyl, wherein the alkenyl may be optionally substituted with one or more R8a's;
m is 1-2;
Z is CN, C3-10 alkyl, cycloalkyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl, all of which may be optionally substituted with one or more R4's, and the heterocyclyl and heterocyclylalkyl contain 1-4 heteroatoms selected from N, O, and S;
provided that W and Z, or when W is absent, X and Z, are attached to the same carbon on Ring A;
R4, at each occurrence, is independently selected from hydrogen, alkyl, aryl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, halo, ═O, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)OR10, —OR10, —OH, —OCF3, —SH, —SR10, —C(═O)NR9R9, —NR9R9, —S(O)2NR9R9, —NR9S(O)2CF3, —C(═O)NR9S(O)2R9, —S(O)2NR9C(═O)OR9, —S(O)2NR9C(═O)NR9R9, —C(═O)NR9S(O)2CF3, —C(═O)R10, —NR9C(═O)R10, —OC(═O)R10, —S(═O)R10, —S(O)2R10, —O—S(O)2R10, —NR9C(═O)OR8 or —NR9S(O2)R8, wherein the alkyl, aryl, alkenyl, alkynyl, cycloalkyl, or heterocyclyl may be optionally substituted with one or more R5's;
R5, at each occurrence, is independently selected from hydrogen, alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, halo, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)OR10, —OCF3, —OR10, —OH, —SH, —SR10, —C(═O)NR9R9, —NR9R9, —S(O)2NR9R9, —NR9S(O)2CF3, —C(═O)NR9S(O)2R9, —S(O)2NR9C(═O)OR9, —S(O)2NR9C(═O)NR9R9, —C(═O)NR9S(O)2CF3, —C(═O)R10, —NR9C(═O)R10, —OC(═O)R10, —S(═O)R10, —S(O)2R10, —O—S(O)2R10, —NR9C(═O)OR8 or —NR9S(O2)R8;
R8, at each occurrence, is independently alkyl, aryl or heterocyclyl;
R8a, at each occurrence, is independently hydrogen, alkyl or aryl;
R8b, at each occurrence, is independently hydrogen, —C(═O)OH, alkyl, —OH, halo, —CN, —OR10, —C(═O)R10 or —C(═O)NR9R9, wherein the alkyl may be optionally substituted with one or more R9a's; or
R8a and R8b are taken together with the carbon to which both are attached to form a 3- to 7-membered ring, which may optionally contain 1-4 heteroatoms selected from N, O, and S and be optionally substituted with 0-3 R9a;
R9, at each occurrence, is independently hydrogen, alkyl, alkoxy, cycloalkyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl, wherein the alkyl, cycloalkyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl may be optionally substituted with 0-5 R9a, and the heterocyclyl or heterocyclylalkyl contain 1-4 heteroatoms selected from N, O, and S; or
two R9's together with the nitrogen to which they are attached form a unsaturated, saturated or partially saturated cyclic ring system containing from 2-10 carbon atoms and from 0-4 additional heteroatoms selected from N, O, S, S(O) and S(O)2, wherein said ring system may be optionally substituted or fused with one or more R9a's;
R9a, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, halo, ═O, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)OR14, —OCF3, —OR10, —OH, —SH, —SR14, —C(═O)NR14R14, —NR14R14, —S(O)2NR14R14, —NR14S(O)2CF3, —C(═O)NR14S(O)2R10, —S(O)2NR14C(═O)OR10, —S(O)2NR14C(═O)NR14R14, —C(═O)NR14S(O)2R14, —C(═O)R14, —NR14C(═O)R14, —OC(═O)R14, —S(═O)R14, —S(O)2R14, —OS(O)2R14, —NR14C(═O)OR10, —NR14S(O2)R8, —C(═O)R10, —OC(═O)NR14R14, —NR14C(═O)NR14R14 or arylalkyl, wherein the alkyl, aryl, cycloalkyl, cycloalkylalkyl, heterocyclyl, and heterocyclylalkyl may be optionally substituted with 0-3 R10a;
R10, at each occurrence, is independently selected from alkyl, cycloalkyl, alkenyl, alkynyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl, wherein the alkyl, cycloalkyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl may be optionally substituted with 0-3 R10a, and the heterocyclyl and heterocyclylalkyl contain 1-4 heteroatoms selected from N, O, and S;
R10a, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, halo, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)OR14, —OCF3, —OR14, —OH, —SH, —SR14, —C(═O)NR14R14, —NR14R14, —S(O)2NR14R14, —NR14S(O)2CF3, —C(═O)NR14S(O)2R14, —S(O)2NR14C(═O)OR14, —S(O)2NR14C(═O)NR14R14, —C(═O)NR14S(O)2CF3, —C(═O)R14, —NR14C(═O)R14, —OC(═O)R14, —S(═O)R14, —S(O)2R14, —NR14C(═O)OR8, —NR14S(O2)R8 or arylalkyl;
R14, at each occurrence, is independently selected from hydrogen, alkyl, cycloalkyl, aryl or arylalkyl, wherein the alkyl, cycloalkyl, aryl or arylalkyl may be optionally substituted with 0-3 R14a;
R14a, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, halo, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)OR15, —OCF3, —OR15, —OH, —SH, —SR15, —C(═O)NR15R15, —NR15R15, —S(O)2NR15R15, —NR15S(O)2CF3, —C(═O)NR15S(O)2R15, —S(O)2NR15C(═O)OR15, —S(O)2NR15C(═O)NR15R15, —C(═O)NR15S(O)2CF3, —C(═O)R15, —NR15C(═O)R15, —OC(═O)R15, —S(═O)R15, —S(O)2R15, —NR15C(═O)OR8, —NR15S(O2)R8 or arylalkyl; and
R15, at each occurrence, is independently selected from hydrogen, alkyl, cycloalkyl, aryl or arylalkyl.
5. The compound of claim 1 , wherein:
A is a 7- to 14-membered non-aromatic bi-, tri- or polycyclic ring system optionally containing 1-3 heteroatoms selected from N, O, S, S(O) and S(O)2, which may be optionally substituted with one or more R4's;
X is —C(═O)OH, —C(═O)NR9R9, or tetrazolyl;
W is absent, (—CR8aR8b—)m, (—CR8aR8b)m—O— or alkenyl, wherein the alkenyl may be optionally substituted with one or more R8a's;
m is 1-2;
Z is cycloalkyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl, all of which may be optionally substituted with one or more R4's, and the heterocyclyl and heterocyclylalkyl contain 1-4 heteroatoms selected from N, O, and S;
provided that W and Z, or when W is absent, X and Z, are attached to the same carbon on Ring A;
R4, at each occurrence, is independently selected from hydrogen, alkyl, aryl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, halo, ═O, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)OR10, —OR10, —OH, —OCF3, —SH, —SR10, —C(═O)NR9R9, —NR9R9, —S(O)2NR9R9, —NR9S(O)2CF3, —C(═O)NR9S(O)2R9, —S(O)2NR9C(═O)OR9, —S(O)2NR9C(═O)NR9R9, —C(═O)NR9S(O)2CF3, —C(═O)R10, —NR9C(═O)R10, —OC(═O)R10, —S(═O)R10, —S(O)2R10, —O—S(O)2R10, —NR9C(═O)OR8 or —NR9S(O2)R8, wherein the alkyl, aryl, alkenyl, alkynyl, cycloalkyl, or heterocyclyl may be optionally substituted with one or more R5's;
R5, at each occurrence, is independently selected from hydrogen, alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, halo, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)OR10, —OCF3, —OR10, —OH, —SH, —SR10, —C(═O)NR9R9, —NR9R9, —S(O)2NR9R9, —NR9S(O)2CF3, —C(═O)NR9S(O)2R9, —S(O)2NR9C(═O)OR9, —S(O)2NR9C(═O)NR9R9, —C(═O)NR9S(O)2CF3, —C(═O)R10, —NR9C(═O)R10, —OC(═O)R10, —S(═O)R10, —S(O)2R10, —O—S(O)2R10, —NR9C(═O)OR8 or —NR9S(O2)R8;
R8, at each occurrence, is independently alkyl, aryl or heterocyclyl;
R8a, at each occurrence, is independently hydrogen, alkyl or aryl;
R8b, at each occurrence, is independently hydrogen, —C(═O)OH, alkyl, —OH, halo, —CN, —OR10, —C(═O)R10 or —C(═O)NR9R9, wherein the alkyl may be optionally substituted with one or more R9a's; or
R8a and R8b are taken together with the carbon to which both are attached to form a 3- to 7-membered ring, which may optionally contain 1-4 heteroatoms selected from N, O, and S and be optionally substituted with 0-3 R9a;
R9, at each occurrence, is independently hydrogen, alkyl, alkoxy, cycloalkyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl, wherein the alkyl, cycloalkyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl may be optionally substituted with 0-5 R9a, and the heterocyclyl or heterocyclylalkyl contain 1-4 heteroatoms selected from N, O, and S; or
two R9's together with the nitrogen to which they are attached form a unsaturated, saturated or partially saturated cyclic ring system containing from 2-10 carbon atoms and from 0-4 additional heteroatoms selected from N, O, S, S(O) and S(O)2, wherein said ring system may be optionally substituted or fused with one or more R9a's;
R9a, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, halo, ═O, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)OR14, —OCF3, —OR10, —OH, —SH, —SR14, —C(═O)NR14R14, —NR14R14, —S(O)2NR14R14, —NR14S(O)2CF3, —C(═O)NR14S(O)2R10, —S(O)2NR14C(═O)OR10, —S(O)2NR14C(═O)NR14R14, —C(═O)NR14S(O)2R14, —C(═O)R14, —NR14C(═O)R14, —OC(═O)R14, —S(═O)R14, —S(O)2R14, —OS(O)2R14, —NR14C(═O)OR10, —NR14S(O2)R8, —C(═O)R10, —OC(═O)NR14R14, —NR14C(═O)NR14R14 or arylalkyl, wherein the alkyl, aryl, cycloalkyl, cycloalkylalkyl, heterocyclyl, and heterocyclylalkyl may be optionally substituted with 0-3 R10a;
R10, at each occurrence, is independently selected from alkyl, cycloalkyl, alkenyl, alkynyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl, wherein the alkyl, cycloalkyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl may be optionally substituted with 0-3 R10a, and the heterocyclyl and heterocyclylalkyl contain 1-4 heteroatoms selected from N, O, and S;
R10a, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, halo, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)OR14, —OCF3, —OR14, —OH, —SH, —SR14, —C(═O)NR14R14, —NR14R14, —S(O)2NR14R14, —NR14S(O)2CF3, —C(═O)NR14S(O)2R14, —S(O)2NR14C(═O)OR14, —S(O)2NR14C(═O)NR14R14, —C(═O)NR14S(O)2CF3, —C(═O)R14, —NR14C(═O)R14, —OC(═O)R14, —S(═O)R14, —S(O)2R14, —NR14C(═O)OR8, —NR14S(O2)R8 or arylalkyl;
R14, at each occurrence, is independently selected from hydrogen, alkyl, cycloalkyl, aryl or arylalkyl, wherein the alkyl, cycloalkyl, aryl or arylalkyl may be optionally substituted with 0-3 R14a;
R14a, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, halo, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)OR15, —OCF3, —OR15, —OH, —SH, —SR15, —C(═O)NR15R15, —NR15R15, —S(O)2NR15R15, —NR15S(O)2CF3, —C(═O)NR15S(O)2R15, —S(O)2NR15C(═O)OR15, —S(O)2NR15C(═O)NR15R15, —C(═O)NR15S(O)2CF3, —C(═O)R15, —NR15C(═O)R15, —OC(═O)R15, —S(═O)R15, —S(O)2R15, —NR15C(═O)OR8, —NR15S(O2)R8 or arylalkyl; and
R15, at each occurrence, is independently selected from hydrogen, alkyl, cycloalkyl, aryl or arylalkyl.
6. The compound of claim 1 , wherein:
A is a 7- to 14-membered non-aromatic bi-, tri- or polycyclic ring system optionally containing 1-3 heteroatoms selected from N, O, S, S(O) and S(O)2, which may be optionally substituted with one or more R4's;
X is —C(═O)OH, —C(═O)NR9R9, or tetrazolyl;
W is absent, (—CR8aR8b—)m, (—CR8aR8b)m—O— or alkenyl, wherein the alkenyl may be optionally substituted with one or more R8a's;
m is 1-2;
Z is aryl, arylalkyl, heterocyclyl or heterocyclylalkyl, all of which may be optionally substituted with one or more R4's, and the heterocyclyl and heterocyclylalkyl contain 1-4 heteroatoms selected from N, O, and S;
provided that W and Z, or when W is absent, X and Z, are attached to the same carbon on Ring A;
R4, at each occurrence, is independently selected from hydrogen, alkyl, aryl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, halo, ═O, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)OR10, —OR10, —OH, —OCF3, —SH, —SR10, —C(═O)NR9R9, —NR9R9, —S(O)2NR9R9, —NR9S(O)2CF3, —C(═O)NR9S(O)2R9, —S(O)2NR9C(═O)OR9, —S(O)2NR9C(═O)NR9R9, —C(═O)NR9S(O)2CF3, —C(═O)R10, —NR9C(═O)R10, —OC(═O)R10, —S(═O)R10, —S(O)2R10, —O—S(O)2R10, —NR9C(═O)OR8 or —NR9S(O2)R8, wherein the alkyl, aryl, alkenyl, alkynyl, cycloalkyl, or heterocyclyl may be optionally substituted with one or more R5's;
R5, at each occurrence, is independently selected from hydrogen, alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, halo, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)OR10, —OCF3, —OR10, —OH, —SH, —SR10, —C(═O)NR9R9, —NR9R9, —S(O)2NR9R9, —NR9S(O)2CF3, —C(═O)NR9S(O)2R9, —S(O)2NR9C(═O)OR9, —S(O)2NR9C(═O)NR9R9, —C(═O)NR9S(O)2CF3, —C(═O)R10, —NR9C(═O)R10, —OC(═O)R10, —S(═O)R10, —S(O)2R10, —O—S(O)2R10, —NR9C(═O)OR8 or —NR9S(O2)R8;
R8, at each occurrence, is independently alkyl, aryl or heterocyclyl;
R8a, at each occurrence, is independently hydrogen, alkyl or aryl;
R8b, at each occurrence, is independently hydrogen, —C(═O)OH, alkyl, —OH, halo, —CN, —OR10, —C(═O)R10 or —C(═O)NR9R9, wherein the alkyl may be optionally substituted with one or more R9a's; or
R8a and R8b are taken together with the carbon to which both are attached to form a 3- to 7-membered ring, which may optionally contain 1-4 heteroatoms selected from N, O, and S and be optionally substituted with 0-3 R9a;
R9, at each occurrence, is independently hydrogen, alkyl, alkoxy, cycloalkyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl, wherein the alkyl, cycloalkyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl may be optionally substituted with 0-5 R9a, and the heterocyclyl or heterocyclylalkyl contain 1-4 heteroatoms selected from N, O, and S; or
two R9's together with the nitrogen to which they are attached form a unsaturated, saturated or partially saturated cyclic ring system containing from 2-10 carbon atoms and from 0-4 additional heteroatoms selected from N, O, S, S(O) and S(O)2, wherein said ring system may be optionally substituted or fused with one or more R9a's;
R9a, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, halo, ═O, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)OR14, —OCF3, —OR10, —OH, —SH, —SR14, —C(═O)NR14R14, —NR14R14, —S(O)2NR14R14, —NR14S(O)2CF3, —C(═O)NR14S(O)2R10, —S(O)2NR14C(═O)OR10, —S(O)2NR14C(═O)NR14R14, —C(═O)NR14S(O)2R14, —C(═O)R14, —NR14C(═O)R14, —OC(═O)R14, —S(═O)R14, —S(O)2R14, —OS(O)2R14, —NR14C(═O)OR10, —NR14S(O2)R8, —C(═O)R10, —OC(═O)NR14R14, —NR14C(═O)NR14R14 or arylalkyl, wherein the alkyl, aryl, cycloalkyl, cycloalkylalkyl, heterocyclyl, and heterocyclylalkyl may be optionally substituted with 0-3 R10a;
R10, at each occurrence, is independently selected from alkyl, cycloalkyl, alkenyl, alkynyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl, wherein the alkyl, cycloalkyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl may be optionally substituted with 0-3 R10a, and the heterocyclyl and heterocyclylalkyl contain 1-4 heteroatoms selected from N, O, and S;
R10a, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, halo, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)OR14, —OCF3, —OR14, —OH, —SH, —SR14, —C(═O)NR14R14, —NR14R14, —S(O)2NR14R14, —NR14S(O)2CF3, —C(═O)NR14S(O)2R14, —S(O)2NR14C(═O)OR14, —S(O)2NR14C(═O)NR14R14, —C(═O)NR14S(O)2CF3, —C(═O)R14, —NR14C(═O)R14, —OC(═O)R14, —S(═O)R14, —S(O)2R14, —NR14C(═O)OR8, —NR14S(O2)R8 or arylalkyl;
R14, at each occurrence, is independently selected from hydrogen, alkyl, cycloalkyl, aryl or arylalkyl, wherein the alkyl, cycloalkyl, aryl or arylalkyl may be optionally substituted with 0-3 R14a;
R14a, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, halo, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)OR15, —OCF3, —OR15, —OH, —SH, —SR15, —C(═O)NR15R15, —NR15R15, —S(O)2NR15R15, —NR15S(O)2CF3, —C(═O)NR15S(O)2R15, —S(O)2NR15C(═O)OR15, —S(O)2NR15C(═O)NR15R15, —C(═O)NR15S(O)2CF3, —C(═O)R15, —NR15C(═O)R15, —OC(═O)R15, —S(═O)R15, —S(O)2R15, —NR15C(═O)OR8, —NR15S(O2)R8 or arylalkyl; and
R15, at each occurrence, is independently selected from hydrogen, alkyl, cycloalkyl, aryl or arylalkyl.
7. The compound of claim 1 , wherein:
A is a 7- to 14-membered non-aromatic bi-, tri- or polycyclic ring system optionally containing 1-3 heteroatoms selected from N, O, S, S(O) and S(O)2, which may be optionally substituted with one or more R4's;
X is —C(═O)OH, —C(═O)NR9R9, or tetrazolyl;
W is absent, (—CR8aR8b—)m, —(CR8aR8b)m—O— or alkenyl, wherein the alkenyl may be optionally substituted with one or more R8a's;
m is 1-2;
Z is aryl, arylalkyl or heterocyclylalkyl, all of which may be optionally substituted with one or more R4's, and the heterocyclylalkyl contain 1-4 heteroatoms selected from N, O, and S;
provided that W and Z, or when W is absent, X and Z, are attached to the same carbon on Ring A;
R4, at each occurrence, is independently selected from hydrogen, alkyl, aryl, alkenyl, cycloalkyl, heterocyclyl, halo, ═O, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)OR10, —OR10, —OH, —OCF3, —SH, —SR10, —C(═O)NR9R9, —NR9R9, —S(O)2NR9R9, —NR9S(O)2CF3, —C(═O)NR9S(O)2R9, —S(O)2NR9C(═O)OR9, —S(O)2NR9C(═O)NR9R9, —C(═O)NR9S(O)2CF3, —C(═O)R10, —NR9C(═O)R10, —OC(═O)R10, —S(═O)R10, —S(O)2R10, —O—S(O)2R10, —NR9C(═O)OR8 or —NR9S(O2)R8, wherein the alkyl, aryl, alkenyl, cycloalkyl, or heterocyclyl may be optionally substituted with one or more R5's;
R5, at each occurrence, is independently selected from hydrogen, alkyl, haloalkyl, aryl, alkenyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, halo, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)OR10, —OCF3, —OR10, —OH, —SH, —SR10, —C(═O)NR9R9, —NR9R9, —S(O)2NR9R9, —NR9S(O)2CF3, —C(═O)NR9S(O)2R9, —S(O)2NR9C(═O)OR9, —S(O)2NR9C(═O)NR9R9, —C(═O)NR9S(O)2CF3, —C(═O)R10, —NR9C(═O)R10, —OC(═O)R10, —S(═O)R10, —S(O)2R10, —O—S(O)2R10, —NR9C(═O)OR8 or —NR9S(O2)R8;
R8, at each occurrence, is independently alkyl, aryl or heterocyclyl;
R8a, at each occurrence, is independently hydrogen, alkyl or aryl;
R8b, at each occurrence, is independently hydrogen, —C(═O)OH, alkyl, —OH, halo, —CN, —OR10, —C(═O)R10 or —C(═O)NR9R9, wherein the alkyl may be optionally substituted with one or more R9a's; or
R8a and R8b are taken together with the carbon to which both are attached to form a 3- to 7-membered ring, which may optionally contain 1-4 heteroatoms selected from N, O, and S and be optionally substituted with 0-3 R9a;
R9, at each occurrence, is independently hydrogen, alkyl, alkoxy, cycloalkyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl, wherein the alkyl, cycloalkyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl may be optionally substituted with 0-5 R9a, and the heterocyclyl or heterocyclylalkyl contain 1-4 heteroatoms selected from N, O, and S; or
two R9's together with the nitrogen to which they are attached form a unsaturated, saturated or partially saturated cyclic ring system containing from 2-10 carbon atoms and from 0-4 additional heteroatoms selected from N, O, S, S(O) and S(O)2, wherein said ring system may be optionally substituted or fused with one or more R9a's;
R9a, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, halo, ═O, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)OR14, —OCF3, —OR10, —OH, —SH, —SR14, —C(═O)NR14R14, —NR14R14, —S(O)2NR14R14, —NR14S(O)2CF3, —C(═O)NR14S(O)2R10, —S(O)2NR14C(═O)OR10, —S(O)2NR14C(═O)NR14R14, —C(═O)NR14S(O)2R14, —C(═O)R14, —NR14C(═O)R14, —OC(═O)R14, —S(═O)R14, —S(O)2R14, —OS(O)2R14, —NR14C(═O)OR10, —NR14S(O2)R8, —C(═O)R10, —OC(═O)NR14R14, —NR14C(═O)NR14R14 or arylalkyl, wherein the alkyl, aryl, cycloalkyl, cycloalkylalkyl, heterocyclyl, and heterocyclylalkyl may be optionally substituted with 0-3 R10a;
R10, at each occurrence, is independently selected from alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl, wherein the alkyl, cycloalkyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl may be optionally substituted with 0-3 R10a, and the heterocyclyl and heterocyclylalkyl contain 1-4 heteroatoms selected from N, O, and S;
R10a, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, halo, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)OR14, —OCF3, —OR14, —OH, —SH, —SR14, —C(═O)NR14R14, —NR14R14, —S(O)2NR14R14, —NR14S(O)2CF3, —C(═O)NR14S(O)2R14, —S(O)2NR14C(═O)OR14, —S(O)2NR14C(═O)NR14R14, —C(═O)NR14S(O)2CF3, —C(═O)R14, —NR14C(═O)R14, —OC(═O)R14, —S(═O)R14, —S(O)2R14, —NR14C(═O)OR8, —NR14S(O2)R8 or arylalkyl;
R14, at each occurrence, is independently selected from hydrogen, alkyl, cycloalkyl, aryl or arylalkyl, wherein the alkyl, cycloalkyl, aryl or arylalkyl may be optionally substituted with 0-3 R14a;
R14a, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, halo, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)OR15, —OCF3, —OR15, —OH, —SH, —SR15, —C(═O)NR15R15, —NR15R15, —S(O)2NR15R15, —NR15S(O)2CF3, —C(═O)NR15S(O)2R15, —S(O)2NR15C(═O)OR15, —S(O)2NR15C(═O)NR15R15, —C(═O)NR15S(O)2CF3, —C(═O)R15, —NR15C(═O)R15, —OC(═O)R15, —S(═O)R15, —S(O)2R15, —NR15C(═O)OR8, —NR15S(O2)R8 or arylalkyl; and
R15, at each occurrence, is independently selected from hydrogen, alkyl, cycloalkyl, aryl or arylalkyl.
8. The compound of claim 1 , wherein:
A is a 7- to 14-membered non-aromatic bi-, tri- or polycyclic ring system optionally containing 1-3 heteroatoms selected from N, O, S, S(O) and S(O)2, which may be optionally substituted with one or more R4's;
X is —C(═O)OH, or —C(═O)NR9R9;
W is absent, (—CR8aR8b—)m, (—CR8aR8b)m—O— or alkenyl, wherein the alkenyl may be optionally substituted with one or more R8a's;
m is 1-2;
Z is aryl, arylalkyl or heterocyclylalkyl, all of which may be optionally substituted with one or more R4's, and the heterocyclylalkyl contain 1-4 heteroatoms selected from N, O, and S;
provided that W and Z, or when W is absent, X and Z, are attached to the same carbon on Ring A;
R4, at each occurrence, is independently selected from hydrogen, alkyl, aryl, cycloalkyl, heterocyclyl, halo, ═O, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)OR10, —OR10, —OH, —OCF3, —SH, —SR10, —C(═O)NR9R9, —NR9R9, —S(O)2NR9R9, —NR9S(O)2CF3, —C(═O)NR9S(O)2R9, —S(O)2NR9C(═O)OR9, —S(O)2NR9C(═O)NR9R9, —C(═O)NR9S(O)2CF3, —C(═O)R10, —NR9C(═O)R10, —OC(═O)R10, —S(═O)R10, —S(O)2R10, —O—S(O)2R10, —NR9C(═O)OR8 or —NR9S(O2)R8, wherein the alkyl, aryl, cycloalkyl or heterocyclyl may be optionally substituted with one or more R5's;
R5, at each occurrence, is independently selected from hydrogen, alkyl, haloalkyl, aryl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, halo, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)OR10, —OCF3, —OR10, —OH, —SH, —SR10, —C(═O)NR9R9, —NR9R9, —S(O)2NR9R9, —NR9S(O)2CF3, —C(═O)NR9S(O)2R9, —S(O)2NR9C(═O)OR9, —S(O)2NR9C(═O)NR9R9, —C(═O)NR9S(O)2CF3, —C(═O)R10, —NR9C(═O)R10, —OC(═O)R10, —S(═O)R10, —S(O)2R10, —O—S(O)2R10, —NR9C(═O)OR8 or —NR9S(O2)R8;
R8, at each occurrence, is independently alkyl, aryl or heterocyclyl;
R8a, at each occurrence, is independently hydrogen, alkyl or aryl;
R8b, at each occurrence, is independently hydrogen, —C(═O)OH, alkyl, —OH, halo, —CN, —OR10, —C(═O)R10 or —C(═O)NR9R9, wherein the alkyl may be optionally substituted with one or more R9a's; or
R8a and R8b are taken together with the carbon to which both are attached to form a 3- to 7-membered ring, which may optionally contain 1-4 heteroatoms selected from N, O, and S and be optionally substituted with 0-3 R9a;
R9, at each occurrence, is independently hydrogen, alkyl, alkoxy, cycloalkyl, aryl, arylalkyl, or heterocyclyl, wherein the alkyl, cycloalkyl, aryl, arylalkyl or heterocyclyl may be optionally substituted with 0-5 R9a, and the heterocyclyl contains 1-4 heteroatoms selected from N, O, and S; or
two R9's together with the nitrogen to which they are attached form a unsaturated, saturated or partially saturated cyclic ring system containing from 2-10 carbon atoms and from 0-4 additional heteroatoms selected from N, O, S, S(O) and S(O)2, wherein said ring system may be optionally substituted or fused with one or more R9a's;
R9a, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, halo, ═O, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)OR14, —OCF3, —OR10, —OH, —SH, —SR14, —C(═O)NR14R14, —NR14R14, —S(O)2NR14R14, —NR14S(O)2CF3, —C(═O)NR14S(O)2R10, —S(O)2NR14C(═O)OR10, —S(O)2NR14C(═O)NR14R14, —C(═O)NR14S(O)2R14, —C(═O)R14, —NR14C(═O)R14, —OC(═O)R14, —S(═O)R14, —S(O)2R14, —OS(O)2R14, —NR14C(═O)OR10, —NR14S(O2)R8, —C(═O)R10, —OC(═O)NR14R14, —NR14C(═O)NR14R14 or arylalkyl, wherein the alkyl, aryl, cycloalkyl, cycloalkylalkyl, heterocyclyl, and heterocyclylalkyl may be optionally substituted with 0-3 R10a;
R10, at each occurrence, is independently selected from alkyl, cycloalkyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl, wherein the alkyl, cycloalkyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl may be optionally substituted with 0-3 R10a, and the heterocyclyl and heterocyclylalkyl contain 1-4 heteroatoms selected from N, O, and S;
R10a, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, halo, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)OR14, —OCF3, —OR14, —OH, —SH, —SR14, —C(═O)NR14R14, —NR14R14, —S(O)2NR14R14, —NR14S(O)2CF3, —C(═O)NR14S(O)2R14, —S(O)2NR14C(═O)OR14, —S(O)2NR14C(═O)NR14R14, —C(═O)NR14S(O)2CF3, —C(═O)R14, —NR14C(═O)R14, —OC(═O)R14, —S(═O)R14, —S(O)2R14, —NR14C(═O)OR8, —NR14S(O2)R8 or arylalkyl;
R14, at each occurrence, is independently selected from hydrogen, alkyl, cycloalkyl, aryl or arylalkyl, wherein the alkyl, cycloalkyl, aryl or arylalkyl may be optionally substituted with 0-3 R14a;
R14a, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, halo, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)OR15, —OCF3, —OR15, —OH, —SH, —SR15, —C(═O)NR15R15, —NR15R15, —S(O)2NR15R15, —NR15S(O)2CF3, —C(═O)NR15S(O)2R15, —S(O)2NR15C(═O)OR15, —S(O)2NR15C(═O)NR15R15, —C(═O)NR15S(O)2CF3, —C(═O)R15, —NR15C(═O)R15, —OC(═O)R15, —S(═O)R15, —S(O)2R15, —NR15C(═O)OR8, —NR15S(O2)R8 or arylalkyl; and
R15, at each occurrence, is independently selected from hydrogen, alkyl, cycloalkyl, aryl or arylalkyl.
9. The compound of claim 1 , wherein:
A is a 7- to 14-membered non-aromatic bi-, tri- or polycyclic ring system optionally containing 1-3 heteroatoms selected from N, O, S, S(O) and S(O)2, which may be optionally substituted with one or more R4's;
X is —C(═O)OH, or —C(═O)NR9R9;
W is absent, (—CR8aR8b—)m or (—CR8aR8b)m—O—;
m is 1-2;
Z is aryl, arylalkyl or heterocyclylalkyl, all of which may be optionally substituted with one or more R4's, and the heterocyclylalkyl contain 1-4 heteroatoms selected from N, O, and S;
provided that W and Z, or when W is absent, X and Z, are attached to the same carbon on Ring A;
R4, at each occurrence, is independently selected from hydrogen, alkyl, aryl, cycloalkyl, heterocyclyl, halo, ═O, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)OR10, —OR10, —OH, —OCF3, —SH, —SR10, —C(═O)NR9R9, —NR9R9, —S(O)2NR9R9, —NR9S(O)2CF3, —C(═O)NR9S(O)2R9, —S(O)2NR9C(═O)OR9, —S(O)2NR9C(═O)NR9R9, —C(═O)NR9S(O)2CF3, —C(═O)R10, —NR9C(═O)R10, —OC(═O)R10, —S(═O)R10, —S(O)2R10, —O—S(O)2R10, —NR9C(═O)OR8 or —NR9S(O2)R8, wherein the alkyl, aryl, cycloalkyl, or heterocyclyl may be optionally substituted with one or more R5's;
R5, at each occurrence, is independently selected from hydrogen, alkyl, haloalkyl, aryl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, halo, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)OR10, —OCF3, —OR10, —OH, —SH, —SR10, —C(═O)NR9R9, —NR9R9, —S(O)2NR9R9, —NR9S(O)2CF3, —C(═O)NR9S(O)2R9, —S(O)2NR9C(═O)OR9, —S(O)2NR9C(═O)NR9R9, —C(═O)NR9S(O)2CF3, —C(═O)R10, —NR9C(═O)R10, —OC(═O)R10, —S(═O)R10, —S(O)2R10, —O—S(O)2R10, —NR9C(═O)OR8 or —NR9S(O2)R8;
R8, at each occurrence, is independently alkyl, aryl or heterocyclyl;
R8a, at each occurrence, is independently hydrogen, alkyl or aryl;
R8b, at each occurrence, is independently hydrogen, —C(═O)OH, alkyl, —OH, halo, —CN, —OR10 or —C(═O)NR9R9, wherein the alkyl may be optionally substituted with one or more R9a's; or
R9, at each occurrence, is independently hydrogen, alkyl, alkoxy, cycloalkyl, aryl, arylalkyl, or heterocyclyl, wherein the alkyl, cycloalkyl, aryl, arylalkyl or heterocyclyl may be optionally substituted with 0-5 R9a, and the heterocyclyl contains 1-4 heteroatoms selected from N, O, and S; or
two R9's together with the nitrogen to which they are attached form a unsaturated, saturated or partially saturated cyclic ring system containing from 2-10 carbon atoms and from 0-4 additional heteroatoms selected from N, O, S, S(O) and S(O)2, wherein said ring system may be optionally substituted or fused with one or more R9a's;
R9a, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, halo, ═O, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)OR14, —OCF3, —OR10, —OH, —SH, —SR14, —C(═O)NR14R14, —NR14R14, —S(O)2NR14R14, —NR14S(O)2CF3, —C(═O)NR14S(O)2R10, —S(O)2NR14C(═O)OR10, —S(O)2NR14C(═O)NR14R14, —C(═O)NR14S(O)2R14, —C(═O)R14, —NR14C(═O)R14, —OC(═O)R14, —S(═O)R14, —S(O)2R14, —OS(O)2R14, —NR14C(═O)OR10, —NR14S(O2)R8, —C(═O)R10, —OC(═O)NR14R14, —NR14C(═O)NR14R14 or arylalkyl, wherein the alkyl, aryl, cycloalkyl, cycloalkylalkyl, heterocyclyl and heterocyclylalkyl may be optionally substituted with 0-3 R10a;
R10, at each occurrence, is independently selected from alkyl, cycloalkyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl, wherein the alkyl, cycloalkyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl may be optionally substituted with 0-3 R10a, and the heterocyclyl and heterocyclylalkyl contain 1-4 heteroatoms selected from N, O, and S;
R10a, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, halo, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)OR14, —OCF3, —OR14, —OH, —SH, —SR14, —C(═O)NR14R14, —NR14R14, —S(O)2NR14R14, —NR14S(O)2CF3, —C(═O)NR14S(O)2R14, —S(O)2NR14C(═O)OR14, —S(O)2NR14C(═O)NR14R14, —C(═O)NR14S(O)2CF3, —C(═O)R14, —NR14C(═O)R14, —OC(═O)R14, —S(═O)R14, —S(O)2R14, —NR14C(═O)OR8, —NR14S(O2)R8 or arylalkyl;
R14, at each occurrence, is independently selected from hydrogen, alkyl, cycloalkyl, or aryl, wherein the alkyl, cycloalkyl or aryl may be optionally substituted with 0-3 R14a;
R14a, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, halo, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)OR15, —OCF3, —OR15, —OH, —SH, —SR15, —C(═O)NR15R15, —NR15R15, —S(O)2NR15R15, —NR15S(O)2CF3, —C(═O)NR15S(O)2R15, —S(O)2NR15C(═O)OR15, —S(O)2NR15C(═O)NR15R15, —C(═O)NR15S(O)2CF3, —C(═O)R15, —NR15C(═O)R15, —OC(═O)R15, —S(═O)R15, —S(O)2R15, —NR15C(═O)OR8, —NR15S(O2)R8 or arylalkyl; and
R15, at each occurrence, is independently selected from hydrogen, alkyl, cycloalkyl or aryl.
10. The compound of claim 1 , wherein:
A is a 7- to 14-membered non-aromatic bi-, tri- or polycyclic ring system optionally containing 1-3 heteroatoms selected from N, O, S, S(O) and S(O)2, which may be optionally substituted with one or more R4's;
X is —C(═O)OH, or —C(═O)NR9R9;
W is absent, (—CR8aR8b—)m or —(CR8aR8b)m—O—;
m is 1-2;
Z is aryl or arylalkyl, both of which may be optionally substituted with one or more R4's;
provided that W and Z, or when W is absent, X and Z, are attached to the same carbon on Ring A;
R4, at each occurrence, is independently selected from hydrogen, alkyl, aryl, cycloalkyl, heterocyclyl, halo, ═O, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)OR10, —OR10, —OH, —OCF3, —SH, —SR10, —C(═O)NR9R9, —NR9R9, —S(O)2NR9R9, —NR9S(O)2CF3, —C(═O)NR9S(O)2R9, —S(O)2NR9C(═O)OR9, —S(O)2NR9C(═O)NR9R9, —C(═O)NR9S(O)2CF3, —C(═O)R10, —NR9C(═O)R10, —OC(═O)R10, —S(═O)R10, —S(O)2R10, —O—S(O)2R10, —NR9C(═O)OR8 or —NR9S(O2)R8, wherein the alkyl, aryl, cycloalkyl, or heterocyclyl may be optionally substituted with one or more R5's;
R5, at each occurrence, is independently selected from hydrogen, alkyl, haloalkyl, aryl, cycloalkyl, cycloalkylalkyl, heterocyclyl, halo, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)OR10, —OCF3, —OR10, —OH, —SH, —SR10, —C(═O)NR9R9, —NR9R9, —S(O)2NR9R9, —NR9S(O)2CF3, —C(═O)NR9S(O)2R9, —S(O)2NR9C(═O)OR9, —S(O)2NR9C(═O)NR9R9, —C(═O)NR9S(O)2CF3, —C(═O)R10, —NR9C(═O)R10, —OC(═O)R10, —S(═O)R10, —S(O)2R10, —O—S(O)2R10, —NR9C(═O)OR8 or —NR9S(O2)R8;
R8, at each occurrence, is independently alkyl, aryl or heterocyclyl;
R8a, at each occurrence, is independently hydrogen, alkyl or aryl;
R8b, at each occurrence, is independently hydrogen, —C(═O)OH, alkyl, —OH, halo, —CN, —OR10 or —C(═O)NR9R9, wherein the alkyl may be optionally substituted with one or more R9a's; or
R9, at each occurrence, is independently hydrogen, alkyl, alkoxy, cycloalkyl, aryl or heterocyclyl, wherein the alkyl, cycloalkyl, aryl or heterocyclyl may be optionally substituted with 0-5 K9a, and the heterocyclyl contains 1-4 heteroatoms selected from N, O, and S; or
two R9's together with the nitrogen to which they are attached form a unsaturated, saturated or partially saturated cyclic ring system containing from 2-10 carbon atoms and from 0-4 additional hetero atoms selected from N, O, S, S(O) and S(O)2, wherein said ring system may be optionally substituted or fused with one or more R9a's;
R9a, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, cycloalkyl, cycloalkylalkyl, heterocyclyl, halo, ═O, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)OR14, —OCF3, —OR10, —OH, —SH, —SR14, —C(═O)NR14R14, —NR14R14, —S(O)2NR14R14, —NR14S(O)2CF3, —C(═O)NR14S(O)2R10, —S(O)2NR14C(═O)OR10, —S(O)2NR14C(═O)NR14R14, —C(═O)NR14S(O)2R14, —C(═O)R14, —NR14C(═O)R14, —OC(═O)R14, —S(═O)R14, —S(O)2R14, —OS(O)2R14, —NR14C(═O)OR10, —NR14S(O2)R8, —C(═O)R10, —OC(═O)NR14R14, —NR14C(═O)NR14R14 or arylalkyl, wherein the alkyl, aryl, cycloalkyl, cycloalkylalkyl and heterocyclyl may be optionally substituted with 0-3 R10a;
R10, at each occurrence, is independently selected from alkyl, cycloalkyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl, wherein the alkyl, cycloalkyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl may be optionally substituted with 0-3 R10a, and the heterocyclyl and heterocyclylalkyl contain 1-4 heteroatoms selected from N, O, and S;
R10a, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, cycloalkyl, cycloalkylalkyl, heterocyclyl, halo, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)OR14, —OCF3, —OR14, —OH, —SH, —SR14, —C(═O)NR14R14, —NR14R14, —S(O)2NR14R14, —NR14S(O)2CF3, —C(═O)NR14S(O)2R14, —S(O)2NR14C(═O)OR14, —S(O)2NR14C(═O)NR14R14, —C(═O)NR14S(O)2CF3, —C(═O)R14, —NR14C(═O)R14, —OC(═O)R14, —S(═O)R14, —S(O)2R14, —NR14C(═O)OR8, —NR14S(O2)R8 or arylalkyl;
R14, at each occurrence, is independently selected from hydrogen, alkyl, cycloalkyl, or aryl, wherein the alkyl, cycloalkyl or aryl may be optionally substituted with 0-3 R14a;
R14a, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, cycloalkyl, cycloalkylalkyl, heterocyclyl, halo, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)OR15, —OCF3, —OR15, —OH, —SH, —SR15, —C(═O)NR15R15, —NR15R15, —S(O)2NR15R15, —NR15S(O)2CF3, —C(═O)NR15S(O)2R15, —S(O)2NR15C(═O)OR15, —S(O)2NR15C(═O)NR15R15, —C(═O)NR15S(O)2CF3, —C(═O)R15, —NR15C(═O)R15, —OC(═O)R15, —S(═O)R15, —S(O)2R15, —NR15C(═O)OR8, —NR15S(O2)R8 or arylalkyl; and
R15, at each occurrence, is independently selected from hydrogen, alkyl, cycloalkyl or aryl.
11. The compound of claim 1 , wherein:
A is a 7- to 14-membered non-aromatic bi-, tri- or polycyclic ring system optionally containing 1-3 heteroatoms selected from N, O, S, S(O) and S(O)2, which may be optionally substituted with one or more R4's;
X is —C(═O)NR9R9;
W is absent, (—CR8aR8b—)m or —(CR8aR8b)m—O—;
m is 1-2;
Z is aryl or arylalkyl, both of which may be optionally substituted with one or more R4's;
provided that W and Z, or when W is absent, X and Z, are attached to the same carbon on Ring A;
R4, at each occurrence, is independently selected from hydrogen, alkyl, aryl, cycloalkyl, heterocyclyl, halo, ═O, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)OR10, —OR10, —OH, —OCF3, —SH, —SR10, —C(═O)NR9R9, —NR9R9, —S(O)2NR9R9, —NR9S(O)2CF3, —C(═O)NR9S(O)2R9, —S(O)2NR9C(═O)OR9, —S(O)2NR9C(═O)NR9R9, —C(═O)NR9S(O)2CF3, —C(═O)R10, —NR9C(═O)R10, —OC(═O)R10, —S(═O)R10, —S(O)2R10, —O—S(O)2R10, —NR9C(═O)OR8 or —NR9S(O2)R8, wherein the alkyl, aryl, cycloalkyl or heterocyclyl may be optionally substituted with one or more R5's;
R5, at each occurrence, is independently selected from hydrogen, alkyl, haloalkyl, aryl, cycloalkyl, heterocyclyl, halo, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)OR10, —OCF3, —OR10, —OH, —SH, —SR10, —C(═O)NR9R9, —NR9R9, —S(O)2NR9R9, —NR9S(O)2CF3, —C(═O)NR9S(O)2R9, —S(O)2NR9C(═O)OR9, —S(O)2NR9C(═O)NR9R9, —C(═O)NR9S(O)2CF3, —C(═O)R10, —NR9C(═O)R10, —OC(═O)R10, —S(═O)R10, —S(O)2R10, —O—S(O)2R10, —NR9C(═O)OR8 or —NR9S(O2)R8;
R8, at each occurrence, is independently alkyl, aryl or heterocyclyl;
R8a, at each occurrence, is independently hydrogen, alkyl or aryl;
R8b, at each occurrence, is independently hydrogen, —C(═O)OH, alkyl, —OH, halo, —CN, —OR10 or —C(═O)NR9R9, wherein the alkyl may be optionally substituted with one or more R9a's; or
R9, at each occurrence, is independently hydrogen, alkyl, alkoxy, cycloalkyl, aryl or heterocyclyl, wherein the alkyl, cycloalkyl, aryl or heterocyclyl may be optionally substituted with 0-5 R9a, and the heterocyclyl contains 1-4 heteroatoms selected from N, O, and S; or
two R9's together with the nitrogen to which they are attached form a unsaturated, saturated or partially saturated cyclic ring system containing from 2-10 carbon atoms and from 0-4 additional heteroatoms selected from N, O, S, S(O) and S(O)2, wherein said ring system may be optionally substituted or fused with one or more R9a's;
R9a, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, cycloalkyl, heterocyclyl, halo, ═O, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)OR14, —OCF3, —OR10, —OH, —SH, —SR14, —C(═O)NR14R14, —NR14R14, —S(O)2NR14R14, —NR14S(O)2CF3, —C(═O)NR14S(O)2R10, —S(O)2NR14C(═O)OR10, —S(O)2NR14C(═O)NR14R14, —C(═O)NR14S(O)2R14, —C(═O)R14, —NR14C(═O)R14, —OC(═O)R14, —S(═O)R14, —S(O)2R14, —OS(O)2R14, —NR14C(═O)OR10, —NR14S(O2)R8, —C(═O)R10, —OC(═O)NR14R14, —NR14C(═O)NR14R14 or arylalkyl, wherein the alkyl, aryl, cycloalkyl and heterocyclyl may be optionally substituted with 0-3 R10a;
R10, at each occurrence, is independently selected from alkyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl, wherein the alkyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl may be optionally substituted with 0-3 R10a, and the heterocyclyl and heterocyclylalkyl contain 1-4 heteroatoms selected from N, O, and S;
R10a, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, cycloalkyl, heterocyclyl, halo, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)OR14, —OCF3, —OR14, —OH, —SH, —SR14, —C(═O)NR14R14, —NR14R14, —S(O)2NR14R14, —NR14S(O)2CF3, —C(═O)NR14S(O)2R14, —S(O)2NR14C(═O)OR14, —S(O)2NR14C(═O)NR14R14, —C(═O)NR14S(O)2CF3, —C(═O)R14, —NR14C(═O)R14, —OC(═O)R14, —S(═O)R14, —S(O)2R14, —NR14C(═O)OR8, —NR14S(O2)R8 or arylalkyl;
R14, at each occurrence, is independently selected from hydrogen, alkyl, cycloalkyl or aryl, wherein the alkyl, cycloalkyl or aryl may be optionally substituted with 0-3 R14a;
R14a, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, cycloalkyl, heterocyclyl, halo, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)OR15, —OCF3, —OR15, —OH, —SH, —SR15, —C(═O)NR15R15, —NR15R15, —S(O)2NR15R15, —NR15S(O)2CF3, —C(═O)NR15S(O)2R15, —S(O)2NR15C(═O)OR15, —S(O)2NR15C(═O)NR15R15, —C(═O)NR15S(O)2CF3, —C(═O)R15, —NR15C(═O)R15, —OC(═O)R15, —S(═O)R15, —S(O)2R15, —NR15C(═O)OR8, —NR15S(O2)R8 or arylalkyl; and
R15, at each occurrence, is independently selected from hydrogen, alkyl, cycloalkyl or aryl.
12. The compound of claim 1 , wherein:
A is a 7- to 12-membered non-aromatic bi-, tri- or polycyclic ring system optionally containing 1-3 heteroatoms selected from N, O, S, S(O) and S(O)2, which is substituted with one or more R4's;
X is —C(═O)NR9R9;
W is absent or (—CR8aR8b—)m;
m is 1-2;
Z is aryl or arylalkyl, both of which may be optionally substituted with one or more R4's;
provided that W and Z, or when W is absent, X and Z, are attached to the same carbon on Ring A;
R4, at each occurrence, is independently selected from hydrogen, alkyl, aryl, cycloalkyl, heterocyclyl, halo, ═O, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)OR10, —OR10, —OH, —OCF3, —SH, —SR10, —C(═O)NR9R9, —NR9R9, —S(O)2NR9R9, —NR9S(O)2CF3, —C(═O)NR9S(O)2R9, —S(O)2NR9C(═O)OR9, —S(O)2NR9C(═O)NR9R9, —C(═O)NR9S(O)2CF3, —C(═O)R10, —NR9C(═O)R10, —OC(═O)R10, —S(═O)R10, —S(O)2R10, —O—S(O)2R10, —NR9C(═O)OR8 or —NR9S(O2)R8, wherein the alkyl, aryl, cycloalkyl, or heterocyclyl may be optionally substituted with one or more R5's;
R5, at each occurrence, is independently selected from hydrogen, alkyl, haloalkyl, aryl, cycloalkyl, heterocyclyl, halo, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)OR10, —OCF3, —OR10, —OH, —SH, —SR10, —C(═O)NR9R9, —NR9R9, —S(O)2NR9R9, —NR9S(O)2CF3, —C(═O)NR9S(O)2R9, —S(O)2NR9C(═O)OR9, —S(O)2NR9C(═O)NR9R9, —C(═O)NR9S(O)2CF3, —C(═O)R10, —NR9C(═O)R10, —OC(═O)R10, —S(═O)R10, —S(O)2R10, —O—S(O)2R10, —NR9C(═O)OR8 or —NR9S(O2)R8;
R8, at each occurrence, is independently alkyl, aryl or heterocyclyl;
R8a, at each occurrence, is independently hydrogen or alkyl;
R8b, at each occurrence, is independently hydrogen, —C(═O)OH, alkyl, —OH, halo, —CN, —OR10 or —C(═O)NR9R9, wherein the alkyl may be optionally substituted with one or more R9a's; or
R9, at each occurrence, is independently hydrogen, alkyl, alkoxy, cycloalkyl, aryl or heterocyclyl, wherein the alkyl, cycloalkyl, aryl or heterocyclyl may be optionally substituted with 0-5 R8a, and the heterocyclyl contains 1-4 heteroatoms selected from N, O, and S; or
two R9's together with the nitrogen to which they are attached form a unsaturated, saturated or partially saturated cyclic ring system containing from 2-10 carbon atoms and from 0-4 additional heteroatoms selected from N, O, S, S(O) and S(O)2, wherein said ring system may be optionally substituted or fused with one or more R9a's;
R9a, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, cycloalkyl, heterocyclyl, halo, ═O, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)OR14, —OCF3, —OR10, —OH, —SH, —SR14, —C(═O)NR14R14, —NR14R14, —S(O)2NR14R14, —NR14S(O)2CF3, —C(═O)NR14S(O)2R10, —S(O)2NR14C(═O)OR10, —S(O)2NR14C(═O)NR14R14, —C(═O)NR14S(O)2R14, —C(═O)R14, —NR14C(═O)R14, —OC(═O)R14, —S(═O)R14, —S(O)2R14, —OS(O)2R14, —NR14C(═O)OR10, —NR14S(O2)R8, —C(═O)R10, —OC(═O)NR14R14, —NR14C(═O)NR14R14 or arylalkyl, wherein the alkyl, aryl, cycloalkyl and heterocyclyl may be optionally substituted with 0-3 R10a;
R10, at each occurrence, is independently selected from alkyl, aryl, arylalkyl or heterocyclyl, wherein the alkyl, aryl, arylalkyl or heterocyclyl may be optionally substituted with 0-3 R10a, and the heterocyclyl contains 1-4 heteroatoms selected from N, O, and S;
R10a, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, cycloalkyl, heterocyclyl, halo, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)OR14, —OCF3, —OR14, —OH, —SH, —SR14, —C(═O)NR14R14, —NR14R14, —S(O)2NR14R14, —NR14S(O)2CF3, —C(═O)NR14S(O)2R14, —S(O)2NR14C(═O)OR14, —S(O)2NR14C(═O)NR14R14, —C(═O)NR14S(O)2CF3, —C(═O)R14, —NR14C(═O)R14, —OC(═O)R14, —S(═O)R14, —S(O)2R14, —NR14C(═O)OR8, —NR14S(O2)R8 or arylalkyl;
R14, at each occurrence, is independently selected from hydrogen, alkyl, cycloalkyl or aryl, wherein the alkyl, cycloalkyl or aryl may be optionally substituted with 0-3 R14a;
R14a, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, cycloalkyl, heterocyclyl, halo, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)OR15, —OCF3, —OR15, —OH, —SH, —SR15, —C(═O)NR15R15, —NR15R15, —S(O)2NR15R15, —NR15S(O)2CF3, —C(═O)NR15S(O)2R15, —S(O)2NR15C(═O)OR15, —S(O)2NR15C(═O)NR15R15, —C(═O)NR15S(O)2CF3, —C(═O)R15, —NR15C(═O)R15, —OC(═O)R15, —S(═O)R15, —S(O)2R15, —NR15C(═O)OR8, —NR15S(O2)R8 or arylalkyl; and
R15, at each occurrence, is independently selected from hydrogen, alkyl, cycloalkyl or aryl.
13. The compound of claim 1 , wherein:
A is a 7- to 12-membered non-aromatic bi-, tri- or polycyclic ring system optionally containing 1-3 heteroatoms selected from N, O, S, S(O) and S(O)2, which is substituted with one or more R4's;
X is —C(═O)NR9R9;
W is absent or (—CR8aR8b—)m;
m is 1;
Z is aryl or arylalkyl, both of which may be optionally substituted with one or more R4's;
provided that W and Z, or when W is absent, X and Z, are attached to the same carbon on Ring A;
R4, at each occurrence, is independently selected from hydrogen, alkyl, aryl, cycloalkyl, heterocyclyl, halo, ═O, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)OR10, —OR10, —OH, —OCF3, —SH, —SR10, —C(═O)NR9R9, —NR9R9, —S(O)2NR9R9, —NR9S(O)2CF3, —C(═O)NR9S(O)2R9, —S(O)2NR9C(═O)OR9, —S(O)2NR9C(═O)NR9R9, —C(═O)NR9S(O)2CF3, —C(═O)R10, —NR9C(═O)R10, —OC(═O)R10, —S(═O)R10, —S(O)2R10, —O—S(O)2R10, —NR9C(═O)OR8 or —NR9S(O2)R8, wherein the alkyl, aryl, cycloalkyl or heterocyclyl may be optionally substituted with one or more R5's;
R5, at each occurrence, is independently selected from hydrogen, alkyl, haloalkyl, aryl, cycloalkyl, heterocyclyl, halo, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)OR10, —OCF3, —OR10, —OH, —SH, —SR10, —C(═O)NR9R9, —NR9R9, —S(O)2NR9R9, —NR9S(O)2CF3, —C(═O)NR9S(O)2R9, —S(O)2NR9C(═O)OR9, —S(O)2NR9C(═O)NR9R9, —C(═O)NR9S(O)2CF3, —C(═O)R10, —NR9C(═O)R10, —OC(═O)R10, —S(═O)R10, —S(O)2R10, —O—S(O)2R10, —NR9C(═O)OR8 or —NR9S(O2)R8;
R8, at each occurrence, is independently alkyl or aryl;
R8a, at each occurrence, is independently hydrogen or alkyl;
R8b, at each occurrence, is independently hydrogen, —C(═O)OH, alkyl, —OH, halo, —CN or —OR10, wherein the alkyl may be optionally substituted with one or more R9a's; or
R9, at each occurrence, is independently hydrogen, alkyl, alkoxy, aryl or heterocyclyl, wherein the alkyl, aryl or heterocyclyl may be optionally substituted with 0-5 R9a, and the heterocyclyl contains 1-4 heteroatoms selected from N, O, and S; or
two R9's together with the nitrogen to which they are attached form a unsaturated, saturated or partially saturated cyclic ring system containing from 2-10 carbon atoms and from 0-4 additional heteroatoms selected from N, O, S, S(O) and S(O)2, wherein said ring system may be optionally substituted or fused with one or more R9a's;
R9a, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, cycloalkyl, heterocyclyl, halo, ═O, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)OR14, —OCF3, —OR10, —OH, —SH, —SR14, —C(═O)NR14R14, —NR14R14, —S(O)2NR14R14, —NR14S(O)2CF3, —C(═O)NR14S(O)2R10, —S(O)2NR14C(═O)OR10, —S(O)2NR14C(═O)NR14R14, —C(═O)NR14S(O)2R14, —C(═O)R14, —NR14C(═O)R14, —OC(═O)R14, —S(═O)R14, —S(O)2R14, —OS(O)2R14, —NR14C(═O)OR10, —NR14S(O2)R8, —C(═O)R10, —OC(═O)NR14R14, or —NR14C(═O)NR14R14, wherein the alkyl, aryl, cycloalkyl and heterocyclyl may be optionally substituted with 0-3 R10a;
R10, at each occurrence, is independently selected from alkyl, aryl or heterocyclyl, wherein the alkyl, aryl or heterocyclyl may be optionally substituted with 0-3 R10a, and the heterocyclyl and heterocyclylalkyl contain 1-4 heteroatoms selected from N, O, and S;
R10a, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, cycloalkyl, heterocyclyl, halo, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)OR14, —OCF3, —OR14, —OH, —SH, —SR14, —C(═O)NR14R14, —NR14R14, —S(O)2NR14R14, —NR14S(O)2CF3, —C(═O)NR14S(O)2R14, —S(O)2NR14C(═O)OR14, —S(O)2NR14C(═O)NR14R14, —C(═O)NR14S(O)2CF3, —C(═O)R14, —NR14C(═O)R14, —OC(═O)R14, —S(═O)R14, —S(O)2R14, —NR14C(═O)OR8, or —NR14S(O2)R8;
R14, at each occurrence, is independently selected from hydrogen, alkyl or aryl, wherein the alkyl or aryl may be optionally substituted with 0-3 R14a;
R14a, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, cycloalkyl, heterocyclyl, halo, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)OR15, —OCF3, —OR15, —OH, —SH, —SR15, —C(═O)NR15R15, —NR15R15, —S(O)2NR15R15, —NR15S(O)2CF3, —C(═O)NR15S(O)2R15, —S(O)2NR15C(═O)OR15, —S(O)2NR15C(═O)NR15R15, —C(═O)NR15S(O)2CF3, —C(═O)R15, —NR15C(═O)R15, —OC(═O)R15, —S(═O)R15, —S(O)2R15, —NR15C(═O)OR8, or —NR15S(O2)R8; and
R15, at each occurrence, is independently selected from hydrogen, alkyl or aryl.
14. The compound of claim 1 , wherein:
A is a 7- to 10-membered non-aromatic bi-, tri- or polycyclic ring system optionally containing 1-3 heteroatoms selected from N, O, S, S(O) and S(O)2, which is substituted with one or more R4's;
X is —C(═O)NR9R9;
W is absent or (—CR8aR8b—)m;
m is 1;
Z is aryl or arylalkyl, both of which may be optionally substituted with one or more R4's;
provided that W and Z, or when W is absent, X and Z, are attached to the same carbon on Ring A;
R4, at each occurrence, is independently selected from hydrogen, alkyl, aryl, cycloalkyl, heterocyclyl, halo, ═O, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)OR10, —OR10, —OH, —OCF3, —SH, —SR10, —C(═O)NR9R9, —NR9R9, —S(O)2NR9R9, —NR9S(O)2CF3, —C(═O)NR9S(O)2R9, —S(O)2NR9C(═O)OR9, —S(O)2NR9C(═O)NR9R9, —C(═O)NR9S(O)2CF3, —C(═O)R10, —NR9C(═O)R10, —OC(═O)R10, —S(═O)R10, —S(O)2R10, —O—S(O)2R10, —NR9C(═O)OR8 or —NR9S(O2)R8, wherein the alkyl, aryl, cycloalkyl or heterocyclyl may be optionally substituted with one or more R5's;
R5, at each occurrence, is independently selected from hydrogen, alkyl, haloalkyl, aryl, cycloalkyl, heterocyclyl, halo, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)OR10, —OCF3, —OR10, —OH, —SH, —SR10, —C(═O)NR9R9, —NR9R9, —S(O)2NR9R9, —NR9S(O)2CF3, —C(═O)NR9S(O)2R9, —S(O)2NR9C(═O)OR9, —S(O)2NR9C(═O)NR9R9, —C(═O)NR9S(O)2CF3, —C(═O)R10, —NR9C(═O)R10, —OC(═O)R10, —S(═O)R10, —S(O)2R10, —O—S(O)2R10, —NR9C(═O)OR8 or —NR9S(O2)R8;
R8, at each occurrence, is independently alkyl or aryl;
R8a, at each occurrence, is independently hydrogen or alkyl;
R8b, at each occurrence, is independently hydrogen, —C(═O)OH, alkyl, —OH, halo, —CN, or —OR10;
R9, at each occurrence, is independently hydrogen, alkyl, alkoxy or aryl, wherein the alkyl or aryl may be optionally substituted with 0-5 R9a; or
two R9's together with the nitrogen to which they are attached form a unsaturated, saturated or partially saturated cyclic ring system containing from 2-10 carbon atoms and from 0-4 additional heteroatoms selected from N, O, S, S(O) and S(O)2, wherein said ring system may be optionally substituted or fused with one or more R9a's;
R9a, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, cycloalkyl, heterocyclyl, halo, ═O, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)OR14, —OCF3, —OR10, —OH, —SH, —SR14, —C(═O)NR14R14, —NR14R14, —S(O)2NR14R14, —NR14S(O)2CF3, —C(═O)NR14S(O)2R10, —S(O)2NR14C(═O)OR10, —S(O)2NR14C(═O)NR14R14, —C(═O)NR14S(O)2R14, —C(═O)R14, —NR14C(═O)R14, —OC(═O)R14, —S(═O)R14, —S(O)2R14, —OS(O)2R14, —NR14C(═O)OR10, —NR14S(O2)R8, —C(═O)R10, —OC(═O)NR14R14, or —NR14C(═O)NR14R14, wherein the alkyl, aryl, cycloalkyl and heterocyclyl may be optionally substituted with 0-3 R10a;
R10, at each occurrence, is independently selected from alkyl or aryl, wherein the alkyl or aryl may be optionally substituted with 0-3 R10a;
R10a, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, cycloalkyl, heterocyclyl, halo, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)OR14, —OCF3, —OR14, —OH, —SH, —SR14, —C(═O)NR14R14, —NR14R14, —S(O)2NR14R14, —NR14S(O)2CF3, —C(═O)NR14S(O)2R14, —S(O)2NR14C(═O)OR14, —S(O)2NR14C(═O)NR14R14, —C(═O)NR14S(O)2CF3, —C(═O)R14, —NR14C(═O)R14, —OC(═O)R14, —S(═O)R14, —S(O)2R14, —NR14C(═O)OR8, or —NR14S(O2)R8;
R14, at each occurrence, is independently selected from hydrogen, alkyl or aryl, wherein the alkyl or aryl may be optionally substituted with 0-3 R14a;
R14a, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, cycloalkyl, heterocyclyl, halo, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)OR15, —OCF3, —OR15, —OH, —SH, —SR15, —C(═O)NR15R15, —NR15R15, —S(O)2NR15R15, —NR15S(O)2CF3, —C(═O)NR15S(O)2R15, —S(O)2NR15C(═O)OR15, —S(O)2NR15C(═O)NR15R15, —C(═O)NR15S(O)2CF3, —C(═O)R15, —NR15C(═O)R15, —OC(═O)R15, —S(═O)R15, —S(O)2R15, —NR15C(═O)OR8, or —NR15S(O2)R8; and
R15, at each occurrence, is independently selected from hydrogen or alkyl.
16. A pharmaceutical composition comprising a compound of claim 1 .
17. The pharmaceutical composition of claim 16 further comprising a pharmaceutically acceptable carrier.
18. The pharmaceutical composition of claim 16 further comprising at least one additional therapeutic agent.
19. A method for treating, preventing, or slowing the progression of diabetes, hyperglycemia, obesity, dislipidemia, hypertension, cognitive impairment, rheumatoid arthritis, osteoarthritis, glaucoma, Cushing's Disease and Metabolic Syndrome, which comprises administering to a mammalian patient in need of treatment a therapeutically effective amount of at least one compound of claim 1 .
20. A process for the preparation of a compound of Formula Ih or Ii
wherein A, X, W and Z are as defined in claim 1 , comprising reducing a racemic compound of Formula If
with an enzymatic reductase, such as a ketoreductase, produced by a microorganism from the group consisting of Pichia, Hansenula, Candida or Rhodotorula.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/759,867 US8299054B2 (en) | 2006-08-24 | 2010-04-14 | Cyclic 11-beta hydroxysteroid dehydrogenase type 1 inhibitors |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US84007106P | 2006-08-24 | 2006-08-24 | |
US11/843,015 US7727978B2 (en) | 2006-08-24 | 2007-08-22 | Cyclic 11-beta hydroxysteroid dehydrogenase type I inhibitors |
US12/759,867 US8299054B2 (en) | 2006-08-24 | 2010-04-14 | Cyclic 11-beta hydroxysteroid dehydrogenase type 1 inhibitors |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/843,015 Division US7727978B2 (en) | 2006-08-24 | 2007-08-22 | Cyclic 11-beta hydroxysteroid dehydrogenase type I inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
US20100204199A1 true US20100204199A1 (en) | 2010-08-12 |
US8299054B2 US8299054B2 (en) | 2012-10-30 |
Family
ID=38896814
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/843,015 Active 2027-10-24 US7727978B2 (en) | 2006-08-24 | 2007-08-22 | Cyclic 11-beta hydroxysteroid dehydrogenase type I inhibitors |
US12/759,867 Active 2028-02-14 US8299054B2 (en) | 2006-08-24 | 2010-04-14 | Cyclic 11-beta hydroxysteroid dehydrogenase type 1 inhibitors |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/843,015 Active 2027-10-24 US7727978B2 (en) | 2006-08-24 | 2007-08-22 | Cyclic 11-beta hydroxysteroid dehydrogenase type I inhibitors |
Country Status (16)
Country | Link |
---|---|
US (2) | US7727978B2 (en) |
EP (2) | EP2054368B1 (en) |
JP (2) | JP5268912B2 (en) |
KR (1) | KR20090057038A (en) |
CN (1) | CN103833544A (en) |
AR (1) | AR062533A1 (en) |
AU (1) | AU2007286629A1 (en) |
BR (1) | BRPI0715839A2 (en) |
CA (1) | CA2661401A1 (en) |
CL (1) | CL2007002492A1 (en) |
EA (1) | EA200900344A1 (en) |
IL (1) | IL196989A0 (en) |
MX (1) | MX2009001687A (en) |
NO (1) | NO20090445L (en) |
TW (1) | TW200817353A (en) |
WO (1) | WO2008024892A2 (en) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7727978B2 (en) * | 2006-08-24 | 2010-06-01 | Bristol-Myers Squibb Company | Cyclic 11-beta hydroxysteroid dehydrogenase type I inhibitors |
EP2025674A1 (en) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituted tetra hydro naphthalines, method for their manufacture and their use as drugs |
US8119658B2 (en) | 2007-10-01 | 2012-02-21 | Bristol-Myers Squibb Company | Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors |
RU2010142655A (en) * | 2008-03-19 | 2012-04-27 | Ауриммед Фарма, Инк. (Us) | COMPOUND SUITABLE FOR TREATMENT OF DISEASES AND DISORDERS OF THE CENTRAL NERVOUS SYSTEM, AND METHOD FOR ITS OBTAINING |
GB0811643D0 (en) | 2008-06-25 | 2008-07-30 | Cancer Rec Tech Ltd | New therapeutic agents |
CA2732437C (en) | 2008-08-01 | 2017-11-21 | Ventirx Pharmaceuticals, Inc. | Toll-like receptor agonist formulations and their use |
WO2010054215A1 (en) | 2008-11-06 | 2010-05-14 | Ventirx Pharmaceuticals, Inc. | Methods of synthesis of benzazepine derivatives |
EP2243479A3 (en) | 2009-04-20 | 2011-01-19 | Abbott Laboratories | Novel amide and amidine derivates and uses thereof |
DK2467377T3 (en) | 2009-08-18 | 2017-04-03 | Ventirx Pharmaceuticals Inc | SUBSTITUTED BENZOAZEPINS AS MODULATORS OF TOLL-LIKE RECEPTORS |
AU2010284241B2 (en) | 2009-08-18 | 2016-11-10 | Array Biopharma, Inc. | Substituted benzoazepines as Toll-like receptor modulators |
WO2011068927A2 (en) * | 2009-12-04 | 2011-06-09 | Abbott Laboratories | 11-β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 (11B-HSD1) INHIBITORS AND USES THEREOF |
WO2011107494A1 (en) | 2010-03-03 | 2011-09-09 | Sanofi | Novel aromatic glycoside derivatives, medicaments containing said compounds, and the use thereof |
EP2582709B1 (en) | 2010-06-18 | 2018-01-24 | Sanofi | Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases |
US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
CA2859628C (en) | 2011-12-23 | 2020-02-18 | Meiji Seika Pharma Co., Ltd. | S1p receptor modulating agent |
US9580422B2 (en) | 2013-10-22 | 2017-02-28 | Bristol-Myers Squibb Company | Isotopically labeled triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors |
GB201517216D0 (en) | 2015-09-29 | 2015-11-11 | Cancer Res Technology Ltd And Astex Therapeutics Ltd | Pharmaceutical compounds |
GB201517217D0 (en) | 2015-09-29 | 2015-11-11 | Astex Therapeutics Ltd And Cancer Res Technology Ltd | Pharmaceutical compounds |
GB201704965D0 (en) | 2017-03-28 | 2017-05-10 | Astex Therapeutics Ltd | Pharmaceutical compounds |
GB201704966D0 (en) | 2017-03-28 | 2017-05-10 | Astex Therapeutics Ltd | Pharmaceutical compounds |
WO2019018185A1 (en) | 2017-07-15 | 2019-01-24 | Arisan Therapeutics Inc. | Enantiomerically pure adamantane derivatives for the treatment of filovirus infection |
Citations (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3083204A (en) * | 1956-06-16 | 1963-03-26 | Knoll Ag | Esters and amides of 2-phenyl-bicyclo-(2, 2, 1) heptane-2-carboxylic acid, 2-phenyl-bcyclo(2, 2, 1)-5-heptene-2-carboxylic acid, 2-phenyl-bicyclo(2, 2, 2)-5-octene-2-carboxylic acid and 2-phenyl-bicyclo(2, 2, 2)octane carboxylic acid |
US4691051A (en) * | 1985-01-04 | 1987-09-01 | Pennwalt Corporation | Adamantyl phenyl β-alanines |
US6242615B1 (en) * | 1997-03-28 | 2001-06-05 | Zeneca Limited | Process for the preparation of N-(3-hydroxy-succinyl)-amino acid derivatives |
US20030114460A1 (en) * | 2001-12-14 | 2003-06-19 | Allergan Sales, Inc. | Pharmaceutical conjugates with enhanced pharmacokinetic characteristics |
US20040042830A1 (en) * | 2002-08-29 | 2004-03-04 | Canon Kabushiki Kaisha | Image processing system |
US6740647B1 (en) * | 1998-01-26 | 2004-05-25 | Abbott Gmbh & Co., Kg | Thrombin inhibitors |
US20040209858A1 (en) * | 2002-10-22 | 2004-10-21 | Bennani Youssef L. | Cycloalkylamides and their therapeutic applications |
US20050070720A1 (en) * | 2002-02-01 | 2005-03-31 | Balkovec James M. | 11-Beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia |
US20050277647A1 (en) * | 2004-04-29 | 2005-12-15 | Link James T | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme |
US20060094699A1 (en) * | 2003-04-11 | 2006-05-04 | Kampen Gita Camilla T | Combination therapy using an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and a glucocorticoid receptor agonist to minimize the side effects associated with glucocorticoid receptor agonist therapy |
US20060111366A1 (en) * | 2003-04-11 | 2006-05-25 | Novo Nordisk A/S | Pharmaceutical use of substituted amides |
US20060148871A1 (en) * | 2005-01-05 | 2006-07-06 | Rohde Jeffrey J | Metabolic stabilization of substituted adamantane |
US20060149070A1 (en) * | 2005-01-05 | 2006-07-06 | Rohde Jeffrey J | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme |
US20090124609A1 (en) * | 2006-07-14 | 2009-05-14 | Amgen Inc. | Fused heterocyclic derivatives and methods of use |
US20090124612A1 (en) * | 2006-07-14 | 2009-05-14 | Amgen Inc. | Fused heterocyclic derivatives and methods of use |
US7799782B2 (en) * | 2003-03-03 | 2010-09-21 | Array Biopharma Inc. | P38 inhibitors and methods of use thereof |
Family Cites Families (73)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3674836A (en) | 1968-05-21 | 1972-07-04 | Parke Davis & Co | 2,2-dimethyl-{11 -aryloxy-alkanoic acids and salts and esters thereof |
US4027009A (en) | 1973-06-11 | 1977-05-31 | Merck & Co., Inc. | Compositions and methods for depressing blood serum cholesterol |
JPS5612114B2 (en) | 1974-06-07 | 1981-03-18 | ||
US4231938A (en) | 1979-06-15 | 1980-11-04 | Merck & Co., Inc. | Hypocholesteremic fermentation products and process of preparation |
DK149080C (en) | 1980-06-06 | 1986-07-28 | Sankyo Co | METHOD FOR PREPARING ML-236B CARBOXYLIC ACID DERIVATIVES |
US4450171A (en) | 1980-08-05 | 1984-05-22 | Merck & Co., Inc. | Antihypercholesterolemic compounds |
US4448784A (en) | 1982-04-12 | 1984-05-15 | Hoechst-Roussel Pharmaceuticals, Inc. | 1-(Aminoalkylphenyl and aminoalkylbenzyl)-indoles and indolines and analgesic method of use thereof |
US5354772A (en) | 1982-11-22 | 1994-10-11 | Sandoz Pharm. Corp. | Indole analogs of mevalonolactone and derivatives thereof |
FR2547814B1 (en) | 1983-06-22 | 1985-10-18 | Sanofi Sa | DERIVATIVES OF BICYCLO ACID (3.2.1.) CARBOXYLIC OCTANE, THEIR PREPARATION PROCESS AND THEIR THERAPEUTIC APPLICATION |
US4681893A (en) | 1986-05-30 | 1987-07-21 | Warner-Lambert Company | Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis |
US4759923A (en) | 1987-06-25 | 1988-07-26 | Hercules Incorporated | Process for lowering serum cholesterol using poly(diallylmethylamine) derivatives |
JP2569746B2 (en) | 1987-08-20 | 1997-01-08 | 日産化学工業株式会社 | Quinoline mevalonolactones |
NO177005C (en) | 1988-01-20 | 1995-07-05 | Bayer Ag | Analogous process for the preparation of substituted pyridines, as well as intermediates for use in the preparation |
FI94339C (en) | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Process for the preparation of pharmaceutically acceptable [R- (R *, R *)] - 2- (4-fluorophenyl) -, - dihydroxy-5- (1-methylethyl) -3-phenyl-4 - [(phenylamino) carbonyl] -1H- for the preparation of pyrrole-1-heptanoic acid and its pharmaceutically acceptable salts |
US5177080A (en) | 1990-12-14 | 1993-01-05 | Bayer Aktiengesellschaft | Substituted pyridyl-dihydroxy-heptenoic acid and its salts |
AU1893492A (en) | 1991-04-17 | 1992-11-17 | Merck & Co., Inc. | Pharmaceutical combination for the treatment of benign prostatic hyperplasia comtaining a 5 alpha-reductase inhibitor |
JP2648897B2 (en) | 1991-07-01 | 1997-09-03 | 塩野義製薬株式会社 | Pyrimidine derivatives |
US5595872A (en) | 1992-03-06 | 1997-01-21 | Bristol-Myers Squibb Company | Nucleic acids encoding microsomal trigyceride transfer protein |
US5594016A (en) | 1992-12-28 | 1997-01-14 | Mitsubishi Chemical Corporation | Naphthalene derivatives |
CA2150372C (en) | 1993-01-19 | 2002-08-20 | Nancy L. Mills | Stable oral ci-981 formulation and process of preparing same |
US5739135A (en) | 1993-09-03 | 1998-04-14 | Bristol-Myers Squibb Company | Inhibitors of microsomal triglyceride transfer protein and method |
IL111175A0 (en) | 1993-10-07 | 1994-12-29 | Du Pont Merck Pharma | Electrophilic peptide analogs as inhibitors of trypsin-like serine proteases and pharmaceutical compositions containing them |
US5776983A (en) | 1993-12-21 | 1998-07-07 | Bristol-Myers Squibb Company | Catecholamine surrogates useful as β3 agonists |
US5488064A (en) | 1994-05-02 | 1996-01-30 | Bristol-Myers Squibb Company | Benzo 1,3 dioxole derivatives |
US5385929A (en) | 1994-05-04 | 1995-01-31 | Warner-Lambert Company | [(Hydroxyphenylamino) carbonyl] pyrroles |
FR2723317B1 (en) | 1994-08-04 | 1996-10-31 | Sanofi Sa | USE OF NEUROTENSIN ANTAGONISTS FOR THE PREPARATION OF DIURETIC DRUGS |
US5612359A (en) | 1994-08-26 | 1997-03-18 | Bristol-Myers Squibb Company | Substituted biphenyl isoxazole sulfonamides |
US5491134A (en) | 1994-09-16 | 1996-02-13 | Bristol-Myers Squibb Company | Sulfonic, phosphonic or phosphiniic acid β3 agonist derivatives |
US5541204A (en) | 1994-12-02 | 1996-07-30 | Bristol-Myers Squibb Company | Aryloxypropanolamine β 3 adrenergic agonists |
US5620997A (en) | 1995-05-31 | 1997-04-15 | Warner-Lambert Company | Isothiazolones |
WO1997012613A1 (en) | 1995-10-05 | 1997-04-10 | Warner-Lambert Company | Method for treating and preventing inflammation and atherosclerosis |
DE69636677D1 (en) | 1995-12-13 | 2006-12-14 | Univ California | Crystals of ligand complexed ligand binding domain of the thyroid hormone receptor |
ES2169848T3 (en) | 1996-03-14 | 2002-07-16 | Warner Lambert Co | NEW CROWNED CYCLINE AMINO ACIDS AS PHARMACEUTICAL AGENTS. |
US5770615A (en) | 1996-04-04 | 1998-06-23 | Bristol-Myers Squibb Company | Catecholamine surrogates useful as β3 agonists |
US5962440A (en) | 1996-05-09 | 1999-10-05 | Bristol-Myers Squibb Company | Cyclic phosphonate ester inhibitors of microsomal triglyceride transfer protein and method |
US5827875A (en) | 1996-05-10 | 1998-10-27 | Bristol-Myers Squibb Company | Inhibitors of microsomal triglyceride transfer protein and method |
US5885983A (en) | 1996-05-10 | 1999-03-23 | Bristol-Myers Squibb Company | Inhibitors of microsomal triglyceride transfer protein and method |
DZ2285A1 (en) | 1996-08-08 | 2002-12-25 | Smithkline Beecham Corp | Cysteine protease inhibitors. |
GB9624611D0 (en) | 1996-11-26 | 1997-01-15 | Zeneca Ltd | Bicyclic amine compounds |
US5760246A (en) | 1996-12-17 | 1998-06-02 | Biller; Scott A. | Conformationally restricted aromatic inhibitors of microsomal triglyceride transfer protein and method |
TW536540B (en) | 1997-01-30 | 2003-06-11 | Bristol Myers Squibb Co | Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe |
GB9713739D0 (en) | 1997-06-27 | 1997-09-03 | Karobio Ab | Thyroid receptor ligands |
CA2298813A1 (en) | 1997-08-28 | 1999-03-04 | Merck & Co., Inc. | Pyrrolidine and piperidine modulators of chemokine receptor activity |
UA57811C2 (en) | 1997-11-21 | 2003-07-15 | Пфайзер Продактс Інк. | Compositions including aldose reductase inhibitors and glycogen phosphorylase inhibitors |
JP2002508362A (en) | 1997-12-16 | 2002-03-19 | ワーナー−ランバート・カンパニー | 1-Substituted-1-aminomethyl-cycloalkane derivatives (= gabapentin analogs), their preparation and their use in the treatment of neurological diseases |
KR20030083004A (en) | 1998-02-27 | 2003-10-23 | 화이자 프로덕츠 인크. | N-[(Substituted Five-Membered Diaza Diunsaturated Ring)Carbonyl] Guanidine Derivatives for the Treatment of Ischemia |
SK18822000A3 (en) | 1998-07-06 | 2001-12-03 | Bristol-Myers Squibb Company | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists |
GB9828442D0 (en) | 1998-12-24 | 1999-02-17 | Karobio Ab | Novel thyroid receptor ligands and method II |
HUP9900445A2 (en) * | 1999-02-24 | 2001-06-28 | EGIS Gyógyszergyár Rt. | Process for producing (1r,2s,4r)-(-)-n,n-(dimethylamino-ethoxy)-2-phenyl-1,7,7-trimethyl-bicyclo[2,2,1]heptane and intermediate of the same |
US6548529B1 (en) | 1999-04-05 | 2003-04-15 | Bristol-Myers Squibb Company | Heterocyclic containing biphenyl aP2 inhibitors and method |
TW200528436A (en) | 1999-09-22 | 2005-09-01 | Bristol Myers Squibb Co | Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method |
PH12000002657B1 (en) | 1999-10-12 | 2006-02-21 | Bristol Myers Squibb Co | C-aryl glucoside SGLT2 inhibitors |
AU2000235960A1 (en) | 2000-02-14 | 2001-08-27 | Tularik, Inc. | Lxr modulators |
US6620829B2 (en) * | 2000-10-17 | 2003-09-16 | Warner-Lambert Company | Method of treating noninflammatory cartilage damage |
EP1375496B1 (en) | 2001-03-27 | 2007-07-04 | Eisai R&D Management Co., Ltd. | N-aryl-substituted cyclic amine derivative and medicine containing the same as active ingredient |
JP4776810B2 (en) | 2001-05-30 | 2011-09-21 | 日本曹達株式会社 | Method for producing α-position trisubstituted acetic acid |
KR20040016882A (en) * | 2001-06-11 | 2004-02-25 | 제노포트 인코포레이티드 | Orally administered dosage forms of gaba analog prodrugs having reduced toxicity |
MXPA04004105A (en) | 2002-01-31 | 2004-11-29 | Warner Lambert Co | Alpha 2 delta ligands to treat tinnitus. |
TW200401635A (en) * | 2002-07-23 | 2004-02-01 | Yamanouchi Pharma Co Ltd | 2-Cyano-4-fluoropyrrolidine derivative or salt thereof |
WO2004056744A1 (en) * | 2002-12-23 | 2004-07-08 | Janssen Pharmaceutica N.V. | Adamantyl acetamides as hydroxysteroid dehydrogenase inhibitors |
TW200503994A (en) | 2003-01-24 | 2005-02-01 | Novartis Ag | Organic compounds |
WO2004089470A2 (en) | 2003-04-11 | 2004-10-21 | Novo Nordisk A/S | New amide derivatives and pharmaceutical use thereof |
JP2006522744A (en) | 2003-04-11 | 2006-10-05 | ノボ ノルディスク アクティーゼルスカブ | Combination therapy using 11β-hydroxysteroid dehydrogenase type 1 inhibitor and glucocorticoid receptor agonist to minimize side effects associated with glucocorticoid receptor agonist therapy |
US7501405B2 (en) | 2003-04-11 | 2009-03-10 | High Point Pharmaceuticals, Llc | Combination therapy using an 11β-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent for the treatment of metabolic syndrome and related diseases and disorders |
JP2006522750A (en) | 2003-04-11 | 2006-10-05 | ノボ ノルディスク アクティーゼルスカブ | Combination therapy using 11β-hydroxysteroid dehydrogenase type 1 inhibitors and antihypertensive agents to treat metabolic syndrome and related diseases and disorders |
TW200528440A (en) * | 2003-10-31 | 2005-09-01 | Fujisawa Pharmaceutical Co | 2-cyanopyrrolidinecarboxamide compound |
WO2005097738A1 (en) * | 2004-04-06 | 2005-10-20 | Dainippon Sumitomo Pharma Co., Ltd. | Novel sulfonamide derivative |
EP1841723A1 (en) | 2004-12-31 | 2007-10-10 | Universität Dortmund | Decaline derived compounds as pharmaceutically active agents |
CA2594098C (en) | 2005-01-05 | 2014-04-01 | Abbott Laboratories | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme |
WO2007038452A1 (en) | 2005-09-28 | 2007-04-05 | Merck & Co., Inc. | Process for synthesizing 1,2,4-triazoles |
EP1940393B1 (en) | 2005-10-20 | 2012-07-25 | Merck Sharp & Dohme Corp. | Triazole derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1 |
EP1801098A1 (en) | 2005-12-16 | 2007-06-27 | Merck Sante | 2-Adamantylurea derivatives as selective 11B-HSD1 inhibitors |
US7727978B2 (en) * | 2006-08-24 | 2010-06-01 | Bristol-Myers Squibb Company | Cyclic 11-beta hydroxysteroid dehydrogenase type I inhibitors |
-
2007
- 2007-08-22 US US11/843,015 patent/US7727978B2/en active Active
- 2007-08-23 BR BRPI0715839-4A patent/BRPI0715839A2/en not_active IP Right Cessation
- 2007-08-23 WO PCT/US2007/076593 patent/WO2008024892A2/en active Application Filing
- 2007-08-23 JP JP2009525773A patent/JP5268912B2/en not_active Expired - Fee Related
- 2007-08-23 KR KR1020097005903A patent/KR20090057038A/en not_active Application Discontinuation
- 2007-08-23 EP EP07814376.5A patent/EP2054368B1/en active Active
- 2007-08-23 EP EP20120181050 patent/EP2527317A1/en not_active Withdrawn
- 2007-08-23 CA CA002661401A patent/CA2661401A1/en not_active Abandoned
- 2007-08-23 CN CN201410057480.5A patent/CN103833544A/en active Pending
- 2007-08-23 EA EA200900344A patent/EA200900344A1/en unknown
- 2007-08-23 MX MX2009001687A patent/MX2009001687A/en active IP Right Grant
- 2007-08-23 AU AU2007286629A patent/AU2007286629A1/en not_active Abandoned
- 2007-08-24 TW TW096131558A patent/TW200817353A/en unknown
- 2007-08-24 CL CL2007002492A patent/CL2007002492A1/en unknown
- 2007-08-24 AR ARP070103783A patent/AR062533A1/en not_active Application Discontinuation
-
2009
- 2009-01-29 NO NO20090445A patent/NO20090445L/en not_active Application Discontinuation
- 2009-02-11 IL IL196989A patent/IL196989A0/en unknown
-
2010
- 2010-04-14 US US12/759,867 patent/US8299054B2/en active Active
-
2013
- 2013-05-07 JP JP2013097499A patent/JP2013173783A/en active Pending
Patent Citations (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3083204A (en) * | 1956-06-16 | 1963-03-26 | Knoll Ag | Esters and amides of 2-phenyl-bicyclo-(2, 2, 1) heptane-2-carboxylic acid, 2-phenyl-bcyclo(2, 2, 1)-5-heptene-2-carboxylic acid, 2-phenyl-bicyclo(2, 2, 2)-5-octene-2-carboxylic acid and 2-phenyl-bicyclo(2, 2, 2)octane carboxylic acid |
US4691051A (en) * | 1985-01-04 | 1987-09-01 | Pennwalt Corporation | Adamantyl phenyl β-alanines |
US6242615B1 (en) * | 1997-03-28 | 2001-06-05 | Zeneca Limited | Process for the preparation of N-(3-hydroxy-succinyl)-amino acid derivatives |
US6740647B1 (en) * | 1998-01-26 | 2004-05-25 | Abbott Gmbh & Co., Kg | Thrombin inhibitors |
US20030114460A1 (en) * | 2001-12-14 | 2003-06-19 | Allergan Sales, Inc. | Pharmaceutical conjugates with enhanced pharmacokinetic characteristics |
US20050070720A1 (en) * | 2002-02-01 | 2005-03-31 | Balkovec James M. | 11-Beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia |
US20040042830A1 (en) * | 2002-08-29 | 2004-03-04 | Canon Kabushiki Kaisha | Image processing system |
US20040209858A1 (en) * | 2002-10-22 | 2004-10-21 | Bennani Youssef L. | Cycloalkylamides and their therapeutic applications |
US7799782B2 (en) * | 2003-03-03 | 2010-09-21 | Array Biopharma Inc. | P38 inhibitors and methods of use thereof |
US20060094699A1 (en) * | 2003-04-11 | 2006-05-04 | Kampen Gita Camilla T | Combination therapy using an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and a glucocorticoid receptor agonist to minimize the side effects associated with glucocorticoid receptor agonist therapy |
US20060111366A1 (en) * | 2003-04-11 | 2006-05-25 | Novo Nordisk A/S | Pharmaceutical use of substituted amides |
US20050277647A1 (en) * | 2004-04-29 | 2005-12-15 | Link James T | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme |
US20060149070A1 (en) * | 2005-01-05 | 2006-07-06 | Rohde Jeffrey J | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme |
US20060148871A1 (en) * | 2005-01-05 | 2006-07-06 | Rohde Jeffrey J | Metabolic stabilization of substituted adamantane |
US20090124609A1 (en) * | 2006-07-14 | 2009-05-14 | Amgen Inc. | Fused heterocyclic derivatives and methods of use |
US20090124612A1 (en) * | 2006-07-14 | 2009-05-14 | Amgen Inc. | Fused heterocyclic derivatives and methods of use |
Non-Patent Citations (3)
Title |
---|
Balkovec et al. CAS: 139: 180065, 2003. * |
Dooley et al. CAS: 139: 164792, 2003. * |
Fleming et al. CAS: 97:109824, 1982. * |
Also Published As
Publication number | Publication date |
---|---|
EP2054368B1 (en) | 2015-09-16 |
BRPI0715839A2 (en) | 2013-07-23 |
KR20090057038A (en) | 2009-06-03 |
JP2010501589A (en) | 2010-01-21 |
TW200817353A (en) | 2008-04-16 |
US8299054B2 (en) | 2012-10-30 |
US7727978B2 (en) | 2010-06-01 |
AU2007286629A1 (en) | 2008-02-28 |
AR062533A1 (en) | 2008-11-12 |
CA2661401A1 (en) | 2008-02-28 |
EP2054368A2 (en) | 2009-05-06 |
EP2527317A1 (en) | 2012-11-28 |
MX2009001687A (en) | 2009-02-25 |
JP2013173783A (en) | 2013-09-05 |
IL196989A0 (en) | 2009-11-18 |
CN103833544A (en) | 2014-06-04 |
WO2008024892A3 (en) | 2008-12-11 |
CL2007002492A1 (en) | 2008-01-11 |
EA200900344A1 (en) | 2009-10-30 |
NO20090445L (en) | 2009-02-26 |
US20080234249A1 (en) | 2008-09-25 |
JP5268912B2 (en) | 2013-08-21 |
WO2008024892A2 (en) | 2008-02-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8299054B2 (en) | Cyclic 11-beta hydroxysteroid dehydrogenase type 1 inhibitors | |
US8119658B2 (en) | Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors | |
US8318941B2 (en) | Pyridone/hydroxypyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors | |
EP1989190B1 (en) | Triazine 11-beta hydroxysteroid dehydrogenase type i inhibitors | |
US7572807B2 (en) | Heteroaryl 11-beta-hydroxysteroid dehydrogenase type I inhibitors | |
US20060235028A1 (en) | Inhibitors of 11-beta hydroxysteroid dehydrogenase type I | |
US8263630B2 (en) | 1,2,3-triazoles as 11-beta hydroxysteroid dehydrogenase type I inhibitors | |
US20100144744A1 (en) | Fused heterocyclic 11-beta-hydroxysteroid dehydrogenase type 1 inhibitors | |
US20140128365A1 (en) | Pyridone/hydroxypyridine 11-beta hydroxysteroid dehydrogenase type i inhibitors | |
CN101506140B (en) | Cyclic 11-beta hydroxysteroid dehydrogenase type I inhibitors | |
LI et al. | Patent 2701355 Summary |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
CC | Certificate of correction | ||
FPAY | Fee payment |
Year of fee payment: 4 |
|
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 8TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1552); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY Year of fee payment: 8 |
|
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 12TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1553); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY Year of fee payment: 12 |